text,chunk_id,title,publication_date,authors,disease
"Systematic Analysis and Insights Into the Mutation Spectrum and Ethnic Differences in ATP7B Mutations Associated With Wilson Disease Wilson disease (WD, OMIM: #277900) is a rare autosomal recessive disorder characterized by impaired metabolism of copper, which causes copper to accumulate and become toxic, affecting the liver and brain among other organs.<sup><xref rid=""bibr1-11772719241297169"" ref-type=""bibr"">1</xref><xref rid=""bibr2-11772719241297169"" ref-type=""bibr""></xref>-<xref",0_0,Systematic Analysis and Insights Into the Mutation Spectrum and Ethnic Differences in ATP7B Mutations Associated With Wilson Disease,4 11 2024,,Wilson_Disease
"ref-type=""bibr""></xref>-<xref rid=""bibr3-11772719241297169"" ref-type=""bibr"">3</xref></sup> The Wilson disease was first described in the year of by Dr. Samuel Alexander Kinnier Wilson, a British neurologist, who observed neurological symptoms and liver disease in affected patients.<sup><xref rid=""bibr1-11772719241297169"" ref-type=""bibr"">1</xref>,<xref rid=""bibr4-11772719241297169"" ref-type=""bibr"">4</xref></sup> Symptoms of WD present in childhood, adolescence or adulthood with a wide range of clinical",0_1,Systematic Analysis and Insights Into the Mutation Spectrum and Ethnic Differences in ATP7B Mutations Associated With Wilson Disease,4 11 2024,,Wilson_Disease
"or adulthood with a wide range of clinical manifestations. A greenish-brown corneal opacity, called as the Kayser-Fleisher ring, has been reported as a key ophthalmologic characteristic presents in WD. Additionally, the accumulation of copper in the liver leads to the damage of cellular, resulting in liver disease. Copper buildup also affects the brain, leading to many neurological diseases, including tremors, dystonia, and mood disorders.<sup><xref rid=""bibr5-11772719241297169""",0_2,Systematic Analysis and Insights Into the Mutation Spectrum and Ethnic Differences in ATP7B Mutations Associated With Wilson Disease,4 11 2024,,Wilson_Disease
"rid=""bibr5-11772719241297169"" ref-type=""bibr"">5</xref>,<xref rid=""bibr6-11772719241297169"" ref-type=""bibr"">6</xref></sup> As the molecular level, the gene of <italic toggle=""yes"">ATP7B</italic> (OMIM: #606882), responsible for Wilson’s disease, was identified by Dr. John H. W. Wason in 1993.<sup>",0_3,Systematic Analysis and Insights Into the Mutation Spectrum and Ethnic Differences in ATP7B Mutations Associated With Wilson Disease,4 11 2024,,Wilson_Disease
"<xref rid=""bibr7-11772719241297169"" ref-type=""bibr"">7</xref>
</sup> The homozygous or compound heterozygous in the coding region and the promoter of <italic toggle=""yes"">ATP7B</italic>, located on chromosome 13q14.3, has been reported to be responsible for this pathology in more than 95% case.<sup><xref rid=""bibr1-11772719241297169"" ref-type=""bibr"">1</xref>,<xref rid=""bibr8-11772719241297169"" ref-type=""bibr"">8</xref>,<xref rid=""bibr9-11772719241297169"" ref-type=""bibr"">9</xref></sup>",0_4,Systematic Analysis and Insights Into the Mutation Spectrum and Ethnic Differences in ATP7B Mutations Associated With Wilson Disease,4 11 2024,,Wilson_Disease
"<italic toggle=""yes"">ATP7B</italic> gene contains 21 exons and 20 introns, and encodes for a 1465-aminoacid protein—a copper-transporting ATPase (Cu-ATPase) across the plasma membrane, which is synthetized in the endoplasmic reticulum and highly located in the trans-Golgi network of hepatocytes.<sup><xref rid=""bibr1-11772719241297169"" ref-type=""bibr"">1</xref>,<xref rid=""bibr3-11772719241297169"" ref-type=""bibr"">3</xref>,<xref rid=""bibr7-11772719241297169"" ref-type=""bibr"">7</xref>,<xref",0_5,Systematic Analysis and Insights Into the Mutation Spectrum and Ethnic Differences in ATP7B Mutations Associated With Wilson Disease,4 11 2024,,Wilson_Disease
"ref-type=""bibr"">7</xref>,<xref rid=""bibr8-11772719241297169"" ref-type=""bibr"">8</xref></sup> The structure of ATP7B protein, are described below, to receive copper ions within the cell, transport them through specific cellular compartments, and ultimately facilitate their incorporation into copper-dependent proteins or their elimination from the cell, maintaining copper homeostasis. ATP7B has a P-type ATPase architecture of conserved domains: a phosphatase domain (A-domain), a phosphorylation domain",0_6,Systematic Analysis and Insights Into the Mutation Spectrum and Ethnic Differences in ATP7B Mutations Associated With Wilson Disease,4 11 2024,,Wilson_Disease
"domain (A-domain), a phosphorylation domain (P-domain), ATP-binding domain (N-domain), and 8 transmembrane domains (M-domain) form an intramembranous Cu channel.<sup><xref rid=""bibr7-11772719241297169"" ref-type=""bibr"">7</xref>,<xref rid=""bibr10-11772719241297169"" ref-type=""bibr"">10</xref>,<xref rid=""bibr11-11772719241297169"" ref-type=""bibr"">11</xref></sup> This multi-domain has the distinctive structural feature: a large cytosolic N-terminal tail that contains 6 70-aa long independently folded Cu (I)",0_7,Systematic Analysis and Insights Into the Mutation Spectrum and Ethnic Differences in ATP7B Mutations Associated With Wilson Disease,4 11 2024,,Wilson_Disease
"contains 6 70-aa long independently folded Cu (I) binding domains (metal binding domains, MBDs, namely MBD1 to MBD6).<sup>",0_8,Systematic Analysis and Insights Into the Mutation Spectrum and Ethnic Differences in ATP7B Mutations Associated With Wilson Disease,4 11 2024,,Wilson_Disease
"<xref rid=""bibr12-11772719241297169"" ref-type=""bibr"">12</xref>
</sup> The function of MBD has been reported as receiving Cu<sup>+</sup> from a cytoplasmic Cu<sup>+</sup> chaperone antioxidant protein 1 and participating in subsequent Cu<sup>+</sup> transport across the membrane.<sup>
<xref rid=""bibr11-11772719241297169"" ref-type=""bibr"">11</xref>",0_9,Systematic Analysis and Insights Into the Mutation Spectrum and Ethnic Differences in ATP7B Mutations Associated With Wilson Disease,4 11 2024,,Wilson_Disease
"</sup> MBDs are found in the N-terminal with MBD1 being the first domain from the N-terminus and MBD6 being the domain nearest to the region of ATP7B that spans the membrane.<sup>
<xref rid=""bibr11-11772719241297169"" ref-type=""bibr"">11</xref>",0_10,Systematic Analysis and Insights Into the Mutation Spectrum and Ethnic Differences in ATP7B Mutations Associated With Wilson Disease,4 11 2024,,Wilson_Disease
"</sup> ATP7B serves a function in the export of copper from cells into bile and delivers copper for the functional synthesis of ceruloplasmin with the energy of ATP hydrolysis.<sup><xref rid=""bibr1-11772719241297169"" ref-type=""bibr"">1</xref>,<xref rid=""bibr2-11772719241297169"" ref-type=""bibr"">2</xref>,<xref rid=""bibr8-11772719241297169"" ref-type=""bibr"">8</xref>,<xref rid=""bibr13-11772719241297169"" ref-type=""bibr"">13</xref></sup> Recent years have seen tremendous progress in our knowledge of characterizing",0_11,Systematic Analysis and Insights Into the Mutation Spectrum and Ethnic Differences in ATP7B Mutations Associated With Wilson Disease,4 11 2024,,Wilson_Disease
"progress in our knowledge of characterizing the mutations of <italic toggle=""yes"">ATP7B</italic> gene related to WD and their effects on protein function. Mutations in the ATP7B gene may impair protein function, leading to copper accumulation in the liver and brain as well as improper ceruloplasmin synthesis.<sup>",0_12,Systematic Analysis and Insights Into the Mutation Spectrum and Ethnic Differences in ATP7B Mutations Associated With Wilson Disease,4 11 2024,,Wilson_Disease
"<xref rid=""bibr14-11772719241297169"" ref-type=""bibr"">14</xref>",0_13,Systematic Analysis and Insights Into the Mutation Spectrum and Ethnic Differences in ATP7B Mutations Associated With Wilson Disease,4 11 2024,,Wilson_Disease
"</sup> Thur far, more than 1,000 variations of ATP7B associated with WD have been reported from various countries (The Human Gene Mutation Database (HGMD<sup>®</sup>). Available at: <ext-link http://www.w3.org/1999/xlink href=""http://www.hgmd.cf.ac.uk/ac/index.php"" ext-link-type=""uri"">http://www.hgmd.cf.ac.uk/ac/index.php</ext-link>, Accessed: 17<sup>th</sup> Dec 2023). Due to the wide-spectrum of phenotypic variations in symptomatology, combined with the rarity of Wilson’s disease, it can lead to",0_14,Systematic Analysis and Insights Into the Mutation Spectrum and Ethnic Differences in ATP7B Mutations Associated With Wilson Disease,4 11 2024,,Wilson_Disease
"the rarity of Wilson’s disease, it can lead to misdiagnosis or delayed diagnosis.<sup>",0_15,Systematic Analysis and Insights Into the Mutation Spectrum and Ethnic Differences in ATP7B Mutations Associated With Wilson Disease,4 11 2024,,Wilson_Disease
"<xref rid=""bibr12-11772719241297169"" ref-type=""bibr"">12</xref>",0_16,Systematic Analysis and Insights Into the Mutation Spectrum and Ethnic Differences in ATP7B Mutations Associated With Wilson Disease,4 11 2024,,Wilson_Disease
"</sup> Promptly identifying the disorder presents, particularly in its early stages when symptoms may be nonspecific, challenges for clinicians. Therefore, for an accurate and timely diagnosis, it becomes essential to combine clinical evaluation, genetic analysis to identify ATP7B mutations, and biochemical testing for copper levels. The purposes of current study is to gain a thorough grasp of the spectrum of genetic variations as well as to consolidate and analyze existing data from various sources,",0_17,Systematic Analysis and Insights Into the Mutation Spectrum and Ethnic Differences in ATP7B Mutations Associated With Wilson Disease,4 11 2024,,Wilson_Disease
"and analyze existing data from various sources, including clinical studies and genetic databases, to identify patterns, prevalence. Overall, understanding the mutation in the ATP7B gene offers insights into the mechanisms behind WD and guides strategies for diagnosis and treatment.   The gene of <italic toggle=""yes"">ATP7B</italic> has been reported to be pivotal in studies of WD related to the metabolism of copper.<sup><xref rid=""bibr1-11772719241297169"" ref-type=""bibr"">1</xref>,<xref",0_18,Systematic Analysis and Insights Into the Mutation Spectrum and Ethnic Differences in ATP7B Mutations Associated With Wilson Disease,4 11 2024,,Wilson_Disease
"ref-type=""bibr"">1</xref>,<xref rid=""bibr12-11772719241297169"" ref-type=""bibr"">12</xref>,<xref rid=""bibr14-11772719241297169"" ref-type=""bibr"">14</xref>,<xref rid=""bibr26-11772719241297169"" ref-type=""bibr"">26</xref></sup> This study comprehensively highlighted the mutation of <italic toggle=""yes"">ATP7B</italic> in WD patients by an analysis of 40 studies from 2001 to 2023. According our systematic analysis, various mutations, notably more than 50% described single nucleotide variations, dispersed among the",0_19,Systematic Analysis and Insights Into the Mutation Spectrum and Ethnic Differences in ATP7B Mutations Associated With Wilson Disease,4 11 2024,,Wilson_Disease
"single nucleotide variations, dispersed among the gene’s 21 exons, were identified. Most detected variants were located in crucial regions such as the transmembrane domain, metal-binding domains, and ATP-binding site, highlighting their potential impact on the gene’s function and the progression of Wilson disease. The mutation profile of previous studies highly presented most of our identified variants located on the exon 8, which exhibited the highest mutation diversity, 18 studies identified 53 distinct",0_20,Systematic Analysis and Insights Into the Mutation Spectrum and Ethnic Differences in ATP7B Mutations Associated With Wilson Disease,4 11 2024,,Wilson_Disease
"diversity, 18 studies identified 53 distinct variants, predominantly missense mutations (81.13%), followed by exons 18, 2, and 14, with exon 1 showing the least variability. Exon 8 encodes part of the transmembrane domain 4 (Tm4) of the ATP7B protein.<sup>",0_21,Systematic Analysis and Insights Into the Mutation Spectrum and Ethnic Differences in ATP7B Mutations Associated With Wilson Disease,4 11 2024,,Wilson_Disease
"<xref rid=""bibr9-11772719241297169"" ref-type=""bibr"">9</xref>",0_22,Systematic Analysis and Insights Into the Mutation Spectrum and Ethnic Differences in ATP7B Mutations Associated With Wilson Disease,4 11 2024,,Wilson_Disease
"</sup> Tm4 spans the cellular membrane, allowing the protein to embed within the lipid bilayer and form a pathway for copper ion transport. The transmembrane domains are essential for the function of ATP7B protein in moving copper ions across cellular membranes. Therefore, mutations occurred in exon 8 can disrupt the structure of the Tm4 domain, impairing the ability to effectively transport copper of ATP7B protein, resulting in the clinical manifestations of Wilson disease. Focusing on exon 8, which",0_23,Systematic Analysis and Insights Into the Mutation Spectrum and Ethnic Differences in ATP7B Mutations Associated With Wilson Disease,4 11 2024,,Wilson_Disease
"of Wilson disease. Focusing on exon 8, which exhibited the highest mutation diversity, 18 studies identified 53 distinct variants, predominantly missense mutations, which constituted 81.13% (43 out of 53 cases). Other notable types included frame-shift, silent, and non-sense mutations. These figures underscore the predominance of missense mutations and the relative rarity of other mutation types in exon 8. In this study, we pointed out the notably frequent variants of as c.2333G>A/T (p.R778Q/L), c.2305A>G",0_24,Systematic Analysis and Insights Into the Mutation Spectrum and Ethnic Differences in ATP7B Mutations Associated With Wilson Disease,4 11 2024,,Wilson_Disease
"variants of as c.2333G>A/T (p.R778Q/L), c.2305A>G (p.M769V), c.2336G>A (p.W779*), and c.2304dupC (p.M769HfsX26) being reported in different populations, with notable prevalences in China, India, France, and Western countries. Based on the calculation of weighted mean of variants’ proportion, the pooled estimate of these percentages of 14.19% for c.2333G>A/T (p.R778Q/L), 2.70% for c.2305A>G (p.M769V), 1.42% for c.2336G>A (p.W779*), and 2.33% for c.2304dupC (p.M769HfsX26), provided critical insights into the",0_25,Systematic Analysis and Insights Into the Mutation Spectrum and Ethnic Differences in ATP7B Mutations Associated With Wilson Disease,4 11 2024,,Wilson_Disease
"provided critical insights into the prevalence and impact of exon 8 mutations. Understanding these proportions is vital for grasping the broader implications across diverse populations and study settings, emphasizing the importance of exon 8 in genetic studies related to Wilson Disease. Therefore, the critical nature of exon 8 mutations is further emphasized by their relevance in diagnosing hepatic failure diseases, particularly Wilson Disease. The method of DNA extraction and Polymerase Chain Reaction",0_26,Systematic Analysis and Insights Into the Mutation Spectrum and Ethnic Differences in ATP7B Mutations Associated With Wilson Disease,4 11 2024,,Wilson_Disease
"of DNA extraction and Polymerase Chain Reaction (PCR) sequencing were widely used to identify these mutations. This technique amplifies specific DNA sequences, making it possible to detect even minor genetic variations with high precision. The significance of mutation types has been reported that it can be used as the element for WD prognosis, as well as influence response to treatment of WD in some cases. Notably, the correlation between the mutations of <italic toggle=""yes"">ATP7B</italic> gene and",0_27,Systematic Analysis and Insights Into the Mutation Spectrum and Ethnic Differences in ATP7B Mutations Associated With Wilson Disease,4 11 2024,,Wilson_Disease
"of <italic toggle=""yes"">ATP7B</italic> gene and clinical parameters has a few reports, and also remains controversial.<sup>",0_28,Systematic Analysis and Insights Into the Mutation Spectrum and Ethnic Differences in ATP7B Mutations Associated With Wilson Disease,4 11 2024,,Wilson_Disease
"<xref rid=""bibr34-11772719241297169"" ref-type=""bibr"">34</xref>",0_29,Systematic Analysis and Insights Into the Mutation Spectrum and Ethnic Differences in ATP7B Mutations Associated With Wilson Disease,4 11 2024,,Wilson_Disease
"</sup> This is how studies are biased. Despite extensive research, studies have yielded inconsistent results regarding how specific mutations influence disease onset, severity, and progression. This controversy arises from several factors, including the genetic diversity across different populations, which can affect mutation prevalence and clinical expression. WD patients, who presented a phenotype of chronic liver disease, on chelation therapy, and carried at least one loss-of-function variant in the",0_30,Systematic Analysis and Insights Into the Mutation Spectrum and Ethnic Differences in ATP7B Mutations Associated With Wilson Disease,4 11 2024,,Wilson_Disease
"at least one loss-of-function variant in the <italic toggle=""yes"">ATP7B</italic> gene, tended to display a worse prognosis during long-term follow-up.<sup>",0_31,Systematic Analysis and Insights Into the Mutation Spectrum and Ethnic Differences in ATP7B Mutations Associated With Wilson Disease,4 11 2024,,Wilson_Disease
"<xref rid=""bibr36-11772719241297169"" ref-type=""bibr"">36</xref>
</sup> This pointed out the importance of identifying genetic mutations of <italic toggle=""yes"">ATP7B</italic> gene in WD patients with hepatic involvement to better predict the progression of disease as well as diagnose the WD. The p.R778L mutation in Chinese population was associated with liver types, and some studies have no significant association between the p.R778L mutation and clinical type, sex, age.<sup>",0_32,Systematic Analysis and Insights Into the Mutation Spectrum and Ethnic Differences in ATP7B Mutations Associated With Wilson Disease,4 11 2024,,Wilson_Disease
"<xref rid=""bibr37-11772719241297169"" ref-type=""bibr"">37</xref>
</sup> One of the best known examples of the genotype-phenotype correlation in WD patients is the p.H1609Q mutation in East German patients with WD.<sup>
<xref rid=""bibr20-11772719241297169"" ref-type=""bibr"">20</xref>",0_33,Systematic Analysis and Insights Into the Mutation Spectrum and Ethnic Differences in ATP7B Mutations Associated With Wilson Disease,4 11 2024,,Wilson_Disease
"</sup> In their study, patients carried the homozygous mutation of p.H1609Q have symptoms started later than compound heterozygous mutation or no mutation. Moreover, they displayed more frequently neurologic symptoms and Kayser-Fleischer rings. The status of mutation did not significantly correlate with liver biopsy findings, serum ceruloplasmin levels or Cu-assay results. Molecular therapies of WD targeting molecular interactions to the mutant protein ATP7B have been studied. For instance, the p.H1609Q",0_34,Systematic Analysis and Insights Into the Mutation Spectrum and Ethnic Differences in ATP7B Mutations Associated With Wilson Disease,4 11 2024,,Wilson_Disease
"have been studied. For instance, the p.H1609Q mutation was reported promoting the interaction between ATP7B and HSP70, resulting in the mutant promoted the accumulation of the endoplasmic reticulum degradation of mutant ATP7B protein led to the copper accelerating in hepatic cells. Domperidone is an HSP70 inhibitor that effectively counteracts the beginning of WD by enhancing the trafficking and function of ATP7B–H1069Q by preventing its access to the HSP70 proteostasis network.<sup>",0_35,Systematic Analysis and Insights Into the Mutation Spectrum and Ethnic Differences in ATP7B Mutations Associated With Wilson Disease,4 11 2024,,Wilson_Disease
"<xref rid=""bibr38-11772719241297169"" ref-type=""bibr"">38</xref>
</sup> Tang et al (2023) developed a WD cell model within a p.R778L mutation. Importantly, they reported that both necroptosis and autophagy are critically involved to the pathogenesis of WD. In this model of a p.R778L mutation, ULK1- and ATG16L1-mediated autophagy inhibits RIPK3- and MLKL-mediated necroptosis.<sup>
<xref rid=""bibr39-11772719241297169"" ref-type=""bibr"">39</xref>",0_36,Systematic Analysis and Insights Into the Mutation Spectrum and Ethnic Differences in ATP7B Mutations Associated With Wilson Disease,4 11 2024,,Wilson_Disease
"</sup> Their finding suggested that the possibility of mutation-specific treatment approaches, in which patients with specific ATP7B mutations, such p.R778L, might benefit from targeting processes like autophagy. The strength of our study focused on the comprehensive approach to analyze the mutations dispersed among the gene’s 21 exons across previous multiple studies. By utilizing a methodical screening procedure, noteworthy patterns and rates of mutations were detected, guaranteeing a comprehensive",0_37,Systematic Analysis and Insights Into the Mutation Spectrum and Ethnic Differences in ATP7B Mutations Associated With Wilson Disease,4 11 2024,,Wilson_Disease
"were detected, guaranteeing a comprehensive comprehension of their frequency and therapeutic consequences. Additionally, the application of a random effects model in our meta-analysis allowed us to account for heterogeneity among studies, providing more accurate pooled estimates. The lack of publication bias, confirmed through Egger’s test, further strengthens the validity of our results. Overall, our study offers a robust and detailed examination of exon 8 mutations, contributing valuable insights to the",0_38,Systematic Analysis and Insights Into the Mutation Spectrum and Ethnic Differences in ATP7B Mutations Associated With Wilson Disease,4 11 2024,,Wilson_Disease
"mutations, contributing valuable insights to the field of genetic research on Wilson Disease. However, the limitation of current study, the heterogeneity among the included studies, which may have impacted the accuracy of the pooled estimates. The results’ applicability to different ethnic populations may be limited by the omission of articles written in languages other than English. Subtle biases in research selection or mutation nomenclature may still exist, despite efforts to assess publication bias",0_39,Systematic Analysis and Insights Into the Mutation Spectrum and Ethnic Differences in ATP7B Mutations Associated With Wilson Disease,4 11 2024,,Wilson_Disease
"exist, despite efforts to assess publication bias having been made. In current study, the results of our comprehensive analyzing presented the knowledge of mutations, especially in exon 8, functioned as the transmembrane domain, occurred on <italic toggle=""yes"">ATP7B</italic>. Consequently, the variations of c.2333G>A/T (p.R778Q/L), c.2305A>G (p.M769V), c.2336G>A (p.W779*), and c.2304dupC (p.M769HfsX26) as hotspot mutations on exon 8 for the present study.",0_40,Systematic Analysis and Insights Into the Mutation Spectrum and Ethnic Differences in ATP7B Mutations Associated With Wilson Disease,4 11 2024,,Wilson_Disease
"Contrast-enhanced ultrasound findings of sclerotic nodules in Wilson disease: A case report Wilson disease, also known as hepatolenticular degeneration, is an autosomal recessive genetic disease found by Samuel Alexander Kinnier Wilson and prevalent in childhood and adolescents.<sup>[<xref rid=""R1"" ref-type=""bibr"">1</xref>,<xref rid=""R2"" ref-type=""bibr"">2</xref>]</sup> Its clinical manifestations are complex and diverse, with liver damage, neuropsychiatric dysfunction, Kayser-Fleischer (K-F) rings, and",1_0,Contrast-enhanced ultrasound findings of sclerotic nodules in Wilson disease: A case report,18 10 2024,,Wilson_Disease
"dysfunction, Kayser-Fleischer (K-F) rings, and kidney damage as the main manifestations.<sup>[<xref rid=""R3"" ref-type=""bibr"">3</xref>]</sup> After reasonable treatment, the prognosis of Wilson disease is good, but it is often delayed due to untimely diagnosis, resulting in a poor prognosis.<sup>[<xref rid=""R4"" ref-type=""bibr"">4</xref>]</sup> Here, through this case report, we found that contrast-enhanced ultrasound (CEUS) has a certain value in the diagnosis of this kind of disease, suggesting that this",1_1,Contrast-enhanced ultrasound findings of sclerotic nodules in Wilson disease: A case report,18 10 2024,,Wilson_Disease
"of this kind of disease, suggesting that this imaging manifestation is likely to become the theoretical basis for the diagnosis of Wilson disease. An 18-year-old female patient was admitted to the Department of Hepatobiliary surgery of our hospital because she found that the number of 3 blood cells decreased for >10 days. When she was admitted to the hospital, she mainly carried a summary of the discharge from the people’s Hospital of Qichun. After careful physical examination, it was found that the",1_2,Contrast-enhanced ultrasound findings of sclerotic nodules in Wilson disease: A case report,18 10 2024,,Wilson_Disease
"physical examination, it was found that the hemogram of the patient was slightly poor, the skin was not yellow, the liver and palm was mild, the transverse finger under the liver ribs was 2 fingers, the spleen was enlarged, the boundary was located at the navel level, there was no percussion pain in the liver and spleen area, and the mobility dullness was negative. In the past, she underwent appendicitis surgery at the age of 8, had a history of thrombocytopenic purpura, denied a history of hepatitis B,",1_3,Contrast-enhanced ultrasound findings of sclerotic nodules in Wilson disease: A case report,18 10 2024,,Wilson_Disease
"purpura, denied a history of hepatitis B, and drinking. Based on the above, the admission diagnosis was diagnosed as decompensation stage of liver cirrhosis. After admission, patients were given blood samples to detect liver function (ALT 62 U/L, AST 63U/L), blood routine and tumor markers. The results showed that liver function was impaired, white blood cells (WBC), red blood cells, hemoglobin (98.9 g/L), and platelets were lower than normal, and CA125 were increased. At present, the cause of liver",1_4,Contrast-enhanced ultrasound findings of sclerotic nodules in Wilson disease: A case report,18 10 2024,,Wilson_Disease
"were increased. At present, the cause of liver cirrhosis is unclear. The whole abdomen CT results showed that there were multiple slightly high-density nodules in the liver parenchyma, and liver cirrhosis and regenerative nodules were considered (Fig. <xref rid=""F1"" ref-type=""fig"">1</xref>). The results of liver ultrasound examination at the same time showed that the liver parenchyma showed diffuse lesions, multiple hypoechoic light masses could be seen in the liver parenchyma, the outline was still clear,",1_5,Contrast-enhanced ultrasound findings of sclerotic nodules in Wilson disease: A case report,18 10 2024,,Wilson_Disease
"liver parenchyma, the outline was still clear, the internal echo was not uniform, and the space occupying effect was obvious (Fig. <xref rid=""F2"" ref-type=""fig"">2</xref>). In further CEUS examination, SonoVue 2.4 mL was injected into the median vein of the left upper limb, and the low echo light mass of the liver was enhanced rapidly and uniformly. The beginning time of enhancement was 9.0 seconds (Fig. <xref rid=""F3"" ref-type=""fig"">3</xref>A), which was earlier than that of the liver parenchyma, and the",1_6,Contrast-enhanced ultrasound findings of sclerotic nodules in Wilson disease: A case report,18 10 2024,,Wilson_Disease
"than that of the liver parenchyma, and the peak time was 17.2 seconds (Fig. <xref rid=""F3"" ref-type=""fig"">3</xref>B). The washout time was slightly earlier than that of the liver parenchyma, and showed continuous slightly higher enhancement in the delayed phases (Fig. <xref rid=""F3"" ref-type=""fig"">3</xref>C). The patient’s liver condition was recorded using ultrasonography to capture real-time images of the liver (Video S1, Supplemental Digital Content, <ext-link http://www.w3.org/1999/xlink",1_7,Contrast-enhanced ultrasound findings of sclerotic nodules in Wilson disease: A case report,18 10 2024,,Wilson_Disease
"Content, <ext-link http://www.w3.org/1999/xlink href=""http://links.lww.com/MD/N738"" ext-link-type=""uri"">http://links.lww.com/MD/N738</ext-link>). The patient performed liver biopsy under the guidance of ultrasound (Fig. S1, Supplemental Digital Content, <ext-link http://www.w3.org/1999/xlink href=""http://links.lww.com/MD/N739"" ext-link-type=""uri"">http://links.lww.com/MD/N739</ext-link>), and the pathological results showed cryptogenic liver cirrhosis. combined with clinical examination (negative hepatitis",1_8,Contrast-enhanced ultrasound findings of sclerotic nodules in Wilson disease: A case report,18 10 2024,,Wilson_Disease
"with clinical examination (negative hepatitis markers and autoimmune related tests), it was inferred that chronic hepatitis with liver cirrhosis of unknown cause could be consistent with Wilson disease (Fig. <xref rid=""F4"" ref-type=""fig"">4</xref>), which needed to be further diagnosed by serum ceruloplasmin (CER) or free copper and genetic testing. The serum CER was detected in the patients, and the result was 0.16 g/L, lower than the normal value. At the same time, an ophthalmologist was invited to",1_9,Contrast-enhanced ultrasound findings of sclerotic nodules in Wilson disease: A case report,18 10 2024,,Wilson_Disease
"the same time, an ophthalmologist was invited to consult with an expert, and the results showed that the patient did not have K-F rings. In addition, the patient’s family refused genetic testing. Based on the patient’s examination, the diagnostic score can be calculated as follows: neuropsychiatric symptoms: the patient presented with sleep disorders, insomnia, irritability, and emotional lability, which were indicative of neuropsychiatric manifestations associated with Wilson disease. This category was",1_10,Contrast-enhanced ultrasound findings of sclerotic nodules in Wilson disease: A case report,18 10 2024,,Wilson_Disease
"associated with Wilson disease. This category was assigned 2 points. Coombs negative hemolytic anemia: The patient’s hemoglobin level was 98.9 g/L, which may suggest the presence of hemolytic anemi when negative for the Coombs test, got 1 point. Serum CER: the serum CER level was 0.16 g/L (16 mg/dL), which was significantly lower than the normal range and was a typical finding in Wilson disease. This category was assigned 1 point. We scored the patient with a total of 4 points on the Leipzig score, which",1_11,Contrast-enhanced ultrasound findings of sclerotic nodules in Wilson disease: A case report,18 10 2024,,Wilson_Disease
"a total of 4 points on the Leipzig score, which typically indicates that the patient meets the diagnostic criteria for Wilson disease. In summary, the patient was considered to be diagnosed with liver cirrhosis caused by Wilson disease. After admission, the patient was given symptomatic support treatment such as zinc salts (150 mg/d), low copper diet, liver protection, and discharged after improvement of symptoms. In our patients, the diagnosis of Wilson disease was made by liver biopsy combined with CER.",1_12,Contrast-enhanced ultrasound findings of sclerotic nodules in Wilson disease: A case report,18 10 2024,,Wilson_Disease
"was made by liver biopsy combined with CER. The concealment of onset and the nonspecific findings of imaging examination make the diagnosis more difficult. According to statistics, the incidence of Wilson is 1/30,000.<sup>[<xref rid=""R5"" ref-type=""bibr"">5</xref>]</sup> Wilson disease is mainly affected by gene mutation and environmental factors. The mutated genes mainly include ATP7B mutation in chromosome 13 or genes related to triglyceride metabolism, fat metabolism, and antioxidant pathway.<sup>[<xref",1_13,Contrast-enhanced ultrasound findings of sclerotic nodules in Wilson disease: A case report,18 10 2024,,Wilson_Disease
"metabolism, and antioxidant pathway.<sup>[<xref rid=""R6"" ref-type=""bibr"">6</xref>,<xref rid=""R7"" ref-type=""bibr"">7</xref>]</sup> The environmental factors include gender, iron, and diet.<sup>[<xref rid=""R8"" ref-type=""bibr"">8</xref>,<xref rid=""R9"" ref-type=""bibr"">9</xref>]</sup> The clinical manifestations of Wilson disease are caused by the accumulation of serum free copper, resulting in nervous system symptoms, liver damage, and K-F ring changes. It is worth noting that previous studies have shown that",1_14,Contrast-enhanced ultrasound findings of sclerotic nodules in Wilson disease: A case report,18 10 2024,,Wilson_Disease
"noting that previous studies have shown that patients with liver as the main manifestation tend to be younger than patients with nervous system changes,<sup>[<xref rid=""R10"" ref-type=""bibr"">10</xref>]</sup> while K-F ring does not appear in all Wilson patients,<sup>[<xref rid=""R11"" ref-type=""bibr"">11</xref>]</sup> only in 30% to 50% of patients with liver lesions, which are consistent with our case reports. Liver lesions caused by Wilson disease often progress from initial mild liver function changes to",1_15,Contrast-enhanced ultrasound findings of sclerotic nodules in Wilson disease: A case report,18 10 2024,,Wilson_Disease
"from initial mild liver function changes to chronic active hepatitis, then cause liver fibrosis, and eventually develop into decompensated cirrhosis.<sup>[<xref rid=""R12"" ref-type=""bibr"">12</xref>]</sup> Although studies have shown that patients with Wilson disease have a lower risk of liver cancer, liver cirrhosis increases the risk of death.<sup>[<xref rid=""R13"" ref-type=""bibr"">13</xref>,<xref rid=""R14"" ref-type=""bibr"">14</xref>]</sup> Therefore, early diagnosis is undoubtedly the focus of improving the",1_16,Contrast-enhanced ultrasound findings of sclerotic nodules in Wilson disease: A case report,18 10 2024,,Wilson_Disease
"is undoubtedly the focus of improving the prognosis of Wilson disease. Because of the rarity of the disease, Wilson disease usually considered after a long period of exclusive diagnosis. The gold standard for the diagnosis of Wilson disease is ATP7B gene testing,<sup>[<xref rid=""R4"" ref-type=""bibr"">4</xref>]</sup> but it is often abandoned because of limited economic conditions. Secondly, the decrease of serum CER, the increase of serum free copper, liver function damage, hemolytic anemia,",1_17,Contrast-enhanced ultrasound findings of sclerotic nodules in Wilson disease: A case report,18 10 2024,,Wilson_Disease
"copper, liver function damage, hemolytic anemia, thrombocytopenia, and brain MRI are auxiliary diagnostic basis.<sup>[<xref rid=""R4"" ref-type=""bibr"">4</xref>]</sup> Our case also echoes some of the above diagnostic basis. At present, the imaging diagnosis of liver damage in Wilson disease has not been reported. In our case report, ultrasound technology was fully used to assist in the diagnosis. Two-dimensional ultrasound diagnosis showed that the patient’s liver diffuse venereal disease with multiple",1_18,Contrast-enhanced ultrasound findings of sclerotic nodules in Wilson disease: A case report,18 10 2024,,Wilson_Disease
"liver diffuse venereal disease with multiple space-occupying nodules. Considering that the accuracy of traditional ultrasound in distinguishing benign and malignant lesions is only 23% to 68%, while the accuracy of CEUS is 92% to 95%.<sup>[<xref rid=""R15"" ref-type=""bibr"">15</xref>]</sup> We suggest that the patients should be examined by CEUS, and the results suggest that there is a great possibility of benign space-occupying lesions in the liver. In addition, in the delayed phase, it is different from the",1_19,Contrast-enhanced ultrasound findings of sclerotic nodules in Wilson disease: A case report,18 10 2024,,Wilson_Disease
"in the delayed phase, it is different from the complete non-enhancement of malignant lesions,<sup>[<xref rid=""R16"" ref-type=""bibr"">16</xref>,<xref rid=""R17"" ref-type=""bibr"">17</xref>]</sup> the complete high enhancement of hemangioma,<sup>[<xref rid=""R18"" ref-type=""bibr"">18</xref>]</sup> the non-enhancement of central scar of focal nodular hyperplasia,<sup>[<xref rid=""R16"" ref-type=""bibr"">16</xref>,<xref rid=""R17"" ref-type=""bibr"">17</xref>]</sup> and the mild low enhancement of hepatocellular",1_20,Contrast-enhanced ultrasound findings of sclerotic nodules in Wilson disease: A case report,18 10 2024,,Wilson_Disease
"and the mild low enhancement of hepatocellular adenoma,<sup>[<xref rid=""R15"" ref-type=""bibr"">15</xref>,<xref rid=""R19"" ref-type=""bibr"">19</xref>]</sup> It is also different from the isoechoic changes of liver cirrhosis compared with normal liver tissue in arterial phase and delayed phase,<sup>[<xref rid=""R20"" ref-type=""bibr"">20</xref>]</sup> the result of our case is rapid enhancement in arterial phase and a slightly higher persistent enhancement in the delayed phase. Most importantly, the biopsy results",1_21,Contrast-enhanced ultrasound findings of sclerotic nodules in Wilson disease: A case report,18 10 2024,,Wilson_Disease
"phase. Most importantly, the biopsy results of hypoechoic nodules in the liver are consistent with Wilson disease. Therefore, we can infer that in the process of CEUS, the contrast medium is rapidly enhanced, the rapid washout after reaching the peak, and the delayed phase shows persistent high enhancement, which is likely to become a suggestive basis for the diagnosis of Wilson disease. Of course, this sign still needs to be supported by a large number of clinical cases. In conclusion, a high degree of",1_22,Contrast-enhanced ultrasound findings of sclerotic nodules in Wilson disease: A case report,18 10 2024,,Wilson_Disease
"clinical cases. In conclusion, a high degree of suspicion index is required for the diagnosis of Wilson disease. As the onset of Wilson is not specific, incorrect treatment will delay the disease and lead to poor outcome, on the contrary, causal treatment can quickly improve the prognosis. Therefore, it is recommended that all cirrhotic nodules should be examined by contrast-enhanced ultrasonography. Hypoechoic nodules caused by unexplained liver cirrhosis are rapidly developed and cleared by SonoVue in",1_23,Contrast-enhanced ultrasound findings of sclerotic nodules in Wilson disease: A case report,18 10 2024,,Wilson_Disease
"are rapidly developed and cleared by SonoVue in the process of CEUS, accompanied by slightly higher persistent enhancement in the delayed phase. According to the imaging findings, it can be considered that hepatolenticular nodules may be caused by Wilson disease, of course, accurate diagnosis needs to be combined with other clinical indicators. <bold>Conceptualization:</bold> Cong Hu, Weiling Huang, Yixin Chen, Ying Wang, Meng Wu. <bold>Data curation:</bold> Kun Liu, Aihua Liu, Meng Wu. <bold>Formal",1_24,Contrast-enhanced ultrasound findings of sclerotic nodules in Wilson disease: A case report,18 10 2024,,Wilson_Disease
"Kun Liu, Aihua Liu, Meng Wu. <bold>Formal analysis:</bold> Meng Wu. <bold>Funding acquisition:</bold> Meng Wu. <bold>Investigation:</bold> Zhiwei Zhao, Qi Zhang, Ying Wang, Meng Wu. <bold>Methodology:</bold> Weiling Huang, Zhiwei Zhao, Yixin Chen, Ying Wang, Meng Wu. <bold>Project administration:</bold> Meng Wu. <bold>Resources:</bold> Meng Wu. <bold>Software:</bold> Aihua Liu, Yuancheng Jiang, Meng Wu. <bold>Supervision:</bold> Weiling Huang, Meng Wu. <bold>Validation:</bold> Meng Wu.",1_25,Contrast-enhanced ultrasound findings of sclerotic nodules in Wilson disease: A case report,18 10 2024,,Wilson_Disease
"Huang, Meng Wu. <bold>Validation:</bold> Meng Wu. <bold>Visualization:</bold> Meng Wu. <bold>Writing – original draft:</bold> Cong Hu, Ying Wang, Meng Wu. <bold>Writing – review & editing:</bold> Cong Hu, Ying Wang, Meng Wu.",1_26,Contrast-enhanced ultrasound findings of sclerotic nodules in Wilson disease: A case report,18 10 2024,,Wilson_Disease
"Zinc gluconate for Wilson disease Due to financial constraints, a patient with Wilson disease required transitioning his maintenance pharmacotherapy from zinc acetate to zinc gluconate. Herein, we report the clinical and laboratory outcomes of this switch and review the relevant literature on the treatment of Wilson disease with zinc. Zinc gluconate can be a viable treatment option for patients with Wilson disease and may be associated with fewer gastrointestinal side effects than zinc acetate and,",2_0,Zinc gluconate for Wilson disease,05 10 2024,,Wilson_Disease
"side effects than zinc acetate and, accordingly, improved long-term compliance and improved clinical outcomes. The majority of textbooks, medical websites (e.g., <ext-link ext-link-type=""uri"" http://www.w3.org/1999/xlink href=""https://www.mayoclinic.org/diseases-conditions/wilsons-disease/diagnosis-treatment/"" id=""ir005"">https://www.mayoclinic.org/diseases-conditions/wilsons-disease/diagnosis-treatment/</ext-link>), and review articles indicate that zinc acetate is an accepted therapeutic option for the",2_1,Zinc gluconate for Wilson disease,05 10 2024,,Wilson_Disease
"acetate is an accepted therapeutic option for the treatment of Wilson disease <xref rid=""b0005"" ref-type=""bibr"">[1]</xref>, <xref rid=""b0010"" ref-type=""bibr"">[2]</xref>, <xref rid=""b0015"" ref-type=""bibr"">[3]</xref>. Zinc acetate is marketed under the brand name Galzin in the United States and Wilzin in Europe. For uninsured patients, Galzin is quite expensive (50 mg PO TID x 30 days > $350, 18AUG2024, <ext-link ext-link-type=""uri"" http://www.w3.org/1999/xlink href=""https://www.goodrx.com""",2_2,Zinc gluconate for Wilson disease,05 10 2024,,Wilson_Disease
"href=""https://www.goodrx.com"" id=""ir010"">https://www.goodrx.com</ext-link>). For insured patients, co-payments can also be burdensome. As such, patients may explore alternative options such as zinc gluconate, zinc citrate, zinc glycerol, zinc picolinate, or zinc monomethionine. These “alternative” forms of zinc can be purchased through a variety of online distributors. For example, a search of the <ext-link ext-link-type=""uri"" http://www.w3.org/1999/xlink href=""https://www.amazon.com""",2_3,Zinc gluconate for Wilson disease,05 10 2024,,Wilson_Disease
"href=""https://www.amazon.com"" id=""ir015"">https://www.amazon.com</ext-link> website on 18AUG2024 with the term “zinc citrate” generated 115 results, “zinc acetate” generated 29 results, “zinc monomethionine” generated 21 results and “zinc picolinate” generated 138 results. In the United States, Good Manufacturing Practice (GMP) requirements of the the Federal Drug Agency (FDA) are less stringent and more flexible for supplements than prescription drugs. For example, supplements do not require an expiration",2_4,Zinc gluconate for Wilson disease,05 10 2024,,Wilson_Disease
"example, supplements do not require an expiration date or associated stability testing (Code of Federal Regulations, Title 21; <ext-link ext-link-type=""uri"" http://www.w3.org/1999/xlink href=""https://www.ecfr.gov/current/title-21"" id=""ir020"">https://www.ecfr.gov/current/title-21</ext-link>). Patients and their treating physicians may be concerned and confused regarding the most appropriate zinc formulation to use. Here we report a patient no longer able to afford Galzin therapy and successful transition to",2_5,Zinc gluconate for Wilson disease,05 10 2024,,Wilson_Disease
"Galzin therapy and successful transition to zinc gluconate. The male patient was diagnosed with Huntington disease at 33 years of age. He presented with an asymmetric action tremor of the upper extremities and mild dysarthria. Kayser-Fleisher rings were present on initial clinical examation. Diagnostic findings included mild cirrhosis, splenomegaly, mild portal venous hypertension, and slight elevation of liver enzymes (aspartate transaminase [AST]: 42 IU/L, 0 – 40 IU/L; alanine transaminase [ALT]:",2_6,Zinc gluconate for Wilson disease,05 10 2024,,Wilson_Disease
"42 IU/L, 0 – 40 IU/L; alanine transaminase [ALT]: 73 IU/L, 0 – 55 IU/L). His initial treatment was zinc acetate and he was prescribed zinc acetate 50 mg capsules (Galzin, Teva Pharmaceuticals, Tel Aviv-Yafo, Israel; 50 mg elemental zinc) one PO TID for over 15 years. His neurological examination nearly normalized within one year of zinc therapy. His liver function testing and imaging studies of cirrhosis also improved. With zinc acetate, he experienced intermittent gastrointestinal cramping, upper",2_7,Zinc gluconate for Wilson disease,05 10 2024,,Wilson_Disease
"intermittent gastrointestinal cramping, upper gastrointestional pain, and occasional nausea, particularly with his first morning dosage. He would typically take zinc acetate with food that included protein to limit gastrointestinal side effects. Yet, he was intermittently non-compliant with TID dosing due to residual side effects. In 2022 his insurance plan would no longer cover Galzin. After discussion of therapeutic options, the patient was switched to zinc gluconate 50 mg tablet (Rugby® Laboratories,",2_8,Zinc gluconate for Wilson disease,05 10 2024,,Wilson_Disease
"zinc gluconate 50 mg tablet (Rugby® Laboratories, Livonia, Michigan, USA; 50 mg elemental zinc; $7.93 for 100 capsules on 17AUG2024) one PO TID. He has had virtually no gastrointestinal side effects with zinc gluconate and his 24 hr urine copper results showed quantitative improvement (<xref rid=""t0005"" ref-type=""table"">Table 1</xref>). In addition, his 24 hr zinc levels increased. As seen in the <xref rid=""t0005"" ref-type=""table"">Table 1</xref>, 24 hr urine copper levels have been inversely correlated",2_9,Zinc gluconate for Wilson disease,05 10 2024,,Wilson_Disease
"copper levels have been inversely correlated with 24 hr zinc levels. His neurological and hepatological conditions have remained stable on zinc gluconate. His most recent ALT and AST were 52 U/L (range: 0–41 U/L) and 38 U/L (0 – 40 U/L), respectively.<table-wrap position=""float"" id=""t0005""><label>Table 1</label><caption><p>Serial Laboratory Testing.</p></caption><table frame=""hsides"" rules=""groups""><thead><tr><th><bold>Date</bold></th><th><bold>Therapy</bold></th><th><bold>24 hr urine",2_10,Zinc gluconate for Wilson disease,05 10 2024,,Wilson_Disease
hr urine copper</bold></th><th><bold>24 hr urine zinc</bold></th><th><bold>24 hr urine creatinine</bold></th><th><bold>Serum creatinine</bold></th><th><bold>Urine creatinine</bold></th></tr></thead><tbody><tr><td>06FEB2024</td><td>zinc gluconate</td><td>74 µg/24hr<break></break>(9–71 ug/24hr)</td><td>3759 µg/24hr<break></break></td><td>*NA</td><td>NA</td><td>NA</td></tr><tr><td>21APR2023</td><td>zinc gluconate</td><td>99 µg/24,2_11,Zinc gluconate for Wilson disease,05 10 2024,,Wilson_Disease
gluconate</td><td>99 µg/24 hr<break></break>(9–71 µg/24hr)</td><td>3165 µg/24hr</td><td>1.69 g/24hr<break></break>(0.98 – 2.20 g/24hr)</td><td>1.31 mg/dl (0.67 – 1.17 mg/dl)</td><td>77.9 mg/dl</td></tr><tr><td>15JUL2021</td><td>zinc<break></break>acetate</td><td>140 µg/24 hr<break></break>(9–71 ug/24hr)</td><td>2832 µg/24hr</td><td>NA</td><td>1.34 mg/dl (0.67–1.17)</td><td>74.0 mg/dl</td></tr><tr><td>23DEC2020</td><td>zinc<break></break>acetate</td><td>180 µg/24,2_12,Zinc gluconate for Wilson disease,05 10 2024,,Wilson_Disease
"hr<break></break>(9–71 µg/24hr)</td><td>NA</td><td>2.43 g/24hr<break></break>(0.98 – 2.20 g/24hr)</td><td>1.36 mg/dl (0.67–1.17 mg/dl)</td><td>NA</td></tr><tr><td>04APR2019</td><td>zinc<break></break>acetate</td><td>173 µg/24 hr<break></break>(3 – 35 µg/24 h)</td><td>2756 µg/24 hr</td><td>2.026 g /24 hr<break></break>(1.0 – 2.0 g/24hr)</td><td>NA</td><td>64.4 mg/dl</td></tr></tbody></table><table-wrap-foot><fn><p>*NA, not acquired.</p></fn></table-wrap-foot></table-wrap> Zinc may be used as first-line",2_13,Zinc gluconate for Wilson disease,05 10 2024,,Wilson_Disease
"Zinc may be used as first-line therapy for patients with Wilson disease, particularly in asymptomatic or minimally symptomatic patients <xref rid=""b0020"" ref-type=""bibr"">[4]</xref>. Zinc is commonly used for maintenance therapy. In the context of Wilson disease, zinc works by inducing synthesis of metallothionein in enterocytes and inhibiting the absorption of copper <xref rid=""b0025"" ref-type=""bibr"">[5]</xref>. Recent guidelines do not address potential differences in side effects among the various zinc",2_14,Zinc gluconate for Wilson disease,05 10 2024,,Wilson_Disease
"in side effects among the various zinc salts <xref rid=""b0020"" ref-type=""bibr"">[4]</xref>. Moreover, clinicians should be aware that the bioaccessibility of zinc in dietary supplements may show significant variability <xref rid=""b0030"" ref-type=""bibr"">[6]</xref>. The Wilson Disease Association (<ext-link ext-link-type=""uri"" http://www.w3.org/1999/xlink href=""https://www.wilsondisease.org"" id=""ir025"">https://www.wilsondisease.org</ext-link>) reports that zinc gluconate is “friendlier on the stomach” and",2_15,Zinc gluconate for Wilson disease,05 10 2024,,Wilson_Disease
"zinc gluconate is “friendlier on the stomach” and provides a link to Gluzin<sup>TM</sup> (50 mg zinc gluconate, $27.99/60 capsules, 18AUG2024). Compliance with zinc therapy is critical and the potential for reduced side effects with zinc gluconate should be expected to improve long-term outcomes. Long-term prospective controlled studies comparing the efficacy and tolerability of zinc acetate and zinc gluconate have not been completed. A randomized intervention study showed that zinc gluconate was",2_16,Zinc gluconate for Wilson disease,05 10 2024,,Wilson_Disease
"intervention study showed that zinc gluconate was non-inferior to zinc acetate in reducing hepatic copper content after 4 weeks of therapy <xref rid=""b0035"" ref-type=""bibr"">[7]</xref>. In summary, zinc gluconate is a viable treatment option for patients with Wilson disease and, like zinc acetate, should be dosed TID <xref rid=""b0035"" ref-type=""bibr"">[7]</xref>. Brewer and colleages have shown that the minimum effective dosage of zinc is 25 mg administered TID <xref rid=""b0005"" ref-type=""bibr"">[1]</xref>.",2_17,Zinc gluconate for Wilson disease,05 10 2024,,Wilson_Disease
"TID <xref rid=""b0005"" ref-type=""bibr"">[1]</xref>. Once daily dosing is significantly less effective than BID dosing and TID dosing is commonly used to provide a margin of safety for noncompliance <xref rid=""b0040"" ref-type=""bibr"">[8]</xref>. Along with serial neurological examinations and laboratory testing of liver function, urine copper and zinc levels should be monitored during the course of zinc therapy and within a few months of switching zinc formulations. In this regard, there is no guarantee that",2_18,Zinc gluconate for Wilson disease,05 10 2024,,Wilson_Disease
"In this regard, there is no guarantee that product bioaccessibility for supplements will remain consistent over time. Dr. LeDoux has been a consultant for USWorldMeds, Teva Pharmaceutical Industries, and Supernus; speaker for Teva Pharmaceutical Industries amd Amneal Pharmaceuticals; and receives publishing royalties from Elsevier (Animal Models of Movement Disorders, and Movement Disorders: Genetics and Models) and TheBookPatch (Parkinson’s Disease Poetry). Dr. LeDoux’s research has been funded by the",2_19,Zinc gluconate for Wilson disease,05 10 2024,,Wilson_Disease
"Dr. LeDoux’s research has been funded by the National Institutes of Health, Teva Pharmaceutical Industries, Pharma Two B, Revance, Cerevel, Cerevance, Aeon, UCB Pharma, Inhibikinase Therapeutics, Scion, Intracellular Therapeutics, Sage Therapeutics, Neurocrine, Department of Defense, Dystonia Medical Research Foundation, and Benign Essential Tremor Research Foundation. The subject of this case report provided written informed consent for publication of his clinical history, radiographic images, and video.",2_20,Zinc gluconate for Wilson disease,05 10 2024,,Wilson_Disease
"clinical history, radiographic images, and video. Dr. LeDoux was funded by the National Institutes of Health (R21NS123827, R56NS123059), Department of Defense, Dystonia Medical Research Foundation, and Benign Essential Blepharospasm Research Foundation. The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.",2_21,Zinc gluconate for Wilson disease,05 10 2024,,Wilson_Disease
"Epidemiology of Wilson disease in Germany – real-world insights from a claims data study Wilson disease (WD) is a rare autosomal recessive disorder of copper metabolism [<xref ref-type=""bibr"" rid=""CR1"">1</xref>], caused by biallelic mutations in homo- or compound heterozygous states in the <italic toggle=""yes"">ATP7B</italic> gene [<xref ref-type=""bibr"" rid=""CR2"">2</xref>, <xref ref-type=""bibr"" rid=""CR3"">3</xref>]. While copper is usually metabolized by hepatocytes or excreted via bile into feces when",3_0,Epidemiology of Wilson disease in Germany – real-world insights from a claims data study,11 9 2024,,Wilson_Disease
"hepatocytes or excreted via bile into feces when present in excess, copper will accumulate in WD patients, mostly in the liver and the brain, although other organs may be affected as well [<xref ref-type=""bibr"" rid=""CR4"">4</xref>, <xref ref-type=""bibr"" rid=""CR5"">5</xref>]. Depending on the severity and the organs involved, the build-up of copper can lead to a rather broad variety of manifestations, such as liver disease, renal tubular acidosis, or movement or cognitive disorders. Deposition of copper in",3_1,Epidemiology of Wilson disease in Germany – real-world insights from a claims data study,11 9 2024,,Wilson_Disease
"or cognitive disorders. Deposition of copper in the Desçemet’s membrane may lead to Kayser-Fleischer rings, which are present in about 50% of WD patients with liver disease and almost all patients with neurologic or psychiatric manifestation of WD [<xref ref-type=""bibr"" rid=""CR5"">5</xref>]. A diagnosis of WD may be made with the combined presence of Kayser–Fleischer rings and low serum ceruloplasmin level (< 0.1 g/L) [<xref ref-type=""bibr"" rid=""CR6"">6</xref>]. The disease is currently not curable, but it",3_2,Epidemiology of Wilson disease in Germany – real-world insights from a claims data study,11 9 2024,,Wilson_Disease
"The disease is currently not curable, but it is well manageable with a copper-restrictive diet and pharmacological treatment to minimize the build-up of copper. Usually, treatment consists of chelators (such as D-penicillamine or trientine) to promote the renal excretion of copper, and zinc to block intestinal copper absorption [<xref ref-type=""bibr"" rid=""CR5"">5</xref>, <xref ref-type=""bibr"" rid=""CR7"">7</xref>]. Due to the variation in the organs affected and the accompanying symptoms, symptomatic WD can",3_3,Epidemiology of Wilson disease in Germany – real-world insights from a claims data study,11 9 2024,,Wilson_Disease
"and the accompanying symptoms, symptomatic WD can be categorized into three main overlapping subtypes according to the cardinal symptoms: hepatic, neurologic, and/or psychiatric. Neurologic manifestations in particular can lead to severe disability as patients may experience increasing difficulty in controlling movement or progressive dystonia [<xref ref-type=""bibr"" rid=""CR6"">6</xref>]. Despite the availability of treatment options, subpar adherence to the treatment has been reported especially in",3_4,Epidemiology of Wilson disease in Germany – real-world insights from a claims data study,11 9 2024,,Wilson_Disease
"to the treatment has been reported especially in pediatric and asymptomatic patients [<xref ref-type=""bibr"" rid=""CR8"">8</xref>]. Considering the potentially fatal risks of insufficient treatment, disease awareness to increase adherence is critical [<xref ref-type=""bibr"" rid=""CR8"">8</xref>, <xref ref-type=""bibr"" rid=""CR9"">9</xref>]. WD is considered a rare disease: besides regional exceptions [<xref ref-type=""bibr"" rid=""CR10"">10</xref>], the prevalence of WD is estimated around 20 to 33.3 patients per",3_5,Epidemiology of Wilson disease in Germany – real-world insights from a claims data study,11 9 2024,,Wilson_Disease
"of WD is estimated around 20 to 33.3 patients per million in the United States, Europe and Asia [<xref ref-type=""bibr"" rid=""CR11"">11</xref>], although prevalence data on national levels vary with regard to region and time period [<xref ref-type=""bibr"" rid=""CR12"">12</xref>–<xref ref-type=""bibr"" rid=""CR15"">15</xref>]. Also, considering the broad range of subtypes and associated symptoms, more detailed assessments regarding epidemiology are needed for a better understanding of the patient population and to",3_6,Epidemiology of Wilson disease in Germany – real-world insights from a claims data study,11 9 2024,,Wilson_Disease
"understanding of the patient population and to improve disease management. For Germany, recent publications have addressed the treatment of WD [<xref ref-type=""bibr"" rid=""CR16"">16</xref>] and estimated prevalence to be around 16.7 patients per million [<xref ref-type=""bibr"" rid=""CR17"">17</xref>]. We aim to complement and update these findings with more comprehensive data from an observational and representative claims-based study by assessing patient characteristics and epidemiology of WD in Germany.    In",3_7,Epidemiology of Wilson disease in Germany – real-world insights from a claims data study,11 9 2024,,Wilson_Disease
"and epidemiology of WD in Germany.    In summary, this study adds valuable real-world data on the prevalence and patient characteristics of WD in Germany. Generally, our findings align with other reports and contribute to the global understanding of WD epidemiology. Still, regional and temporal trends remain to be investigated more thoroughly to further the understanding of the natural history and epidemiology of this rare disease.",3_8,Epidemiology of Wilson disease in Germany – real-world insights from a claims data study,11 9 2024,,Wilson_Disease
"Unusual Confluence: Exploring the Association of Biliary Atresia, Wilson Disease, and Iron Overload The case involves a 33-year-old man with biliary atresia, Wilson disease (WD), and iron overload. Biliary atresia, a cholangiodestructive disease, leads to cirrhosis if untreated. WD, caused by ATP7B gene mutations, results in copper accumulation affecting the liver and brain. Iron overload can be seen in cases of WD and with hereditary hemochromatosis gene mutations. The patient's concurrent presentation of",4_0,"Unusual Confluence: Exploring the Association of Biliary Atresia, Wilson Disease, and Iron Overload",10 2024,,Wilson_Disease
"The patient's concurrent presentation of these conditions poses a unique clinical challenge. Elevated iron levels may worsen WD outcomes. A detailed history and physical examination, genetic testing, and close follow-up are crucial. The case highlights the need for increased awareness and vigilant monitoring of patients with overlapping liver diseases. Biliary atresia (BA) is a cholangiodestructive disease that affects the biliary tract, leading to cirrhosis, liver failure, and potentially death,",4_1,"Unusual Confluence: Exploring the Association of Biliary Atresia, Wilson Disease, and Iron Overload",10 2024,,Wilson_Disease
"cirrhosis, liver failure, and potentially death, particularly prevalent in Asian countries. Up to 10% of cases may involve congenital anomalies such as splenic or venous malformations. The atresia of extrahepatic and intrahepatic bile ducts in BA obstructs the transport of conjugated bilirubin to the intestine, causing inflammation and cholestatic cirrhosis. Genes such as Adducin 3, Glypican 1, and ADP ribosylation factor 6 have been associated with BA. Early detection within the first 3 months allows for",4_2,"Unusual Confluence: Exploring the Association of Biliary Atresia, Wilson Disease, and Iron Overload",10 2024,,Wilson_Disease
"detection within the first 3 months allows for Kasai hepatoportoenterostomy, offering a chance of survival for half of the affected children after 2 years.<sup><xref rid=""R1"" ref-type=""bibr"">1</xref>–<xref rid=""R4"" ref-type=""bibr"">4</xref></sup> Wilson disease (WD) is an autosomal recessive disorder caused by homozygous or compound heterozygous mutations in the ATP7B gene, which facilitates the transport of copper into bile for the synthesis of ceruloplasmin (CP).<sup><xref rid=""R5""",4_3,"Unusual Confluence: Exploring the Association of Biliary Atresia, Wilson Disease, and Iron Overload",10 2024,,Wilson_Disease
"of ceruloplasmin (CP).<sup><xref rid=""R5"" ref-type=""bibr"">5</xref></sup> This dysfunction leads to copper accumulation in other organs, primarily the liver and the brain, resulting in pathognomonic symptoms.<sup><xref rid=""R6"" ref-type=""bibr"">6</xref></sup> Copper and iron metabolism are interrelated, with copper influencing iron homeostasis positively, while iron antagonizes copper metabolism.<sup><xref rid=""R7"" ref-type=""bibr"">7</xref></sup> Hereditary hemochromatosis (HH) is defined by systemic iron",4_4,"Unusual Confluence: Exploring the Association of Biliary Atresia, Wilson Disease, and Iron Overload",10 2024,,Wilson_Disease
"hemochromatosis (HH) is defined by systemic iron overload (IO) due to genetic mutations of the hereditary hemochromatosis gene (HFE), causing reduced levels of hepcidin or hepcidin-ferroportin binding.<sup><xref rid=""R8"" ref-type=""bibr"">8</xref></sup> The HFE genetic test identifies the most common inherited defect in Whites predisposing to HFE-related HH, that is, p.Cys282Tyr homozygosity. p.Cys282Tyr and p.His63Asp heterozygosity have minimal or no clinical penetrance and is not considered diagnostic for",4_5,"Unusual Confluence: Exploring the Association of Biliary Atresia, Wilson Disease, and Iron Overload",10 2024,,Wilson_Disease
"penetrance and is not considered diagnostic for HH but is associated with mild-to-moderate IO.<sup><xref rid=""R6"" ref-type=""bibr"">6</xref>,<xref rid=""R9"" ref-type=""bibr"">9</xref></sup> This case report describes a 33-year-old man with a history of BA who underwent the Kasai procedure 2 months age. He presented with complaints of abdominal pain, fatigue, dyspnea on exertion, blurry vision, and bilateral lower extremity swelling. Further investigation revealed liver cirrhosis due to WD. The patient had",4_6,"Unusual Confluence: Exploring the Association of Biliary Atresia, Wilson Disease, and Iron Overload",10 2024,,Wilson_Disease
"liver cirrhosis due to WD. The patient had multiple hospital visits for hepatic encephalopathy and abdominal tenderness while on active military duty. Liver biopsy confirmed WD with liver copper levels of 300 ncg (more than 250 ncg). On admission, he had scleral icterus, jaundiced skin with excoriations, and spider angiomas were observed on the chest and abdomen. The slit-lamp examination revealed Kayser-Fleischer rings. He had a 14 cm horizontal laparotomy scar in his right upper quadrant and diffuse",4_7,"Unusual Confluence: Exploring the Association of Biliary Atresia, Wilson Disease, and Iron Overload",10 2024,,Wilson_Disease
"scar in his right upper quadrant and diffuse abdominal tenderness. The significant laboratory results are listed below in Table <xref rid=""T1"" ref-type=""table"">1</xref>. His imaging revealed liver cysts, ruling out hepatocellular carcinoma. His serum CP was low normal at 26 mg/dL, and urine copper levels were elevated at 275 mcg/24 hr. His Leipzig score was greater than 4, establishing a high suspicion of WD. Tests for HH showed positive results for heterozygous mutations of the HFE gene (H63D), and he was",4_8,"Unusual Confluence: Exploring the Association of Biliary Atresia, Wilson Disease, and Iron Overload",10 2024,,Wilson_Disease
"mutations of the HFE gene (H63D), and he was negative for the C282Y pathogenic variant, indicating his carrier status. His ferritin levels were very elevated, greater than 2,000 ng/mL, but he had low transferrin levels and transferrin saturation. His new Wilson Index was 13 (indicating greater mortality without transplant), Model for End-Stage Liver Disease was 40 points (with a 71.3% estimated 3-month mortality), and Child-Pugh was 13 points (with a life expectancy of 1–3 years). The patient has since",4_9,"Unusual Confluence: Exploring the Association of Biliary Atresia, Wilson Disease, and Iron Overload",10 2024,,Wilson_Disease
"expectancy of 1–3 years). The patient has since been readmitted to our facility multiple times for the management of decompensated cirrhosis. He underwent liver transplantation and is currently doing well. Our case provides the first documented instance of clinical correlation between 3 distinct liver diseases, namely BA, WD, and HH. WD typically manifests with isolated liver disease, and diagnosis involves evaluating Kayser-Fleischer rings, serum CP levels, urine copper levels, liver biopsy, and genetic",4_10,"Unusual Confluence: Exploring the Association of Biliary Atresia, Wilson Disease, and Iron Overload",10 2024,,Wilson_Disease
"urine copper levels, liver biopsy, and genetic testing. Neuroimaging is recommended for patients with neurological symptoms.<sup><xref rid=""R10"" ref-type=""bibr"">10</xref></sup> Nguyen Pham Anh Hoa et al reported a case of an 8-year-old Vietnamese girl who suffered from BA as an infant and later was diagnosed with WD, presenting severe symptoms of acute liver failure<sup><xref rid=""R11"" ref-type=""bibr"">11</xref></sup>. The authors identified a homozygous variant in the ATP-binding cassette, sub-family B",4_11,"Unusual Confluence: Exploring the Association of Biliary Atresia, Wilson Disease, and Iron Overload",10 2024,,Wilson_Disease
"variant in the ATP-binding cassette, sub-family B member 11 gene as a precipitator of bile accumulation, responsible for inflammation and destruction of biliary ducts resulting in BA, particularly in the Vietnamese population.<sup><xref rid=""R11"" ref-type=""bibr"">11</xref></sup> The case presented here is unique, involving a Polynesian male with coexisting BA and WD, a scenario not reported in the literature (Figure <xref rid=""F1"" ref-type=""fig"">1</xref>). Extremely elevated iron levels have sporadically",4_12,"Unusual Confluence: Exploring the Association of Biliary Atresia, Wilson Disease, and Iron Overload",10 2024,,Wilson_Disease
"Extremely elevated iron levels have sporadically been described in patients with WD, and phenotypic variability with increased ferritin levels in male patients compared with female patients has been proposed in the background of HFE mutations.<sup><xref rid=""R12"" ref-type=""bibr"">12</xref>,<xref rid=""R13"" ref-type=""bibr"">13</xref></sup> Various copper-dependent enzymes are associated with iron metabolism, the most notable being CP, an iron ferroxidase that also serves as the primary copper transporter in",4_13,"Unusual Confluence: Exploring the Association of Biliary Atresia, Wilson Disease, and Iron Overload",10 2024,,Wilson_Disease
"also serves as the primary copper transporter in the blood. In WD, reduced incorporation of copper into apoceruloplasmin by ATP7B leads to rapid degradation, resulting in decreased cellular secretion of CP and lower serum CP concentrations. This also leads to reduced CP oxidase activity. Consequently, CP-facilitated basolateral iron transport may be impaired in WD. Eventually, this impairment could lead to cellular iron trapping and a subsequently reduced bioavailability of iron.<sup><xref rid=""R13""",4_14,"Unusual Confluence: Exploring the Association of Biliary Atresia, Wilson Disease, and Iron Overload",10 2024,,Wilson_Disease
"bioavailability of iron.<sup><xref rid=""R13"" ref-type=""bibr"">13</xref></sup> Abuzetun et al reported a rare case of HH and WD coexisting, describing similar heterozygous mutations of HH (H63D), while Gromadzka et al conducted a study on the effect of homeostatic iron regulatory protein gene mutations on WD manifestations, finding that 31% of their subjects with WD also had coexisting heterozygous HFE 63HD mutations, with male HFE 63HD heterozygotes showing symptoms of WD slightly earlier than HFE 63HH",4_15,"Unusual Confluence: Exploring the Association of Biliary Atresia, Wilson Disease, and Iron Overload",10 2024,,Wilson_Disease
"symptoms of WD slightly earlier than HFE 63HH homozygotes; our patient exhibits similar findings with a heterozygous HFE 63HD mutation and biopsy-confirmed WD.<sup><xref rid=""R14"" ref-type=""bibr"">14</xref>,<xref rid=""R15"" ref-type=""bibr"">15</xref></sup> As the role of HFE mutations in HH is controversial, IO in our patient may be secondary to WD rather than hemochromatosis. Elevated iron levels may lead to worse outcomes in patients with WD due to iron accumulation in the liver or brain (putamen and globus",4_16,"Unusual Confluence: Exploring the Association of Biliary Atresia, Wilson Disease, and Iron Overload",10 2024,,Wilson_Disease
"in the liver or brain (putamen and globus pallidus), worsening the overall prognosis.<sup><xref rid=""R15"" ref-type=""bibr"">15</xref>–<xref rid=""R17"" ref-type=""bibr"">17</xref></sup> A lower threshold of Model for End-Stage Liver Disease scores for liver transplant consideration is required in patients with WD and coexisting HH mutations. WD requires a thorough evaluation involving history, physical examination, and various tests for a definitive diagnosis. For children diagnosed with BA, close follow-up and",4_17,"Unusual Confluence: Exploring the Association of Biliary Atresia, Wilson Disease, and Iron Overload",10 2024,,Wilson_Disease
"children diagnosed with BA, close follow-up and genetic workup for liver diseases such as WD and HH are recommended to prevent later complications. Concurrent liver diseases can worsen the prognosis, leading to rapid liver failure in young individuals. Clinicians are urged to remain vigilant for such associations, as timely treatment is crucial to avoid serious consequences for the patient. Author contributions: This paper was conceptualized by S. Duggal, S. Meza-Rodriguez, and S. Shahid. The investigation",4_18,"Unusual Confluence: Exploring the Association of Biliary Atresia, Wilson Disease, and Iron Overload",10 2024,,Wilson_Disease
"Meza-Rodriguez, and S. Shahid. The investigation and review of relevant data and articles done by S. Duggal, S. Meza-Rodriguez, and S. Shahid. Case analysis was done by S. Duggal, SMR, and S. Shahid. The original draft was written by S. Duggal, S. Meza-Rodriguez, and S. Shahid. Review and editing were done by M Zuckerman and JC Borges. All authors discussed the findings described in the case and approved the final manuscript. JC Borges is article guarantor. Financial disclosure: None to report. Informed",4_19,"Unusual Confluence: Exploring the Association of Biliary Atresia, Wilson Disease, and Iron Overload",10 2024,,Wilson_Disease
Financial disclosure: None to report. Informed consent was obtained for this case report.,4_20,"Unusual Confluence: Exploring the Association of Biliary Atresia, Wilson Disease, and Iron Overload",10 2024,,Wilson_Disease
"Structural lesions and transcriptomic specializations shape gradient perturbations in Wilson disease Functional dysregulations in multiple regions are caused by excessive copper deposition in the brain in Wilson disease (WD) patients. The genetic mechanism of WD is thought to involve the abnormal expression of <italic toggle=""yes"">ATP7B</italic> in the liver, whereas the biological and molecular processes involved in functional dysregulation within the brain remain unexplored. The objective of this study",5_0,Structural lesions and transcriptomic specializations shape gradient perturbations in Wilson disease,2024,,Wilson_Disease
"remain unexplored. The objective of this study was to unravel the underpinnings of functional gradient perturbations underlying structural lesions and transcriptomic specializations in WD. In this study, we included 105 WD patients and 93 healthy controls who underwent structural and functional MRI assessments. We used the diffusion mapping embedding model to derive the functional connectome gradient and further employed gray matter volume to uncover structure–function decoupling for WD. Then, we used",5_1,Structural lesions and transcriptomic specializations shape gradient perturbations in Wilson disease,2024,,Wilson_Disease
"decoupling for WD. Then, we used Neurosynth, clinical data, and whole-brain gene expression data to examine the meta-analytic cognitive function, clinical phenotypes, and transcriptomic specializations related to WD gradient alterations. Compared with controls, WD patients exhibited global topographic changes in the principal pramary-to-transmodal gradient. Meta-analytic terms and clinical characteristics were correlated with these gradient alterations in motor-related processing, higher-order cognition,",5_2,Structural lesions and transcriptomic specializations shape gradient perturbations in Wilson disease,2024,,Wilson_Disease
"motor-related processing, higher-order cognition, neurological symptoms, and age. Spatial correlations revealed structure–function decoupling in multiple networks, especially in subcortical and visual networks. Within the cortex, the spatial association between gradient alterations and gene expression profiles has revealed transcriptomic specilizations in WD that display properties indicative of ion homeostasis, neural development, and motor control. Furthermore, for the first time, we characterized the",5_3,Structural lesions and transcriptomic specializations shape gradient perturbations in Wilson disease,2024,,Wilson_Disease
"for the first time, we characterized the role of the <italic toggle=""yes"">ATP7B</italic> gene in impacting subcortical function. The transcriptomic specializations of WD were also associated with other neurological and psychiatric disorders. Finally, we revealed that structural lesions and gradient perturbations may share similar transcriptomic specializations in WD. In conclusion, these findings bridged functional gradient perturbations to structural lesions and gene expression profiles in WD patients,",5_4,Structural lesions and transcriptomic specializations shape gradient perturbations in Wilson disease,2024,,Wilson_Disease
"and gene expression profiles in WD patients, possibly promoting our understanding of the neurobiological mechanisms underlying the emergence of complex neurological and psychiatric phenotypes. Hu et al. report functional gradient perturbation in Wilson disease. Association analysis between gradient perturbation and transcriptional data reveals that the ATP7B gene is for the first time identified to impact on subcortical function. Further spatial correlation analysis suggests gradient perturbation sharing",5_5,Structural lesions and transcriptomic specializations shape gradient perturbations in Wilson disease,2024,,Wilson_Disease
analysis suggests gradient perturbation sharing similar transcriptional specializations with structural lesions.,5_6,Structural lesions and transcriptomic specializations shape gradient perturbations in Wilson disease,2024,,Wilson_Disease
"<fig position=""anchor"" id=""fcae329_ga""><label>Graphical Abstract</label><graphic http://www.w3.org/1999/xlink href=""fcae329_ga"" position=""float""></graphic></fig>",5_7,Structural lesions and transcriptomic specializations shape gradient perturbations in Wilson disease,2024,,Wilson_Disease
"Wilson disease (WD) is an autosomal recessive disorder of copper metabolism caused by a lack of biliary copper excretion.<sup><xref rid=""fcae329-B1"" ref-type=""bibr"">1</xref></sup> Mutation of the <italic toggle=""yes"">ATP7B</italic> gene, which is most highly expressed in the liver, results in the absence and reduced expression of the <italic toggle=""yes"">ATP7B</italic> protein, identifying it as causative of copper dysmetabolism.<sup><xref rid=""fcae329-B2"" ref-type=""bibr"">2</xref></sup> Excessive copper",5_8,Structural lesions and transcriptomic specializations shape gradient perturbations in Wilson disease,2024,,Wilson_Disease
"ref-type=""bibr"">2</xref></sup> Excessive copper accumulation in the liver and brain ultimately leads to neurological and psychiatric phenotypes in WD patients.<sup><xref rid=""fcae329-B3"" ref-type=""bibr"">3</xref></sup> However, in an animal model of WD, <italic toggle=""yes"">ATP7B</italic> is also expressed in neuronal cells of the hippocampus, olfactory bulbs, cerebellum, brainstem, and cerebral cortex. The concurrent high levels of copper in these regions further indicated that dysfunctional <italic",5_9,Structural lesions and transcriptomic specializations shape gradient perturbations in Wilson disease,2024,,Wilson_Disease
"further indicated that dysfunctional <italic toggle=""yes"">ATP7B</italic> protein is related to local copper accumulation and the cerebral manifestations of WD.<sup><xref rid=""fcae329-B4"" ref-type=""bibr"">4</xref></sup> The toxic effect of copper results in damaged astrocytes, neurons, and oligodendrocytes, which gradually develop structural lesions, especially in subcortical regions (SUB), including the basal ganglia, thalamus, and brainstem.<sup><xref rid=""fcae329-B5"" ref-type=""bibr"">5</xref>,<xref",5_10,Structural lesions and transcriptomic specializations shape gradient perturbations in Wilson disease,2024,,Wilson_Disease
"rid=""fcae329-B5"" ref-type=""bibr"">5</xref>,<xref rid=""fcae329-B6"" ref-type=""bibr"">6</xref></sup> Notably, multimodal MRI studies revealed functional abnormalities across the entire brain and structure–function decoupling in WD patients.<sup><xref rid=""fcae329-B7"" ref-type=""bibr"">7</xref>,<xref rid=""fcae329-B8"" ref-type=""bibr"">8</xref></sup> Furthermore, defective cortical function may be due to dysfunction of cortio-subcortical pathways, leading to neurological and psychiatric symptoms in WD",5_11,Structural lesions and transcriptomic specializations shape gradient perturbations in Wilson disease,2024,,Wilson_Disease
"to neurological and psychiatric symptoms in WD patients.<sup><xref rid=""fcae329-B9"" ref-type=""bibr"">9</xref>,<xref rid=""fcae329-B10"" ref-type=""bibr"">10</xref></sup> However, the neurobiological mechanisms underlying brain dysfunction remain to be elucidated. Given that genes have an essential influence on brain function,<sup><xref rid=""fcae329-B11"" ref-type=""bibr"">11</xref></sup> brain dysfunction in WD may also be shaped by specific mutated genes, such as <italic toggle=""yes"">ATP7B</italic>. Moreover,",5_12,Structural lesions and transcriptomic specializations shape gradient perturbations in Wilson disease,2024,,Wilson_Disease
"as <italic toggle=""yes"">ATP7B</italic>. Moreover, considering the variability of gene expression profiles across the entire brain, such as the cortex and SUB,<sup><xref rid=""fcae329-B12"" ref-type=""bibr"">12</xref></sup> their relation to the WD topology of dysfunction may provide insights into the neurobiological pathways contributing to the neurological pathogenesis of WD. Brain hierarchical theories revealed that functional connectome patterns are governed by the graded macroscale axis that spans the",5_13,Structural lesions and transcriptomic specializations shape gradient perturbations in Wilson disease,2024,,Wilson_Disease
"by the graded macroscale axis that spans the primary sensorimotor areas to transmodal regions of the default mode network (DMN).<sup><xref rid=""fcae329-B13"" ref-type=""bibr"">13</xref></sup> Perturbation in these patterns shapes clinical phenotypes, such as perception, cognition, and neurological symptoms, in multiple neurodegenerative diseases.<sup><xref rid=""fcae329-B14"" ref-type=""bibr"">14</xref>,<xref rid=""fcae329-B15"" ref-type=""bibr"">15</xref></sup> Furthermore, the macroscale axis of the cortex is also",5_14,Structural lesions and transcriptomic specializations shape gradient perturbations in Wilson disease,2024,,Wilson_Disease
"the macroscale axis of the cortex is also intrinsic to gene expression and microstructural topography, indicating that the functional basis strongly depends on intact gene expression and microstructural profiles.<sup><xref rid=""fcae329-B12"" ref-type=""bibr"">12</xref></sup> Although many studies have revealed alterations in functional connectivity (FC) involving the basal ganglia, sensorimotor, and DMN regions in patients with WD,<sup><xref rid=""fcae329-B7"" ref-type=""bibr"">7</xref>,<xref rid=""fcae329-B8""",5_15,Structural lesions and transcriptomic specializations shape gradient perturbations in Wilson disease,2024,,Wilson_Disease
"ref-type=""bibr"">7</xref>,<xref rid=""fcae329-B8"" ref-type=""bibr"">8</xref>,<xref rid=""fcae329-B16"" ref-type=""bibr"">16</xref></sup> no studies have reported whether and how these alterations are affected by structural and transcriptomic vulnerability. Therefore, if WD patients exhibit perturbations in the functional hierarchy, these abnormalities might be associated with gene expression and structural topography. The illustration of such alterations would provide complementary insights into the structural and",5_16,Structural lesions and transcriptomic specializations shape gradient perturbations in Wilson disease,2024,,Wilson_Disease
"complementary insights into the structural and molecular genetic underpinnings of the dysfunctional hierarchy in WD. Functional connectome patterns are facilitated by decomposing FC data into different gradients to capture the topography of the connectome.<sup><xref rid=""fcae329-B17"" ref-type=""bibr"">17</xref></sup> Such a principal functional gradient is present in the macroscale organization of functional brain networks, reflecting the hierarchical macroscale axis.<sup><xref rid=""fcae329-B13""",5_17,Structural lesions and transcriptomic specializations shape gradient perturbations in Wilson disease,2024,,Wilson_Disease
"macroscale axis.<sup><xref rid=""fcae329-B13"" ref-type=""bibr"">13</xref></sup> This study aimed to investigate the structural and genetic underpinnings of functional hierarchical perturbation in WD. For this purpose, we mapped the functional gradient using functional MRI and determined the perturbation of the hierarchical macroscale axis of the WD. Then, the gray matter volume (GV) evaluated by 3D high-resolution MRI was used to perform a spatial correlation analysis, revealing whether structure–function is",5_18,Structural lesions and transcriptomic specializations shape gradient perturbations in Wilson disease,2024,,Wilson_Disease
"analysis, revealing whether structure–function is decoupled in WD. Moreover, we calculated the spatial correlation of the connectome gradient perturbation with whole-brain gene expression data from the Allen Human Brain Atlas<sup><xref rid=""fcae329-B18"" ref-type=""bibr"">18</xref></sup> (AHBA) and further examined whether structural lesions and gradient perturbations are mediated by similar transcriptomic specializations. Gene enrichment analysis was finally used to probe transcriptomic associations for",5_19,Structural lesions and transcriptomic specializations shape gradient perturbations in Wilson disease,2024,,Wilson_Disease
"used to probe transcriptomic associations for known pathogenic WD variants, as well as other neurological and psychiatric disorders.   Macroscale hierarchy has been widely regarded as a key principle of brain organization that spans from primary to transmodal networks.<sup><xref rid=""fcae329-B13"" ref-type=""bibr"">13</xref></sup> Hierarchical representations account for the spatial arrangement of local processing streams throughout the cerebral cortex, ensuring that sensory signals are progressively",5_20,Structural lesions and transcriptomic specializations shape gradient perturbations in Wilson disease,2024,,Wilson_Disease
"ensuring that sensory signals are progressively integrated as abstract representations.<sup><xref rid=""fcae329-B17"" ref-type=""bibr"">17</xref></sup> According to the hierarchical theory, both WD patients and HCs revealed that principal functional gradient mapping captured the macroscale axis of connectivity variations, with the primary network and transmodal DMN anchored at two opposite ends and the remaining networks emerging between them.<sup><xref rid=""fcae329-B17"" ref-type=""bibr"">17</xref></sup> Since",5_21,Structural lesions and transcriptomic specializations shape gradient perturbations in Wilson disease,2024,,Wilson_Disease
"ref-type=""bibr"">17</xref></sup> Since WD has been clinically characterized as a disorder with multiple neurological and psychiatric phenotypes,<sup><xref rid=""fcae329-B35"" ref-type=""bibr"">35</xref></sup> it may result in errors in information flow from sensorimotor to cognitive processing. Therefore, the principal gradient of WD was globally suppressed at both ends compared with that of HC in the present study. Notably, VBM analysis also illustrated that in WD, GV significantly decreased in multiple",5_22,Structural lesions and transcriptomic specializations shape gradient perturbations in Wilson disease,2024,,Wilson_Disease
"in WD, GV significantly decreased in multiple systems, including the SMN, VIS, and transmodal areas. Further spatial correlations between the gradient and GV revealed structure–function decoupling in the VIS, VAN, and SUB, suggesting that hierarchical imbalances might be derived from structural alterations in the WD. At the regional level, patients with WD exhibited increased gradient scores in primary systems such as the SMA and V1 and decreased scores in transmodal regions, including the mTP and mPFC.",5_23,Structural lesions and transcriptomic specializations shape gradient perturbations in Wilson disease,2024,,Wilson_Disease
"transmodal regions, including the mTP and mPFC. Consistent with the present study, WD-related abnormalities in intrinsic brain activity in the SMN and VN have been highlighted in RS-fMRI<sup><xref rid=""fcae329-B8"" ref-type=""bibr"">8</xref></sup> and tomography-electrophysiology studies.<sup><xref rid=""fcae329-B36"" ref-type=""bibr"">36</xref></sup> Generally, an important role of the SMA and V1 in motor control and visual processing has been identified in the motor and visual systems, particularly for postural",5_24,Structural lesions and transcriptomic specializations shape gradient perturbations in Wilson disease,2024,,Wilson_Disease
"and visual systems, particularly for postural stabilization of the body and spatial recognition.<sup><xref rid=""fcae329-B37"" ref-type=""bibr"">37-40</xref></sup> Moreover, cortical thickness damage in these regions was also reported to be correlated with neurological symptoms in WD patients.<sup><xref rid=""fcae329-B41"" ref-type=""bibr"">41</xref></sup> Thus, these findings indicated that gradient imbalances in the SMA and VN contribute to neurological symptoms in WD patients, such as dyskinesia. On the other",5_25,Structural lesions and transcriptomic specializations shape gradient perturbations in Wilson disease,2024,,Wilson_Disease
"in WD patients, such as dyskinesia. On the other hand, DMN areas, such as the mPFC and mTP, are thought to be involved in several different functions, such as self-referential and introspective cognition as well as mentalizing.<sup><xref rid=""fcae329-B42"" ref-type=""bibr"">42</xref>,<xref rid=""fcae329-B43"" ref-type=""bibr"">43</xref></sup> Dysfunction in these regions may lead to neuropsychological and attention network deficits in patients with WD.<sup><xref rid=""fcae329-B9"" ref-type=""bibr"">9</xref>,<xref",5_26,Structural lesions and transcriptomic specializations shape gradient perturbations in Wilson disease,2024,,Wilson_Disease
"rid=""fcae329-B9"" ref-type=""bibr"">9</xref>,<xref rid=""fcae329-B44"" ref-type=""bibr"">44</xref></sup> Thus, gradient perturbations in the DMN may result in neuropsychological symptoms in WD patients. Notably, our meta-analysis revealed that increased WD-related gradient scores are primarily involved in low-level sensory and motor-related processes, while decreased gradient scores are more strongly associated with higher-order cognitive function. Thus, these findings suggested that the imbalance in the",5_27,Structural lesions and transcriptomic specializations shape gradient perturbations in Wilson disease,2024,,Wilson_Disease
"findings suggested that the imbalance in the functional hierarchy might arise from the disorder of local processing streams from primary to transmodal systems within the cerebral cortex of WD patients. In addition, our results also showed increased gradient scores in SUB, such as in the putamen and thalamus, in WD patients. Due to the impaired regions leading to disrupted networks,<sup><xref rid=""fcae329-B16"" ref-type=""bibr"">16</xref></sup> the interactions among SUB and between subcortical-cortical",5_28,Structural lesions and transcriptomic specializations shape gradient perturbations in Wilson disease,2024,,Wilson_Disease
"among SUB and between subcortical-cortical networks could impact the topology of the subcortical macroscale connectome in WD patients. Furthermore, recent studies have reported that connectivity among SUB was strongly associated with deficits in neurological symptoms,<sup><xref rid=""fcae329-B45"" ref-type=""bibr"">45</xref></sup> and the subcortical-cortical pathways were related to neuropsychological disorders in WD patients.<sup><xref rid=""fcae329-B9"" ref-type=""bibr"">9</xref></sup> In this context, the",5_29,Structural lesions and transcriptomic specializations shape gradient perturbations in Wilson disease,2024,,Wilson_Disease
"In this context, the relationships between the primary gradients and UWDRS-N were mediated by GV alteration, indicating that structural vulnerability impacts the macroscale hierarchy and ultimately leads to deficits in the WD phenotype. We identified the spatial association between the perturbations in the connectome gradient and gene expression profiles to determine the transcriptomic specialization of WD. Within the cortex, PLS-1 mediated the regulation of ion transmembrane transport, metal ion",5_30,Structural lesions and transcriptomic specializations shape gradient perturbations in Wilson disease,2024,,Wilson_Disease
"of ion transmembrane transport, metal ion transport, and transporter activity. In biology, the transporter is a transmembrane protein that moves ions across biological membranes to accomplish different biological functions, such as cellular communication and maintaining homeostasis.<sup><xref rid=""fcae329-B46"" ref-type=""bibr"">46</xref></sup> Ion transport is a biological process in which ions are transported along a concentration gradient from high to low concentrations.<sup><xref rid=""fcae329-B47""",5_31,Structural lesions and transcriptomic specializations shape gradient perturbations in Wilson disease,2024,,Wilson_Disease
"low concentrations.<sup><xref rid=""fcae329-B47"" ref-type=""bibr"">47</xref></sup> Thus, these findings may reflect the biological mechanism of abnormal copper ion metabolism in WD patients. Moreover, PLS-2 within the cortex also mediated the regulation of ion transmembrane transport and ion gated channel activity but more strongly reflected the regulation of neuron projection development and axon development, as well as a muscle system process. Neuronal projection is any process extending from a neural cell,",5_32,Structural lesions and transcriptomic specializations shape gradient perturbations in Wilson disease,2024,,Wilson_Disease
"is any process extending from a neural cell, such as axons and dendrites. Its development progresses from neural formation to mature structure<sup><xref rid=""fcae329-B48"" ref-type=""bibr"">48</xref></sup> and promotes neuron differentiation.<sup><xref rid=""fcae329-B49"" ref-type=""bibr"">49</xref></sup> The muscle system in vertebrates is controlled through the nervous system, and its impairment leads to different movement disorders.<sup><xref rid=""fcae329-B50"" ref-type=""bibr"">50</xref></sup> Indeed, WD is a",5_33,Structural lesions and transcriptomic specializations shape gradient perturbations in Wilson disease,2024,,Wilson_Disease
"ref-type=""bibr"">50</xref></sup> Indeed, WD is a disorder of copper transport within the cell resulting in copper accumulation in the brain,<sup><xref rid=""fcae329-B51"" ref-type=""bibr"">51</xref></sup> which may trigger abnormal degeneration of neurons. Therefore, PLS-1 likely represents biological mechanisms underlying ion homeostasis inside and outside nerve cells, while PLS-2 was more strongly associated with neural organization and cell growth as well as controlling muscle signaling. Furthermore,",5_34,Structural lesions and transcriptomic specializations shape gradient perturbations in Wilson disease,2024,,Wilson_Disease
"as controlling muscle signaling. Furthermore, transcriptomic specilizations of WD have also been reported to be associated with risk genes for schizophrenia, depression and Parkinson’s disease, which may explain why WD patients present multiple complex neurological and psychiatric symptoms at the biological level. Within SUB, we demonstrated that PLS-1 was associated with the WD pathogenic gene, which indicates that the <italic toggle=""yes"">ATP7B</italic> gene has lower expression in SUB. Thus, for the",5_35,Structural lesions and transcriptomic specializations shape gradient perturbations in Wilson disease,2024,,Wilson_Disease
"gene has lower expression in SUB. Thus, for the first time, we provided evidence that WD pathogenic genes impact subcortical function in WD patients. Within SUB, transcriptomic specilization identified by PLS-1 and PLS-2 was associated with risk genes for schizophrenia and Alzheimer’s disease. Consistent with our results, recent studies have reported that the risk genes for schizophrenia<sup><xref rid=""fcae329-B52"" ref-type=""bibr"">52</xref></sup> and Alzheimer’s disease<sup><xref rid=""fcae329-B53""",5_36,Structural lesions and transcriptomic specializations shape gradient perturbations in Wilson disease,2024,,Wilson_Disease
"Alzheimer’s disease<sup><xref rid=""fcae329-B53"" ref-type=""bibr"">53</xref></sup> are significantly associated with subcortical dysfunction. Therefore, these findings demonstrated that functional gradient perturbations in SUB also contribute to complex neurological or psychiatric symptoms. Notably, we found that the spatial pattern of GV alterations is negatively related to that of PLS-1 score in SUB. However, GV alterations had a positive spatial correlation with PLS-1 in the cortex. This might be",5_37,Structural lesions and transcriptomic specializations shape gradient perturbations in Wilson disease,2024,,Wilson_Disease
"with PLS-1 in the cortex. This might be attributed to differences in gene expression in the cerebral cortex and SUB.<sup><xref rid=""fcae329-B54"" ref-type=""bibr"">54</xref></sup> Collectively, the present findings indicate that GV impairments and gradient perturbations might be shapped by similar transcriptomic specializations. The findings must be interpreted in the context of potential limitations. First, gene sets from AHBA were sampled from a small sample of donors. Therefore, in the PLS analysis, the",5_38,Structural lesions and transcriptomic specializations shape gradient perturbations in Wilson disease,2024,,Wilson_Disease
"of donors. Therefore, in the PLS analysis, the associations between the connectome gradient and gene expression were susceptible to intersubject variability. On the other hand, all the gene samples were not from the brains of patients with WD. Therefore, the spatial correlation between gradient changes and transcriptomic data cannot directly reflect how connectome gradient purturbation is affected by transcriptional abnormalities in WD. In the future, a larger sample of whole-brain gene expression data",5_39,Structural lesions and transcriptomic specializations shape gradient perturbations in Wilson disease,2024,,Wilson_Disease
"larger sample of whole-brain gene expression data from WD patients is required to represent and validate the relationship between the connectome gradient and transcriptome. Second, the difference in age between the two groups was significant. Although we used age as a covariate in the statistical analysis, we cannot completely eliminate the effect of age on the results. Therefore, in future studies, we will recruit age- and sex-matched healthy subjects to study structural and functional abnormalities in WD",5_40,Structural lesions and transcriptomic specializations shape gradient perturbations in Wilson disease,2024,,Wilson_Disease
"structural and functional abnormalities in WD patients and their relationships with gene expression. Finally, long-term copper deficiency leading to structural changes in the brain has been reported in a previous study,<sup><xref rid=""fcae329-B55"" ref-type=""bibr"">55</xref></sup> which may also result in brain damages in individuals. In future studies, adding patients with copper deficiency phenotype as a comparison will be of great significance to further understand the neural mechanism of WD. This study",5_41,Structural lesions and transcriptomic specializations shape gradient perturbations in Wilson disease,2024,,Wilson_Disease
"understand the neural mechanism of WD. This study revealed gradient perturbations related to cognitive terms and clinical phenotypes in WD patients. Then, we evaluated the associations of the gradient perturbation with specific GV alterations and gene expression profiles. Furthermore, we revealed the biological underpinnings of these gradient-derived gene sets by enrichment analysis. The biological underpinnings were determined by underlying factors, including (1) structure–function is decoupled in WD; (2)",5_42,Structural lesions and transcriptomic specializations shape gradient perturbations in Wilson disease,2024,,Wilson_Disease
"(1) structure–function is decoupled in WD; (2) strong associations between gene expression and gradient differences have identified transcriptomic specializations within both the cortex and SUB of WD; (3) gradient perturbations are implicated in psychiatric and neurological diseases and for the first time characterized the role of <italic toggle=""yes"">ATP7B</italic> in subcortical function; and (4) GV impairments and gradient perturbations were mediated by similar transcriptomic specializations. In",5_43,Structural lesions and transcriptomic specializations shape gradient perturbations in Wilson disease,2024,,Wilson_Disease
"by similar transcriptomic specializations. In summary, these findings reveal the structural and transcriptomic underpinnings of gradient perturbations in WD, providing deep insight into the neurobiological mechanisms underlying the emergence of complex neurological and psychiatric phenotypes in WD patients.",5_44,Structural lesions and transcriptomic specializations shape gradient perturbations in Wilson disease,2024,,Wilson_Disease
"Progressive familial intrahepatic cholestasis 3 Camouflaging as Wilson disease in a 12-year-old: a diagnostic Odyssey  Primary Familial Intrahepatic Cholestasis type 3 is an exceedingly rare genetic cholestatic disorder characterized by the defective hepatocanaliculr bile acid transport leading to progressive liver disease. In this case report, we describe the course of treatment for a 12-year-old kid diagnosed with Wilson disease based on Leipzig score and copper investigations. The child did not improve",6_0,Progressive familial intrahepatic cholestasis 3 Camouflaging as Wilson disease in a 12-year-old: a diagnostic Odyssey ,2024,,Wilson_Disease
"copper investigations. The child did not improve with chelation therapy and was subsequently genetically classified as PFIC-3. This case highlighted the caveats in Wilson disease diagnostic scoring system. The diagnostic odyssey, therapeutic interventions, and outcome of this case underscore the intricate interplay between clinical suspicion, investigative strategies, and the pivotal role of genetic testing to elucidate rare liver disorders in children. Chronic liver diseases (CLD) in the pediatric",6_1,Progressive familial intrahepatic cholestasis 3 Camouflaging as Wilson disease in a 12-year-old: a diagnostic Odyssey ,2024,,Wilson_Disease
"Chronic liver diseases (CLD) in the pediatric population present diagnostic conundrums owing to the heterogeneity of etiologies, and overlapping clinical manifestations. Although the astounding development of molecular diagnostic tools over the past decade helped identify previously undiagnosed entities, it has put a tremendous burden on physicians to give accurate diagnoses to patients and families. Wilson disease (WD) is a hereditary copper metabolism illness caused by a mutation in the ATP7B gene, which",6_2,Progressive familial intrahepatic cholestasis 3 Camouflaging as Wilson disease in a 12-year-old: a diagnostic Odyssey ,2024,,Wilson_Disease
"caused by a mutation in the ATP7B gene, which leads to systemic copper excess. Potential pharmacological treatability of WD with oral chelation therapy if diagnosed early thus averting need for liver transplantation combined with its diverse clinical manifestations which can range from asymptomatic transaminitis to fulminant liver failure or decompensation, compels hepatologists to keep it as one of the clinical differentials in quite a many cases of chronic liver disease. The diagnosis of WD is based on",6_3,Progressive familial intrahepatic cholestasis 3 Camouflaging as Wilson disease in a 12-year-old: a diagnostic Odyssey ,2024,,Wilson_Disease
"liver disease. The diagnosis of WD is based on Leipzig score which encompasses clinical features with a battery of biochemical tests including copper studies (<xref rid=""B1"" ref-type=""bibr"">1</xref>-<xref rid=""B3"" ref-type=""bibr"">3</xref>). Nevertheless, several liver disorders characterized by cholestasis, such as sclerosing cholangitis, exhibit indications of excessive copper throughout the body and display aberrant copper test results. These findings have the potential to mimic Wilson's disease (4).",6_4,Progressive familial intrahepatic cholestasis 3 Camouflaging as Wilson disease in a 12-year-old: a diagnostic Odyssey ,2024,,Wilson_Disease
"have the potential to mimic Wilson's disease (4). Progressive familial intrahepatic cholestasis (PFIC) is a group of inherited cholestatic disorders in terms of genetic defect in hepatocanaliculr bile acid transport system that leads to progressive liver injury (<xref rid=""B5"" ref-type=""bibr"">5</xref>). PFIC type 3, one of the subtypes of PFIC, is attributed to mutations in ABCB4 gene (<xref rid=""B6"" ref-type=""bibr"">6</xref>) which in rare instances can mimic WD clinically and biochemically thus posing a",6_5,Progressive familial intrahepatic cholestasis 3 Camouflaging as Wilson disease in a 12-year-old: a diagnostic Odyssey ,2024,,Wilson_Disease
"WD clinically and biochemically thus posing a diagnostic challenge for clinicians (<xref rid=""B7"" ref-type=""bibr"">7</xref>). Hence, we present case report of a 12-year-old patient initially considered and treated as WD, but ultimately diagnosed as PFIC-3, emphasizing the pivotal role of genetic analysis in rare liver disorders, and underscoring the potential drawbacks in the conventional diagnostic scoring system for WD especially in cases with secondary copper overload. A 12-year-male presented to our",6_6,Progressive familial intrahepatic cholestasis 3 Camouflaging as Wilson disease in a 12-year-old: a diagnostic Odyssey ,2024,,Wilson_Disease
"copper overload. A 12-year-male presented to our pediatric hepatology unit with two-month history of progressively increasing abdominal distension associated with flank fullness & swelling of lower limbs for 15 days. He had previously undergone therapeutic ascitic tap for this complaint prior to his admission to our hospital. Upon further investigation, the mother disclosed that she had experienced yellowish discoloration in her urine for the previous three months. He had no history of pain abdomen, fever,",6_7,Progressive familial intrahepatic cholestasis 3 Camouflaging as Wilson disease in a 12-year-old: a diagnostic Odyssey ,2024,,Wilson_Disease
"months. He had no history of pain abdomen, fever, haematemesis, melena, altered sleep-wake cycle or personality changes, neurological symptoms, autoimmune features like rash /joint pain, or any cholestatic symptoms like pruritus. There was no family history of liver disease or consanguinity. Child's developmental milestones were age-appropriate, and he had been previously healthy with no chronic medical conditions. Physical examination was notable for mild pallor & icterus, b/l pedal edema, and gross",6_8,Progressive familial intrahepatic cholestasis 3 Camouflaging as Wilson disease in a 12-year-old: a diagnostic Odyssey ,2024,,Wilson_Disease
"mild pallor & icterus, b/l pedal edema, and gross ascites with hepatosplenomegaly. The liver was detected by touch 3 cm below the xiphisternum, with a hard texture and a span of 7 cm. Additionally, the spleen was found to be enormous, extending 5 cm beyond the left costal border. Examination of other systems was unremarkable. He was both stunted and underweight for his age. Based on history & clinical examination, syndromic diagnosis of decompensated chronic liver disease with the portal hypertension was",6_9,Progressive familial intrahepatic cholestasis 3 Camouflaging as Wilson disease in a 12-year-old: a diagnostic Odyssey ,2024,,Wilson_Disease
"liver disease with the portal hypertension was made and workup was planned for common etiologies like WD/autoimmune hepatitis/chronic viral hepatitis. He was started on supportive management such as vitamin K, 20 % albumin, and diuretics.  Laboratory investigations showed deranged liver function tests, with elevated bilirubin (Total/direct):3.3/2.8 mg/dl; alanine aminotransferase (ALT): 137U/L and aspartate aminotransferase (AST): 128U/L with low serum albumin (1.89 gm/dl) and persistent coagulopathy",6_10,Progressive familial intrahepatic cholestasis 3 Camouflaging as Wilson disease in a 12-year-old: a diagnostic Odyssey ,2024,,Wilson_Disease
"albumin (1.89 gm/dl) and persistent coagulopathy [International normalized ratio (INR:2.92)]. Gamma-glutamyl transferase (GGT):188U/L, and alkaline phosphatase (ALP):486U/L were mildly elevated. Complete blood count showed pancytopenia [hemoglobin:8.2 gm/dl, total leukocyte count:3200/mm3, total platelet count: 30,000/mm3] s/o hypersplenism related to portal hypertension. The right liver was diminished with an irregular margin and the USG abdomen with doppler of the splenoportal axis revealed nodularity,",6_11,Progressive familial intrahepatic cholestasis 3 Camouflaging as Wilson disease in a 12-year-old: a diagnostic Odyssey ,2024,,Wilson_Disease
"of the splenoportal axis revealed nodularity, heterogeneous parenchymal echotexture, nodularity, caudate lobe hypertrophy with splenomegaly, and multiple collaterals with extensive ascites. Upper GI endoscopy revealed grade 2 oesophageal varices with mild portal hypertensive gastropathy. Liver stiffness measurement by transient elastography was 75 kPa suggestive of cirrhotic liver. Etiological workup for chronic liver disease showed normal immunoglobulin G; autoimmune markers and viral markers [hepatitis B",6_12,Progressive familial intrahepatic cholestasis 3 Camouflaging as Wilson disease in a 12-year-old: a diagnostic Odyssey ,2024,,Wilson_Disease
"autoimmune markers and viral markers [hepatitis B & hepatitis C serology] were negative. However, Ceruloplasmin level came out to be low [9 mg/dl], raising suspicion for WD. Slit lamp examination for Kayser Fleischer (KF) ring was negative, but 24-hour urine copper excretion (UCE) was high (182 mcg/day).  Transjugular liver biopsy was scheduled for histopathology and liver dry copper estimation due to the persistent coagulopathy of the infant. However, the family declined to provide assent for the",6_13,Progressive familial intrahepatic cholestasis 3 Camouflaging as Wilson disease in a 12-year-old: a diagnostic Odyssey ,2024,,Wilson_Disease
"the family declined to provide assent for the procedure. Hence, as our patient had Leipzig score of 4, the diagnosis of WD was made. Chelation therapy with D-penicillamine was initiated promptly and the dose was gradually increased to 20 mg/kg/day. Despite adherence to chelation therapy with adequate dosing for 3 months, he did not show any improvement. Liver function tests worsened with a further decline in serum albumin, increase in transaminitis, and increase in INR. Given the lack of clinical",6_14,Progressive familial intrahepatic cholestasis 3 Camouflaging as Wilson disease in a 12-year-old: a diagnostic Odyssey ,2024,,Wilson_Disease
"and increase in INR. Given the lack of clinical improvement, despite adequate treatment, further investigations were pursued. Nevertheless, genetic analysis that focused on mutations in the ATP7B gene that are linked to WD produced negative results. As a result of this unexpected discovery, we were compelled to reconsider the diagnosis and workup for other rare inherited causes of CLD in children. Comprehensive genetic testing, including whole exome sequencing, was undertaken which showed a homozygous",6_15,Progressive familial intrahepatic cholestasis 3 Camouflaging as Wilson disease in a 12-year-old: a diagnostic Odyssey ,2024,,Wilson_Disease
"was undertaken which showed a homozygous missense mutations c.2906 G>A in exon 23 of ABCB4 gene, resulting in amino acid substitution p.Arg969His, consistent with diagnosis of PFIC-3.  Following the diagnosis of PFIC-3, chelation therapy was stopped, and Ursodeoxycholic acid was started, in addition to supportive measures, such as fat-soluble vitamin supplementation & nutritional support. Despite these interventions, his clinical status continued to deteriorate with persistent ascites, increasing jaundice,",6_16,Progressive familial intrahepatic cholestasis 3 Camouflaging as Wilson disease in a 12-year-old: a diagnostic Odyssey ,2024,,Wilson_Disease
"with persistent ascites, increasing jaundice, and coagulopathy, highlighting the progressive nature of PFIC-3. Considering advanced liver disease and failure to respond to medical therapy, he was listed for liver transplant, currently waiting for a donor. The diagnostic journey of our patient from initial consideration of WD to the ultimate diagnosis of PFIC-3 underscores the intricacies involved in the evaluation of pediatric patients with CLD. CLD in pediatric populations encompass a broad spectrum of",6_17,Progressive familial intrahepatic cholestasis 3 Camouflaging as Wilson disease in a 12-year-old: a diagnostic Odyssey ,2024,,Wilson_Disease
"populations encompass a broad spectrum of etiologies, including inherited metabolic disorders, autoimmune conditions, infectious hepatitis, and genetic cholestatic syndromes. Due to overlapping clinical characteristics and differing illness presentations, it may sometimes be difficult to distinguish between these entities. In our instance, biochemical characteristics including abnormal copper tests (high UCE and low ceruloplasmin) led to the first clinical suspicion of WD. However, no improvement in",6_18,Progressive familial intrahepatic cholestasis 3 Camouflaging as Wilson disease in a 12-year-old: a diagnostic Odyssey ,2024,,Wilson_Disease
"suspicion of WD. However, no improvement in clinical symptoms and liver biochemistry after adequate chelation therapy for 3 months along with absence of pathogenic mutations in ATP7B gene prompted us for further investigation into alternative causes of CLD. WD is an autosomal recessive disorder of copper metabolism caused by the mutations in ATP7B gene, resulting in the accumulation of copper within liver, brain, cornea, etc. Clinically, WD patient can have hepatic and/or neurological symptoms though",6_19,Progressive familial intrahepatic cholestasis 3 Camouflaging as Wilson disease in a 12-year-old: a diagnostic Odyssey ,2024,,Wilson_Disease
"have hepatic and/or neurological symptoms though pediatric patients usually manifest with isolated hepatic involvement, however, presentation can be highly variable, which can range from asymptomatic hepatomegaly/transaminitis to fulminant liver failure (<xref rid=""B1"" ref-type=""bibr"">1</xref>). In contrast, PFIC-3 is characterized by the mutation in ABCB4 gene, encoding the multidrug resistance protein 3 (MDR3) expressed in bile canalicular membrane, which plays a crucial role in transport of",6_20,Progressive familial intrahepatic cholestasis 3 Camouflaging as Wilson disease in a 12-year-old: a diagnostic Odyssey ,2024,,Wilson_Disease
"which plays a crucial role in transport of phosphatidylcholine from hepatocyte to bile. Disruption of MDR3 function leads to impaired phospholipid secretion resulting in hydrophobic bile which damages the bile ducts leading to intrahepatic cholestasis (<xref rid=""B5"" ref-type=""bibr"">5</xref>-<xref rid=""B6"" ref-type=""bibr"">6</xref>). The age of disease onset is highly variable, ranging from childhood to early adulthood. Jaundice, pruritus, poor growth, fat-soluble vitamin deficiencies such as reduced bone",6_21,Progressive familial intrahepatic cholestasis 3 Camouflaging as Wilson disease in a 12-year-old: a diagnostic Odyssey ,2024,,Wilson_Disease
"vitamin deficiencies such as reduced bone density, steatorrhea, and, ultimately, liver cirrhosis and portal hypertension with decompensation and a distinctive biochemical feature of high GGT cholestasis are the typical manifestations of PFIC-3. However, our patient did not show any cholestatic features, such as pruritus during the whole clinical course, although cholestatic markers like alkaline phosphatase and GGT were mildly elevated. In hindsight, this was a missed clue about possibility of cholestatic",6_22,Progressive familial intrahepatic cholestasis 3 Camouflaging as Wilson disease in a 12-year-old: a diagnostic Odyssey ,2024,,Wilson_Disease
"a missed clue about possibility of cholestatic etiology. Albeit, the absence of any cholestatic symptoms like pruritus along with deranged copper studies precluded us from considering PFIC-3 as a possibility in the beginning. Pediatric hepatologists are compelled to keep WD as one of the clinical differentials in quite a few cases of CLD in terms of the disease's diverse clinical manifestations, which can range from asymptomatic transaminitis to fulminant liver failure or decompensation, as well as its",6_23,Progressive familial intrahepatic cholestasis 3 Camouflaging as Wilson disease in a 12-year-old: a diagnostic Odyssey ,2024,,Wilson_Disease
"liver failure or decompensation, as well as its potential pharmacological treatability with oral chelation therapy if diagnosed early thus preventing the need for liver transplantation. However, Leipzig score, used to diagnose WD (a score of ≥ 4) has certain caveats which may result in misdiagnosis as highlighted in our patient (<xref rid=""B1"" ref-type=""bibr"">1</xref>).  It is now a proven fact that UCE, and liver copper content [two of the components of Leipzig score] can increase in many cholestatic",6_24,Progressive familial intrahepatic cholestasis 3 Camouflaging as Wilson disease in a 12-year-old: a diagnostic Odyssey ,2024,,Wilson_Disease
Leipzig score] can increase in many cholestatic liver diseases such as sclerosing cholangitis in terms of secondary copper overload. The suggested causes of the secondary copper overload in cholestatic liver disorders are the disturbance of copper transport via bile caused by duct collapse and a failure in hepatic lysosomal activity. Sood et al. published a series of 4 patients who were initially diagnosed as WD based Leipzig score which was subsequently proven to be cases of small duct sclerosing,6_25,Progressive familial intrahepatic cholestasis 3 Camouflaging as Wilson disease in a 12-year-old: a diagnostic Odyssey ,2024,,Wilson_Disease
"proven to be cases of small duct sclerosing cholangitis (<xref rid=""B4"" ref-type=""bibr"">4</xref>). Similarly, serum ceruloplasmin, most common and initial screening biomarker used for WD diagnosis could be falsely low if there is hypoalbuminemia due to advanced liver disease affecting synthetic function. Given that KF rings are seen in around half of individuals with hepatic impairment, their presence or absence does not provide useful information for diagnosing or ruling out the condition. Sood et al.",6_26,Progressive familial intrahepatic cholestasis 3 Camouflaging as Wilson disease in a 12-year-old: a diagnostic Odyssey ,2024,,Wilson_Disease
"or ruling out the condition. Sood et al. concluded that borderline serum ceruloplasmin values (i.e. 10-20 mg/dl) and UCE (40-100 mcg/day) might result in overdiagnosis of WD under current international guidelines (<xref rid=""B4"" ref-type=""bibr"">4</xref>). Recommended UCE cutoffs for diagnosing WD in adults and pediatric patients are >100 mcg/day and >40 mcg/day, respectively. However, AASLD in their latest guideline acknowledged that secondary copper overload can cause a higher urine copper excretion than",6_27,Progressive familial intrahepatic cholestasis 3 Camouflaging as Wilson disease in a 12-year-old: a diagnostic Odyssey ,2024,,Wilson_Disease
"can cause a higher urine copper excretion than normal leading to the misdiagnosis of WD though ceruloplasmin usually remains normal in these patients (<xref rid=""B1"" ref-type=""bibr"">1</xref>). Nonetheless, UCE of our patient was 178 mcg day which is well above the recommended cutoff. Moreover, his ceruloplasmin was low <10 mg/dl; unlike previous published case reports of PFIC 3 mimicking WD. Five case reports documenting 6 patients (1 adult, 5 pediatric) were published to date where an initial diagnosis of",6_28,Progressive familial intrahepatic cholestasis 3 Camouflaging as Wilson disease in a 12-year-old: a diagnostic Odyssey ,2024,,Wilson_Disease
"published to date where an initial diagnosis of WD was contemplated based on biochemical tests, which turned out to be PFIC 3 after genetic testing (<xref rid=""T1"" ref-type=""table"">Table 1</xref>). A 2-year female with chronic liver disease, who was initially diagnosed as WD due to elevated liver copper levels, was subsequently genetically diagnosed as PFIC 3 in the first case report published in 2011 (<xref rid=""B8"" ref-type=""bibr"">8</xref>). Ramraj et al. reported two children of age 13 years and 5 years",6_29,Progressive familial intrahepatic cholestasis 3 Camouflaging as Wilson disease in a 12-year-old: a diagnostic Odyssey ,2024,,Wilson_Disease
"reported two children of age 13 years and 5 years who presented with chronic liver disease, diagnosed as WD based on high UCE and liver copper, but did not show any improvement with chelation and subsequently underwent genetic analysis; only to be showed as cases of PFIC-3 (<xref rid=""B9"" ref-type=""bibr"">9</xref>). Two such identical cases were reported by Sticova et al in a 11-year-male and by Boga et al in a 15-year old child (<xref rid=""B7"" ref-type=""bibr"">7</xref>, <xref rid=""B10""",6_30,Progressive familial intrahepatic cholestasis 3 Camouflaging as Wilson disease in a 12-year-old: a diagnostic Odyssey ,2024,,Wilson_Disease
"ref-type=""bibr"">7</xref>, <xref rid=""B10"" ref-type=""bibr"">10</xref>). Bansal et al reported a 21-year-male with acute on chronic liver failure who initially was considered WD and underwent liver transplant. On the other hand, the histology of the explant liver showed that MDR3 expression was absent, suggesting PFIC-3. Two of his other siblings later had pruritus, and a liver biopsy from them revealed that MDR 3 expression was absent, which is indicative with PFIC-3 (<xref rid=""B11""",6_31,Progressive familial intrahepatic cholestasis 3 Camouflaging as Wilson disease in a 12-year-old: a diagnostic Odyssey ,2024,,Wilson_Disease
"which is indicative with PFIC-3 (<xref rid=""B11"" ref-type=""bibr"">11</xref>). The initial impression of WD in these reports may be questioned because, except last case, all other cases had ceruloplasmin >20 mg/dl, along with high GGT & ALP. However, in our case, the ceruloplasmin was very low (9 mg/dl) and GGT /ALP was only mildly raised. Very low ceruloplasmin of our patient correlates with his decompensated liver disease status with hypoalbuminemia. Genetic testing plays a pivotal role in the diagnosis of",6_32,Progressive familial intrahepatic cholestasis 3 Camouflaging as Wilson disease in a 12-year-old: a diagnostic Odyssey ,2024,,Wilson_Disease
"testing plays a pivotal role in the diagnosis of inherited liver diseases, particularly in cases with atypical presentations or inconclusive biochemical findings. The absence of pathogenic mutations in the ATP7B gene in our case necessitated additional research into alternative genetic causes. Timely recognition of PFIC-3 in our patient facilitated appropriate management and prompt referral for liver transplantation.  In conclusion, our case highlights the importance of considering the alternative",6_33,Progressive familial intrahepatic cholestasis 3 Camouflaging as Wilson disease in a 12-year-old: a diagnostic Odyssey ,2024,,Wilson_Disease
"the importance of considering the alternative diagnoses, and utilizing advanced genetic testing modalities to establish an accurate diagnosis, especially if a patient initially considered to be WD is not showing improvement despite adequate chelation dose & compliance.",6_34,Progressive familial intrahepatic cholestasis 3 Camouflaging as Wilson disease in a 12-year-old: a diagnostic Odyssey ,2024,,Wilson_Disease
"Phenotypic and genetic characterization of children with Wilson Disease from Northeast China Wilson disease (WD) is a rare autosomal recessive disorder caused by mutations in ATP7B [<xref ref-type=""bibr"" rid=""CR1"">1</xref>]. ATP7B is located on the short arm of chromosome 13 and encodes a copper-transporting P-type ATPase [<xref ref-type=""bibr"" rid=""CR2"">2</xref>, <xref ref-type=""bibr"" rid=""CR3"">3</xref>]. ATP7B is responsible for transporting copper from intracellular chaperone proteins into the secretory",7_0,Phenotypic and genetic characterization of children with Wilson Disease from Northeast China,12 9 2024,,Wilson_Disease
"chaperone proteins into the secretory pathway, both for excretion into bile and incorporation into apo-ceruloplasmin for the synthesis of functional ceruloplasmin [<xref ref-type=""bibr"" rid=""CR3"">3</xref>]. The absence or reduced function of the ATP7B protein leads to copper accumulation and liver injury. Eventually, copper is released into the bloodstream and deposited in other organs, notably the brain, kidneys, and cornea [<xref ref-type=""bibr"" rid=""CR4"">4</xref>]. WD can develop at any age and often",7_1,Phenotypic and genetic characterization of children with Wilson Disease from Northeast China,12 9 2024,,Wilson_Disease
"WD can develop at any age and often occurs between 5 and 35 years of age [<xref ref-type=""bibr"" rid=""CR3"">3</xref>]. WD is increasingly diagnosed in children younger than 5 years of age, and the clinical findings may be nonspecific in children younger than 2 years [<xref ref-type=""bibr"" rid=""CR5"">5</xref>]. Most children present with liver dysfunction, ranging from incidental findings of elevated serum transaminases in otherwise asymptomatic patients, acute hepatitis, and hepatomegaly, to acute liver",7_2,Phenotypic and genetic characterization of children with Wilson Disease from Northeast China,12 9 2024,,Wilson_Disease
"acute hepatitis, and hepatomegaly, to acute liver failure (ALF) or cirrhosis [<xref ref-type=""bibr"" rid=""CR6"">6</xref>]. However, children with WD are often asymptomatic, making the clinical diagnosis difficult. Therefore, more accurate methods are required for clinical diagnosis. Given these diagnostic challenges, genetic testing has become increasingly important for early, rapid, and accurate diagnosis of WD. To date, more than 700 ATP7B variants have been identified [<xref ref-type=""bibr""",7_3,Phenotypic and genetic characterization of children with Wilson Disease from Northeast China,12 9 2024,,Wilson_Disease
"have been identified [<xref ref-type=""bibr"" rid=""CR7"">7</xref>]. The most common variant in patients from Europe is the point variant H1069Q (exon 14), and that in Asia is R778L (exon 8) [<xref ref-type=""bibr"" rid=""CR8"">8</xref>]. More than 50% of the variants are missense and nonsense, and the rest may be insertion/deletion or splice-site variants [<xref ref-type=""bibr"" rid=""CR9"">9</xref>, <xref ref-type=""bibr"" rid=""CR10"">10</xref>]. Studies have shown that variants affecting critical portions of the",7_4,Phenotypic and genetic characterization of children with Wilson Disease from Northeast China,12 9 2024,,Wilson_Disease
"that variants affecting critical portions of the protein, including copper-binding domains or the ATPase loop, may lead to the early onset of liver disease [<xref ref-type=""bibr"" rid=""CR11"">11</xref>]. Other studies have indicated that p.H1069Q is more frequently associated with neurological presentation and later symptom onset [<xref ref-type=""bibr"" rid=""CR12"">12</xref>, <xref ref-type=""bibr"" rid=""CR13"">13</xref>]. Loss-of-function (LOF) of ATP7B gene variants has been associated with ALF and an earlier",7_5,Phenotypic and genetic characterization of children with Wilson Disease from Northeast China,12 9 2024,,Wilson_Disease
"has been associated with ALF and an earlier age of onset [<xref ref-type=""bibr"" rid=""CR14"">14</xref>, <xref ref-type=""bibr"" rid=""CR15"">15</xref>]. However, there are no confirmed genotype–phenotype correlations [<xref ref-type=""bibr"" rid=""CR16"">16</xref>]. The objective of our study was to summarize the clinical manifestations and laboratory and genetic characteristics of children with WD in northeast China. We aimed to determine the spectrum and frequency of ATP7B variants and the genotype–phenotype",7_6,Phenotypic and genetic characterization of children with Wilson Disease from Northeast China,12 9 2024,,Wilson_Disease
"of ATP7B variants and the genotype–phenotype correlation in pediatric patients with WD.   Most children (50/65, 76.9%) in our study were asymptomatic with elevated serum transaminase levels observed only on routine physical examination. The mean age of onset in asymptomatic children was 5 (3–6) years and it was therefore significantly younger than that of the other groups. Asymptomatic children only manifested hepatomegaly and liver steatosis, which were detected using liver ultrasonography. If left",7_7,Phenotypic and genetic characterization of children with Wilson Disease from Northeast China,12 9 2024,,Wilson_Disease
"detected using liver ultrasonography. If left untreated, asymptomatic patients with signs of organ damage typically develop symptomatic WD [<xref ref-type=""bibr"" rid=""CR22"">22</xref>]. Therefore, the early diagnosis and treatment of WD are crucial to achieve better outcomes. However, the early diagnosis of asymptomatic children with WD is challenging. Therefore, clinical and laboratory characteristics, as well as support for genetic testing, are essential. ALF is the leading cause of death in children with",7_8,Phenotypic and genetic characterization of children with Wilson Disease from Northeast China,12 9 2024,,Wilson_Disease
"is the leading cause of death in children with WD, with a mortality rate of approximately 95% if left untreated [<xref ref-type=""bibr"" rid=""CR3"">3</xref>]. In our study, four pediatric patients with WD and ALF were identified, two of whom showed improvement after appropriate treatment, one after liver transplantation, and one who died because she did not receive a liver transplant in time. Prompt diagnosis is crucial, as these patients urgently require liver transplantation to survive [<xref",7_9,Phenotypic and genetic characterization of children with Wilson Disease from Northeast China,12 9 2024,,Wilson_Disease
"require liver transplantation to survive [<xref ref-type=""bibr"" rid=""CR4"">4</xref>]. Six patients presented neurological symptoms. In addition to involuntary movements, tremors, and dysarthria because of extrapyramidal involvement, they may be associated with cognitive difficulties, depressive disorders, sleep disorders, and other psychiatric symptoms. All patients had brain MRI abnormalities, including abnormal signal intensities in the basal ganglia, thalamus, brainstem, and corpus callosum. In addition,",7_10,Phenotypic and genetic characterization of children with Wilson Disease from Northeast China,12 9 2024,,Wilson_Disease
"brainstem, and corpus callosum. In addition, all patients had abnormal liver ultrasound findings, and 50% of the patients had liver cirrhosis on liver ultrasound. Therefore, attention should be paid to the possibility of WD in children with neurological symptoms, particularly those with concomitant ultrasound abnormalities of the liver. Previous studies have suggested that KF rings are usually absent in children with WD and liver disease [<xref ref-type=""bibr"" rid=""CR23"">23</xref>, <xref ref-type=""bibr""",7_11,Phenotypic and genetic characterization of children with Wilson Disease from Northeast China,12 9 2024,,Wilson_Disease
"rid=""CR23"">23</xref>, <xref ref-type=""bibr"" rid=""CR24"">24</xref>]. In our study, they were absent in asymptomatic children and were present in children with ALF and neurological symptoms. This suggests that the positivity rate of the KF ring is very low in the early stages, especially in asymptomatic children. The KF ring is often associated with disease progression, particularly neurological and severe hepatic manifestations, in WD. Therefore, the KF ring cannot be used as a basis for early diagnosis. In",7_12,Phenotypic and genetic characterization of children with Wilson Disease from Northeast China,12 9 2024,,Wilson_Disease
"cannot be used as a basis for early diagnosis. In our study, 92% of children had 24 h urinary Cu excretion > 40 µg, and 64.4% of children had 24 h urinary Cu excretion > 100 µg. Thus, these results suggest that > 40 µg appears to be more sensitive to the abnormality of 24 h urinary Cu. This is consistent with previous studies [<xref ref-type=""bibr"" rid=""CR25"">25</xref>]. A recent study showed that cholestasis prevents biliary copper excretion and may lead to systemic copper overload with markedly increased",7_13,Phenotypic and genetic characterization of children with Wilson Disease from Northeast China,12 9 2024,,Wilson_Disease
"systemic copper overload with markedly increased urinary copper excretion, particularly in children [<xref ref-type=""bibr"" rid=""CR26"">26</xref>]. In our study, children in Group 3 with ALF also had significantly increased 24 h urinary Cu excretion compared to the other three groups (<italic toggle=""yes"">p</italic> < 0.05). We suspected that cholestasis occurred during ALF, resulting in abnormally high 24 h urine levels. Previous studies have mainly focused on southern China, and there are few reports on",7_14,Phenotypic and genetic characterization of children with Wilson Disease from Northeast China,12 9 2024,,Wilson_Disease
"on southern China, and there are few reports on northern China. In our study, the high frequencies were p.R778L, p.P992L, p.R919G, and p.A874V, which accounted for 54.8% of all variants, which differs from previous studies in southern China, where the three most common variants were p.R778L, p.P992L, and p.T935M, accounting for 50–60% of all variants [<xref ref-type=""bibr"" rid=""CR24"">24</xref>, <xref ref-type=""bibr"" rid=""CR27"">27</xref>]. Furthermore, in southern China, the major ATP7B variants are",7_15,Phenotypic and genetic characterization of children with Wilson Disease from Northeast China,12 9 2024,,Wilson_Disease
"in southern China, the major ATP7B variants are concentrated in exons 8, 12, 13, and 16 [<xref ref-type=""bibr"" rid=""CR28"">28</xref>, <xref ref-type=""bibr"" rid=""CR29"">29</xref>], whereas the variants detected in our study were mainly present in exons 8, 11, and 13. The results regarding the exons are the same in Qingdao and are also prevalent in northern China [<xref ref-type=""bibr"" rid=""CR30"">30</xref>], suggesting that these regions may be hotspots for variants in northern China. Seven novel variants have",7_16,Phenotypic and genetic characterization of children with Wilson Disease from Northeast China,12 9 2024,,Wilson_Disease
"in northern China. Seven novel variants have not been previously reported, including c.2572 A > C, c.-362G > A, c.51 + 4 A > C, c.1543 + 40G > A, c.3903 + 2T > C, c.2664-2665delCC, and c.3524-3528delAAGGA. These had not yet been included in the Exome Aggregation Consortium or 1000 Genomes Project databases. Bioinformatics software analysis assumes that they are pathogenic or probably pathogenic. The relationship between the clinical phenotypes and genotypes is complex. Most studies suggest that the",7_17,Phenotypic and genetic characterization of children with Wilson Disease from Northeast China,12 9 2024,,Wilson_Disease
"is complex. Most studies suggest that the phenotypic variability in WD may be caused by additional genetic, epigenetic, and even environmental factors that play a role in the timing of disease onset and clinical phenotype [<xref ref-type=""bibr"" rid=""CR31"">31</xref>–<xref ref-type=""bibr"" rid=""CR33"">33</xref>]. LOF variants result in severe impairment of ATP7B gene function owing to the lack of a full-length gene product. European studies have suggested that patients with LOF variants have lower serum",7_18,Phenotypic and genetic characterization of children with Wilson Disease from Northeast China,12 9 2024,,Wilson_Disease
"that patients with LOF variants have lower serum ceruloplasmin oxidase activity and earlier onset of WD than those with missense variants [<xref ref-type=""bibr"" rid=""CR14"">14</xref>, <xref ref-type=""bibr"" rid=""CR15"">15</xref>, <xref ref-type=""bibr"" rid=""CR34"">34</xref>, <xref ref-type=""bibr"" rid=""CR35"">35</xref>]. The current research suggests that the presence of at least one LOF variant in patients receiving chelation therapy is associated with poor transplant-free survival over a long follow-up [<xref",7_19,Phenotypic and genetic characterization of children with Wilson Disease from Northeast China,12 9 2024,,Wilson_Disease
"survival over a long follow-up [<xref ref-type=""bibr"" rid=""CR20"">20</xref>]. In our study, the LOF variant was significantly associated with lower albumin levels, which may be associated with ALF, similar to previous studies [<xref ref-type=""bibr"" rid=""CR14"">14</xref>, <xref ref-type=""bibr"" rid=""CR15"">15</xref>]. Furthermore, patients carrying the p.R778L variant had lower serum ceruloplasmin levels and higher zinc levels for both alleles than patients with other variants. Recent studies showed that",7_20,Phenotypic and genetic characterization of children with Wilson Disease from Northeast China,12 9 2024,,Wilson_Disease
"with other variants. Recent studies showed that p.R778L was also associated with lower ceruloplasmin levels [<xref ref-type=""bibr"" rid=""CR27"">27</xref>, <xref ref-type=""bibr"" rid=""CR29"">29</xref>]. Some observations suggest that serum Zn levels could be related to the clinical phenotype of patients with WD and its severity; patients with excessive Cu overload have lower serum Zn levels [<xref ref-type=""bibr"" rid=""CR36"">36</xref>]. The toxicity of Cu observed in WD might be caused by the disruption of",7_21,Phenotypic and genetic characterization of children with Wilson Disease from Northeast China,12 9 2024,,Wilson_Disease
"in WD might be caused by the disruption of numerous Zn-dependent and Zn-responsive proteins, including transcription factors [<xref ref-type=""bibr"" rid=""CR37"">37</xref>]. However, the role of Zn in WD remains unclear. Our study had several limitations. The sample size of our study was small. Therefore, errors and outliers may have a greater impact on the statistical results. Therefore, multicenter and large-scale studies are needed to test these conclusions and investigate the relationship between",7_22,Phenotypic and genetic characterization of children with Wilson Disease from Northeast China,12 9 2024,,Wilson_Disease
"and investigate the relationship between different genotypes and phenotypes of WD. In conclusion, the diagnosis of WD in children can be challenging, particularly during the early stages of liver disease and neurological symptoms. Therefore, supportive clinical and laboratory characteristics and genetic testing are essential.",7_23,Phenotypic and genetic characterization of children with Wilson Disease from Northeast China,12 9 2024,,Wilson_Disease
"Single Pass Albumin Dialysis and Plasma Exchange for Copper Toxicity in Acute Wilson Disease Wilson disease (WD) is a rare autosomal recessive disorder of copper metabolism, with mutations in the <italic toggle=""yes"">ATP7B</italic> gene on chromosome 13 [<xref rid=""ref1_500104"" ref-type=""bibr"">1</xref>]. Clinical manifestations predominantly reflect hepatic injury, but also include neuropsychiatric manifestations and hemolytic anemia [<xref rid=""ref2_500104"" ref-type=""bibr"">2</xref>]. A diagnosis of WD is",8_0,Single Pass Albumin Dialysis and Plasma Exchange for Copper Toxicity in Acute Wilson Disease,May-Aug 2019,,Wilson_Disease
"ref-type=""bibr"">2</xref>]. A diagnosis of WD is supported by low ceruloplasmin, elevated hepatic copper, increased urinary copper excretion, and detection of Kayser-Fleischer rings on ophthalmologic examination [<xref rid=""ref3_500104"" ref-type=""bibr"">3</xref>]. Patients with fulminant WD present with liver failure, hepatic encephalopathy, and hemolytic anemia, the last a result of the direct toxicity of copper released from necrotic hepatocytes [<xref rid=""ref4_500104"" ref-type=""bibr"">4</xref>]. Therapy",8_1,Single Pass Albumin Dialysis and Plasma Exchange for Copper Toxicity in Acute Wilson Disease,May-Aug 2019,,Wilson_Disease
"ref-type=""bibr"">4</xref>]. Therapy includes chelation with agents such as D-penicillamine and trientine to reduce serum copper levels [<xref rid=""ref5_500104"" ref-type=""bibr"">5</xref>], but this is often limited by the presence of acute kidney injury, which prevents adequate urinary copper removal by chelation. The mortality rate among such patients approaches 100% without a liver transplant [<xref rid=""ref6_500104"" ref-type=""bibr"">6</xref>]. Copper is predominantly incorporated into ceruloplasmin, with",8_2,Single Pass Albumin Dialysis and Plasma Exchange for Copper Toxicity in Acute Wilson Disease,May-Aug 2019,,Wilson_Disease
"incorporated into ceruloplasmin, with only about 10% reversibly bound to various amino acids and albumin. This non-ceruloplasmin-bound serum copper is significantly increased and represents a potentially toxic portion of the copper load in fulminant WD [<xref rid=""ref7_500104"" ref-type=""bibr"">7</xref>]. It is not removed by conventional dialytic therapies, which are poor in removing protein-bound substances. As albumin has specific binding sites for metals such as copper [<xref rid=""ref8_500104""",8_3,Single Pass Albumin Dialysis and Plasma Exchange for Copper Toxicity in Acute Wilson Disease,May-Aug 2019,,Wilson_Disease
"metals such as copper [<xref rid=""ref8_500104"" ref-type=""bibr"">8</xref>], albumin dialysis, which involves dialyzing blood against an albumin-containing dialysate across a semi-permeable membrane, may allow better clearance of both non-ceruloplasmin-bound and free copper and may play a role as a bridging therapy to liver transplantation in patients with fulminant WD. Various methods reported to bridge to transplantation include single pass albumin dialysis (SPAD), plasma exchange (PLEX), and molecular",8_4,Single Pass Albumin Dialysis and Plasma Exchange for Copper Toxicity in Acute Wilson Disease,May-Aug 2019,,Wilson_Disease
"(SPAD), plasma exchange (PLEX), and molecular adsorbent recirculating systems (MARS), but no consensus exists on the preferred treatment [<xref rid=""ref4_500104"" ref-type=""bibr"">4</xref>, <xref rid=""ref6_500104"" ref-type=""bibr"">6</xref>, <xref rid=""ref9_500104"" ref-type=""bibr"">9‒14</xref>]. We report the effective use of SPAD alone and in combination with PLEX as a bridge to liver transplantation in 2 patients with fulminant WD.  SPAD is a form of albumin dialysis which utilizes a standard continuous",8_5,Single Pass Albumin Dialysis and Plasma Exchange for Copper Toxicity in Acute Wilson Disease,May-Aug 2019,,Wilson_Disease
"dialysis which utilizes a standard continuous hemodialysis system with the addition of albumin to a standard dialysate. The albumin-containing dialysate allows for improved clearance of protein-bound substances like non-ceruloplasmin-bound copper, which is elevated in Wilsonian liver failure [<xref rid=""ref16_500104"" ref-type=""bibr"">16</xref>]. It is one of four methods available to provide extracorporeal liver support, the others being MARS, the Prometheus dialysis system, and PLEX combined with",8_6,Single Pass Albumin Dialysis and Plasma Exchange for Copper Toxicity in Acute Wilson Disease,May-Aug 2019,,Wilson_Disease
"dialysis system, and PLEX combined with hemodialysis [<xref rid=""ref11_500104"" ref-type=""bibr"">11</xref>]. While the utility of MARS and the Prometheus dialysis system requires the added cost of purchasing specific new equipment and staff training, SPAD is not difficult to set up and does not require special filters/adsorbers or specific new equipment. Many members of staff within intensive care units require little re-training, as they are already familiar with the setup for continuous venovenous",8_7,Single Pass Albumin Dialysis and Plasma Exchange for Copper Toxicity in Acute Wilson Disease,May-Aug 2019,,Wilson_Disease
"familiar with the setup for continuous venovenous hemodiafiltration. Several case reports have reported the efficacy of using SPAD as supportive treatment to successfully bridge patients with fulminant Wilsonian liver failure to liver transplantation [<xref rid=""ref4_500104"" ref-type=""bibr"">4, 9</xref>]. Unlike MARS, where the albumin solution is regenerated by removing protein-bound substances through an activated charcoal column and an anion exchange resin, the albumin dialysate in SPAD is discarded",8_8,Single Pass Albumin Dialysis and Plasma Exchange for Copper Toxicity in Acute Wilson Disease,May-Aug 2019,,Wilson_Disease
"resin, the albumin dialysate in SPAD is discarded after a single pass, necessitating a large supply of albumin [<xref rid=""ref8_500104"" ref-type=""bibr"">8</xref>]. One strategy to conserve albumin and limit the cost of SPAD would be to reduce the clearance, and the slower dialysate flow rates may improve dissociation of copper off binding sites and across the membrane. Although the MARS has been used successfully to bridge patients with WD to liver transplantation, analysis of the albumin dialysate in one",8_9,Single Pass Albumin Dialysis and Plasma Exchange for Copper Toxicity in Acute Wilson Disease,May-Aug 2019,,Wilson_Disease
"analysis of the albumin dialysate in one of the patients reported on by Sen et al. [<xref rid=""ref17_500104"" ref-type=""bibr"">17</xref>] suggested that the MARS was saturated with copper after the initial few hours, with no significant copper removal thereafter, presumably as there is no cation exchanger in the circuit, potentially limiting its effectiveness for the treatment of copper-related hemolysis. In contrast, SPAD has a potential advantage based on continuous removal of copper without saturation of",8_10,Single Pass Albumin Dialysis and Plasma Exchange for Copper Toxicity in Acute Wilson Disease,May-Aug 2019,,Wilson_Disease
"removal of copper without saturation of the albumin-binding capacity. In patient 1, SPAD with a 4.5% (45 g/L) albumin dialysate reduced serum copper levels by 28.7% and stabilized hemolysis and multiorgan failure, bridging to a successful liver transplantation. PLEX is useful for removing protein-bound substances that are poorly removed via conventional dialysis. An added advantage in this clinical situation is the replenishment of coagulation factors with plasma replacement. The efficacy of PLEX in",8_11,Single Pass Albumin Dialysis and Plasma Exchange for Copper Toxicity in Acute Wilson Disease,May-Aug 2019,,Wilson_Disease
"with plasma replacement. The efficacy of PLEX in removing excess copper in patients with fulminant WD has been illustrated in several case reports [<xref rid=""ref6_500104"" ref-type=""bibr"">6</xref>, <xref rid=""ref10_500104"" ref-type=""bibr"">10</xref>, <xref rid=""ref12_500104"" ref-type=""bibr"">12</xref>, <xref rid=""ref13_500104"" ref-type=""bibr"">13</xref>, <xref rid=""ref18_500104"" ref-type=""bibr"">18‒21</xref>]. In our second patient, serum copper levels were reduced by 47% after the first PLEX, confirming its",8_12,Single Pass Albumin Dialysis and Plasma Exchange for Copper Toxicity in Acute Wilson Disease,May-Aug 2019,,Wilson_Disease
"by 47% after the first PLEX, confirming its efficacy. However, significant acute kidney injury in a hemodynamically unstable child necessitated the initiation of continuous renal replacement therapy, which influenced our decision to add SPAD to effect a more sustained reduction in serum copper levels. Unfortunately, the serum copper level had not been checked prior to commencing SPAD to assess for a potential rebound in serum copper level after PLEX. In combination, a sustained 54.4% reduction of serum",8_13,Single Pass Albumin Dialysis and Plasma Exchange for Copper Toxicity in Acute Wilson Disease,May-Aug 2019,,Wilson_Disease
"combination, a sustained 54.4% reduction of serum copper levels was achieved, together with stabilization of hemolysis, bilirubin levels, and multiorgan failure for 4 days, bridging the patient to a successful liver transplantation. As the patient also had a concomitant acute kidney injury, the addition of SPAD allowed for an improvement of his fluid and acid-base management. Our report has limitations, of course, due to its retrospective nature, the fact that blood levels were taken opportunistically, and",8_14,Single Pass Albumin Dialysis and Plasma Exchange for Copper Toxicity in Acute Wilson Disease,May-Aug 2019,,Wilson_Disease
"blood levels were taken opportunistically, and lack of generalizability, as is common with all case reports. However, in these rare cases, the importance of sharing clinical experiences is well recognized. In these 2 patients, we demonstrated the clinical utility of SPAD alone and SPAD in combination with PLEX as potentially effective measures to reduce serum copper levels, stabilize hemolysis, and improve the clinical status of patients with fulminant WD as a bridge to liver transplantation; however,",8_15,Single Pass Albumin Dialysis and Plasma Exchange for Copper Toxicity in Acute Wilson Disease,May-Aug 2019,,Wilson_Disease
"WD as a bridge to liver transplantation; however, further clinical studies are needed to confirm its efficacy. PLEX is widely available and effective in reducing serum copper levels. However, rebound rises in serum copper levels between exchanges can occur. The addition of SPAD may prevent such rebound and has the added advantage of removing small-molecular-weight solutes that cause hepatic coma, managing fluid overload, and correcting electrolyte and acid-base abnormalities [<xref rid=""ref22_500104""",8_16,Single Pass Albumin Dialysis and Plasma Exchange for Copper Toxicity in Acute Wilson Disease,May-Aug 2019,,Wilson_Disease
"acid-base abnormalities [<xref rid=""ref22_500104"" ref-type=""bibr"">22</xref>]. The authors have no ethical conflicts to disclose. Consent was obtained from the parents of the patients for publication of the case reports. The authors have no conflicts of interest to disclose. S.B. and C.W.T. contributed equally to conceptualizing, drafting, reviewing, and revising of the manuscript. E.A.H. and D.G.N. contributed to the conception and design of the report, and critically reviewed the manuscript. All authors",8_17,Single Pass Albumin Dialysis and Plasma Exchange for Copper Toxicity in Acute Wilson Disease,May-Aug 2019,,Wilson_Disease
critically reviewed the manuscript. All authors approved the final manuscript as submitted and agree to be accountable for all aspects of the work.,8_18,Single Pass Albumin Dialysis and Plasma Exchange for Copper Toxicity in Acute Wilson Disease,May-Aug 2019,,Wilson_Disease
"Nontraumatic intra-diploic arachnoid cyst communicating with sphenoid bone and in close proximity to cavernous sinus in a known case of Wilson disease: A rare entity Arachnoid cysts can be intra-cranial or along the spinal cord. Intracranial arachnoid cyst is a very rare finding, trauma being the leading case of it. It is extremely rare for the development of intra-diploic arachnoid cyst without a traumatic history. We present a case of an intra-diploic arachnoid cyst communicating with the greater wing of",9_0,Nontraumatic intra-diploic arachnoid cyst communicating with sphenoid bone and in close proximity to cavernous sinus in a known case of Wilson disease: A rare entity,21 8 2024,,Wilson_Disease
"cyst communicating with the greater wing of the sphenoid and in close proximity to the cavernous sinus in a known case of Wilson disease for 22 years. Due to its low incidence, there is a gap in the knowledge and discussion of this cystic lesion, its pathophysiology and management, which are discussed in this case report. The benign anomalies involving the intracranial arachnoidal membranes include arachnoid cysts, which are defined as a cerebrospinal fluid (CSF) filled collection. Very rarely, these cysts",9_1,Nontraumatic intra-diploic arachnoid cyst communicating with sphenoid bone and in close proximity to cavernous sinus in a known case of Wilson disease: A rare entity,21 8 2024,,Wilson_Disease
"(CSF) filled collection. Very rarely, these cysts may appear in the intra-diploic spaces and are classified into traumatic and nontraumatic. Intra-diploic arachnoid cysts have a variety of nomenclature, including intra-osseous leptomeningeal cyst, intra-diploic CSF fistula, posttraumatic and traumatic arachnoid cysts [<xref rid=""bib0001"" ref-type=""bibr"">[1]</xref>, <xref rid=""bib0002"" ref-type=""bibr"">[2]</xref>, <xref rid=""bib0003"" ref-type=""bibr"">[3]</xref>]. The differential diagnosis of the arachnoid",9_2,Nontraumatic intra-diploic arachnoid cyst communicating with sphenoid bone and in close proximity to cavernous sinus in a known case of Wilson disease: A rare entity,21 8 2024,,Wilson_Disease
"The differential diagnosis of the arachnoid cyst is an epidermoid cyst, which can be differentiated based on the diffusion-weighted imaging sequence, with the latter showing diffusion restriction. We present a case of the rare appearance of an intra-diploic arachnoid cyst near the cavernous sinus in a known case of Wilson's disease. A 28-year-old male with a known case of Wilson disease, diagnosed 22 years ago and on medications since then, presented to the medicine outpatient department with complaints of",9_3,Nontraumatic intra-diploic arachnoid cyst communicating with sphenoid bone and in close proximity to cavernous sinus in a known case of Wilson disease: A rare entity,21 8 2024,,Wilson_Disease
"medicine outpatient department with complaints of weakness in all 4 limbs for the past 4 days, along with speech difficulties. The patient has had a history of seizures for the past 2 months, which are on and off, and the last episode of seizure was 7 days ago. The patient's sister was also diagnosed with Wilson disease, and she succumbed to it. Blood investigations were done, which revealed increased 24-hour urinary copper and spot urinary copper and low serum ceruloplasmin with associated proteinuria. On",9_4,Nontraumatic intra-diploic arachnoid cyst communicating with sphenoid bone and in close proximity to cavernous sinus in a known case of Wilson disease: A rare entity,21 8 2024,,Wilson_Disease
"ceruloplasmin with associated proteinuria. On physical examination, Keyser-Fleischer rings and signs of upper motor neuron lesion were present, and the patient was advised of an MRI. The patient did not undergo any previous radiological investigations. On MRI, an intra-diploic lesion measuring approx. About 14 × 7 mm was seen adjacent to the cavernous sinus on the left side, which appears isointense to CSF on T2WI, hypo to isointense to CSF on T1WI/FLAIR, showing no restriction on DWI and corresponding",9_5,Nontraumatic intra-diploic arachnoid cyst communicating with sphenoid bone and in close proximity to cavernous sinus in a known case of Wilson disease: A rare entity,21 8 2024,,Wilson_Disease
"showing no restriction on DWI and corresponding high signal in ADC, and no blooming noted at GRE sequences. The above features suggested the lesion to be an arachnoid cyst, which seems to communicate with the greater wing of the left sphenoid bone, as shown in <xref rid=""fig0001"" ref-type=""fig"">Fig. 1</xref>, <xref rid=""fig0002"" ref-type=""fig"">Fig. 2</xref>, <xref rid=""fig0003"" ref-type=""fig"">Fig. 3</xref>.<fig id=""fig0001""><label>Fig. 1</label><caption><p>MRI brain axial images of Fluid attenuation",9_6,Nontraumatic intra-diploic arachnoid cyst communicating with sphenoid bone and in close proximity to cavernous sinus in a known case of Wilson disease: A rare entity,21 8 2024,,Wilson_Disease
"brain axial images of Fluid attenuation inversion recovery sequence (A), T2 weighted imaging (B), T1 weighted imaging (C), and Diffusion Weighted Imaging (D) showing an intra-diploic lesion measuring approximately 14 × 7 mm adjacent to the left cavernous sinus, which appears isointense to CSF on T2WI, hypo to isointense to CSF on T1WI/FLAIR, and no restricted diffusion on DWI.</p></caption><alt-text id=""alt0001"">Fig 1:</alt-text><graphic http://www.w3.org/1999/xlink href=""gr1""",9_7,Nontraumatic intra-diploic arachnoid cyst communicating with sphenoid bone and in close proximity to cavernous sinus in a known case of Wilson disease: A rare entity,21 8 2024,,Wilson_Disease
"http://www.w3.org/1999/xlink href=""gr1"" id=""celink0001""></graphic></fig><fig id=""fig0002""><label>Fig. 2</label><caption><p>MRI brain sagittal image T2 weighted imaging (A-C) showing an intra-diploic lesion measuring approximately 14 × 7 mm adjacent to the left cavernous sinus, which appears isointense to CSF.</p></caption><alt-text id=""alt0002"">Fig 2:</alt-text><graphic http://www.w3.org/1999/xlink href=""gr2"" id=""celink0002""></graphic></fig><fig id=""fig0003""><label>Fig. 3</label><caption><p>MRI brain",9_8,Nontraumatic intra-diploic arachnoid cyst communicating with sphenoid bone and in close proximity to cavernous sinus in a known case of Wilson disease: A rare entity,21 8 2024,,Wilson_Disease
"3</label><caption><p>MRI brain coronal image T2 weighted imaging (A) and (B) showing an intra-diploic lesion measuring approximately 14 × 7 mm adjacent to the left cavernous sinus, which appears isointense to CSF and is noted communicating with the greater wing of the left sphenoid bone.</p></caption><alt-text id=""alt0003"">Fig 3:</alt-text><graphic http://www.w3.org/1999/xlink href=""gr3"" id=""celink0003""></graphic></fig> Arachnoid cysts are benign and appear as cerebrospinal fluid (CSF) filled cystic",9_9,Nontraumatic intra-diploic arachnoid cyst communicating with sphenoid bone and in close proximity to cavernous sinus in a known case of Wilson disease: A rare entity,21 8 2024,,Wilson_Disease
"appear as cerebrospinal fluid (CSF) filled cystic structures [<xref rid=""bib0004"" ref-type=""bibr"">4</xref>,<xref rid=""bib0005"" ref-type=""bibr"">5</xref>]. These cysts are most seen in the middle cranial fossa and may be symptomatic [<xref rid=""bib0006"" ref-type=""bibr"">6</xref>]. They are mostly formed because of traumatic insult to the head, the occipital region being the most common location [<xref rid=""bib0007"" ref-type=""bibr"">[7]</xref>, <xref rid=""bib0008"" ref-type=""bibr"">[8]</xref>, <xref rid=""bib0009""",9_10,Nontraumatic intra-diploic arachnoid cyst communicating with sphenoid bone and in close proximity to cavernous sinus in a known case of Wilson disease: A rare entity,21 8 2024,,Wilson_Disease
"ref-type=""bibr"">[8]</xref>, <xref rid=""bib0009"" ref-type=""bibr"">[9]</xref>], and rarely are they present without a traumatic history. Intra-diploic arachnoid cyst is a very rare entity and may remain asymptomatic for a very long time. These cysts may cause diagnostic challenges, and radiological investigations like computed tomography and magnetic resonance imaging are a great support. To avoid any misinterpretation in diagnosing it, radiologic and clinicopathologic knowledge about the disease is",9_11,Nontraumatic intra-diploic arachnoid cyst communicating with sphenoid bone and in close proximity to cavernous sinus in a known case of Wilson disease: A rare entity,21 8 2024,,Wilson_Disease
"clinicopathologic knowledge about the disease is important. Arachnoid cysts are CSF filled cystic structures within the arachnoid layer, lined by collagen and arachnoidal cells. Its pathogenesis is still not completely clear due to its extremely rare incidence. They can be present at birth due to some congenital malformation in the early gestational life and are termed primary. These malformations can be caused due to abnormality in the drainage of CSF due to venous dysplasia or agenesis. These cysts may",9_12,Nontraumatic intra-diploic arachnoid cyst communicating with sphenoid bone and in close proximity to cavernous sinus in a known case of Wilson disease: A rare entity,21 8 2024,,Wilson_Disease
"to venous dysplasia or agenesis. These cysts may later grow due to secretion by the cells lining the cyst, unidirectional action of the valves or movement of liquid secondary to the vein pulsations [<xref rid=""bib0005"" ref-type=""bibr"">5</xref>]. There is no association of the arachnoid cyst with any disease in particular and has not been described in the recent literature. Its association with the Wilson disease has not been previously described in the recent literature. Secondary arachnoid cysts develop",9_13,Nontraumatic intra-diploic arachnoid cyst communicating with sphenoid bone and in close proximity to cavernous sinus in a known case of Wilson disease: A rare entity,21 8 2024,,Wilson_Disease
"literature. Secondary arachnoid cysts develop mostly due to trauma. Traumatic insult to the head may cause bony defects and fractures. In these bony defects, arachnoid villi may extend, forming an intra-osseous cyst [<xref rid=""bib0009"" ref-type=""bibr"">9</xref>,<xref rid=""bib0010"" ref-type=""bibr"">10</xref>]. Leptomeningeal cysts and CSF fistula are other synonyms for post-traumatic arachnoid cysts [<xref rid=""bib0010"" ref-type=""bibr"">[10]</xref>, <xref rid=""bib0011"" ref-type=""bibr"">[11]</xref>, <xref",9_14,Nontraumatic intra-diploic arachnoid cyst communicating with sphenoid bone and in close proximity to cavernous sinus in a known case of Wilson disease: A rare entity,21 8 2024,,Wilson_Disease
"rid=""bib0011"" ref-type=""bibr"">[11]</xref>, <xref rid=""bib0012"" ref-type=""bibr"">[12]</xref>]. Nontraumatic intra-diploic cysts are very rare and mostly are seen in the occipital region and rarely in temporal or frontal regions [<xref rid=""bib0008"" ref-type=""bibr"">8</xref>,<xref rid=""bib0010"" ref-type=""bibr"">10</xref>,<xref rid=""bib0011"" ref-type=""bibr"">11</xref>]. The size and location of the cyst determine the severity of the signs and symptoms. Symptoms may include bulging of the head, raised intracranial",9_15,Nontraumatic intra-diploic arachnoid cyst communicating with sphenoid bone and in close proximity to cavernous sinus in a known case of Wilson disease: A rare entity,21 8 2024,,Wilson_Disease
"include bulging of the head, raised intracranial pressure, neurological defects, seizures, endocrine disorders, and psychomotor distortion. It is important to rule out various differentials for the arachnoid cyst for which MRI plays a major role. As in the case of the epidermoid cyst, the cystic lesion appears isointense to CSF in both T1WI AND T2WI but hyperintense to CSF on FLAIR and shows restriction on DWI [<xref rid=""bib0013"" ref-type=""bibr"">13</xref>]. Neuroglial cyst follows CSF signal intensity on",9_16,Nontraumatic intra-diploic arachnoid cyst communicating with sphenoid bone and in close proximity to cavernous sinus in a known case of Wilson disease: A rare entity,21 8 2024,,Wilson_Disease
"Neuroglial cyst follows CSF signal intensity on all sequences, as in the case of arachnoid cysts, but these are present in the white matter of the brain [<xref rid=""bib0014"" ref-type=""bibr"">14</xref>]. Other differentials may include subdural hygroma, which may appear isointense to CSF on T1WI and T2WI but hyperintense to CSF on the FLAIR sequence. Hemangioblastoma, pilocytic astrocytoma, etc., might mimic arachnoid cysts [<xref rid=""bib0015"" ref-type=""bibr"">15</xref>]. Asymptomatic arachnoid cysts do not",9_17,Nontraumatic intra-diploic arachnoid cyst communicating with sphenoid bone and in close proximity to cavernous sinus in a known case of Wilson disease: A rare entity,21 8 2024,,Wilson_Disease
"Asymptomatic arachnoid cysts do not need any management. Once the symptoms start to develop, these cysts must be excavated by a surgical approach, which includes marsupialization or fenestration through endoscopic or microscopic techniques or excision of the cyst [<xref rid=""bib0005"" ref-type=""bibr"">5</xref>]. Arachnoid cysts may be due to traumatic and nontraumatic causes. In the presented case, the arachnoid cyst is present at a very rare location and in close proximity to the cavernous sinus. Unusual",9_18,Nontraumatic intra-diploic arachnoid cyst communicating with sphenoid bone and in close proximity to cavernous sinus in a known case of Wilson disease: A rare entity,21 8 2024,,Wilson_Disease
close proximity to the cavernous sinus. Unusual location and low incidence may lead to misdiagnosis of the cyst. Proper clinical and radiological knowledge is of utmost importance in the diagnosis of the lesion and in differentiating it from other such lesions. An informed verbal and written consent were obtained from the patient.,9_19,Nontraumatic intra-diploic arachnoid cyst communicating with sphenoid bone and in close proximity to cavernous sinus in a known case of Wilson disease: A rare entity,21 8 2024,,Wilson_Disease
"Wilson disease (novel <italic toggle=""yes"">ATP7B</italic> variants) with concomitant <italic toggle=""yes"">FLNC</italic>-related cardiomyopathy We report a case of Wilson disease (WD) with dilated cardiomyopathy in which whole-genome sequencing (WGS) revealed the rare co-occurrence of two novel compound heterozygous <italic toggle=""yes"">ATP7B</italic> pathogenic variants (NM_001005918.3:c.2250del/p.N751Tfs*9 and c.3496C>T/p.L1166F) and a known FLNC pathogenic variant. Our results highlight the usefulness of",10_0,"Wilson disease (novel <italic toggle=""yes"">ATP7B</italic> variants) with concomitant <italic toggle=""yes"">FLNC</italic>-related cardiomyopathy",29 8 2024,,Wilson_Disease
"variant. Our results highlight the usefulness of WGS, even in the diagnosis of well-characterized genetic diseases such as WD. The relevant data from this Data Report are hosted at the Human Genome Variation Database at 10.6084/m9.figshare.hgv.3403, 10.6084/m9.figshare.hgv.3406, 10.6084/m9.figshare.hgv.3409",10_1,"Wilson disease (novel <italic toggle=""yes"">ATP7B</italic> variants) with concomitant <italic toggle=""yes"">FLNC</italic>-related cardiomyopathy",29 8 2024,,Wilson_Disease
"Macrothrombocytopenia with leukocyte inclusions in a patient with Wilson disease: a case report and literature review Wilson disease (WD) is an autosomal recessive disorder resulting from <italic toggle=""yes"">ATP7B</italic> gene dysfunction due to mutation, leading to copper accumulation in various tissues, primarily in the liver and brain [<xref ref-type=""bibr"" rid=""CR1"">1</xref>]. The spectrum of manifestations varies, encompassing liver cirrhosis, brain neuronal degeneration, Kayser–Fleischer (K-F) rings",11_0,Macrothrombocytopenia with leukocyte inclusions in a patient with Wilson disease: a case report and literature review,17 7 2024,,Wilson_Disease
"degeneration, Kayser–Fleischer (K-F) rings in the corneal limbus, kidney damage, and hemolytic anemia [<xref ref-type=""bibr"" rid=""CR2"">2</xref>–<xref ref-type=""bibr"" rid=""CR4"">4</xref>]. WD is often misdiagnosed because of the diverse clinical presentations. In this study, we present a case of a middle-aged woman exhibiting thrombocytopenia, giant platelets, and Döhle-like cytoplasmic inclusions in leukocytes. Whole-exome sequencing (WES) revealed a heterozygous <italic toggle=""yes"">ATP7B</italic> gene",11_1,Macrothrombocytopenia with leukocyte inclusions in a patient with Wilson disease: a case report and literature review,17 7 2024,,Wilson_Disease
"<italic toggle=""yes"">ATP7B</italic> gene mutation. Two years after this finding, the patient developed hand tremors, lower limb stiffness, and foreign body sensation in the eyes. We questioned whether these symptoms were associated with WD. To explore this possibility further, we performed copper metabolism analysis, slit-lamp examination, magnetic resonance imaging (MRI), transmission electron microscopy (TEM) observation, and leukocyte copper content detection. In June 2021, a 48-year-old woman presented",11_2,Macrothrombocytopenia with leukocyte inclusions in a patient with Wilson disease: a case report and literature review,17 7 2024,,Wilson_Disease
"In June 2021, a 48-year-old woman presented at our hospital with a 2-year history of easy bruising. Complete blood counts were normal; however, thrombocytopenia was observed (white blood cell count: 3.88 × 10<sup>9</sup>/L; red blood cell count: 3.80 × 10<sup>12</sup>/L; hemoglobin: 115 g/L; platelet count: 65 × 10<sup>9</sup>/L). Other laboratory parameters, including antiplatelet and antinuclear antibodies, thromboaggregation function, von Willebrand factor antigens, prothrombin time, and activated",11_3,Macrothrombocytopenia with leukocyte inclusions in a patient with Wilson disease: a case report and literature review,17 7 2024,,Wilson_Disease
"factor antigens, prothrombin time, and activated partial thromboplastin time, were within normal limits. Liver function test results were mainly normal, except for reduced albumin levels (37.84 g/L; normal range: 40.0–55.0 g/L). Peripheral blood smear revealed thrombocytopenia, with large and giant platelets and Döhle-like cytoplasmic inclusions in the leukocytes. Bone marrow smears showed easily observable Döhle-like cytoplasmic inclusions in neutrophils and megakaryocytes, with degenerative cells being",11_4,Macrothrombocytopenia with leukocyte inclusions in a patient with Wilson disease: a case report and literature review,17 7 2024,,Wilson_Disease
"and megakaryocytes, with degenerative cells being common (Fig. <xref rid=""Fig1"" ref-type=""fig"">1</xref>). Initially, the May–Hegglin anomaly (MHA) was provisionally diagnosed. However, WES showed no mutation in the <italic toggle=""yes"">MYH9</italic> gene but indicated a heterozygous mutation in the twelfth exon of the <italic toggle=""yes"">ATP7B</italic> gene (C.2804 C > T, p.T935M), altering threonine at codon 935 to methionine. The vatiant was verified by Sanger sequencing (Fig. <xref rid=""Fig2""",11_5,Macrothrombocytopenia with leukocyte inclusions in a patient with Wilson disease: a case report and literature review,17 7 2024,,Wilson_Disease
"by Sanger sequencing (Fig. <xref rid=""Fig2"" ref-type=""fig"">2</xref>). This variant is a hotspot mutation in <italic toggle=""yes"">ATP7B</italic>. However, the patient lacked typical WD symptoms, so a diagnosis of WD was not made at that time. Dexamethasone therapy (10 mg/dose, tid, p.o) was initiated but showed a poor response, with platelet counts fluctuating within the range 62–68 × 10<sup>9</sup>/L. No further treatment was administered.",11_6,Macrothrombocytopenia with leukocyte inclusions in a patient with Wilson disease: a case report and literature review,17 7 2024,,Wilson_Disease
"<fig id=""Fig1""><label>Fig. 1</label><caption><p>Peripheral blood and bone marrow smears of the patient. (<bold>A</bold>) Larger platelet (yellow arrow) and Döhle-like cytoplasmic inclusion (red arrow) in neutrophils on the peripheral blood smear. (<bold>B</bold>) Giant platelet (blue arrow) on the peripheral blood smear. (<bold>C</bold>) Döhle-like cytoplasmic inclusions in neutrophils (red arrow) on the bone marrow smear. (<bold>D</bold>) Döhle-like cytoplasmic inclusions in a megakaryocyte (red arrow) on",11_7,Macrothrombocytopenia with leukocyte inclusions in a patient with Wilson disease: a case report and literature review,17 7 2024,,Wilson_Disease
"inclusions in a megakaryocyte (red arrow) on the bone marrow smear (Wright’s stain, ×400, all)</p></caption><graphic http://www.w3.org/1999/xlink href=""12920_2024_1960_Fig1_HTML"" id=""d33e308""></graphic></fig>",11_8,Macrothrombocytopenia with leukocyte inclusions in a patient with Wilson disease: a case report and literature review,17 7 2024,,Wilson_Disease
"<fig id=""Fig2""><label>Fig. 2</label><caption><p>Sequence chromatogram showing the heterozygous nucleotide sequence of c.2840 C > T. Red arrow indicates the mutation site</p></caption><graphic http://www.w3.org/1999/xlink href=""12920_2024_1960_Fig2_HTML"" id=""d33e318""></graphic></fig>",11_9,Macrothrombocytopenia with leukocyte inclusions in a patient with Wilson disease: a case report and literature review,17 7 2024,,Wilson_Disease
"In March 2023, the patient returned to our hospital with extremity ecchymosis, hand tremors, lower limb stiffness, and foreign body sensation in the eyes. Automatic blood cell analysis revealed a platelet count of 46 × 10<sup>9</sup>/L. Peripheral blood and bone marrow smears were similar to those from two years prior. Copper metabolism assessment showed serum ceruloplasmin, serum copper, and 24-hour urine copper levels of 23 (normal range: 25–45) mg/dL, 1161.4 (normal range: 800.0–1550.0) µg/L, and 21.1",11_10,Macrothrombocytopenia with leukocyte inclusions in a patient with Wilson disease: a case report and literature review,17 7 2024,,Wilson_Disease
"(normal range: 800.0–1550.0) µg/L, and 21.1 (normal range: 15.0–60.0) µg/24 h, respectively. Liver function tests indicated decreased albumin levels (35.97 g/L; normal range: 40.00–55.00 g/L). Brain MRI displayed minimal T1W1 low-intensity signal and T2W1 high-intensity signal in both ventricular anterior corners. Abdominal MRI showed multiple liver nodules with prolonged T1 and T2 signals. Slit-lamp examination revealed K-F rings in the corneal limbus (Fig. <xref rid=""Fig3"" ref-type=""fig"">3</xref>A). TEM",11_11,Macrothrombocytopenia with leukocyte inclusions in a patient with Wilson disease: a case report and literature review,17 7 2024,,Wilson_Disease
"rid=""Fig3"" ref-type=""fig"">3</xref>A). TEM showed abundant α particles and dense particles in the giant platelets, along with irregularly expanded and fuzzy inclusion bodies (mitochondria) with broken cristae in leukocytes (Fig. <xref rid=""Fig3"" ref-type=""fig"">3</xref>B).",11_12,Macrothrombocytopenia with leukocyte inclusions in a patient with Wilson disease: a case report and literature review,17 7 2024,,Wilson_Disease
"<fig id=""Fig3""><label>Fig. 3</label><caption><p>(<bold>A</bold>) Brown-spotted, arc-shaped copper deposits observed in the corneal limbus (red arrow). (<bold>B</bold>) Large platelets with adequate α granules and dense particles observed via Transmission electron microscopy (TEM) (green arrow). Swollen mitochondria in leukocytes observed by TEM (red arrow)</p></caption><graphic http://www.w3.org/1999/xlink href=""12920_2024_1960_Fig3_HTML"" id=""d33e347""></graphic></fig>",11_13,Macrothrombocytopenia with leukocyte inclusions in a patient with Wilson disease: a case report and literature review,17 7 2024,,Wilson_Disease
"Leukocyte copper content, measured using inductively coupled plasma mass spectrometry, was 1.41 fg/cell for the patient and 0.07 ± 0.04 fg/cell for the control group (<italic toggle=""yes"">n</italic> = 10), representing nearly a 20-fold increase in the patient. Based on these findings, the patient was diagnosed with WD according to the Leipzig scoring system proposed by an international group for the study of WD [<xref ref-type=""bibr"" rid=""CR5"">5</xref>]. The patient’s Leipzig score was 4 points (K-F rings",11_14,Macrothrombocytopenia with leukocyte inclusions in a patient with Wilson disease: a case report and literature review,17 7 2024,,Wilson_Disease
"patient’s Leipzig score was 4 points (K-F rings present, score 2; neurological symptoms, score 1; and only one chromosome detected, score 1). Therefore, the patient was prescribed the full dose of zinc sulfate (60 mg/dose, tid, p.o.) to treat WD. After 6 months of follow-up, they showed substantial improvement in their hand tremors, lower limb stiffness, ocular discomfort, and limb ecchymosis symptoms. Laboratory tests revealed a platelet count of 78 × 10<sup>9</sup>/L, serum ceruloplasmin concentration",11_15,Macrothrombocytopenia with leukocyte inclusions in a patient with Wilson disease: a case report and literature review,17 7 2024,,Wilson_Disease
"serum ceruloplasmin concentration increase from 23 mg/dL to 25 mg/dL, and serum albumin level rise from 35.97 g/L to 42.3 g/L. WD arises from homozygous or compound heterozygous mutations in <italic toggle=""yes"">ATP7B</italic>, a gene encoding a copper-transporting P-type ATPase [<xref ref-type=""bibr"" rid=""CR6"">6</xref>, <xref ref-type=""bibr"" rid=""CR7"">7</xref>]. Dysfunction in <italic toggle=""yes"">ATP7B</italic> leads to hepatic copper accumulation and excessive nonceruloplasmin-bound copper in the",11_16,Macrothrombocytopenia with leukocyte inclusions in a patient with Wilson disease: a case report and literature review,17 7 2024,,Wilson_Disease
"excessive nonceruloplasmin-bound copper in the circulation, resulting in copper uptake and subsequent injury to the brain and kidneys, among other organs [<xref ref-type=""bibr"" rid=""CR8"">8</xref>, <xref ref-type=""bibr"" rid=""CR9"">9</xref>]. Hepatic manifestations of WD range from asymptomatic transaminase elevation to fibrosis, cirrhosis, and acute liver failure. Heterozygotic carriers of faulty <italic toggle=""yes"">ATP7B</italic> may remain asymptomatic; however, 20% of cases exhibit copper metabolism",11_17,Macrothrombocytopenia with leukocyte inclusions in a patient with Wilson disease: a case report and literature review,17 7 2024,,Wilson_Disease
"however, 20% of cases exhibit copper metabolism abnormalities [<xref ref-type=""bibr"" rid=""CR10"">10</xref>]. Notably, some heterozygotic mutation carriers show limb tremors or liver symptoms [<xref ref-type=""bibr"" rid=""CR11"">11</xref>–<xref ref-type=""bibr"" rid=""CR13"">13</xref>]. A single T935M heterozygotic mutation in the <italic toggle=""yes"">ATP7B</italic> gene of patients with WD has not been previously reported. In this case, a single T935M heterozygotic mutation in <italic toggle=""yes"">ATP7B</italic>",11_18,Macrothrombocytopenia with leukocyte inclusions in a patient with Wilson disease: a case report and literature review,17 7 2024,,Wilson_Disease
"mutation in <italic toggle=""yes"">ATP7B</italic> was detected using WES and validated using Sanger sequencing. Furthermore, the patient gradually developed neurological symptoms and ocular discomfort, with K-F rings in the corneal limbus evident upon slit-lamp examination. Collectively, these findings confirmed the WD diagnosis. Moreover, effective zinc sulfate treatment corroborated the occurrence of excessive copper accumulation in the patient. Hemolysis is an important hematologic manifestation of",11_19,Macrothrombocytopenia with leukocyte inclusions in a patient with Wilson disease: a case report and literature review,17 7 2024,,Wilson_Disease
"is an important hematologic manifestation of Wilson’s disease. An analysis of 321 case notes of patients with Wilson’s disease seen between 1955 and 2000 and one case seen in 1949 has revealed that 22 patients presented with a haemolytic crisis. [<xref ref-type=""bibr"" rid=""CR14"">14</xref>]. Pop et al. reported that 8 children had Coombs-negative hemolytic anemia in the total analyzed cases with 51 WD patients (15.67%) [<xref ref-type=""bibr"" rid=""CR15"">15</xref>]. Despite large number of cases have been",11_20,Macrothrombocytopenia with leukocyte inclusions in a patient with Wilson disease: a case report and literature review,17 7 2024,,Wilson_Disease
"Despite large number of cases have been reported, however, the mechanism of hemolysis in WD remains unclear. In addition, other hematologic manifestations, including leukopenia and thrombocytopenia have been rarely reported [<xref ref-type=""bibr"" rid=""CR16"">16</xref>, <xref ref-type=""bibr"" rid=""CR17"">17</xref>]. In the present case, the patient exhibited thrombocytopenia, giant platelets, and Döhle-like cytoplasmic inclusions in leukocytes, similar to MHA. Interestingly, no <italic",11_21,Macrothrombocytopenia with leukocyte inclusions in a patient with Wilson disease: a case report and literature review,17 7 2024,,Wilson_Disease
"similar to MHA. Interestingly, no <italic toggle=""yes"">MYH9</italic> gene mutation was found. Therefore, we questioned whether these abnormal hematological findings were associated with WD. Mass spectrometry revealed that leukocyte copper levels were almost 20-fold higher in the patient than in the control group. Previous studies have shown that, compared with patients with homozygous mutations, carriers exhibit slower copper deposition due to a partial decline in <italic toggle=""yes"">ATP7B</italic> gene",11_22,Macrothrombocytopenia with leukocyte inclusions in a patient with Wilson disease: a case report and literature review,17 7 2024,,Wilson_Disease
"in <italic toggle=""yes"">ATP7B</italic> gene function [<xref ref-type=""bibr"" rid=""CR18"">18</xref>, <xref ref-type=""bibr"" rid=""CR19"">19</xref>]. In tissues, the toxicity of excess copper is attributed to its redox activity, which induces oxidative stress and results in lipid, protein, DNA, and RNA molecule damage [<xref ref-type=""bibr"" rid=""CR20"">20</xref>]. At the subcellular level, mitochondria are highly sensitive to copper-induced toxicity, with excess copper causing mitochondrial impairment as well as",11_23,Macrothrombocytopenia with leukocyte inclusions in a patient with Wilson disease: a case report and literature review,17 7 2024,,Wilson_Disease
"causing mitochondrial impairment as well as DNA damage through reactive oxygen species production [<xref ref-type=""bibr"" rid=""CR21"">21</xref>]. In the present case, Döhle-like cytoplasmic inclusions were clearly observed in leukocytes, with TEM indicating that the inclusion bodies of leukocytes were swollen mitochondria. Therefore, we postulated that chronic copper accumulation could induce toxic changes in the mitochondria of these cells. The mechanism underlying thrombocytopenia in patients with WD is",11_24,Macrothrombocytopenia with leukocyte inclusions in a patient with Wilson disease: a case report and literature review,17 7 2024,,Wilson_Disease
"thrombocytopenia in patients with WD is not fully understood. Thrombocytopenia with negative antiplatelet antibodies has been reported in children, attributed to hypersplenism and/or D-penicillamine therapy’s side-effects [<xref ref-type=""bibr"" rid=""CR22"">22</xref>]. A few studies have indicated idiopathic thrombocytopenia as an initial sign in patients with WD [<xref ref-type=""bibr"" rid=""CR23"">23</xref>, <xref ref-type=""bibr"" rid=""CR24"">24</xref>]. Our patient presented with thrombocytopenia,",11_25,Macrothrombocytopenia with leukocyte inclusions in a patient with Wilson disease: a case report and literature review,17 7 2024,,Wilson_Disease
"Our patient presented with thrombocytopenia, macroplatelets, and Döhle-like cytoplasmic inclusions in the megakaryocytes. They initially showed unresponsiveness to hormonal therapy, and zinc sulfate administration after WD diagnosis resulted in a platelet count increase from 46 × 10<sup>9</sup>/L to 78 × 10<sup>9</sup>/L, suggesting WD-related thrombocytopenia. However, the contribution of excess copper accumulation to these phenomena warrants further investigation. Because the patient declined a bone",11_26,Macrothrombocytopenia with leukocyte inclusions in a patient with Wilson disease: a case report and literature review,17 7 2024,,Wilson_Disease
"Because the patient declined a bone marrow biopsy, we will investigate the effects of copper exposure on megakaryocytes in vitro. In summary, this case is the first report that WD patient was presented by thrombocytopenia, giant platelets, Dohle-like cytoplasmic inclusions in the leukocytes. Clinically, if patients have the above manifestations, genetic analysis should be performed to distinguish them from MHA to avoid misdiagnosis. A heterozygous carrier with a defective <italic",11_27,Macrothrombocytopenia with leukocyte inclusions in a patient with Wilson disease: a case report and literature review,17 7 2024,,Wilson_Disease
"A heterozygous carrier with a defective <italic toggle=""yes"">ATP7B</italic> gene might also show the similar symptoms of WD. The carriers with clinical symptoms should be paid more attention, and the progress of patients’ conditions should be monitored. The early diagnosis and timely treatment of WD are quite critical. This study has stimulated our interests in further exploring the pathophysiological mechanism of abnormal hematological changes caused by copper accumulation, especially how excessive copper",11_28,Macrothrombocytopenia with leukocyte inclusions in a patient with Wilson disease: a case report and literature review,17 7 2024,,Wilson_Disease
"accumulation, especially how excessive copper affects megakaryocytes to induce thrombocytopenia with abnormal morphology will be the focus of our further research.",11_29,Macrothrombocytopenia with leukocyte inclusions in a patient with Wilson disease: a case report and literature review,17 7 2024,,Wilson_Disease
"Efficacy and safety of D-penicillamine, trientine, and zinc in pediatric Wilson disease patients Wilson disease (WD) is a genetic disease caused by mutations in ATP7B, an ATPase responsible for the excretion of copper from the liver into bile [<xref ref-type=""bibr"" rid=""CR1"">1</xref>]. Initially, copper deposition occurs in the liver; however, as the disease progresses, copper accumulates in other organs, including the brain. The clinical symptoms of WD vary depending on the affected organ, leading to",12_0,"Efficacy and safety of D-penicillamine, trientine, and zinc in pediatric Wilson disease patients",9 7 2024,,Wilson_Disease
"vary depending on the affected organ, leading to variations in the age at symptom onset. Hepatic symptoms typically manifest after 2 years of age, whereas neurological and psychiatric symptoms usually arise after the age of 10 years [<xref ref-type=""bibr"" rid=""CR2"">2</xref>–<xref ref-type=""bibr"" rid=""CR6"">6</xref>]. Recently, genetic testing has facilitated the diagnosis of WD, allowing the identification of asymptomatic individuals before 2 years of age [<xref ref-type=""bibr"" rid=""CR7"">7</xref>]. Lifelong",12_1,"Efficacy and safety of D-penicillamine, trientine, and zinc in pediatric Wilson disease patients",9 7 2024,,Wilson_Disease
"ref-type=""bibr"" rid=""CR7"">7</xref>]. Lifelong treatment is necessary to maintain a negative copper balance, as failure to do so can result in liver failure or neurological complications leading to death [<xref ref-type=""bibr"" rid=""CR8"">8</xref>]. Treatment options consist of chelators, which enhance copper excretion in urine by eliminating copper deposits, and zinc, which inhibits copper absorption in the intestinal tract [<xref ref-type=""bibr"" rid=""CR9"">9</xref>]. An adult study demonstrated that zinc",12_2,"Efficacy and safety of D-penicillamine, trientine, and zinc in pediatric Wilson disease patients",9 7 2024,,Wilson_Disease
"An adult study demonstrated that zinc monotherapy is less effective than chelator therapy in patients with declining liver function [<xref ref-type=""bibr"" rid=""CR10"">10</xref>]; however, no relevant studies have been conducted in children. Moreover, there currently is no separate analysis of trientine in both pediatric and adult populations. Although the therapeutic and adverse effects of WD drugs may vary among toddlers, adolescents, and adults, few studies have compared these drugs, particularly in",12_3,"Efficacy and safety of D-penicillamine, trientine, and zinc in pediatric Wilson disease patients",9 7 2024,,Wilson_Disease
"have compared these drugs, particularly in children. The present study aimed to compare the therapeutic and adverse effects of D-penicillamine (DPA), trientine, and zinc in children with WD.   WD is a genetic disease that can be treated. The early initiation of medication is crucial to prevent complications arising from the accumulation of copper in the liver and other organs. In the past, the prevalence of WD was estimated to be approximately 30 per 1 million people [<xref ref-type=""bibr""",12_4,"Efficacy and safety of D-penicillamine, trientine, and zinc in pediatric Wilson disease patients",9 7 2024,,Wilson_Disease
"30 per 1 million people [<xref ref-type=""bibr"" rid=""CR12"">12</xref>]; however, with the rise in genetic testing for diagnosis, there has been an increase in the rate of early detection. Recent reports from Hong Kong indicate an annual incidence rate of 1.4 per 1 million people [<xref ref-type=""bibr"" rid=""CR13"">13</xref>], while in Thailand, the annual incidence was reported to be 2.7 per 1 million people [<xref ref-type=""bibr"" rid=""CR14"">14</xref>]. A recent study conducted in Korea utilized the National",12_5,"Efficacy and safety of D-penicillamine, trientine, and zinc in pediatric Wilson disease patients",9 7 2024,,Wilson_Disease
"study conducted in Korea utilized the National Health Insurance Service (NHIS) database from 2010 to 2016. The findings revealed an annual incidence rate of 3.8 per 1 million people for WD, with 43.1% of patients diagnosed before the age of 20 years [<xref ref-type=""bibr"" rid=""CR15"">15</xref>]. Consequently, there is a pressing need for active research focused on the diagnosis and treatment of WD in children across Asia. However, to date, there is a scarcity of comparative studies examining the efficacy",12_6,"Efficacy and safety of D-penicillamine, trientine, and zinc in pediatric Wilson disease patients",9 7 2024,,Wilson_Disease
"of comparative studies examining the efficacy and potential adverse effects of WD treatment, particularly in the pediatric population. Over the past two decades, guidelines regarding the diagnosis and management of WD have been published [<xref ref-type=""bibr"" rid=""CR9"">9</xref>, <xref ref-type=""bibr"" rid=""CR16"">16</xref>–<xref ref-type=""bibr"" rid=""CR20"">20</xref>]. For pediatric patients, European guidelines recommend using DPA and trientine as the initial treatment for children with significant liver",12_7,"Efficacy and safety of D-penicillamine, trientine, and zinc in pediatric Wilson disease patients",9 7 2024,,Wilson_Disease
"treatment for children with significant liver disease, such as cirrhosis or abnormal INR, whereas zinc therapy is recommended for presymptomatic patients or as maintenance therapy after decoppering with chelators [<xref ref-type=""bibr"" rid=""CR19"">19</xref>]. However, due to a lack of consensus on defined criteria for clinical classification of WD, guidelines cannot be universally applied to individual patients. As a result, the management of WD patients globally exhibits heterogeneity [<xref",12_8,"Efficacy and safety of D-penicillamine, trientine, and zinc in pediatric Wilson disease patients",9 7 2024,,Wilson_Disease
"patients globally exhibits heterogeneity [<xref ref-type=""bibr"" rid=""CR21"">21</xref>]. DPA has been used as a treatment for WD since the 1950s [<xref ref-type=""bibr"" rid=""CR22"">22</xref>]. However, it is associated with known adverse effects that occur in approximately 30% of patients [<xref ref-type=""bibr"" rid=""CR23"">23</xref>–<xref ref-type=""bibr"" rid=""CR25"">25</xref>]. Notably, owing to the potential for significant neurological deterioration as a serious adverse effect, DPA is not recommended as a",12_9,"Efficacy and safety of D-penicillamine, trientine, and zinc in pediatric Wilson disease patients",9 7 2024,,Wilson_Disease
"adverse effect, DPA is not recommended as a treatment option for patients presenting with neurological symptoms [<xref ref-type=""bibr"" rid=""CR26"">26</xref>–<xref ref-type=""bibr"" rid=""CR29"">29</xref>]. In the present study, the incidence of adverse effects was relatively high (approximately 45%) in the patients treated with DPA. However, among the 16 patients who experienced adverse effects, only one case of irreversible complications was reported. The patient was diagnosed with WD at 5 years of age and",12_10,"Efficacy and safety of D-penicillamine, trientine, and zinc in pediatric Wilson disease patients",9 7 2024,,Wilson_Disease
"was diagnosed with WD at 5 years of age and switched to DPA at 8 years of age. Despite previous treatment with trientine and a combination of trientine and zinc, no improvement in liver function was observed. After taking DPA for 5 years, the patient developed symptoms, such as pulmonary hemorrhage, microscopic hematuria, and proteinuria, at approximately 13 years of age. Subsequent kidney biopsy confirmed pauci-immune crescentic glomerulonephritis, leading to diagnosis of D-penicillamine-induced",12_11,"Efficacy and safety of D-penicillamine, trientine, and zinc in pediatric Wilson disease patients",9 7 2024,,Wilson_Disease
"leading to diagnosis of D-penicillamine-induced ANCA-associated vasculitis [<xref ref-type=""bibr"" rid=""CR30"">30</xref>]. In this study, only two patients had neurological symptoms as the initial symptom of the disease, and DPA was not used as the first treatment for these patients. DPA administration was started at 5–10 mg/kg or 150–300 mg/day, and the dose was gradually increased to 20 mg/kg while monitoring the effects and side effects. None of the patients taking DPA developed new neurological symptoms",12_12,"Efficacy and safety of D-penicillamine, trientine, and zinc in pediatric Wilson disease patients",9 7 2024,,Wilson_Disease
"taking DPA developed new neurological symptoms while taking the drug. Although DPA had a relatively high incidence of adverse effects, it was more effective than other drugs. Among the patients treated with DPA, only two out of 37 (5%) showed no improvement and required a change in medication. Initially, DPA was the first-line treatment for both patients, but it was subsequently switched to trientine. However, even with trientine, there was no improvement in drug efficacy, necessitating a change in",12_13,"Efficacy and safety of D-penicillamine, trientine, and zinc in pediatric Wilson disease patients",9 7 2024,,Wilson_Disease
"in drug efficacy, necessitating a change in treatment to a combination therapy involving zinc. Weiss et al<italic toggle=""yes"">.</italic> compared chelator and zinc monotherapy in the study involving 288 adults with WD. The treatment effect of chelator was significantly greater than that of zinc, but there was no significant difference in adverse effects sufficient to change the treatment [<xref ref-type=""bibr"" rid=""CR10"">10</xref>]. A recent systematic review examining the treatment of WD in both",12_14,"Efficacy and safety of D-penicillamine, trientine, and zinc in pediatric Wilson disease patients",9 7 2024,,Wilson_Disease
"review examining the treatment of WD in both pediatric and adult patients reported similar treatment effects between DPA and zinc, but with a higher occurrence of adverse effects associated with DPA [<xref ref-type=""bibr"" rid=""CR31"">31</xref>]. Patients treated with DPA showed a significantly higher frequency of neurological deterioration compared to those treated with zinc (RR: 1.96, 95% CI: 1.31%–2.93%, <italic toggle=""yes"">p</italic> = 0.001). It is important to exercise caution when interpreting the",12_15,"Efficacy and safety of D-penicillamine, trientine, and zinc in pediatric Wilson disease patients",9 7 2024,,Wilson_Disease
"to exercise caution when interpreting the therapeutic effect of the drug, as the studies included in the systematic review employed varying doses of DPA and zinc. In 1969, trientine was introduced as a second-line treatment for adverse effects of DPA [<xref ref-type=""bibr"" rid=""CR32"">32</xref>, <xref ref-type=""bibr"" rid=""CR33"">33</xref>]. Currently, it is used as first-line treatment along with DPA for symptomatic patients with WD, with trientine being the preferred option in the presence of neurological",12_16,"Efficacy and safety of D-penicillamine, trientine, and zinc in pediatric Wilson disease patients",9 7 2024,,Wilson_Disease
"preferred option in the presence of neurological symptoms [<xref ref-type=""bibr"" rid=""CR8"">8</xref>]. In this study, only two patients experienced reversible adverse effects. Among the 50 patients who received trientine, 22 switched to another medication due to its low therapeutic efficacy. However, during the follow-up period, six of the 22 patients were re-treated with trientine. Among them, three patients demonstrated a positive therapeutic response to trientine and continued with trientine monotherapy.",12_17,"Efficacy and safety of D-penicillamine, trientine, and zinc in pediatric Wilson disease patients",9 7 2024,,Wilson_Disease
"and continued with trientine monotherapy. Considering the potential changes in copper absorption, metabolism, and pharmacokinetics with age among pediatric patients, further studies on sequential therapy in WD will be necessary. Zinc is recommended as a maintenance treatment for symptomatic patients with WD and as a first-line treatment for asymptomatic patients [<xref ref-type=""bibr"" rid=""CR9"">9</xref>]. In this study, all of the adverse effects associated with zinc were gastrointestinal symptoms.",12_18,"Efficacy and safety of D-penicillamine, trientine, and zinc in pediatric Wilson disease patients",9 7 2024,,Wilson_Disease
"with zinc were gastrointestinal symptoms. Previous studies have reported additional adverse effects of zinc, including copper deficiency-related anemia, neutropenia, sensorimotor neuropathy, myelopathy, and worsening of neurological symptoms [<xref ref-type=""bibr"" rid=""CR34"">34</xref>–<xref ref-type=""bibr"" rid=""CR37"">37</xref>]; however, in this study, there were no adverse effects other than gastrointestinal symptoms. Zinc treatment is generally considered relatively tolerable in children [<xref",12_19,"Efficacy and safety of D-penicillamine, trientine, and zinc in pediatric Wilson disease patients",9 7 2024,,Wilson_Disease
"relatively tolerable in children [<xref ref-type=""bibr"" rid=""CR38"">38</xref>–<xref ref-type=""bibr"" rid=""CR42"">42</xref>]. Importantly, this study found that zinc was significantly more effective than trientine, a chelator, in treating WD. Therefore, zinc therapy can be effectively utilized in the early diagnosis and treatment of pediatric WD. This study had some limitations inherent to retrospective research. The study included five patients out of the seven diagnosed with ALF, excluding the two patients",12_20,"Efficacy and safety of D-penicillamine, trientine, and zinc in pediatric Wilson disease patients",9 7 2024,,Wilson_Disease
"diagnosed with ALF, excluding the two patients who underwent emergency LT. Among the included patients, three had been receiving medical treatment for more than 2–6 years and were under observation. The remaining two patients had an INR over 2.0 and bilirubin levels ranging from 2 to 5 mg/dL at the time of diagnosis. Despite receiving inpatient treatment for 2 weeks and 3 weeks, respectively, there was no improvement in liver function, leading to the decision to undergo LT [<xref ref-type=""bibr""",12_21,"Efficacy and safety of D-penicillamine, trientine, and zinc in pediatric Wilson disease patients",9 7 2024,,Wilson_Disease
"the decision to undergo LT [<xref ref-type=""bibr"" rid=""CR43"">43</xref>]. One of the two patients developed pancytopenia during DPA therapy and was included as a case of DPA adverse effects in the Kaplan–Meier analysis. However, these patients may be challenging to assess for treatment response, which could be considered a limitation of the study design. Another limitation of our study is the low proportion of treatment blocks used in the analysis, and the short duration of each treatment. This is due to",12_22,"Efficacy and safety of D-penicillamine, trientine, and zinc in pediatric Wilson disease patients",9 7 2024,,Wilson_Disease
"short duration of each treatment. This is due to many cases of medication changes due to lack of drug stock and improved treatment effects, such as changes from chelators to zinc or from combination therapy to monotherapy. Our study aimed to comprehensively understand the reasons for medication changes in the actual treatment of pediatric WD patients without considering the duration of medication administration. Since drug adverse effects can appear abruptly within a month or even a week, this study is",12_23,"Efficacy and safety of D-penicillamine, trientine, and zinc in pediatric Wilson disease patients",9 7 2024,,Wilson_Disease
"within a month or even a week, this study is thought to be more helpful in interpreting the impact of drug adverse effects on maintenance therapy in pediatric WD patients compared to adult studies that only include statistical analysis of cases with a medication duration of six months or more [<xref ref-type=""bibr"" rid=""CR10"">10</xref>). Despite the retrospective study's limitations, this is the first study to compare the treatment effectiveness and adverse effects of DPA, trientine, and zinc in the",12_24,"Efficacy and safety of D-penicillamine, trientine, and zinc in pediatric Wilson disease patients",9 7 2024,,Wilson_Disease
"effects of DPA, trientine, and zinc in the real-world practice of pediatric WD patients. In conclusion, DPA, zinc, and trientine have therapeutic effects in that order, but DPA and zinc each have more adverse effects than trientine in pediatric WD.",12_25,"Efficacy and safety of D-penicillamine, trientine, and zinc in pediatric Wilson disease patients",9 7 2024,,Wilson_Disease
The history of Wilson disease Full text not available in PMC,13_0,The history of Wilson disease,Jan-Jun 2024,,Wilson_Disease
"Decoding Wilson disease: a machine learning approach to predict neurological symptoms Wilson disease (WD), alsoknown as hepatolenticular degeneration (HLD), was described by Wilson in 1912 and is a rare autosomal recessive inherited disorder (<xref rid=""B1"" ref-type=""bibr"">1</xref>, <xref rid=""B2"" ref-type=""bibr"">2</xref>). The disease is caused by homozygous or compound heterozygous mutations in ATP7B, which encodes the transmembrane copper-transporting ATPase 2 (commonly referred to as ATP7B). Abnormal",14_0,Decoding Wilson disease: a machine learning approach to predict neurological symptoms,19 6 2024,,Wilson_Disease
"2 (commonly referred to as ATP7B). Abnormal function of ATP7B can lead to impaired copper homeostasis and copper overload in the brain, liver and other organs (<xref rid=""B3"" ref-type=""bibr"">3</xref>). Neurological symptoms are one of the most common types of symptoms associated with this disease. According to research reports, 18–68% of WD patients experience neurological symptoms for the first time, with an average age of 20–30 years (<xref rid=""B4"" ref-type=""bibr"">4</xref>, <xref rid=""B5""",14_1,Decoding Wilson disease: a machine learning approach to predict neurological symptoms,19 6 2024,,Wilson_Disease
"rid=""B4"" ref-type=""bibr"">4</xref>, <xref rid=""B5"" ref-type=""bibr"">5</xref>). However, most patients exhibit liver symptoms in the early stages, followed by severe neurological symptoms (<xref rid=""B1"" ref-type=""bibr"">1</xref>). Although UWDRS, GAS and other scales can assess the neurological symptoms of patients, the treatment effect is often poor when patients experience neurological symptoms (<xref rid=""B6"" ref-type=""bibr"">6</xref>–<xref rid=""B8"" ref-type=""bibr"">8</xref>). Therefore, predicting and",14_2,Decoding Wilson disease: a machine learning approach to predict neurological symptoms,19 6 2024,,Wilson_Disease
"Therefore, predicting and intervening in advance on the relevant influencing factors that cause neurological symptoms in patients is crucial for their prognosis. Machine learning is a research field dedicated to understanding how computers acquire knowledge from data (<xref rid=""B9"" ref-type=""bibr"">9</xref>). Machine learning technology involves computer-based statistical methods that are trained to identify common patterns and hidden correlations in large datasets. In clinical practice, machine learning",14_3,Decoding Wilson disease: a machine learning approach to predict neurological symptoms,19 6 2024,,Wilson_Disease
"datasets. In clinical practice, machine learning methods can help clinicians classify patients with multiple diseases according to several variables (<xref rid=""B10"" ref-type=""bibr"">10</xref>–<xref rid=""B12"" ref-type=""bibr"">12</xref>). In recent years, multiple studies have been reported on the application of machine learning methods in predicting Parkinson's disease and Alzheimer's disease (<xref rid=""B13"" ref-type=""bibr"">13</xref>, <xref rid=""B14"" ref-type=""bibr"">14</xref>). In addition, research on",14_4,Decoding Wilson disease: a machine learning approach to predict neurological symptoms,19 6 2024,,Wilson_Disease
"In addition, research on machine learning-based prediction of liver cirrhosis in WD has also achieved great success (<xref rid=""B15"" ref-type=""bibr"">15</xref>). However, so far, no model was used to predict the development of neurological symptoms in WD. Therefore, this study combines machine learning with clinical multidimensional indicators, such as general clinical information, imaging examinations, blood and urine tests, and clinical scale measurements, to determine the most important indicators",14_5,Decoding Wilson disease: a machine learning approach to predict neurological symptoms,19 6 2024,,Wilson_Disease
"to determine the most important indicators related to WD neurological symptoms and construct a predictive model for the occurrence of neurological symptoms in WD patients. Intended to provide clinical decision-making tools for clinicians, it is hoped that through early intervention of these important factors, patients can delay or even avoid the occurrence of neurological symptoms. The flowchart of this study was shown in <xref rid=""F1"" ref-type=""fig"">Figure 1</xref>.   As far as we know, this is the first",14_6,Decoding Wilson disease: a machine learning approach to predict neurological symptoms,19 6 2024,,Wilson_Disease
"1</xref>.   As far as we know, this is the first prospective case-control study to combine machine learning methods with multidimensional clinical data to predict the onset of neurological symptoms in WD patients. In this study, the XGB method in machine learning was employed to construct models to predict the occurrence of neurological symptoms in WD patients. The MCC, ACC, AUC, and AUPRC values on the test set were 0.556, 0.929, 0.835, and 0.975, respectively, achieving good results. The results",14_7,Decoding Wilson disease: a machine learning approach to predict neurological symptoms,19 6 2024,,Wilson_Disease
"respectively, achieving good results. The results suggested that brainstem damage (0.794), Cr (0.702), age (0.627), IBIL (0.577), and CP (0.533) were the top five important predictors of Gini impurity, and the presence of brainstem damage and the higher the values of Cr, Age, and IBIL, the more likely neurological symptoms were to occur, while the lower the CP value, the more likely neurological symptoms were to occur. When comparing the demographic and clinical characteristics of the patients in the WD-N",14_8,Decoding Wilson disease: a machine learning approach to predict neurological symptoms,19 6 2024,,Wilson_Disease
"characteristics of the patients in the WD-N and no-WD-N groups, the latter were significantly older than the former, which is consistent with previous findings (<xref rid=""B27"" ref-type=""bibr"">27</xref>). Meanwhile, serological tests showed that patients with neurological symptoms had a significantly higher Cr value and a significantly lower CP value than those without neurological symptoms, and both were good predictors of the occurrence of neurological symptoms. Previous studies have found that Cr may",14_9,Decoding Wilson disease: a machine learning approach to predict neurological symptoms,19 6 2024,,Wilson_Disease
"symptoms. Previous studies have found that Cr may have a certain correlation with neurological symptoms (<xref rid=""B28"" ref-type=""bibr"">28</xref>). Additionally, previous studies have found that CP plays an important role in the metabolism and development of neural tissues (<xref rid=""B29"" ref-type=""bibr"">29</xref>), and the deficiency or functional impairment of ceruloplasmin is a typical feature of various neurodegenerative diseases (<xref rid=""B30"" ref-type=""bibr"">30</xref>, <xref rid=""B31""",14_10,Decoding Wilson disease: a machine learning approach to predict neurological symptoms,19 6 2024,,Wilson_Disease
"ref-type=""bibr"">30</xref>, <xref rid=""B31"" ref-type=""bibr"">31</xref>). Therefore, it can be speculated that elevated Cr with diminished CP may be associated with the development of neurological symptoms. Moreover, it was found that the WD-N group had a higher incidence of the K-F ring than the no-WD-N group. These results are consistent with previous research findings (<xref rid=""B16"" ref-type=""bibr"">16</xref>, <xref rid=""B32"" ref-type=""bibr"">32</xref>–<xref rid=""B34"" ref-type=""bibr"">34</xref>).",14_11,Decoding Wilson disease: a machine learning approach to predict neurological symptoms,19 6 2024,,Wilson_Disease
"rid=""B34"" ref-type=""bibr"">34</xref>). Furthermore, the WD-N group had significantly higher psychiatric symptom scores and liver symptom scores than the no-WD-N group. This suggests that neurological patients often have psychiatric symptoms, and they tend to have more pronounced hepatic symptoms than hepatic patients. Also, it was found that the WD-N group had a higher incidence of lenticular nucleus damage, thalamus damage, brainstem damage, cerebral ventricular system dilation, deepening of the sulci, and",14_12,Decoding Wilson disease: a machine learning approach to predict neurological symptoms,19 6 2024,,Wilson_Disease
"system dilation, deepening of the sulci, and fissures of the brain cerebral peduncle damage and other brain region damage than the no-WD-N group. This finding is also consistent with clinical practice. However, some patients have imaging manifestations but no neurological symptoms in clinical practice, and the accuracy of determining whether a patient has neurological symptoms by looking at them for imaging damage is not very high, which has drawn our attention. Therefore, this study employed a machine",14_13,Decoding Wilson disease: a machine learning approach to predict neurological symptoms,19 6 2024,,Wilson_Disease
"Therefore, this study employed a machine learning approach to predict the onset of neurological symptoms in WD patients, in an attempt to find more sensitive predictive indicators. In this experiment, five machine learning methods, namely RF, SVM, XGB, logistic regression, and BP neural network, were used to construct a prediction model, and the results indicated that the XGB model achieved the best prediction performance among the five machine learning models. Finally, the SHAP model interpretation",14_14,Decoding Wilson disease: a machine learning approach to predict neurological symptoms,19 6 2024,,Wilson_Disease
"models. Finally, the SHAP model interpretation package was utilized to analyze the features of the XGB classifier. It was found that the most important predictors in the prediction model were brainstem damage, Cr, age, IBIL, and CP. The brainstem or truncus cerebri forms the intermediate part of the vertebrate central nervous system, and it is rostral to the diencephalon and caudal to the spinal cord (<xref rid=""B35"" ref-type=""bibr"">35</xref>). Brainstem damage is correlated with multiple neurological",14_15,Decoding Wilson disease: a machine learning approach to predict neurological symptoms,19 6 2024,,Wilson_Disease
"damage is correlated with multiple neurological symptoms of ataxia, dysarthria, gait abnormalities, and muscle spasms (<xref rid=""B36"" ref-type=""bibr"">36</xref>–<xref rid=""B38"" ref-type=""bibr"">38</xref>). Additionally, age is also an important predictor of neurological symptoms in WD patients. Considering the previous findings that the average age of N-WD is older than that of no-N-WD (<xref rid=""B27"" ref-type=""bibr"">27</xref>), it can be speculated that the likelihood of neurological symptoms in WD",14_16,Decoding Wilson disease: a machine learning approach to predict neurological symptoms,19 6 2024,,Wilson_Disease
"the likelihood of neurological symptoms in WD patients increases with age. A study has found that the bilirubin/albumin ratio is an important risk factor for the occurrence of hepatic encephalopathy, and reducing free bilirubin may provide a new approach to the treatment of hepatic encephalopathy. It can be seen that indirect bilirubin is also closely related to neurological symptoms (<xref rid=""B39"" ref-type=""bibr"">39</xref>). Finally, it was found that CP is an important predictor of WD. Combined with",14_17,Decoding Wilson disease: a machine learning approach to predict neurological symptoms,19 6 2024,,Wilson_Disease
"CP is an important predictor of WD. Combined with our finding that CP values in the N-WD group were lower than those in the no-N-WD group, it can be speculated that the lower the CP, the more likely patients are to develop neurological symptoms. To sum up, the presence of brainstem damage and the higher the values of Cr, Age, and IBIL, the more likely neurological symptoms were to occur, while the lower the CP value, the more likely neurological symptoms were to occur. Therefore, when the patient is older,",14_18,Decoding Wilson disease: a machine learning approach to predict neurological symptoms,19 6 2024,,Wilson_Disease
"to occur. Therefore, when the patient is older, it is important to be alert to the occurrence of neurological symptoms; When patients experience brainstem damage or low CP values, we should actively intervene to prevent neurological symptoms from occurring. During daily care, patients should be advised to reduce their intake of foods that can cause elevated Cr and IBIL levels, and actively reduce Cr and IBIL when it is high to prevent the occurrence of neurological symptoms. However, our study still has",14_19,Decoding Wilson disease: a machine learning approach to predict neurological symptoms,19 6 2024,,Wilson_Disease
"symptoms. However, our study still has some limitations. Firstly, the study does not include external validation, which increases the risk of overfitting. Secondly, the number of samples in this study queue does not match well, so there exists selection bias and recall bias. Finally, this prediction model can only predict the presence of neurological symptoms and cannot evaluate the severity of neurological symptoms. Therefore, our future work aims to address the issues of data scarcity and imbalance by",14_20,Decoding Wilson disease: a machine learning approach to predict neurological symptoms,19 6 2024,,Wilson_Disease
"the issues of data scarcity and imbalance by using methods such as oversampling or data augmentation. In conclusion, the prediction model for predicting neurological symptoms in WD, constructed by using the XGB method in machine learning, achieved good performance, and furthermore, we will continue to collect patient data to keep the model updated. Meanwhile, the SHAP method was used to analyze clinical indicators and their impact on neurological symptoms. The results revealed that the most important",14_21,Decoding Wilson disease: a machine learning approach to predict neurological symptoms,19 6 2024,,Wilson_Disease
"The results revealed that the most important factors in the prediction model were brainstem damage, Cr, age, IBIL, and CP. And the presence of brainstem damage and the higher the values of Cr, Age, and IBIL, the more likely neurological symptoms were to occur, while the lower the CP value, the more likely neurological symptoms were to occur. It provides assistance for clinical decision-making. The training data presented in the study is included in the article/<xref rid=""SM1""",14_22,Decoding Wilson disease: a machine learning approach to predict neurological symptoms,19 6 2024,,Wilson_Disease
"study is included in the article/<xref rid=""SM1"" ref-type=""supplementary-material"">Supplementary material</xref>, further inquiries can be directed to the corresponding authors. The studies involving humans were approved by the First Affiliated Hospital of Anhui University of Chinese Medicine (Approval number: 2021AH-66). The studies were conducted in accordance with the local legislation and institutional requirements. Written informed consent for participation in this study was provided by the",14_23,Decoding Wilson disease: a machine learning approach to predict neurological symptoms,19 6 2024,,Wilson_Disease
"participation in this study was provided by the participants' legal guardians/next of kin. YY: Writing – original draft, Writing – review & editing, Data curation, Formal analysis, Methodology, Project administration, Resources, Supervision, Validation. G-AW: Writing – original draft, Writing – review & editing, Data curation, Methodology, Supervision. SF: Writing – original draft, Writing – review & editing. XL: Data curation, Methodology, Writing – original draft, Writing – review & editing. YD: Data",14_24,Decoding Wilson disease: a machine learning approach to predict neurological symptoms,19 6 2024,,Wilson_Disease
"draft, Writing – review & editing. YD: Data curation, Methodology, Supervision, Writing – original draft, Writing – review & editing. YS: Writing – original draft, Writing – review & editing, Formal analysis, Project administration. WH: Writing – original draft, Writing – review & editing, Formal analysis, Project administration, Validation. ZR: Writing – original draft, Writing – review & editing, Data curation, Methodology, Supervision. KD: Writing – original draft, Writing – review & editing, Data",14_25,Decoding Wilson disease: a machine learning approach to predict neurological symptoms,19 6 2024,,Wilson_Disease
"original draft, Writing – review & editing, Data curation, Formal analysis, Methodology, Project administration. XZ: Conceptualization, Data curation, Formal analysis, Funding acquisition, Investigation, Methodology, Project administration, Resources, Software, Supervision, Validation, Visualization, Writing – original draft. WY: Conceptualization, Data curation, Formal analysis, Funding acquisition, Investigation, Methodology, Project administration, Resources, Software, Supervision, Validation,",14_26,Decoding Wilson disease: a machine learning approach to predict neurological symptoms,19 6 2024,,Wilson_Disease
"Resources, Software, Supervision, Validation, Visualization, Writing – original draft, Writing – review & editing.",14_27,Decoding Wilson disease: a machine learning approach to predict neurological symptoms,19 6 2024,,Wilson_Disease
"Distinctive Pattern of Metal Deposition in Neurologic Wilson Disease Wilson disease (WD), also known as hepatolenticular degeneration, is a rare inherited autosomal recessive disorder caused by variants in <italic toggle=""yes"">ATP7B</italic>, leading to pathologic copper accumulation mainly in the liver and brain.<sup><xref rid=""R1"" ref-type=""bibr"">1</xref></sup> WD patients with neurologic manifestations such as parkinsonism, dysarthria, and postural tremor are classified as neurologic WD (NWD).<sup><xref",15_0,Distinctive Pattern of Metal Deposition in Neurologic Wilson Disease,25 6 2024,,Wilson_Disease
"are classified as neurologic WD (NWD).<sup><xref rid=""R2"" ref-type=""bibr"">2</xref><xref rid=""R3"" ref-type=""bibr"">-</xref><xref rid=""R4"" ref-type=""bibr"">4</xref></sup> Early diagnosis of NWD is crucial because early treatment can prevent irreversible neurologic sequelae. However, delayed diagnosis of NWD is common<sup><xref rid=""R5"" ref-type=""bibr"">5</xref>,<xref rid=""R6"" ref-type=""bibr"">6</xref></sup> because its phenotypic manifestations often overlap with other neurologic disorders. Although brain MRI is",15_1,Distinctive Pattern of Metal Deposition in Neurologic Wilson Disease,25 6 2024,,Wilson_Disease
"other neurologic disorders. Although brain MRI is routinely included in the diagnostic approach of WD,<sup><xref rid=""R7"" ref-type=""bibr"">7</xref></sup> we still lack a neuroimaging feature with high sensitivity and specificity. Most patients with NWD show T2 hyperintensities in the basal ganglia, thalamus, and/or brainstem because both lenticular nucleus and tectal plate signal changes have been reported to be present in approximately 75% of patients with NWD.<sup><xref rid=""R8""",15_2,Distinctive Pattern of Metal Deposition in Neurologic Wilson Disease,25 6 2024,,Wilson_Disease
"75% of patients with NWD.<sup><xref rid=""R8"" ref-type=""bibr"">8</xref>,<xref rid=""R9"" ref-type=""bibr"">9</xref></sup> Another recognized feature, “face of the giant panda” sign, was only observed in 14.3%–27.3% of patients with NWD.<sup><xref rid=""R9"" ref-type=""bibr"">9</xref>,<xref rid=""R10"" ref-type=""bibr"">10</xref></sup> These signal changes, however, have been reported in other metabolic diseases and infectious diseases.<sup><xref rid=""R11"" ref-type=""bibr"">11</xref>,<xref rid=""R12""",15_3,Distinctive Pattern of Metal Deposition in Neurologic Wilson Disease,25 6 2024,,Wilson_Disease
"ref-type=""bibr"">11</xref>,<xref rid=""R12"" ref-type=""bibr"">12</xref></sup> Although WD is primarily characterized by an abnormal copper metabolism, postmortem studies have found excessive accumulation of both copper and iron in the putamen, caudate nucleus, and dentate nucleus.<sup><xref rid=""R13"" ref-type=""bibr"">13</xref>,<xref rid=""R14"" ref-type=""bibr"">14</xref></sup> MRI studies using susceptibility-weighted imaging (SWI), quantitative susceptibility mapping (QSM), and T2* sequences have also reported",15_4,Distinctive Pattern of Metal Deposition in Neurologic Wilson Disease,25 6 2024,,Wilson_Disease
"(QSM), and T2* sequences have also reported excessive metal deposition in the globus pallidus and putamen.<sup><xref rid=""R15"" ref-type=""bibr"">15</xref><xref rid=""R16"" ref-type=""bibr"">-</xref><xref rid=""R19"" ref-type=""bibr"">19</xref></sup> Nevertheless, clinical application of these quantitative sequences is currently limited by the lack of standardized scanning processes and quantitative parameters. Although pathologic studies have revealed different microscopic patterns of iron deposition in WD and other",15_5,Distinctive Pattern of Metal Deposition in Neurologic Wilson Disease,25 6 2024,,Wilson_Disease
"patterns of iron deposition in WD and other neurologic disorders,<sup><xref rid=""R20"" ref-type=""bibr"">20</xref></sup> it remains unclear as to whether the macroscopic metal deposition pattern of NWD, especially in the basal ganglia, is distinct from that observed in other diseases with brain metal accumulation. With submillimeter spatial resolution and increased tissue contrast, susceptibility imaging in ultra-high-field 7T MRI is superior to 3 T MRI.<sup><xref rid=""R21"" ref-type=""bibr"">21</xref>,<xref",15_6,Distinctive Pattern of Metal Deposition in Neurologic Wilson Disease,25 6 2024,,Wilson_Disease
"rid=""R21"" ref-type=""bibr"">21</xref>,<xref rid=""R22"" ref-type=""bibr"">22</xref></sup> 7T MRI has proven to be a feasible tool in the visualization of the nigrosome 1<sup><xref rid=""R23"" ref-type=""bibr"">23</xref></sup> and the central vein sign,<sup><xref rid=""R24"" ref-type=""bibr"">24</xref></sup> both of which are useful in guiding disease diagnosis. Taken together, 7T SWI may be used to identify a distinctive pattern of metal deposition in NWD, which could increase the accuracy of NWD diagnosis. No such",15_7,Distinctive Pattern of Metal Deposition in Neurologic Wilson Disease,25 6 2024,,Wilson_Disease
"increase the accuracy of NWD diagnosis. No such study has been conducted to date. Using 7T MRI, we conducted a cross-sectional diagnostic study including patients with NWD, non-NWD (nNWD) patients, monoallelic <italic toggle=""yes"">ATP7B</italic> variant carriers, and healthy controls (HCs). We aim to identify a novel imaging feature, which related to the distinctive pattern of metal deposition of NWD, to accurately diagnose NWD. On successful identification, we investigated its diagnostic value and",15_8,Distinctive Pattern of Metal Deposition in Neurologic Wilson Disease,25 6 2024,,Wilson_Disease
"we investigated its diagnostic value and correlation with neurologic severity of NWD. In addition, we performed a preliminary exploratory analysis in patients with comparable clinical or imaging manifestations, including early-onset Parkinson disease (EOPD), multiple system atrophy (MSA), progressive supranuclear palsy (PSP), and neurodegeneration with brain iron accumulation (NBIA),<sup><xref rid=""R25"" ref-type=""bibr"">25</xref><xref rid=""R26"" ref-type=""bibr"">-</xref><xref rid=""R27""",15_9,Distinctive Pattern of Metal Deposition in Neurologic Wilson Disease,25 6 2024,,Wilson_Disease
"rid=""R26"" ref-type=""bibr"">-</xref><xref rid=""R27"" ref-type=""bibr"">27</xref></sup> to examine the specificity of this pattern of metal deposition. QSM and principal component analysis (PCA) were performed to illustrate the underlying pathophysiologic mechanism.   In this cross-sectional diagnostic study, we identified a distinctive pattern of metal deposition in NWD using 7T SWI, termed “hyperintense globus pallidus rim sign,” which demonstrated excellent diagnostic performance. It was observed in 38 of the",15_10,Distinctive Pattern of Metal Deposition in Neurologic Wilson Disease,25 6 2024,,Wilson_Disease
"performance. It was observed in 38 of the 41 patients with NWD and was absent in all patients with nNWD, EOPD, MSA, PSP, and NBIA, as well as monoallelic <italic toggle=""yes"">ATP7B</italic> variant carriers and HC in our study. Moreover, the scoring criteria of the hyperintense globus pallidus rim sign proved useful in monitoring neurologic severity of NWD. QSM and PCA showed excessive metal deposition in the lenticular nucleus with high regional weights in the lateral globus pallidus and medial putamen in",15_11,Distinctive Pattern of Metal Deposition in Neurologic Wilson Disease,25 6 2024,,Wilson_Disease
"the lateral globus pallidus and medial putamen in patients with NWD, implying a special metal deposition pattern of NWD. The hyperintense globus pallidus rim sign demonstrated excellent diagnostic sensitivity and specificity (92.7% and 100%, respectively). Although efforts have been made to identify specific imaging characteristics of WD, such as the “face of the giant panda,” “miniature panda,” “split thalamus,” “bright claustrum,” and “whorl” signs, these features have been associated with edema,",15_12,Distinctive Pattern of Metal Deposition in Neurologic Wilson Disease,25 6 2024,,Wilson_Disease
"these features have been associated with edema, demyelination, gliosis, and brain atrophy, all of which are common among neurodegenerative or metabolic diseases.<sup><xref rid=""R8"" ref-type=""bibr"">8</xref><xref rid=""R9"" ref-type=""bibr"">-</xref><xref rid=""R10"" ref-type=""bibr"">10</xref></sup> T2/SWI hypointensity was also detected in nNWD, EOPD, MSA, PSP, and NBIA patients, indicating its low diagnostic specificity compared with the hyperintense globus pallidus rim sign. In addition, we found high prevalence",15_13,Distinctive Pattern of Metal Deposition in Neurologic Wilson Disease,25 6 2024,,Wilson_Disease
"rim sign. In addition, we found high prevalence of the hyperintense globus pallidus rim sign in drug-naive NWD subgroups, reflecting its high diagnostic efficacy. As brain MRI is used in the current diagnostic process of NWD,<sup><xref rid=""R7"" ref-type=""bibr"">7</xref></sup> the novel hyperintense globus pallidus rim sign can improve the diagnostic accuracy of NWD. Although WD is inherited in an autosomal recessive manner, between 1% and 39.9% of patients were found with only 1 pathogenic <italic",15_14,Distinctive Pattern of Metal Deposition in Neurologic Wilson Disease,25 6 2024,,Wilson_Disease
"were found with only 1 pathogenic <italic toggle=""yes"">ATP7B</italic> variant,<sup><xref rid=""R37"" ref-type=""bibr"">37</xref>,<xref rid=""R38"" ref-type=""bibr"">38</xref></sup> and many novel variants are yet to be discovered.<sup><xref rid=""R37"" ref-type=""bibr"">37</xref></sup> In our study, the hyperintense globus pallidus rim sign was positive in the only 1 NWD patient with monoallelic <italic toggle=""yes"">ATP7B</italic> variants and was negative in all 22 monoallelic <italic toggle=""yes"">ATP7B</italic>",15_15,Distinctive Pattern of Metal Deposition in Neurologic Wilson Disease,25 6 2024,,Wilson_Disease
"monoallelic <italic toggle=""yes"">ATP7B</italic> variant carriers. For individuals with monoallelic <italic toggle=""yes"">ATP7B</italic> variants, the genetic test alone may be insufficient to make a definitive diagnosis. The hyperintense globus pallidus rim sign can thus assist in the diagnosis of these cases. We also established a semiquantitative scoring criterion, termed “hyperintense globus pallidus rim sign score,” and confirmed its positive correlation with UWDRS scores in patients with NWD.",15_16,Distinctive Pattern of Metal Deposition in Neurologic Wilson Disease,25 6 2024,,Wilson_Disease
"with UWDRS scores in patients with NWD. Therefore, apart from its high diagnostic accuracy, the hyperintense globus pallidus rim sign could also be used as a reliable biomarker for the monitoring of neurologic impairment. Anatomically, the linear hyperintensity at the lateral border of the globus pallidus likely corresponds to the external medullary lamina, which consists of white matter fiber bundles between the globus pallidus and the putamen.<sup><xref rid=""R39"" ref-type=""bibr"">39</xref>,<xref rid=""R40""",15_17,Distinctive Pattern of Metal Deposition in Neurologic Wilson Disease,25 6 2024,,Wilson_Disease
"ref-type=""bibr"">39</xref>,<xref rid=""R40"" ref-type=""bibr"">40</xref></sup> The presence of the hyperintense globus pallidus rim sign could be related to (1) a pseudohyperintensity change due to contrast of signal intensity between the external medullary lamina and its adjacent structures, i.e., the lenticular nucleus, and (2) hyperintensity change of the external medullary lamina itself due to impairments such as edema or gliosis. However, as the external medullary lamina is a thin structure, with a width",15_18,Distinctive Pattern of Metal Deposition in Neurologic Wilson Disease,25 6 2024,,Wilson_Disease
"lamina is a thin structure, with a width of less than 0.6 mm, regional QSM or fiber tracking analysis could not be performed on this particular area. We instead examined the susceptibility change and metal distribution pattern of its adjacent structures. Increased susceptibility in the globus pallidus and putamen in patients with NWD compared with nNWD patients and HC was observed, with similar results found in previous studies.<sup><xref rid=""R41"" ref-type=""bibr"">41</xref>,<xref rid=""R42""",15_19,Distinctive Pattern of Metal Deposition in Neurologic Wilson Disease,25 6 2024,,Wilson_Disease
"ref-type=""bibr"">41</xref>,<xref rid=""R42"" ref-type=""bibr"">42</xref></sup> A post mortem 7T MRI and histopathologic study confirmed both copper and iron deposition in the putamen and copper deposition in the globus pallidus of NWD, and established positive correlations between the R2* value and iron (rather than copper) concentrations of the globus pallidus and putamen.<sup><xref rid=""R13"" ref-type=""bibr"">13</xref></sup> Another 9.4 T MRI study reported positive correlations between QSM values and copper",15_20,Distinctive Pattern of Metal Deposition in Neurologic Wilson Disease,25 6 2024,,Wilson_Disease
"correlations between QSM values and copper concentrations in the primary motor cortex, sensorimotor cortex, amygdaloid nucleus, hippocampus, corpus striatum, and cerebellum in a mouse model.<sup><xref rid=""R43"" ref-type=""bibr"">43</xref></sup> As these studies had different magnetic fields, species, and brain regions of interest, additional in vitro and in vivo studies on the relationship between imaging and histopathology measurements are required. Nonetheless, both copper and iron deposition should be",15_21,Distinctive Pattern of Metal Deposition in Neurologic Wilson Disease,25 6 2024,,Wilson_Disease
"both copper and iron deposition should be accounted when interpreting the current QSM results in patients with NWD. We found lower susceptibility values in the globus pallidus and putamen in patients with EOPD compared with patients with NWD, and no significant differences were found among patients with NWD, MSA-P, MSA-C, and PSP. As the hyperintense globus pallidus rim sign was absent in all nNWD, EOPD, MSA-P, MSA-C, and PSP patients despite altered susceptibility values in our study, it could be",15_22,Distinctive Pattern of Metal Deposition in Neurologic Wilson Disease,25 6 2024,,Wilson_Disease
"susceptibility values in our study, it could be hypothesized that the existence of this pseudohyperintensity change may be attributed to 2 mechanisms: (1) excessive metal deposition in the lenticular nucleus revealed by its increased susceptibility values and (2) abnormal metal distribution in a particular region of the lenticular nucleus adjacent to the external medullary lamina, with relatively milder iron deposition in the external medullary lamina. To validate this hypothesis, we performed PCA of QSM",15_23,Distinctive Pattern of Metal Deposition in Neurologic Wilson Disease,25 6 2024,,Wilson_Disease
"validate this hypothesis, we performed PCA of QSM values in the lenticular nucleus. A specific metal distribution pattern characterized by excessive metal deposition in the lenticular nucleus with high regional weights in both lateral globus pallidus and medial putamen was established in patients with NWD. By contrast, patients with MSA-P, MSA-C, and PSP demonstrated high regional weights mostly in the caudal putamen and not in the globus pallidus. For the NBIA group, although these patients were not",15_24,Distinctive Pattern of Metal Deposition in Neurologic Wilson Disease,25 6 2024,,Wilson_Disease
"the NBIA group, although these patients were not included in the QSM analysis because of limited sample size, we observed hypointensity of the globus pallidus in NBIA patients with <italic toggle=""yes"">PLA2G6</italic>, <italic toggle=""yes"">C19orf12</italic>, or <italic toggle=""yes"">PANK2</italic> variants compared with HC. As discussed in a recent review, while WD, phospholipase A2-associated neurodegeneration (PLAN), mitochondrial membrane protein-associated neurodegeneration (MPAN), and pantothenate",15_25,Distinctive Pattern of Metal Deposition in Neurologic Wilson Disease,25 6 2024,,Wilson_Disease
"neurodegeneration (MPAN), and pantothenate kinase-associated neurodegeneration (PKAN) all showed excessive iron deposits in the globus pallidus macroscopically, their microscopic patterns and presumably also pathophysiologic mechanisms of iron deposits were different: for WD, iron was deposited in macrophages and astrocytes; for MPAN and PKAN, in astrocytes, macrophages, and neurons; and for PLAN, in macrophages.<sup><xref rid=""R20"" ref-type=""bibr"">20</xref></sup> Thus, we may conclude that the",15_26,Distinctive Pattern of Metal Deposition in Neurologic Wilson Disease,25 6 2024,,Wilson_Disease
"Thus, we may conclude that the hyperintense globus pallidus rim sign reflects a pseudohyperintense signal of the external medullary lamina due to excessive metal accumulation in the lenticular nucleus, especially in the lateral globus pallidus and medial putamen, indicating a specific metal distribution pattern in the lenticular nucleus of NWD. However, whether the external medullary lamina itself is involved in the pathophysiologic mechanism of NWD is warranted in further investigation. Consistent with",15_27,Distinctive Pattern of Metal Deposition in Neurologic Wilson Disease,25 6 2024,,Wilson_Disease
"in further investigation. Consistent with our observation that the hyperintense globus pallidus rim sign reflected neurologic severity, we found it absent in all nNWD patients, with no significant difference of susceptibility found between nNWD patients and HC. However, other researchers have reported increased susceptibility value in the right globus pallidus of hepatic WD compared with HC and no significant difference between NWD and hepatic WD.<sup><xref rid=""R44"" ref-type=""bibr"">44</xref></sup> This",15_28,Distinctive Pattern of Metal Deposition in Neurologic Wilson Disease,25 6 2024,,Wilson_Disease
"rid=""R44"" ref-type=""bibr"">44</xref></sup> This discrepancy could be attributed to the limited number of cases and different definitions and disease stages of the patient subgroups. As nNWD may represent an earlier stage of NWD without neurologic impairment, whether the hyperintense globus pallidus rim sign can be detected in the current cohort of nNWD patients who later develop neurologic symptoms requires validation in further longitudinal study. For patients with NWD with negative hyperintense globus",15_29,Distinctive Pattern of Metal Deposition in Neurologic Wilson Disease,25 6 2024,,Wilson_Disease
"with NWD with negative hyperintense globus pallidus rim sign, 2 of the 3 patients received long-term treatment at an early stage of the disease and were experiencing mild clinical symptoms during this study. The third patient, who was also under treatment and had mild neurologic impairment with a UWDRS score of 2, exhibited a trend resembling the hyperintense globus pallidus rim sign with a hypointense signal in the anterior putamen forming a linear hyperintensity less than half of the lateral border of",15_30,Distinctive Pattern of Metal Deposition in Neurologic Wilson Disease,25 6 2024,,Wilson_Disease
"less than half of the lateral border of the globus pallidus. A previous study has demonstrated both imaging (measured by corrected phase values of the putamen and globus pallidus) and clinical (assessed by the modified Young scale) recovery after metal chelating treatment,<sup><xref rid=""R15"" ref-type=""bibr"">15</xref></sup> which may influence the appearance of the hyperintense globus pallidus rim sign. As the hyperintense globus pallidus rim sign was observed in all drug-naive patients with NWD, it could",15_31,Distinctive Pattern of Metal Deposition in Neurologic Wilson Disease,25 6 2024,,Wilson_Disease
"in all drug-naive patients with NWD, it could have higher diagnostic accuracy in drug-naive NWD. Further longitudinal studies will be essential to examine the treatment effect on this feature. Several limitations should be noted. First, as a cross-sectional study, alterations of the hyperintense globus pallidus rim sign in patients with NWD due to treatment effect and in nNWD patients who later develop neurologic symptoms require further verification in cohort studies. Second, confined by the current",15_32,Distinctive Pattern of Metal Deposition in Neurologic Wilson Disease,25 6 2024,,Wilson_Disease
"cohort studies. Second, confined by the current analysis approach, regional susceptibility and fiber analysis could not be performed on the linear hyperintensity signal area. As well, the number of asymptomatic patient with WD identified through family screening was small (3 in this study), and future studies will require larger patient population. Imaging characteristics of patient subgroups with pure psychiatric symptoms and with liver failure also deserve particular emphasis. Finally, as a single-center",15_33,Distinctive Pattern of Metal Deposition in Neurologic Wilson Disease,25 6 2024,,Wilson_Disease
"particular emphasis. Finally, as a single-center study, our imaging protocols require validation in multicenter studies using different MRI scanners and sequence parameters. More research on the contraindications of 7T MRI in human studies is warranted. Meanwhile, despite the increased utilization of 7T systems in the past decade, its availability is still rather limited compared with scanners of lower magnetic field intensities such as 1.5 and 3 T. Thus, investigations of the presence of the hyperintense",15_34,Distinctive Pattern of Metal Deposition in Neurologic Wilson Disease,25 6 2024,,Wilson_Disease
"of the presence of the hyperintense globus pallidus rim sign at lower magnetic field intensities are needed. In conclusion, our study identified a distinctive pattern of metal deposition, termed the “hyperintense globus pallidus rim sign,” which may serve as an effective neuroimaging biomarker for the diagnosis, differential diagnosis, and monitoring of the neurologic impairment of NWD using SWI at 7T. It revealed a unique pattern of metal deposition in the lenticular nucleus of patients with NWD. Further",15_35,Distinctive Pattern of Metal Deposition in Neurologic Wilson Disease,25 6 2024,,Wilson_Disease
lenticular nucleus of patients with NWD. Further pathologic studies are warranted to elucidate the pathogenetic mechanisms of our findings.,15_36,Distinctive Pattern of Metal Deposition in Neurologic Wilson Disease,25 6 2024,,Wilson_Disease
"Characteristics of patients with Wilson disease in the United States: An insurance claims database study Wilson disease (WD) is a progressive, potentially fatal degenerative disease, principally affecting the liver and the central nervous system[<xref rid=""B1"" ref-type=""bibr"">1</xref>,<xref rid=""B2"" ref-type=""bibr"">2</xref>]. It is caused by loss-of-function mutations in the <italic toggle=""yes"">ATP7B</italic> gene, localised on chromosome 13, which encodes the copper-transporting ATPase ATP7B[<xref",16_0,Characteristics of patients with Wilson disease in the United States: An insurance claims database study,27 5 2024,,Wilson_Disease
"the copper-transporting ATPase ATP7B[<xref rid=""B3"" ref-type=""bibr"">3</xref>,<xref rid=""B4"" ref-type=""bibr"">4</xref>]. In the absence of a functional ATB7B protein, copper is no longer eliminated correctly in the bile and accumulates in tissues to toxic levels, where it may lead to irreversible hepatic injury and neurodegeneration[<xref rid=""B1"" ref-type=""bibr"">1</xref>,<xref rid=""B5"" ref-type=""bibr"">5</xref>]. Moreover, around 30%-40% of patients with WD present with psychiatric symptoms, such as",16_1,Characteristics of patients with Wilson disease in the United States: An insurance claims database study,27 5 2024,,Wilson_Disease
"WD present with psychiatric symptoms, such as depression or acute psychosis[<xref rid=""B6"" ref-type=""bibr"">6</xref>]. Based on clinical studies, the prevalence of WD has been estimated to be between 1:30,000 and 1:50,000 (2 to 3.3 cases per 100000) in most countries[<xref rid=""B7"" ref-type=""bibr"">7</xref>]. Genetic studies have suggested a higher prevalence[<xref rid=""B8"" ref-type=""bibr"">8</xref>], but this may be an over estimate due to inclusion of <italic toggle=""yes"">ATP7B</italic> gene mutations with",16_2,Characteristics of patients with Wilson disease in the United States: An insurance claims database study,27 5 2024,,Wilson_Disease
"toggle=""yes"">ATP7B</italic> gene mutations with low penetrance, or mutation that are not pathogenic. Accurate determination of prevalence is also complicated by frequent misdiagnosis[<xref rid=""B1"" ref-type=""bibr"">1</xref>]. Effective treatments exist, which can generally halt or slow down the progression of WD,[<xref rid=""B9"" ref-type=""bibr"">9</xref>,<xref rid=""B10"" ref-type=""bibr"">10</xref>] and the most recent treatment guidelines of the American Association for the Study of Liver Diseases recommend",16_3,Characteristics of patients with Wilson disease in the United States: An insurance claims database study,27 5 2024,,Wilson_Disease
"for the Study of Liver Diseases recommend that these should be initiated as soon as possible after diagnosis and continued for life or until liver transplantation, which is be a cure for WD[<xref rid=""B11"" ref-type=""bibr"">11</xref>]. These specific treatments include copper chelators such as D-penicillamine and trientine, or zinc salts, although the long-term effectiveness of the latter may be less than that of copper chelators[<xref rid=""B12"" ref-type=""bibr"">12</xref>]. Although large prospective clinical",16_4,Characteristics of patients with Wilson disease in the United States: An insurance claims database study,27 5 2024,,Wilson_Disease
"Although large prospective clinical studies in WD are challenging to perform due to the rarity of the disease, the existence of national reference centres in some countries may allow for retrospective analyses on relatively large patient cohorts. For example, a report from Poland describes a cohort of 929 patients attending the reference centre for WD in Warsaw for a period of over 60 years[<xref rid=""B13"" ref-type=""bibr"">13</xref>]. In addition, the availability of comprehensive insurance claims databases",16_5,Characteristics of patients with Wilson disease in the United States: An insurance claims database study,27 5 2024,,Wilson_Disease
"of comprehensive insurance claims databases in recent years provides a powerful tool to collect retrospective data on large numbers of patients with rare diseases[<xref rid=""B14"" ref-type=""bibr"">14</xref>-<xref rid=""B16"" ref-type=""bibr"">16</xref>]. Insurance claims database studies of WD have now been reported from Taiwan[<xref rid=""B17"" ref-type=""bibr"">17</xref>], South Korea[<xref rid=""B18"" ref-type=""bibr"">18</xref>] and France[<xref rid=""B19"" ref-type=""bibr"">19</xref>,<xref rid=""B20""",16_6,Characteristics of patients with Wilson disease in the United States: An insurance claims database study,27 5 2024,,Wilson_Disease
"ref-type=""bibr"">19</xref>,<xref rid=""B20"" ref-type=""bibr"">20</xref>]. As the structure of healthcare provision in general, and for rare diseases in particular, differs significantly between countries, it is of interest to extend these observations to other health systems. In this study, the objective was to explore the characteristics of patients with WD in the United States and to document treatment patterns. This was a retrospective, longitudinal, health insurance claims database study of patients with",16_7,Characteristics of patients with Wilson disease in the United States: An insurance claims database study,27 5 2024,,Wilson_Disease
"insurance claims database study of patients with WD in the United States. Data were extracted from the Clarivate Real-World Data Product (Clarivate RWD) for all patients with at least two submitted claims for WD between January 1, 2016 (the date when the full database was first available) and December 31, 2021 (the most recent full year of validated data available), identified by ICD-10 codes. The index date was defined as the date of the first claim associated with WD. Patients were followed from the",16_8,Characteristics of patients with Wilson disease in the United States: An insurance claims database study,27 5 2024,,Wilson_Disease
"with WD. Patients were followed from the index date until they died or until the end of the study period (December 31, 2021) if that occurred first (Figure <xref rid=""F1"" ref-type=""fig"">1</xref>).  We identified 5376 unique patients with ≥ 2 claims associated with an ICD-10 code for WD in the Clarivate RWD database over a 6-year inclusion period, corresponding to around 2250 prevalent patients each year, with the exception of the first year (2016), when case identification was potentially not exhaustive.",16_9,Characteristics of patients with Wilson disease in the United States: An insurance claims database study,27 5 2024,,Wilson_Disease
"identification was potentially not exhaustive. Assuming the diagnosis was correctly assigned in all cases and a prevalence of clinically-diagnosed WD between 1:30000 and 1:50000[<xref rid=""B7"" ref-type=""bibr"">7</xref>], these cases should account for between 50% and 80% of all patients with WD in the United States. With regard to treatment, we found that only 15% of patients had been documented to have received a WD-specific treatment at least once during the follow-up period. Overall, 273 patients died",16_10,Characteristics of patients with Wilson disease in the United States: An insurance claims database study,27 5 2024,,Wilson_Disease
"the follow-up period. Overall, 273 patients died during the study period, corresponding to 5.1% of the WD cohort. Compared with the American general population, the standardised mortality ratio in patients with WD was 2.19. This suggests that WD was associated with excess mortality, as previously reported in other recent studies elsewhere[<xref rid=""B13"" ref-type=""bibr"">13</xref>,<xref rid=""B18"" ref-type=""bibr"">18</xref>,<xref rid=""B20"" ref-type=""bibr"">20</xref>]. In addition, the mean age at death was",16_11,Characteristics of patients with Wilson disease in the United States: An insurance claims database study,27 5 2024,,Wilson_Disease
"In addition, the mean age at death was 57.9 years, compared with a life expectancy of 77 years in the American general population in 2020, representing a loss of around 20 life years. The observed mortality data are consistent with data from the Polish national WD registry, in which patients with WD have also shown around 20 life years lost compared with the general population[<xref rid=""B13"" ref-type=""bibr"">13</xref>]. A recent study of > 17,000 patients with WD identified between 2007 and 2017 in the",16_12,Characteristics of patients with Wilson disease in the United States: An insurance claims database study,27 5 2024,,Wilson_Disease
"with WD identified between 2007 and 2017 in the United States National Inpatient Sample has also described an elevated mortality in patients with WD (unadjusted mortality rate: 2.51% in patients with WD <italic toggle=""yes"">vs</italic> 2.05% in patients without)[<xref rid=""B20"" ref-type=""bibr"">20</xref>]. At the index date, the median age of the patients was 40 years, similar to that reported in the French insurance claims database study (39 years)[<xref rid=""B21"" ref-type=""bibr"">21</xref>]. This age is",16_13,Characteristics of patients with Wilson disease in the United States: An insurance claims database study,27 5 2024,,Wilson_Disease
"rid=""B21"" ref-type=""bibr"">21</xref>]. This age is older than the age of first diagnosis reported in WD registry studies, which is typically between 20 years and 30 years of age[<xref rid=""B13"" ref-type=""bibr"">13</xref>,<xref rid=""B22"" ref-type=""bibr"">22</xref>]. This is most simply explained by the fact that the Clarivate database only became available in 2016 and patients who were diagnosed prior to that date may appear in the database for the first time many years after they were originally diagnosed. In",16_14,Characteristics of patients with Wilson disease in the United States: An insurance claims database study,27 5 2024,,Wilson_Disease
"years after they were originally diagnosed. In addition, there may be an issue with coding in certain insurance claims databases, where the ICD-10 code for WD is not consistently documented at the time of diagnosis. In the Taiwanese insurance claims database study, in which patients with WD were identified not by ICD codes associated with the claim, but by linking from the national WD patient registry, the incidence of first documentation in the database peaked in the 15-year-old to 19-year-old age",16_15,Characteristics of patients with Wilson disease in the United States: An insurance claims database study,27 5 2024,,Wilson_Disease
"peaked in the 15-year-old to 19-year-old age group[<xref rid=""B17"" ref-type=""bibr"">17</xref>]. The observed proportion of treated patients (15%) is certainly an underestimate of the true treatment rate in this population. Zinc salts are available over the counter in the United States, and if purchased that way, are not reimbursed through health insurance and therefore not documented in the database. In addition, patients in the United States can purchase medications from online pharmacies in other",16_16,Characteristics of patients with Wilson disease in the United States: An insurance claims database study,27 5 2024,,Wilson_Disease
"medications from online pharmacies in other countries such as Canada or India and may have an incentive to do so if that would be substantially cheaper. In the United States, copper chelators (D-penicillamine and trientine), even in generic formulations, are expensive, up to $91 a pill for trientine and up to $35 a pill for D-penicillamine, and there may thus have been an unknown amount of purchasing from online pharmacies. For these reasons, treatment of WD may have been undocumented in a potentially",16_17,Characteristics of patients with Wilson disease in the United States: An insurance claims database study,27 5 2024,,Wilson_Disease
"of WD may have been undocumented in a potentially large number of patients. Documented treatment or prescription rates in insurance claims database studies from other countries range from 34.9% in South Korea[<xref rid=""B18"" ref-type=""bibr"">18</xref>] to 43.8% in France[<xref rid=""B21"" ref-type=""bibr"">21</xref>]. As well as underestimating the number of patients treated (the numerator), the number of patients with an ascertained diagnosis of WD (the denominator) may be overestimated, as it is not uncommon",16_18,Characteristics of patients with Wilson disease in the United States: An insurance claims database study,27 5 2024,,Wilson_Disease
"may be overestimated, as it is not uncommon in the United States, for health insurance purposes, to assign an ICD code for WD before diagnostic confirmation, and the code be may not revised subsequently if the diagnosis was not confirmed. For this reason, the diagnosis remains uncertain in an unknown proportion of patients without an associated WD-specific treatment. In contrast, the diagnosis of WD should not be open to question in patients with a documented specific treatment. At the index date, no major",16_19,Characteristics of patients with Wilson disease in the United States: An insurance claims database study,27 5 2024,,Wilson_Disease
"specific treatment. At the index date, no major differences between patients with a documented treatment and those without were observed, except that patients of the former group were younger and more frequently presented hepatic symptoms, consistent with previous reports for age in the French, South Korean and Polish setting[<xref rid=""B13"" ref-type=""bibr"">13</xref>,<xref rid=""B18"" ref-type=""bibr"">18</xref>,<xref rid=""B21"" ref-type=""bibr"">21</xref>]. However, over time the proportion of patients in the no",16_20,Characteristics of patients with Wilson disease in the United States: An insurance claims database study,27 5 2024,,Wilson_Disease
"over time the proportion of patients in the no documented treatment group who presented neurological or psychiatric manifestations tended to rise following the index date, whereas that was not the case in the documented treatment group. This may reflect the fact that WD is frequently diagnosed on the basis of hepatic symptoms, with neurological and psychiatric symptoms developing later[<xref rid=""B22"" ref-type=""bibr"">22</xref>]. It should be noted that persistence, and even aggravation of neurological",16_21,Characteristics of patients with Wilson disease in the United States: An insurance claims database study,27 5 2024,,Wilson_Disease
"persistence, and even aggravation of neurological symptoms is well-documented in patients with WD who are under treatment[<xref rid=""B10"" ref-type=""bibr"">10</xref>]. The most frequent clinical manifestations evocative of WD that were documented were psychiatric manifestations in 44.0% of patients. This finding was unanticipated, as in previous registry studies[<xref rid=""B13"" ref-type=""bibr"">13</xref>,<xref rid=""B22"" ref-type=""bibr"">22</xref>] and insurance claims database studies[<xref rid=""B17""",16_22,Characteristics of patients with Wilson disease in the United States: An insurance claims database study,27 5 2024,,Wilson_Disease
"insurance claims database studies[<xref rid=""B17"" ref-type=""bibr"">17</xref>,<xref rid=""B18"" ref-type=""bibr"">18</xref>,<xref rid=""B21"" ref-type=""bibr"">21</xref>], hepatic manifestations tended to dominate, being observed in over half the patients. This is generally the case in patients with typical early-onset WD in adolescence or young adulthood[<xref rid=""B23"" ref-type=""bibr"">23</xref>]. Psychotropic medications such as anxiolytics and antidepressants, which contribute to the definition of psychiatric",16_23,Characteristics of patients with Wilson disease in the United States: An insurance claims database study,27 5 2024,,Wilson_Disease
"which contribute to the definition of psychiatric manifestations, may have been prescribed to manage the psychological distress arising from living with WD, rather than to treat psychiatric manifestations of the disease sensu stricto. This explanation may also account for the unexpectedly large rise in the proportion of patients with psychiatric manifestations over the years following the index date. In this study, only hepatic manifestations were observed in 33% of patients. It is possible that these",16_24,Characteristics of patients with Wilson disease in the United States: An insurance claims database study,27 5 2024,,Wilson_Disease
"in 33% of patients. It is possible that these hepatic manifestations require treatment generating a reimbursement claim less frequently than neurological or psychiatric manifestations, and given the relatively short follow-up duration, claims related to hepatic manifestations were under-represented. It should also be noted that the proportion of patients undergoing liver transplantation (2.3%) was relatively low compared to previous studies in Europe[<xref rid=""B19"" ref-type=""bibr"">19</xref>,<xref",16_25,Characteristics of patients with Wilson disease in the United States: An insurance claims database study,27 5 2024,,Wilson_Disease
"rid=""B19"" ref-type=""bibr"">19</xref>,<xref rid=""B22"" ref-type=""bibr"">22</xref>] and South Korea[<xref rid=""B18"" ref-type=""bibr"">18</xref>]. However, the number of liver transplantations is also probably underestimated as transplants occurring before the database became available in 2016 could not be identified. The principal strength of the study resides in the large number of patients available for analysis (5376 unique patients). Limitations include the fact that WD was documented from reimbursement",16_26,Characteristics of patients with Wilson disease in the United States: An insurance claims database study,27 5 2024,,Wilson_Disease
"fact that WD was documented from reimbursement claims only and without independent clinical ascertainment: The proportion of patients whose clinical diagnosis of WD was not confirmed, without the disease code being corrected in the database is unknown. This may lead to an over-estimation of the number of patients with a confirmed and definite diagnosis of WD who do not receive a specific treatment. In addition, treatment rates were probably underestimated because, as mentioned above, over the counter and",16_27,Characteristics of patients with Wilson disease in the United States: An insurance claims database study,27 5 2024,,Wilson_Disease
"because, as mentioned above, over the counter and online drug purchases were not identified. This illustrates the need to reinforce database quality by ascertaining medical data and correcting coding when necessary so that data on rare diseases from reimbursement claims databases can be used with confidence. In addition, patients with a documented liver transplantation are not treated with copper-depleting drugs, and in this study they were assigned for this reason to the no documented treatment group.",16_28,Characteristics of patients with Wilson disease in the United States: An insurance claims database study,27 5 2024,,Wilson_Disease
"this reason to the no documented treatment group. However, this only concerned 121 patients (2.3%). Another limitation is that the period over which individual patients could be followed in the database was also relatively short (around 2 years). In addition, the hepatic, neurological and psychiatric manifestations that were documented could not be ascribed unequivocally to WD. The data on deaths is probably incomplete, and in consequence, mortality might be underestimated, even though it was clearly",16_29,Characteristics of patients with Wilson disease in the United States: An insurance claims database study,27 5 2024,,Wilson_Disease
"be underestimated, even though it was clearly elevated in patients with WD. During the first year of the database (2016), all deaths were probably not captured and this is also the case in the most recent year (2021). There is a lag time between the date of death in the community and the date when the information is transferred to health insurance databases. It should also be noted that the different health insurance plans in the United States do not provide identical coverage and what is actually",16_30,Characteristics of patients with Wilson disease in the United States: An insurance claims database study,27 5 2024,,Wilson_Disease
"provide identical coverage and what is actually reimbursed may differ from one plan to another. A future way forward may be to perform a bridging study between hospital patient registries and insurance claims databases to evaluate the completeness and accuracy of claims coding rare diseases such as WD. This insurance claims database study describes a large cohort of 5376 patients with ICD-10 codes for WD in the United States, although the number of actual WD cases is expected to be lower due to unconfirmed",16_31,Characteristics of patients with Wilson disease in the United States: An insurance claims database study,27 5 2024,,Wilson_Disease
"cases is expected to be lower due to unconfirmed diagnoses. Patients with a documented WD treatment together with a WD diagnosis code can be confidently assumed to have WD. These patients are frequently symptomatic and have an excess early mortality compared with the American general population, despite the fact that effective treatments can halt or slow the progression of disease. Despite the study limitations, our data suggest that a significant number of patients may not be receiving best standard of",16_32,Characteristics of patients with Wilson disease in the United States: An insurance claims database study,27 5 2024,,Wilson_Disease
"of patients may not be receiving best standard of care in terms of treatment, compliance, and follow-up. These findings indicate that there is a significant unmet need for effective treatment for WD in the United States. We wish to thank Adam Doble, Foxymed (Paris, France) for medical writing support and Claire Leboucher, Putnam PHMR (Lyon, France) for advice on data analysis.",16_33,Characteristics of patients with Wilson disease in the United States: An insurance claims database study,27 5 2024,,Wilson_Disease
"WilsonGenAI a deep learning approach to classify pathogenic variants in Wilson Disease Wilson’s Disease (WD) is a rare autosomal recessive disorder characterized by the presence of pathogenic mutations in the copper-transporting <italic toggle=""yes"">ATP7B</italic> gene. Located on chromosome 13q14.2, <italic toggle=""yes"">ATP7B</italic> spans 21 exons, encoding a 1465-amino-acid copper-transporting ATPase [<xref rid=""pone.0303787.ref001"" ref-type=""bibr"">1</xref>]. Altered gene function in WD results in",17_0,WilsonGenAI a deep learning approach to classify pathogenic variants in Wilson Disease,17 5 2024,,Wilson_Disease
"Altered gene function in WD results in copper accumulation in the liver and brain, leading to impaired functions and movement disorders. WD patients exhibit pathogenic mutations causing reduced serum holo-ceruloplasmin production. Excessive copper deposition induces oxidative stress, contributing to clinical problems like cirrhosis and fulminant hepatitis. Neurological complications arise from copper deposits in specific brain regions, leading to movement disorders and associated symptoms [<xref",17_1,WilsonGenAI a deep learning approach to classify pathogenic variants in Wilson Disease,17 5 2024,,Wilson_Disease
"movement disorders and associated symptoms [<xref rid=""pone.0303787.ref002"" ref-type=""bibr"">2</xref>]. This complex interplay of genetic factors and copper metabolism underscores the multisystemic impact of WD. WD is an underdiagnosed and treatable genetic condition with an estimated worldwide prevalence of around 13.9 per 100,000, derived from known pathogenic variants [<xref rid=""pone.0303787.ref003"" ref-type=""bibr"">3</xref>]. Several recent publications have highlighted an estimated carrier frequency of",17_2,WilsonGenAI a deep learning approach to classify pathogenic variants in Wilson Disease,17 5 2024,,Wilson_Disease
"highlighted an estimated carrier frequency of 1 in 90 individuals [<xref rid=""pone.0303787.ref004"" ref-type=""bibr"">4</xref>–<xref rid=""pone.0303787.ref006"" ref-type=""bibr"">6</xref>]. The known prevalence and carrier frequency of WD however, are confined to a few specific populations [<xref rid=""pone.0303787.ref007"" ref-type=""bibr"">7</xref>, <xref rid=""pone.0303787.ref008"" ref-type=""bibr"">8</xref>] while in large populations like India, they remain unexplored. This opens up a unique opportunity to",17_3,WilsonGenAI a deep learning approach to classify pathogenic variants in Wilson Disease,17 5 2024,,Wilson_Disease
unexplored. This opens up a unique opportunity to understand the genetic architecture of the disease in populations rich in genetic diversity such as India. The recent availability of a framework for the interpretation of pathogenicity of genetic variants put forward by the American College of Medical Genetics and Genomics and the Association of Molecular Pathologists (ACMG & AMP) has opened up a unique opportunity to create a standardised system for interpretation of genetic variants for clinical,17_4,WilsonGenAI a deep learning approach to classify pathogenic variants in Wilson Disease,17 5 2024,,Wilson_Disease
"interpretation of genetic variants for clinical diagnosis and genetic counselling. To assist in a better understanding of variant pathogenicity, our group has recently put together one of the most comprehensive collections of genetic variants classified according to the ACMG & AMP Guidelines [<xref rid=""pone.0303787.ref009"" ref-type=""bibr"">9</xref>], <ext-link http://www.w3.org/1999/xlink href=""https://paperpile.com/c/ROae26/ZRAHf"" ext-link-type=""uri"">in form of the WilsonGen database, a</ext-link> robust",17_5,WilsonGenAI a deep learning approach to classify pathogenic variants in Wilson Disease,17 5 2024,,Wilson_Disease
"of the WilsonGen database, a</ext-link> robust compilation of all publicly reported <italic toggle=""yes"">ATP7B</italic> variants exhaustively collected from literature and across 9 large databases [<xref rid=""pone.0303787.ref010"" ref-type=""bibr"">10</xref>], making it the largest, most comprehensive database of it’s kind, to the best of our knowledge. While classification according to the ACMG & AMP guidelines is time-consuming and at times limited by literature and experimental evidence to confirm the",17_6,WilsonGenAI a deep learning approach to classify pathogenic variants in Wilson Disease,17 5 2024,,Wilson_Disease
"and experimental evidence to confirm the pathogenicity, a number of variants remain unclassified as variants of uncertain significance (VUS). This significantly impacts the ability to classify variants, especially from unique population groups and rare variants identified from patient cohorts. The advent of machine learning approaches in clinical medicine have accelerated the ability to analyse and interpret medical data and have been extensively used in a number of scenarios, including the rapid",17_7,WilsonGenAI a deep learning approach to classify pathogenic variants in Wilson Disease,17 5 2024,,Wilson_Disease
"in a number of scenarios, including the rapid classification of large numbers of variants. The widespread application of such approaches in genomics however, has been limited by the lack of gold-standard datasets for training. The availability of WilsonGen database thus provides a unique opportunity in this aspect. Here, we describe a machine learning approach trained on a gold-standard ACMG-classified variant dataset for pathogenicity in the <italic toggle=""yes"">ATP7B</italic> gene for accurate",17_8,WilsonGenAI a deep learning approach to classify pathogenic variants in Wilson Disease,17 5 2024,,Wilson_Disease
"toggle=""yes"">ATP7B</italic> gene for accurate classification of variants. We also use the approach for reclassification of VUS variants in public datasets so as to enable quick variant interpretation in clinical and research settings. To the best of our knowledge, ours is the only approach based on a manually ACMG-classified dataset, dedicated specifically to WD variants. A public implementation of the algorithm is available at: <ext-link http://www.w3.org/1999/xlink",17_9,WilsonGenAI a deep learning approach to classify pathogenic variants in Wilson Disease,17 5 2024,,Wilson_Disease
"at: <ext-link http://www.w3.org/1999/xlink href=""https://github.com/aastha-v/WilsonGenAI"" ext-link-type=""uri"">https://github.com/aastha-v/WilsonGenAI</ext-link>.  Both models performed best with a 70–30% train-test split. The TabNet model additionally split the 30% test set into 50% train and 50% validation subsets during training. In our work we have created two tools that can be used to classify variants of the <italic toggle=""yes"">ATP7B</italic> gene linked with Wilson’s Disease. While tree-based",17_10,WilsonGenAI a deep learning approach to classify pathogenic variants in Wilson Disease,17 5 2024,,Wilson_Disease
"linked with Wilson’s Disease. While tree-based XGBoost is one of the most reliable algorithms for tabular data, our study shows that TabNet, a deep learning model designed specifically for tabular data, slightly outperforms it in the classification of <italic toggle=""yes"">ATP7B</italic> variants. We have trained these models on a dataset classified through the application of ACMG guidelines, the gold standard in variant classification. Additionally, the data is a robust compilation of all publicly",17_11,WilsonGenAI a deep learning approach to classify pathogenic variants in Wilson Disease,17 5 2024,,Wilson_Disease
"the data is a robust compilation of all publicly available variants of the gene exhaustively collected from literature and across 9 large databases. Thus the models were trained on accurately classified variants that capture all currently known types of exonic variants associated with Wilson’s Disease, due to which we anticipate the models to be able to generalize to newly reported variants in the future. We have shown our models’ accuracy through functional validation as well as comparison with other",17_12,WilsonGenAI a deep learning approach to classify pathogenic variants in Wilson Disease,17 5 2024,,Wilson_Disease
"validation as well as comparison with other models. Finally, to address the large numbers of already reported variants of uncertain significance, we have collected and classified 977 exonic variants through both models; the predictions achieved a 91.4% concordance across 726 pathogenic and 167 benign variants. We have made these predictions openly available, along with their class probabilities to facilitate a better understanding of variant pathogenicity for clinicians and researchers. Clinical diagnosis",17_13,WilsonGenAI a deep learning approach to classify pathogenic variants in Wilson Disease,17 5 2024,,Wilson_Disease
"clinicians and researchers. Clinical diagnosis of Wilson’s Disease is often challenging due to the heterogenous nature of symptoms it presents with. Genetic testing has thus been included in the diagnosis process as part of the Leipzig scoring system [<xref rid=""pone.0303787.ref023"" ref-type=""bibr"">23</xref>]. Additionally, testing can also rule out other genetic disorders such as some congenital disorders of glycosylation that mimic Wilson disease, but are not caused by <italic toggle=""yes"">ATP7B</italic>",17_14,WilsonGenAI a deep learning approach to classify pathogenic variants in Wilson Disease,17 5 2024,,Wilson_Disease
"not caused by <italic toggle=""yes"">ATP7B</italic> variants [<xref rid=""pone.0303787.ref035"" ref-type=""bibr"">35</xref>]. Since early diagnosis may prevent patients ever becoming symptomatic, infant and newborn screening, as well as family screening also become important. Accurate clinical interpretation of variants is therefore essential for diagnosis. Our models offer a means of applying learning of patterns based on classification by ACMG rapidly to a large number of variants, which otherwise is a time",17_15,WilsonGenAI a deep learning approach to classify pathogenic variants in Wilson Disease,17 5 2024,,Wilson_Disease
"number of variants, which otherwise is a time consuming and expertise-dependent process. Given the complex nature and varied mechanisms of genetic diseases, adopting a generalized approach to classifying causative variants is ill advised. We have shown this through the superior performance of our models over other general ACMG based models. To the best of our knowledge, no other models based on the ACMG classification of Wilson’s disease variants currently exist. We believe therefore, that our models can",17_16,WilsonGenAI a deep learning approach to classify pathogenic variants in Wilson Disease,17 5 2024,,Wilson_Disease
"exist. We believe therefore, that our models can be utilized for the rapid classification of Wilson’s Disease variants for better understanding of their pathogenicity in both research and clinical settings. Limitations: Even though the WilsonGen database is an exhaustive compendium of currently known and classified variants, the number of classified exonic variants still remains small. ACMG classification of variants is also a time-consuming process, and thus a newer dataset may take time to make. We have",17_17,WilsonGenAI a deep learning approach to classify pathogenic variants in Wilson Disease,17 5 2024,,Wilson_Disease
"a newer dataset may take time to make. We have thus been able to test model generalization on a dataset of 156 test variants. Additionally, the functional classification of ATP7B variants is still ongoing. Upon its completion, a clearer picture of which of the two models has performed better will be able to be obtained.",17_18,WilsonGenAI a deep learning approach to classify pathogenic variants in Wilson Disease,17 5 2024,,Wilson_Disease
"Wilson Disease and the COVID-19 pandemic: exploring patients’ mental health and vaccination attitudes in a longitudinal study Wilson’s disease (WD), previously known as hepatolenticular degeneration, is a rare genetic disorder characterized by defective copper transport and metabolism, leading to copper accumulation in various tissues, including the liver, brain, cornea, and kidneys. The disease is associated with a spectrum of psychological difficulties. Patients with WD often experience neuropsychiatric",18_0,Wilson Disease and the COVID-19 pandemic: exploring patients’ mental health and vaccination attitudes in a longitudinal study,13 5 2024,,Wilson_Disease
"with WD often experience neuropsychiatric symptoms, significantly impacting their mental health and well-being, with an estimated prevalence of 30–40%. However, the exact prevalence of psychiatric disorders in WD remains uncertain due to limited prospective cohort studies. Given the susceptibility of this population to psychiatric issues (<xref rid=""ref59"" ref-type=""bibr"">Zimbrean and Schilsky, 2014</xref>), especially during the COVID-19 pandemic, it is crucial to assess the impact on mental health and",18_1,Wilson Disease and the COVID-19 pandemic: exploring patients’ mental health and vaccination attitudes in a longitudinal study,13 5 2024,,Wilson_Disease
"crucial to assess the impact on mental health and relevant factors. This study aims to examine the impact of COVID-19 and its associated consequences on patients with chronic liver diseases, including WD. During the early stages of the pandemic, the significant impact of COVID-19 on mental health became apparent. SARS-CoV-2 is found to have neurotropic effects that can lead to various neurological symptoms by affecting the central nervous system or triggering immune responses and inflammation, contributing",18_2,Wilson Disease and the COVID-19 pandemic: exploring patients’ mental health and vaccination attitudes in a longitudinal study,13 5 2024,,Wilson_Disease
"immune responses and inflammation, contributing to increased neuropsychiatric symptoms in survivors (e.g., <xref rid=""ref44"" ref-type=""bibr"">Troyer et al., 2020</xref>; <xref rid=""ref47"" ref-type=""bibr"">Vindegaard and Benros, 2020</xref>). Stress and uncertainty related to the virus, along with mandatory isolation from educational, social, and work activities due to widespread lockdowns, have led to changes in mental health needs (<xref rid=""ref35"" ref-type=""bibr"">Moreno et al., 2020</xref>). Compared to",18_3,Wilson Disease and the COVID-19 pandemic: exploring patients’ mental health and vaccination attitudes in a longitudinal study,13 5 2024,,Wilson_Disease
"et al., 2020</xref>). Compared to pre-pandemic conditions, the general population has experienced a decline in psychological well-being, with increased levels of anxiety, stress, and depression (<xref rid=""ref48"" ref-type=""bibr"">Wang et al., 2020</xref>). Patients with chronic conditions, including WD, have shown increased susceptibility to morbidity and mortality from SARS-CoV-2 infection, leading to heightened levels of anxiety, stress, and depression (<xref rid=""ref28"" ref-type=""bibr"">Lee et al.,",18_4,Wilson Disease and the COVID-19 pandemic: exploring patients’ mental health and vaccination attitudes in a longitudinal study,13 5 2024,,Wilson_Disease
"(<xref rid=""ref28"" ref-type=""bibr"">Lee et al., 2020</xref>; <xref rid=""ref39"" ref-type=""bibr"">Pedrozo-Pupo and Campo-Arias, 2020</xref>). During the COVID-19 pandemic, guidelines were issued to assist healthcare providers in delivering optimal care for individuals with chronic liver disease, with a particular focus on understanding the effects of the virus on liver function and how pre-existing liver conditions might influence disease progression (<xref rid=""ref4"" ref-type=""bibr"">Boettler et al.,",18_5,Wilson Disease and the COVID-19 pandemic: exploring patients’ mental health and vaccination attitudes in a longitudinal study,13 5 2024,,Wilson_Disease
"rid=""ref4"" ref-type=""bibr"">Boettler et al., 2020</xref>). Despite these efforts, the impact of the pandemic on the mental health of liver disease patients, including various subgroups within this population, remains to be fully explored. As stated earlier, individuals with Wilson disease face a range of psychological challenges. One of the prominent psychological challenges experienced by Wilson’s disease patients is mood disorders. Research has shown a high prevalence of mood disturbances, with depression",18_6,Wilson Disease and the COVID-19 pandemic: exploring patients’ mental health and vaccination attitudes in a longitudinal study,13 5 2024,,Wilson_Disease
"prevalence of mood disturbances, with depression being a common manifestation (<xref rid=""ref59"" ref-type=""bibr"">Zimbrean and Schilsky, 2014</xref>; <xref rid=""ref32"" ref-type=""bibr"">Medici et al., 2018</xref>). These mood disorders can exacerbate the overall psychological burden experienced by individuals with Wilson’s disease. Cognitive impairment is another critical aspect of psychological difficulties in this population. Memory deficits and executive dysfunction are prevalent cognitive symptoms among",18_7,Wilson Disease and the COVID-19 pandemic: exploring patients’ mental health and vaccination attitudes in a longitudinal study,13 5 2024,,Wilson_Disease
"are prevalent cognitive symptoms among Wilson’s disease patients (<xref rid=""ref59"" ref-type=""bibr"">Zimbrean and Schilsky, 2014</xref>; <xref rid=""ref32"" ref-type=""bibr"">Medici et al., 2018</xref>). These cognitive impairments can impact daily functioning and quality of life. Furthermore, psychosis is observed in some cases, adding to the complexity of psychological difficulties associated with Wilson’s disease. Psychotic symptoms may include hallucinations and delusions (<xref rid=""ref59""",18_8,Wilson Disease and the COVID-19 pandemic: exploring patients’ mental health and vaccination attitudes in a longitudinal study,13 5 2024,,Wilson_Disease
"hallucinations and delusions (<xref rid=""ref59"" ref-type=""bibr"">Zimbrean and Schilsky, 2014</xref>; <xref rid=""ref32"" ref-type=""bibr"">Medici et al., 2018</xref>). Anxiety disorders, such as generalized anxiety disorder and panic disorder, can also occur (<xref rid=""ref59"" ref-type=""bibr"">Zimbrean and Schilsky, 2014</xref>). These anxiety-related problems can contribute to the overall psychological distress of affected individuals. Moreover, personality changes have been documented in Wilson’s disease",18_9,Wilson Disease and the COVID-19 pandemic: exploring patients’ mental health and vaccination attitudes in a longitudinal study,13 5 2024,,Wilson_Disease
"changes have been documented in Wilson’s disease patients. These changes can manifest as alterations in behavior, interpersonal relationships, and emotional regulation. In conclusion, Wilson’s disease is linked to a range of psychological difficulties, encompassing mood disorders, cognitive impairment, psychosis, anxiety disorders, and personality changes. Understanding and addressing these psychological challenges are crucial components of the holistic care and management of individuals affected by this",18_10,Wilson Disease and the COVID-19 pandemic: exploring patients’ mental health and vaccination attitudes in a longitudinal study,13 5 2024,,Wilson_Disease
"and management of individuals affected by this condition during the pandemic. Individuals have been significantly impacted by the changes brought about by COVID-19. Essential personnel, including those in healthcare, law enforcement, food and agriculture, and energy industries faced a heightened risk of contracting the virus due to their on-site work requirements. In contrast, non-essential personnel have had to adapt to new work-from-home arrangements which posed challenges to their productivity (<xref",18_11,Wilson Disease and the COVID-19 pandemic: exploring patients’ mental health and vaccination attitudes in a longitudinal study,13 5 2024,,Wilson_Disease
"posed challenges to their productivity (<xref rid=""ref11"" ref-type=""bibr"">Chong et al., 2020</xref>; <xref rid=""ref43"" ref-type=""bibr"">Trougakos et al., 2020</xref>). Some employees have also experienced job loss or a reduction in their income sources. Global attempts to alleviate the socioeconomic and health-related consequences of the pandemic initially relied on preventative measures (<xref rid=""ref7"" ref-type=""bibr"">Calina et al., 2020</xref>) such as wearing masks, vaccinating, and social distancing.",18_12,Wilson Disease and the COVID-19 pandemic: exploring patients’ mental health and vaccination attitudes in a longitudinal study,13 5 2024,,Wilson_Disease
"masks, vaccinating, and social distancing. Given the psychological vulnerability of WD patients, it is essential to analyze their perspectives on crucial aspects such as COVID-19 vaccination, work arrangements, and income loss. Understanding these factors will aid in identifying potential issues and developing appropriate interventions. In summary, this study seeks to explore WD patients’ understanding, attitudes, and perceptions concerning the COVID-19 pandemic and vaccination efforts. Additionally, it",18_13,Wilson Disease and the COVID-19 pandemic: exploring patients’ mental health and vaccination attitudes in a longitudinal study,13 5 2024,,Wilson_Disease
"and vaccination efforts. Additionally, it aims to assess the pandemic’s impact on the mental well-being of WD patients, focusing on changes in self-reported depression, anxiety, stress levels, quality of life, cognitive function, and associated factors. The specific objectives include evaluating: (i) the vaccination rate and preference (ii) patients’ experiences during the pandemic (iii) the infection rate (iv) the perception of the pandemic among the WD population (v) the course of stress, anxiety, and",18_14,Wilson Disease and the COVID-19 pandemic: exploring patients’ mental health and vaccination attitudes in a longitudinal study,13 5 2024,,Wilson_Disease
"population (v) the course of stress, anxiety, and depression before and during the pandemic (vi) the effect of the pandemic on quality of life (vii) changes in cognitive function and (viii) any clinical, behavioral, or social factors that may have influenced the observed outcomes.  We divided our analysis into two sections: first, we report findings of the whole cohort (<italic toggle=""yes"">N</italic> = 62) who responded to our survey on knowledge, attitudes, and perceptions of WD patients towards the",18_15,Wilson Disease and the COVID-19 pandemic: exploring patients’ mental health and vaccination attitudes in a longitudinal study,13 5 2024,,Wilson_Disease
"and perceptions of WD patients towards the COVID-19 pandemic and vaccinations. The second part of our analysis reports on a sub-cohort (<italic toggle=""yes"">N</italic> = 33) that had multiple data points before and after the onset of the pandemic. This group was examined to evaluate the mental impacts of the COVID-19 pandemic. To our knowledge, this study represents the first attempt to investigate the vaccination attitudes, experiences during the COVID-19 pandemic, and perceptions among individuals with",18_16,Wilson Disease and the COVID-19 pandemic: exploring patients’ mental health and vaccination attitudes in a longitudinal study,13 5 2024,,Wilson_Disease
"pandemic, and perceptions among individuals with Wilson’s disease (WD), alongside examining the neuropsychiatric effects of the pandemic on this particular population. Our findings unveiled a remarkably high vaccination rate among WD patients, with 94% of participants reporting being vaccinated. Furthermore, a substantial proportion of participants expressed confidence in the safety (77%) and necessity (69%) of COVID-19 vaccination. The pandemic appeared to have adverse effects on the mental well-being of",18_17,Wilson Disease and the COVID-19 pandemic: exploring patients’ mental health and vaccination attitudes in a longitudinal study,13 5 2024,,Wilson_Disease
"have adverse effects on the mental well-being of WD patients, as evidenced by increased rates of depression and lower self-perceived mental health. Additionally, a subset of participants reported experiencing elevated levels of stress and anxiety, prompting them to adopt various wellness activities to cope with these challenges. Moreover, our study identified some variations in cognitive function among WD patients. It’s worth noting that our patient population differed in several respects from the general",18_18,Wilson Disease and the COVID-19 pandemic: exploring patients’ mental health and vaccination attitudes in a longitudinal study,13 5 2024,,Wilson_Disease
"differed in several respects from the general population. Predominantly comprised of individuals of Caucasian ethnicity (87%) (<xref rid=""ref3"" ref-type=""bibr"">Beinhardt et al., 2014</xref>), this population also exhibited higher levels of education (<xref rid=""ref10"" ref-type=""bibr"">Census Bureau Releases New Educational Attainment Data, n.d.</xref>) and greater income compared to national averages (<xref rid=""ref24"" ref-type=""bibr"">Income in the United States: 2021, n.d.</xref>). A significant portion of",18_19,Wilson Disease and the COVID-19 pandemic: exploring patients’ mental health and vaccination attitudes in a longitudinal study,13 5 2024,,Wilson_Disease
"2021, n.d.</xref>). A significant portion of the U.S. workforce, totaling approximately 55 million individuals (39% of the workforce), was classified as essential during the pandemic, continuing to work outside their homes despite the risks (<xref rid=""ref52"" ref-type=""bibr"">Who are essential workers? A comprehensive look at their wages, demographics, and unionization rates|Economic Policy Institute, n.d.</xref>). This essential workforce included healthcare professionals, first responders, grocery store",18_20,Wilson Disease and the COVID-19 pandemic: exploring patients’ mental health and vaccination attitudes in a longitudinal study,13 5 2024,,Wilson_Disease
"professionals, first responders, grocery store staff, public transit operators, and others vital for maintaining critical services and infrastructure. Within our patient cohort, 36% were classified as essential workers, providing a unique opportunity to examine the pandemic’s neuropsychiatric impact on this subgroup. Recent research indicates that 44% of the U.S. population experienced a decline in household income during the pandemic. Certain demographic groups, including Hispanics, ethnic minorities,",18_21,Wilson Disease and the COVID-19 pandemic: exploring patients’ mental health and vaccination attitudes in a longitudinal study,13 5 2024,,Wilson_Disease
"groups, including Hispanics, ethnic minorities, unmarried individuals, and those with lower education levels, were disproportionately affected (<xref rid=""ref6"" ref-type=""bibr"">Bruce et al., 2022</xref>). In our study, approximately one-third of participants (31%) reported a decrease in income. Notably, our patient population, predominantly consisting of white, non-Hispanic, married, and highly educated individuals, may have experienced a lesser financial impact compared to the broader population. Social",18_22,Wilson Disease and the COVID-19 pandemic: exploring patients’ mental health and vaccination attitudes in a longitudinal study,13 5 2024,,Wilson_Disease
"impact compared to the broader population. Social support has been identified as a protective factor against negative pandemic-related outcomes (<xref rid=""ref56"" ref-type=""bibr"">Xu and Zhang, 2022</xref>), with cohabitation associated with higher levels of life satisfaction (<xref rid=""ref20"" ref-type=""bibr"">Geprägs et al., 2022</xref>). A national survey revealed that 36% of respondents reported significant loneliness during the pandemic (<xref rid=""ref51"" ref-type=""bibr"">Weissbourd et al., 2021</xref>).",18_23,Wilson Disease and the COVID-19 pandemic: exploring patients’ mental health and vaccination attitudes in a longitudinal study,13 5 2024,,Wilson_Disease
"ref-type=""bibr"">Weissbourd et al., 2021</xref>). Within our study group, 84% lived with others during the pandemic. However, due to the small sample size and data limitations, we were unable to analyze the impact of loneliness on mental health and quality of life perceptions. As of February 2023, it is estimated that 43.9% of the global population has experienced at least one COVID-19 infection (<xref rid=""ref15"" ref-type=""bibr"">COVID-19 Cumulative Infection Collaborators, 2022</xref>). While the",18_24,Wilson Disease and the COVID-19 pandemic: exploring patients’ mental health and vaccination attitudes in a longitudinal study,13 5 2024,,Wilson_Disease
"Infection Collaborators, 2022</xref>). While the relationship between chronic liver disease (CLD) and SARS-CoV-2 risk has yet to be fully established, evidence suggests that (CLD) worsens COVID-19 outcomes, increasing severity and mortality. To our knowledge, there is no information on the prevalence of COVID-19 infection in WD patients. In our cohort, we found the infection risk appears to be slightly higher (61%) than the general population, only one patient in our cohort required hospitalization. Out",18_25,Wilson Disease and the COVID-19 pandemic: exploring patients’ mental health and vaccination attitudes in a longitudinal study,13 5 2024,,Wilson_Disease
"in our cohort required hospitalization. Out cohort had a high immunization rate (94%), which surpasses the global vaccination average of 69.4%, and a low rate of COVID-related hospitalization, which supports that vaccination might have provided some level of protection against severe COVID-19 infection (<xref rid=""ref14"" ref-type=""bibr"">Coronavirus (COVID-19) Vaccinations - Our World in Data, n.d.</xref>). The control of the COVID-19 pandemic through vaccination requires not only the vaccine’s safety and",18_26,Wilson Disease and the COVID-19 pandemic: exploring patients’ mental health and vaccination attitudes in a longitudinal study,13 5 2024,,Wilson_Disease
"requires not only the vaccine’s safety and efficacy but also the acceptance of the population. In this study group, just a small percentage of individuals consider vaccination unsafe (5%) or unnecessary (7%). Regular health monitoring, well-established and reliable provider-patient relationships, and high health awareness might have played a significant role in this rate which emphasizes the importance of collaboration between governments, health policymakers, and media to build trust in COVID-19",18_27,Wilson Disease and the COVID-19 pandemic: exploring patients’ mental health and vaccination attitudes in a longitudinal study,13 5 2024,,Wilson_Disease
"and media to build trust in COVID-19 vaccination by spreading accurate messages through trusted channels (<xref rid=""ref40"" ref-type=""bibr"">Sallam, 2021</xref>). Our study also informs about patient’s perceptions of the COVID-19 Pandemic. Current findings suggest that having a chronic medical condition or poor health perception was linked to higher risk awareness (<xref rid=""ref12"" ref-type=""bibr"">Cipolletta et al., 2022</xref>). Another plausible interpretation for the heightened risk awareness observed",18_28,Wilson Disease and the COVID-19 pandemic: exploring patients’ mental health and vaccination attitudes in a longitudinal study,13 5 2024,,Wilson_Disease
"for the heightened risk awareness observed in our sample could be attributed to their higher education levels. The individuals being investigated in this study tend to have a relatively higher level of education compared to the broader population. This elevated educational status might enhance their awareness of the severe impact of the virus, prompting them to take preventive measures, such as vaccination. Additionally, this patient population had been followed annually for the registry study and had",18_29,Wilson Disease and the COVID-19 pandemic: exploring patients’ mental health and vaccination attitudes in a longitudinal study,13 5 2024,,Wilson_Disease
"followed annually for the registry study and had access to ongoing medical care. Having an established channel of primary care might be our strongest defense against future pandemics. In addition, educating patients on vaccination and early interventions through established primary care might increase individuals’ awareness of ongoing and future pandemics. Several studies have highlighted a negative association between COVID-19 risk perception and well-being. While heightened awareness of COVID-19 risk is",18_30,Wilson Disease and the COVID-19 pandemic: exploring patients’ mental health and vaccination attitudes in a longitudinal study,13 5 2024,,Wilson_Disease
"While heightened awareness of COVID-19 risk is often linked with increased fear, anxiety, and stress (<xref rid=""ref21"" ref-type=""bibr"">Germani et al., 2020</xref>; <xref rid=""ref36"" ref-type=""bibr"">Motta Zanin et al., 2020</xref>), it can also lead to the adoption of coping mechanisms and proactive measures to curb the spread of the virus (<xref rid=""ref27"" ref-type=""bibr"">Krok and Zarzycka, 2020</xref>). The evaluation of perception was conducted 2.5 years following the onset of the pandemic, allowing",18_31,Wilson Disease and the COVID-19 pandemic: exploring patients’ mental health and vaccination attitudes in a longitudinal study,13 5 2024,,Wilson_Disease
"following the onset of the pandemic, allowing participants to make more informed assessments regarding preventive measures, infection risks, disease progression, mortality rates, and the safety and efficacy of vaccinations. A small proportion of the study participants perceived COVID-19 as non-threatening, with the majority acknowledging varying degrees of severity depending on individual cases. In the initial phases of the pandemic, uncertainty and stringent preventive measures contributed to heightened",18_32,Wilson Disease and the COVID-19 pandemic: exploring patients’ mental health and vaccination attitudes in a longitudinal study,13 5 2024,,Wilson_Disease
"preventive measures contributed to heightened levels of fear, stress, and anxiety. However, as the pandemic evolved, perceptions shifted to recognize the gravity of the disease while considering factors such as the health status of affected individuals. The COVID-19 pandemic presented significant psychological distress for EWs leading to elevated levels of anxiety, depression (<xref rid=""ref19"" ref-type=""bibr"">Firew et al., 2020</xref>; <xref rid=""ref37"" ref-type=""bibr"">Muller et al., 2020</xref>),",18_33,Wilson Disease and the COVID-19 pandemic: exploring patients’ mental health and vaccination attitudes in a longitudinal study,13 5 2024,,Wilson_Disease
"ref-type=""bibr"">Muller et al., 2020</xref>), insomnia (<xref rid=""ref58"" ref-type=""bibr"">Zhang et al., 2020</xref>), and post-traumatic stress (<xref rid=""ref8"" ref-type=""bibr"">Carmassi et al., 2020</xref>). Heavy workloads, shortages, or excessive use of protective equipment, witnessing patient deaths, separation from family, stigmatization, and personal circumstances such as caring for children or supporting infected family members have added to the already mental distress faced by EWs during the",18_34,Wilson Disease and the COVID-19 pandemic: exploring patients’ mental health and vaccination attitudes in a longitudinal study,13 5 2024,,Wilson_Disease
"already mental distress faced by EWs during the pandemic (<xref rid=""ref45"" ref-type=""bibr"">Tsamakis et al., 2021</xref>). Our study showed that EW had higher depression levels and lower self-perceived mental health during the pandemic, but no significant change was found in their anxiety or stress levels. During the COVID-19 pandemic, while the rate of depression was higher among people with chronic illnesses (<xref rid=""ref49"" ref-type=""bibr"">Wang et al., 2021</xref>) individuals with chronic illnesses",18_35,Wilson Disease and the COVID-19 pandemic: exploring patients’ mental health and vaccination attitudes in a longitudinal study,13 5 2024,,Wilson_Disease
"2021</xref>) individuals with chronic illnesses may have developed efficient coping skills and have experienced less stress and anxiety during the pandemic. The COVID-19 pandemic has caused widespread unemployment and decreased income, leading to financial difficulties. This had a negative effect on individuals’ well-being and mental health (<xref rid=""ref5"" ref-type=""bibr"">Borrescio-Higa et al., 2022</xref>). Job uncertainty and financial distress caused by the pandemic, as well as debt management",18_36,Wilson Disease and the COVID-19 pandemic: exploring patients’ mental health and vaccination attitudes in a longitudinal study,13 5 2024,,Wilson_Disease
"by the pandemic, as well as debt management challenges (<xref rid=""ref1"" ref-type=""bibr"">Andelic and Feeney, 2023</xref>), are linked to increased anxiety and depression (<xref rid=""ref54"" ref-type=""bibr"">Wilson et al., 2020</xref>). Similarly, our study found that WD patients who suffered income loss reported elevated levels of stress, anxiety, and a decrease in perceived mental health. Interestingly, the differences in stress, anxiety, and mental health between the individuals who lost their jobs and",18_37,Wilson Disease and the COVID-19 pandemic: exploring patients’ mental health and vaccination attitudes in a longitudinal study,13 5 2024,,Wilson_Disease
"between the individuals who lost their jobs and those who did not were apparent before the pandemic started. These findings suggest that individuals’ elevated stress and anxiety might be the cause of losing jobs, more than the effect. In our study population, we noted a higher level of stress and anxiety among participants who initiated wellness practices following the onset of the COVID-19 pandemic as compared to both their prior state before the pandemic and those who did not adopt such practices. At",18_38,Wilson Disease and the COVID-19 pandemic: exploring patients’ mental health and vaccination attitudes in a longitudinal study,13 5 2024,,Wilson_Disease
"and those who did not adopt such practices. At first, this finding may appear to contradict existing literature; however, a closer examination can deduce that individuals experiencing elevated levels of stress and anxiety might have adopted wellness practices as a coping mechanism. A subsequent study may be required to see a clear picture of the impact of wellness behavior. Cognitive function appeared to be better in patients who engaged in wellness activities which is consistent with the literature which",18_39,Wilson Disease and the COVID-19 pandemic: exploring patients’ mental health and vaccination attitudes in a longitudinal study,13 5 2024,,Wilson_Disease
"which is consistent with the literature which found that short-term aerobic exercise (<xref rid=""ref34"" ref-type=""bibr"">Miyazaki et al., 2022</xref>) or practicing meditation can enhance the cognitive functions of individuals (<xref rid=""ref23"" ref-type=""bibr"">Hausswirth et al., 2023</xref>). The COVID-19 pandemic caused lifestyle changes such as less physical activity, social isolation, and disrupted sleep patterns, which affected dietary habits and led to a decline in mental health (<xref rid=""ref9""",18_40,Wilson Disease and the COVID-19 pandemic: exploring patients’ mental health and vaccination attitudes in a longitudinal study,13 5 2024,,Wilson_Disease
"to a decline in mental health (<xref rid=""ref9"" ref-type=""bibr"">Caroppo et al., 2021</xref>). A study found a correlation between healthier-sustainable food consumption and lower anxiety, depression, and stress symptoms (<xref rid=""ref57"" ref-type=""bibr"">Zanatta et al., 2022</xref>). Moderate-intensity physical activity, including walking, jogging, and house cleaning, may also be beneficial (<xref rid=""ref29"" ref-type=""bibr"">Marconcin et al., 2022</xref>). Additionally, small studies suggest that",18_41,Wilson Disease and the COVID-19 pandemic: exploring patients’ mental health and vaccination attitudes in a longitudinal study,13 5 2024,,Wilson_Disease
"Additionally, small studies suggest that meditation, yoga, and breathing exercises may help improve mental health (<xref rid=""ref16"" ref-type=""bibr"">Desai et al., 2021</xref>; <xref rid=""ref46"" ref-type=""bibr"">Upadhyay et al., 2022</xref>). SARS-CoV-2 infection leads to increased neurocognitive decline in patients (<xref rid=""ref55"" ref-type=""bibr"">Xie et al., 2022</xref>). This effect persists even after 6 months which poses the question of whether or when the neuropsychiatric outcomes of it will return",18_42,Wilson Disease and the COVID-19 pandemic: exploring patients’ mental health and vaccination attitudes in a longitudinal study,13 5 2024,,Wilson_Disease
"the neuropsychiatric outcomes of it will return to baseline. The outcome is relevant not only for infected patients but also for healthcare providers and for policymakers tasked with establishing strategies to address this delayed sequela (<xref rid=""ref42"" ref-type=""bibr"">Taquet et al., 2022</xref>). Our study group did not reveal this interaction which may be attributed to just a single patient requiring hospitalization and high vaccination rates in the cohort. As such, studies indicate a higher",18_43,Wilson Disease and the COVID-19 pandemic: exploring patients’ mental health and vaccination attitudes in a longitudinal study,13 5 2024,,Wilson_Disease
"in the cohort. As such, studies indicate a higher susceptibility to neurocognitive decline among the elderly, those with comorbidities (<xref rid=""ref17"" ref-type=""bibr"">Evans et al., 2021</xref>), and hospitalized patients (<xref rid=""ref33"" ref-type=""bibr"">Miskowiak et al., 2023</xref>). Our study has several noteworthy limitations. Since WD is a rare genetic disease, the study has a small sample size which raises concerns about the statistical power of the analysis. Second, the results are specific to",18_44,Wilson Disease and the COVID-19 pandemic: exploring patients’ mental health and vaccination attitudes in a longitudinal study,13 5 2024,,Wilson_Disease
"the analysis. Second, the results are specific to WD patients limiting the generalizability to other populations. Third, the mental health analysis was based on a limited sample size of 33 patients who had at least two assessments before the pandemic. This can create a risk of selection bias, and the results may not accurately reflect the mental health of entire WD patients. Although the analysis attempted to control for potential confounding factors, such as EW, income loss, SARS-CoV-2 infection, or",18_45,Wilson Disease and the COVID-19 pandemic: exploring patients’ mental health and vaccination attitudes in a longitudinal study,13 5 2024,,Wilson_Disease
"such as EW, income loss, SARS-CoV-2 infection, or health-promoting activities; there might be other factors affecting mental health that were not assessed due to the limited sample size. Finally, the study did not investigate the effects of disease severity and timing of infection and their effects on mental health. Our study provides a starting point for future studies with a larger cohort for monitoring and addressing the mental health consequences arising from the COVID-19 pandemic among patients with",18_46,Wilson Disease and the COVID-19 pandemic: exploring patients’ mental health and vaccination attitudes in a longitudinal study,13 5 2024,,Wilson_Disease
"from the COVID-19 pandemic among patients with chronic diseases such as WD. Additionally, it highlights the need for further investigations into the long-term cognitive effects of COVID-19 infection and mitigation strategies. The COVID-19 pandemic has led to significant consequences on a global scale. In addition to efforts to control and eliminate the virus, it is vital to pay attention to mental health during and after the pandemic. The results of this research hold considerable relevance for",18_47,Wilson Disease and the COVID-19 pandemic: exploring patients’ mental health and vaccination attitudes in a longitudinal study,13 5 2024,,Wilson_Disease
"of this research hold considerable relevance for policymakers, organizations, and healthcare providers in addressing the challenges posed by the COVID-19 pandemic and its influence on the mental well-being of individuals with WD. It also emphasizes the need for monitoring and effective strategies to improve mental health throughout the post-pandemic recovery period. The raw data supporting the conclusions of this article will be made available by the authors, without undue reservation. The studies",18_48,Wilson Disease and the COVID-19 pandemic: exploring patients’ mental health and vaccination attitudes in a longitudinal study,13 5 2024,,Wilson_Disease
"authors, without undue reservation. The studies involving humans were approved by Yale University Institutional Review Board. The studies were conducted in accordance with the local legislation and institutional requirements. The participants provided their written informed consent to participate in this study. AC: Conceptualization, Data curation, Investigation, Methodology, Project administration, Resources, Writing – review & editing. AA: Conceptualization, Investigation, Methodology, Writing – original",18_49,Wilson Disease and the COVID-19 pandemic: exploring patients’ mental health and vaccination attitudes in a longitudinal study,13 5 2024,,Wilson_Disease
"Investigation, Methodology, Writing – original draft. ST: Formal analysis, Methodology, Visualization, Writing – original draft, Writing – review & editing, Conceptualization. UT: Conceptualization, Data curation, Investigation, Writing – review & editing. SR: Data curation, Funding acquisition, Investigation, Resources, Supervision, Writing – review & editing. MS: Conceptualization, Data curation, Funding acquisition, Resources, Supervision, Writing – review & editing. PZ: Funding acquisition, Resources,",18_50,Wilson Disease and the COVID-19 pandemic: exploring patients’ mental health and vaccination attitudes in a longitudinal study,13 5 2024,,Wilson_Disease
"& editing. PZ: Funding acquisition, Resources, Supervision, Writing – review & editing.",18_51,Wilson Disease and the COVID-19 pandemic: exploring patients’ mental health and vaccination attitudes in a longitudinal study,13 5 2024,,Wilson_Disease
"Wilson Disease in Children in the Eastern Region of Morocco: Analysis of 24 Cases Wilson's disease (WD), or ""hepato-lenticular degeneration,"" is a rare genetic disorder of autosomal recessive inheritance causing toxic tissue accumulation of copper, mainly in the liver, brain, and cornea. Its phenotypic and genotypic heterogeneity characterizes it. This study aimed to clarify the clinical features and spectrum of Wilson's disease in children from the eastern region of Morocco and to study the evolutionary",19_0,Wilson Disease in Children in the Eastern Region of Morocco: Analysis of 24 Cases,10 5 2024,,Wilson_Disease
"region of Morocco and to study the evolutionary profile and survival in this population while discussing and highlighting the various diagnostic and therapeutic difficulties encountered in the management of WD in our context. This retrospective study encompassed 24 children diagnosed with Wilson's disease, selected from the gastroenterology-hepatology and pediatric nutrition units at Mohamed VI University Hospital in Oujda, Morocco, over a span of nine years, from January 2015 to November 2023. Our series",19_1,Wilson Disease in Children in the Eastern Region of Morocco: Analysis of 24 Cases,10 5 2024,,Wilson_Disease
"from January 2015 to November 2023. Our series results show 14 boys and 10 girls; the median age of discovery was 11 years, with extremes ranging from 18 months to 15 years. The consanguinity was found in 13 patients. Clinically, the edemato-ascitic syndrome was noted in 14 patients with an alteration of the general state; icterus was found in 13 patients; signs of portal hypertension were present in six patients; and neurological signs in seven cases. Skin manifestations occurred in three cases, and",19_2,Wilson Disease in Children in the Eastern Region of Morocco: Analysis of 24 Cases,10 5 2024,,Wilson_Disease
"Skin manifestations occurred in three cases, and arthralgia in three cases. Six children were diagnosed on the occasion of a family screening. Biologically, hepatic cytolysis was found in 20 patients, with signs of hepatocellular failure in 15 cases. Hemolytic anemia was present in nine patients. Ceruloplasminemia was decreased in 21 patients and cupremia in 19 patients. Cupruria was increased in 22 cases. The Kayser-Fleicher ring was found in 10 cases. Abdominal ultrasound showed ascites in 16 patients,",19_3,Wilson Disease in Children in the Eastern Region of Morocco: Analysis of 24 Cases,10 5 2024,,Wilson_Disease
"ultrasound showed ascites in 16 patients, hepatomegaly in 1, splenomegaly in two cases, hepatosplenomegaly in five cases, and cirrhosis in two. MRI showed signal abnormalities in 11 patients. Therapeutically, D-penicillamine was initially introduced in 18 patients and zinc acetate in 6 patients. The evolution was favorable for 15 patients still followed up in the department. Three patients died of hepatocellular failure, and two died of hepatic encephalopathy. Four patients were lost to follow-up. Wilson's",19_4,Wilson Disease in Children in the Eastern Region of Morocco: Analysis of 24 Cases,10 5 2024,,Wilson_Disease
"Four patients were lost to follow-up. Wilson's disease (WD) is a rare autosomal recessive genetic disorder affecting copper metabolism. It is a copper toxicosis characterized by tissue accumulation of free copper, mainly in the liver, brain, and pericornea [<xref rid=""REF1"" ref-type=""bibr"">1</xref>,<xref rid=""REF2"" ref-type=""bibr"">2</xref>]. It results from mutations in the ATP7B gene on chromosome 13. This ATP7B protein transports copper in the hepatocyte. In France, 906 cases of WD were identified in",19_5,Wilson Disease in Children in the Eastern Region of Morocco: Analysis of 24 Cases,10 5 2024,,Wilson_Disease
"In France, 906 cases of WD were identified in 2013, representing a clinical prevalence of 15.4 cases per million inhabitants [<xref rid=""REF2"" ref-type=""bibr"">2</xref>]. In Morocco, it remains underestimated due to the difficulty of diagnosis. The age of onset of the disease is often between 10 and 20 years, but it can occur at extreme ages [<xref rid=""REF3"" ref-type=""bibr"">3</xref>]. Diagnosis is based on a number of factors: clinical, biological (cardiac work-up), radiological (MRI), and even",19_6,Wilson Disease in Children in the Eastern Region of Morocco: Analysis of 24 Cases,10 5 2024,,Wilson_Disease
"(cardiac work-up), radiological (MRI), and even histological [<xref rid=""REF4"" ref-type=""bibr"">4</xref>]. This rare genetic disease has a good prognosis if treatment is initiated early and continued for life. In the absence of any treatment, spontaneous evolution is usually fatal. Currently, several therapeutic options are available to stabilize the disease and avoid the damage associated with copper accumulation, subject to good compliance [<xref rid=""REF2"" ref-type=""bibr"">2</xref>-<xref rid=""REF4""",19_7,Wilson Disease in Children in the Eastern Region of Morocco: Analysis of 24 Cases,10 5 2024,,Wilson_Disease
"ref-type=""bibr"">2</xref>-<xref rid=""REF4"" ref-type=""bibr"">4</xref>]. Our work aimed to clarify the clinical features and spectrum of Wilson's disease in children from the eastern region of Morocco and to study the evolutionary profile and survival in this population while discussing and highlighting the various diagnostic and therapeutic difficulties encountered in the management of WD in our context. We conducted a retrospective study of 24 children followed in the Pediatric Gastroenterology-Hepatology",19_8,Wilson Disease in Children in the Eastern Region of Morocco: Analysis of 24 Cases,10 5 2024,,Wilson_Disease
"in the Pediatric Gastroenterology-Hepatology and Nutrition Unit in the Pediatrics Department of the Mohamed VI Hospital and University Center in Oujda over a nine-year period from January 2015 to November 2023. The inclusion criteria used in our series were children under 16 years of age with liver damage and/or neurological impairment, disturbed copper balance, and/or the presence of a Kayser-Fleischer ring. We have excluded children aged over 16 who had a normal copper balance. Data were collected from",19_9,Wilson Disease in Children in the Eastern Region of Morocco: Analysis of 24 Cases,10 5 2024,,Wilson_Disease
"a normal copper balance. Data were collected from the patient's medical records. An Excel file (Microsoft® Corp., Redmond, WA) was created to collect anamnestic, clinical, biological, radiological, and therapeutic data. We analyzed clinical, biological (hepatic and cupric), and evolutionary characteristics. Family screening was carried out by clinical examination and analysis of the siblings' copper levels. The average number of cases in our series was three per year. The average age of onset of Wilson's",19_10,Wilson Disease in Children in the Eastern Region of Morocco: Analysis of 24 Cases,10 5 2024,,Wilson_Disease
"per year. The average age of onset of Wilson's disease was 11 years, with extremes of 18 months and 15 years. The age group most affected was 8 to 12 years old. Among all patients, there was a predominance of males, with 14 boys out of 24 (58%) and 10 girls (42%), giving a sex ratio (M/F) of 1.4. Consanguinity was found in 13 patients (54%). Nine of them had first-degree consanguinity; the other four had second-degree consanguinity. The case histories of our patients included eight cases of death in",19_11,Wilson Disease in Children in the Eastern Region of Morocco: Analysis of 24 Cases,10 5 2024,,Wilson_Disease
"of our patients included eight cases of death in siblings with similar symptoms, one child who had failed at school, four cases of recurrent epistaxis, and one child with chronic headaches. All our patients had a progressive onset of clinical manifestations. However, the delay between the appearance of the first clinical signs and the diagnostic consultation varied from 6 days to 12 months, with an average of two months. The main reason for consultation was the edemato-ascitic syndrome, seen in 14 children",19_12,Wilson Disease in Children in the Eastern Region of Morocco: Analysis of 24 Cases,10 5 2024,,Wilson_Disease
"the edemato-ascitic syndrome, seen in 14 children (58%), with edema of the lower limbs and ascites, and an altered general state, with asthenia, anorexia, and weight loss, seen in 18 patients (75%). Jaundice was present in 13 patients, i.e., half the cases, and digestive signs (abdominal pain, nausea, vomiting, and diarrhea) in seven patients. Seven out of twenty-four children had hepatomegaly; collateral venous circulation was present in seven patients; and splenomegaly was present in six children as part",19_13,Wilson Disease in Children in the Eastern Region of Morocco: Analysis of 24 Cases,10 5 2024,,Wilson_Disease
"splenomegaly was present in six children as part of portal hypertension syndrome (PHS). Neuropsychiatric signs were present in seven patients aged between 8 and 15 years. The average time to onset of clinical signs in these seven cases was two months, with extremes of 13 days and 7 months. The neurological examination revealed extrapyramidal signs in four cases (slowness of gestures and ideation, frozen face), a sardonic smile in one case, a behavioral disorder in two cases, and micrography in three cases,",19_14,Wilson Disease in Children in the Eastern Region of Morocco: Analysis of 24 Cases,10 5 2024,,Wilson_Disease
"in two cases, and micrography in three cases, one of which was associated with one of the two patients with a behavioral disorder. Three patients presented with arthralgia and/or limited joint mobility, and five patients were asymptomatic at the time of screening among the siblings of the patients in our series. Regarding the dermatological manifestations of WD, cutaneous hyperpigmentation was noted in two patients in our series and one case of cutaneous xerosis. Clinical signs are shown in Table <xref",19_15,Wilson Disease in Children in the Eastern Region of Morocco: Analysis of 24 Cases,10 5 2024,,Wilson_Disease
"xerosis. Clinical signs are shown in Table <xref rid=""TAB1"" ref-type=""table"">1</xref>. Slit-lamp ophthalmological examination revealed the presence of the Kayser-Fleisher ring (KFR) in 10 patients, i.e., 42% of cases (Figure <xref rid=""FIG1"" ref-type=""fig"">1</xref>), nine of whom were over eight years old and one six-year-old with incipient KFR. The mean time for disease progression was five weeks. Biologically, transaminases were normal in four patients (17%), moderately elevated in 11 (46%), and very",19_16,Wilson Disease in Children in the Eastern Region of Morocco: Analysis of 24 Cases,10 5 2024,,Wilson_Disease
"(17%), moderately elevated in 11 (46%), and very elevated in nine children (37%). Prothrombin level (PT) was below 40% in 13 patients (54% of cases), between 40% and 70% in two children, and normal in nine patients, six of whom had undergone family screening. Factor V was performed in 11 patients and collapsed in 8. Hypoalbuminemia was noted in 16 patients, i.e., 67% of cases. Protein electrophoresis (PEP), performed in seven patients, showed hypoalbuminemia in all cases, associated with polyclonal",19_17,Wilson Disease in Children in the Eastern Region of Morocco: Analysis of 24 Cases,10 5 2024,,Wilson_Disease
"in all cases, associated with polyclonal hypergamma-globulinemia characterized by a beta-gamma-globulinemia block compatible with hepatocellular failure in six cases. Hematologically, hemolytic anemia was found in nine patients (37%), thrombocytopenia in 11 (46%), and moderate leukopenia with WBC counts of between 1,500 and 4,500 elements/mm3 in four patients. Ceruleoplasminemia was reduced in 21 patients (88%), normal in one child (4%), and not performed in two cases. Cupremia was reduced in 19 patients",19_18,Wilson Disease in Children in the Eastern Region of Morocco: Analysis of 24 Cases,10 5 2024,,Wilson_Disease
"in two cases. Cupremia was reduced in 19 patients (79%), increased in one, and not performed in four. Cupruria was performed in 22 patients and was found to be increased in all children. Relative exchangeable copper (REC) was measured in nine patients and found to be elevated (Table <xref rid=""TAB2"" ref-type=""table"">2</xref>). Abdominal ultrasonography showed ascites in 16 patients (67%) associated with cirrhosis of the liver in two cases, hepatosplenomegaly in five cases, hepatomegaly alone in one case,",19_19,Wilson Disease in Children in the Eastern Region of Morocco: Analysis of 24 Cases,10 5 2024,,Wilson_Disease
"in five cases, hepatomegaly alone in one case, and splenomegaly alone in two cases. Hepatosplenomegaly without ascites was noted in two cases and isolated hepatomegaly in two children. The other patients were diagnosed by family screening and had normal ultrasounds. Digestive fibroscopy was performed on three patients. It showed stage I esophageal varices without red signs in one patient and moderate antritis in another. In the remaining case, eso-gastroduodenal fibroscopy was normal. A cerebral MRI was",19_20,Wilson Disease in Children in the Eastern Region of Morocco: Analysis of 24 Cases,10 5 2024,,Wilson_Disease
"fibroscopy was normal. A cerebral MRI was carried out in all our patients and revealed bilateral and symmetrical T1 hyper-signal of the pallidum in four cases, bilateral and symmetrical involvement of the basal ganglia in four cases (T2 hypersignal; Figure <xref rid=""FIG2"" ref-type=""fig"">2</xref>), bilateral and symmetrical involvement of the lenticular and mesencephalic nuclei in one case, a giant Panda head appearance in one case and an appearance consistent with leukodystrophy in another. In the",19_21,Wilson Disease in Children in the Eastern Region of Morocco: Analysis of 24 Cases,10 5 2024,,Wilson_Disease
"consistent with leukodystrophy in another. In the remaining cases, MRI scans showed no abnormalities. A liver biopsy was performed on only one patient in our series, showing chronic liver disease. It was not performed in the other patients, given the severe liver damage and very low prothrombin levels. In terms of treatment, all the children and their parents benefited from a dietary consultation with the introduction of a low-copper diet. Eighteen of our patients were treated with D-penicillamine",19_22,Wilson Disease in Children in the Eastern Region of Morocco: Analysis of 24 Cases,10 5 2024,,Wilson_Disease
"of our patients were treated with D-penicillamine (TROLOVOL® /CUPRIPEN®), with doses gradually increased to two to three times daily on an empty stomach, reaching the full dose by the fourth week. Of these 18 patients, three were switched to zinc acetate due to severe toxidermia with hematological damage in one patient and the unavailability of D-penicillamine on the Moroccan pharmacological market in two patients. The last six patients were treated immediately with zinc acetate (WILZIN®), with the dosage",19_23,Wilson Disease in Children in the Eastern Region of Morocco: Analysis of 24 Cases,10 5 2024,,Wilson_Disease
"with zinc acetate (WILZIN®), with the dosage depending on the age and weight of each patient. None of the patients received vitamin B6. Liver transplantation was not indicated in any patient in our series. As adjuvant therapy, 14 patients with edemato-ascitic syndrome were started on diuretics (spironolactone, furosemide) at a dose of 2-4 mg/kg/d with diuresis monitoring, and 15 patients were started on vitamin K (10 mg/d), in view of clinical and biological cholestasis and low PT, in addition to",19_24,Wilson Disease in Children in the Eastern Region of Morocco: Analysis of 24 Cases,10 5 2024,,Wilson_Disease
"biological cholestasis and low PT, in addition to transfusions of fresh frozen plasma (nine cases for hepatocellular insufficiency), platelet and red blood cells (one case with poorly tolerated anemia and severe thrombocytopenia), as well as albumin infusions (seven children). Treatment-related side effects were noted in 11 patients, i.e., half the cases. Hematological side effects included 10 cases of thrombocytopenia and 6 cases of leukopenia. On the neurological front, two cases of neurological",19_25,Wilson Disease in Children in the Eastern Region of Morocco: Analysis of 24 Cases,10 5 2024,,Wilson_Disease
"the neurological front, two cases of neurological aggravation, such as agitation, were observed in connection with hepatic encephalopathy and generalized convulsive seizures (without post-critical deficit) one week after the initiation of D-penicillamine. On the gastrointestinal front, only one patient suffered mild hematemesis with melena due to an error in the administration of zinc acetate [75 mg divided into two doses (50 mg and 25 mg) instead of 3], necessitating transfusion of the patient with packed",19_26,Wilson Disease in Children in the Eastern Region of Morocco: Analysis of 24 Cases,10 5 2024,,Wilson_Disease
"transfusion of the patient with packed red blood cells and the administration of a PPI (2 mg/kg/d). Side effects such as nausea, vomiting, and disgust were observed in five patients. In addition, a case of severe cutaneous toxidermia (pruritic maculopapular lesions and purpuric spots) associated with hematological damage two days after the start of treatment, necessitating a change in treatment, and a case of stretch marks after administration of D-penicillamine were noted. After an average follow-up of",19_27,Wilson Disease in Children in the Eastern Region of Morocco: Analysis of 24 Cases,10 5 2024,,Wilson_Disease
"were noted. After an average follow-up of four and a half years, with extremes ranging from two months to nine years, the evolution was favorable, with good efficacy and clinico-biological tolerance, including the disappearance of symptoms, normal growth and schooling, and normalization of the biological balance, in 15 patients who are still being followed in the Pediatric Department. On the other hand, there were five deaths, three of which were the result of decompensated cirrhosis in patients who had",19_28,Wilson Disease in Children in the Eastern Region of Morocco: Analysis of 24 Cases,10 5 2024,,Wilson_Disease
"of decompensated cirrhosis in patients who had consulted us late for edematous-ascitic syndrome, jaundice, and hepatocellular insufficiency, and two of which were the result of hepatic encephalopathy. In addition, the evolution of four patients could not be assessed because they had been lost to follow-up. In our series, a family investigation was systematically carried out in all patients, with a copper work-up in the siblings. This investigation led to the diagnosis of five cases included in the series.",19_29,Wilson Disease in Children in the Eastern Region of Morocco: Analysis of 24 Cases,10 5 2024,,Wilson_Disease
"diagnosis of five cases included in the series. The genetic prevalence of WD in France is estimated at 30/1,000,00 [<xref rid=""REF5"" ref-type=""bibr"">5</xref>]. In France, 906 cases of WD were identified in 2013, representing a clinical prevalence of 15.4 cases per million inhabitants [<xref rid=""REF2"" ref-type=""bibr"">2</xref>]. Consanguinity considerably increases the incidence of WD [<xref rid=""REF4"" ref-type=""bibr"">4</xref>]. Given the frequency of consanguineous marriages, it is thought to be fairly",19_30,Wilson Disease in Children in the Eastern Region of Morocco: Analysis of 24 Cases,10 5 2024,,Wilson_Disease
"marriages, it is thought to be fairly common in Maghreb countries. Its exact incidence in these countries is unknown. In Morocco, it remains underestimated due to the difficulty of diagnosis. The age of onset of the disease is often between 10 and 20 years, but it can occur at the extremes of life [<xref rid=""REF3"" ref-type=""bibr"">3</xref>]. This disease is characterized by a diversity of clinical manifestations, dominated by hepatic, neurological, and ocular symptoms, which may be isolated, associated, or",19_31,Wilson Disease in Children in the Eastern Region of Morocco: Analysis of 24 Cases,10 5 2024,,Wilson_Disease
"symptoms, which may be isolated, associated, or follow one another [<xref rid=""REF2"" ref-type=""bibr"">2</xref>]. In children, the first symptoms are usually hepatic, whereas in adults, the symptoms are mainly neuropsychiatric. The disease may also manifest itself through renal, hematological, endocrine, or cardiovascular manifestations [<xref rid=""REF6"" ref-type=""bibr"">6</xref>]. Some authors report that forms with a hepatic presentation have a risk of death five times higher than forms with a neurological",19_32,Wilson Disease in Children in the Eastern Region of Morocco: Analysis of 24 Cases,10 5 2024,,Wilson_Disease
"five times higher than forms with a neurological presentation [<xref rid=""REF7"" ref-type=""bibr"">7</xref>]. In our study, the first manifestations were hepatic in 22 patients (92%) and neurological in 2 patients (8%). Hepatic involvement is often isolated in children, discovered between the ages of 5 and 13. Several clinical pictures can be revealed, ranging from a simple increase in transaminases to fulminant hepatitis [<xref rid=""REF8"" ref-type=""bibr"">8</xref>]. In our series, the majority of our patients",19_33,Wilson Disease in Children in the Eastern Region of Morocco: Analysis of 24 Cases,10 5 2024,,Wilson_Disease
"In our series, the majority of our patients presented immediately with cirrhosis, suggesting a delay in diagnosis probably due to three factors: most often, a delay in consultation, but sometimes also due to the clinical heterogeneity that makes the diagnostic hypothesis difficult, as well as a rapidly severe evolution, since the average time to progression found in Moroccan children with WD in the eastern region was two months. Admittedly, the first symptoms are mainly hepatic in children, but in our",19_34,Wilson Disease in Children in the Eastern Region of Morocco: Analysis of 24 Cases,10 5 2024,,Wilson_Disease
"are mainly hepatic in children, but in our series, we reported one child who presented purely with neuropsychiatric symptoms with no other associated damage, notably hepatic. Although neurological involvement is exceptional before the age of 12, we have described three children under the age of 12 (8 and 10 years old) whose neurological symptoms occurred after liver involvement in two cases and concomitantly with liver damage in only one child. Gradually and without treatment, the classic neurological",19_35,Wilson Disease in Children in the Eastern Region of Morocco: Analysis of 24 Cases,10 5 2024,,Wilson_Disease
"and without treatment, the classic neurological picture of the disease develops a dystonic syndrome characterized by dystonic postures and choreoathetotic movements, an ataxic syndrome with postural and intention tremor and limb ataxia, and an extrapyramidal syndrome with hypokinesia, mainly axial hypertonia and rest tremor [<xref rid=""REF2"" ref-type=""bibr"">2</xref>,<xref rid=""REF6"" ref-type=""bibr"">6</xref>,<xref rid=""REF9"" ref-type=""bibr"">9</xref>]. The facial expression of the ""Wilsonian"" patient is",19_36,Wilson Disease in Children in the Eastern Region of Morocco: Analysis of 24 Cases,10 5 2024,,Wilson_Disease
"facial expression of the ""Wilsonian"" patient is often very suggestive: the face is set, the mouth is open, and the hypertonicity of the perioral muscles gives the appearance of a permanent sardonic smile [<xref rid=""REF6"" ref-type=""bibr"">6</xref>,<xref rid=""REF9"" ref-type=""bibr"">9</xref>]. In most cases, symptoms develop very gradually, but a sudden onset after a triggering factor such as trauma or especially surgery under general anesthesia has been described [<xref rid=""REF6"" ref-type=""bibr"">6</xref>].",19_37,Wilson Disease in Children in the Eastern Region of Morocco: Analysis of 24 Cases,10 5 2024,,Wilson_Disease
"[<xref rid=""REF6"" ref-type=""bibr"">6</xref>]. It should also be noted that WD may be manifested by torticollis [<xref rid=""REF10"" ref-type=""bibr"">10</xref>]. Psychiatric disorders are inaugural in 15% of cases or accompany neurological manifestations [<xref rid=""REF11"" ref-type=""bibr"">11</xref>]. The usual ophthalmological feature of WD is the green pericorneal Kayser-Fleischer ring, which reflects copper deposits in Descemet's membrane. It is carefully examined with a slit lamp and is almost pathognomonic",19_38,Wilson Disease in Children in the Eastern Region of Morocco: Analysis of 24 Cases,10 5 2024,,Wilson_Disease
"with a slit lamp and is almost pathognomonic of the disease. However, it can also be observed in cases of severe cholestasis, notably in primary or cryptogenic biliary cirrhosis and in primary sclerosing cholangitis [<xref rid=""REF12"" ref-type=""bibr"">12</xref>]. It is almost always present in patients with neurological disorders [<xref rid=""REF2"" ref-type=""bibr"">2</xref>]. However, in hepatic forms, it may be absent in 25% of cases. If it is absent, the diagnosis of WD cannot be ruled out. In our series,",19_39,Wilson Disease in Children in the Eastern Region of Morocco: Analysis of 24 Cases,10 5 2024,,Wilson_Disease
"of WD cannot be ruled out. In our series, it was present in 42% of cases, three of which were unaccompanied by neurological involvement. The ring disappears in a few years under chelation therapy, and its reappearance in a patient undergoing medical treatment should raise suspicions of poor compliance with treatment [<xref rid=""REF12"" ref-type=""bibr"">12</xref>]. Another ophthalmological manifestation is the much rarer sunflower cataract, visible only on slit-lamp examination [<xref rid=""REF12""",19_40,Wilson Disease in Children in the Eastern Region of Morocco: Analysis of 24 Cases,10 5 2024,,Wilson_Disease
"only on slit-lamp examination [<xref rid=""REF12"" ref-type=""bibr"">12</xref>,<xref rid=""REF13"" ref-type=""bibr"">13</xref>]. These two manifestations do not alter vision [<xref rid=""REF12"" ref-type=""bibr"">12</xref>,<xref rid=""REF14"" ref-type=""bibr"">14</xref>]. Other organ damage may occur in WD. Skin involvement may include hyperpigmentation, azure lunules on the nails, and xerosis of the skin [<xref rid=""REF8"" ref-type=""bibr"">8</xref>,<xref rid=""REF13"" ref-type=""bibr"">13</xref>,<xref rid=""REF15""",19_41,Wilson Disease in Children in the Eastern Region of Morocco: Analysis of 24 Cases,10 5 2024,,Wilson_Disease
"ref-type=""bibr"">13</xref>,<xref rid=""REF15"" ref-type=""bibr"">15</xref>]. Osteoarticular damage, which occurs later, is multifactorial and can affect all joints [<xref rid=""REF9"" ref-type=""bibr"">9</xref>,<xref rid=""REF16"" ref-type=""bibr"">16</xref>]. Endocrine and cardiac manifestations have also been described in WD [<xref rid=""REF3"" ref-type=""bibr"">3</xref>,<xref rid=""REF8"" ref-type=""bibr"">8</xref>,<xref rid=""REF9"" ref-type=""bibr"">9</xref>,<xref rid=""REF13"" ref-type=""bibr"">13</xref>,<xref rid=""REF15""",19_42,Wilson Disease in Children in the Eastern Region of Morocco: Analysis of 24 Cases,10 5 2024,,Wilson_Disease
"ref-type=""bibr"">13</xref>,<xref rid=""REF15"" ref-type=""bibr"">15</xref>,<xref rid=""REF16"" ref-type=""bibr"">16</xref>]. Acute or subacute Coombs-negative hemolytic anemia may be the first sign of WD [<xref rid=""REF3"" ref-type=""bibr"">3</xref>,<xref rid=""REF17"" ref-type=""bibr"">17</xref>]. Most cases have cirrhosis with a low-noise, chronic hemolytic anemia, with a few acute episodes that may precede the hepatic or neurological symptomatology by several years [<xref rid=""REF18"" ref-type=""bibr"">18</xref>].",19_43,Wilson Disease in Children in the Eastern Region of Morocco: Analysis of 24 Cases,10 5 2024,,Wilson_Disease
"[<xref rid=""REF18"" ref-type=""bibr"">18</xref>]. Thrombocytopenia is often found in Wilsonian patients with prominent splenomegaly [<xref rid=""REF14"" ref-type=""bibr"">14</xref>]. It is secondary both to the hypersplenism caused by cirrhosis and to the direct toxicity of copper, which affects megakaryogenesis by causing platelet production abnormalities [<xref rid=""REF13"" ref-type=""bibr"">13</xref>]. Leukopenia secondary to hypersplenism has also been described in WD [<xref rid=""REF13""",19_44,Wilson Disease in Children in the Eastern Region of Morocco: Analysis of 24 Cases,10 5 2024,,Wilson_Disease
"has also been described in WD [<xref rid=""REF13"" ref-type=""bibr"">13</xref>]. In our series, it was found in four patients. Renal involvement is almost always present but is usually clinically unobtrusive [<xref rid=""REF19"" ref-type=""bibr"">19</xref>]. Its manifestations are most often related to proximal tubular lesions, much more rarely to glomerular damage [<xref rid=""REF13"" ref-type=""bibr"">13</xref>]. Glomerulonephritis with immune complex or IgA nephrotic syndrome has also been described during the",19_45,Wilson Disease in Children in the Eastern Region of Morocco: Analysis of 24 Cases,10 5 2024,,Wilson_Disease
"syndrome has also been described during the disease itself or under treatment with D-penicillamine [<xref rid=""REF13"" ref-type=""bibr"">13</xref>]. In all cases, they are secondary to copper toxicity [<xref rid=""REF20"" ref-type=""bibr"">20</xref>]. In our series, we found three cases of renal involvement at the time of the diagnosis of Wilson's disease. Asymptomatic forms are usually detected, ideally around the age of 3 or 4, in the siblings of a child newly diagnosed with WD. Biological signs can be summed",19_46,Wilson Disease in Children in the Eastern Region of Morocco: Analysis of 24 Cases,10 5 2024,,Wilson_Disease
"diagnosed with WD. Biological signs can be summed up as a moderate and persistent rise in transaminases, but this may be absent even though the copper balance has been positive for many years. Molecular biology can make an important diagnostic contribution here when sibling studies have proved informative. Biological disturbances specific to WD are based on analysis of the copper balance, which must include ceruloplasminemia, total cupremia, exchangeable copper, enabling calculation of the exchangeable",19_47,Wilson Disease in Children in the Eastern Region of Morocco: Analysis of 24 Cases,10 5 2024,,Wilson_Disease
"copper, enabling calculation of the exchangeable copper/total copper ratio, and 24-hour cupruria. Studies have suggested that the sensitivity of a low ceruloplasmin level for WD ranges from 80% to 99%, although the specificity is lower. Furthermore, in patients with hepatic presentations, a low ceruloplasmin level may be less predictive of WD [<xref rid=""REF3"" ref-type=""bibr"">3</xref>]. However, in 5-10% of patients, this level may approach normal or even be normal. The ceruloplasmin level may, therefore,",19_48,Wilson Disease in Children in the Eastern Region of Morocco: Analysis of 24 Cases,10 5 2024,,Wilson_Disease
"normal. The ceruloplasmin level may, therefore, be a factor in the suspicion, but not the diagnosis, of WD. Serum copper is generally very low. Total cupremia is made up of ceruloplasmin-bound copper (92%) and ionic-free copper. Total cupremia is normally low but not collapsed, as there is an increase in the free copper fraction. This dosage is often highly variable during the course of the disease and is, therefore, of little practical use [<xref rid=""REF2"" ref-type=""bibr"">2</xref>,<xref rid=""REF3""",19_49,Wilson Disease in Children in the Eastern Region of Morocco: Analysis of 24 Cases,10 5 2024,,Wilson_Disease
"ref-type=""bibr"">2</xref>,<xref rid=""REF3"" ref-type=""bibr"">3</xref>]. Urinary copper levels are essential for diagnosing WD. In symptomatic patients, the level is systematically high (>100 μg/24 h). This level must be confirmed on 24-hour urine samples repeated once or twice, as there is day-to-day variability, influenced in particular by diet. There is only one other situation in which urinary copper levels may be elevated: obstructive liver disease, such as primary biliary cirrhosis or cholestasis. In",19_50,Wilson Disease in Children in the Eastern Region of Morocco: Analysis of 24 Cases,10 5 2024,,Wilson_Disease
"as primary biliary cirrhosis or cholestasis. In this situation, both hepatic and urinary copper levels may be elevated, and even the Kayser-Fleischer ring may be present. A urinary copper level <50 μg/24 h in a symptomatic patient in the absence of renal insufficiency, as it cannot be interpreted in the case of renal impairment, virtually rules out the diagnosis of WD. If the urinary copper value is between 50 and 100 μg/24 h, further investigations are warranted. This assay is also extremely important for",19_51,Wilson Disease in Children in the Eastern Region of Morocco: Analysis of 24 Cases,10 5 2024,,Wilson_Disease
"This assay is also extremely important for monitoring treatment efficacy and compliance [<xref rid=""REF21"" ref-type=""bibr"">21</xref>]. Exchangeable copper is a new assay for free copper, and the exchangeable copper/total copper ratio, or REC, is certainly the best method of analysis. It is an excellent diagnostic biomarker, with a sensitivity close to 100% when its value is greater than 18.5%. The REC ratio can be used to differentiate Wilsonian hepatopathy from hepatopathy of other etiologies",19_52,Wilson Disease in Children in the Eastern Region of Morocco: Analysis of 24 Cases,10 5 2024,,Wilson_Disease
"hepatopathy from hepatopathy of other etiologies (non-alcoholic steatohepatitis [Nash], autoimmune, or infectious, whether in children or adults). In family screening for WD, the REC ratio can also be used to differentiate heterozygous carriers or healthy subjects from diseased subjects. The determination of exchangeable copper provides a direct and accurate measure of copper overload. At the time of diagnosis, it provides information on the spread and severity of the disease [<xref rid=""REF1""",19_53,Wilson Disease in Children in the Eastern Region of Morocco: Analysis of 24 Cases,10 5 2024,,Wilson_Disease
"and severity of the disease [<xref rid=""REF1"" ref-type=""bibr"">1</xref>,<xref rid=""REF2"" ref-type=""bibr"">2</xref>]. In neurological forms, cerebral CT scans may be normal, even when the Kayser-Fleischer ring is present. In most cases, it shows a characteristic bilateral hypodensity of the lenticular nuclei. MRI, on the other hand, is almost always pathological in neurological forms, revealing gray-nucleus hypersignals of variable size and shape on T2-weighted and FLAIR sequences involving the putamen,",19_54,Wilson Disease in Children in the Eastern Region of Morocco: Analysis of 24 Cases,10 5 2024,,Wilson_Disease
"and FLAIR sequences involving the putamen, striatum, and pallidum, as well as cortical atrophy and white matter changes [<xref rid=""REF12"" ref-type=""bibr"">12</xref>,<xref rid=""REF22"" ref-type=""bibr"">22</xref>]. Hyper-signaling in the midbrain around the red nucleus and substantia nigra can give the appearance of a ""panda sign,"" which is most often seen in Wilsonian patients and has been shown to be fairly specific for WD but not very sensitive [<xref rid=""REF3"" ref-type=""bibr"">3</xref>,<xref rid=""REF22""",19_55,Wilson Disease in Children in the Eastern Region of Morocco: Analysis of 24 Cases,10 5 2024,,Wilson_Disease
"ref-type=""bibr"">3</xref>,<xref rid=""REF22"" ref-type=""bibr"">22</xref>]. Brain imaging is also useful for monitoring the evolution of lesions under treatment. WD is one of the few treatable metabolic diseases. Treatment must be initiated early and for life, because once irreversible damage has set in, the effect of treatment is limited, and the patient's life quality is permanently compromised. Treatment involves a diet that avoids copper-rich foods (mushrooms, liver, seafood, nuts, and chocolate). Copper",19_56,Wilson Disease in Children in the Eastern Region of Morocco: Analysis of 24 Cases,10 5 2024,,Wilson_Disease
"liver, seafood, nuts, and chocolate). Copper chelators are the mainstay of treatment (DPenicillamine [DP] or Trolovol®, and Triethy-tetramine (TETA) or Trientine®). Their doses are administered two to four times a day, without food, i.e., one hour before or two hours after meals. They are increased to an approximate dose based on body weight of around 20 mg/kg/d for initial treatment. Inhibitors of digestive copper absorption (mainly zinc acetate or sulfate) represent another possible therapeutic approach",19_57,Wilson Disease in Children in the Eastern Region of Morocco: Analysis of 24 Cases,10 5 2024,,Wilson_Disease
"represent another possible therapeutic approach [<xref rid=""REF20"" ref-type=""bibr"">20</xref>]. Treatment must be monitored both clinically and biologically (cupruria). The effectiveness of therapeutic management is only observed several months after its introduction, notably through normalization of the liver balance. Liver transplantation may be considered in cases of fulminant hepatitis [<xref rid=""REF6"" ref-type=""bibr"">6</xref>]. In presymptomatic or paucisymptomatic forms, it is generally accepted to",19_58,Wilson Disease in Children in the Eastern Region of Morocco: Analysis of 24 Cases,10 5 2024,,Wilson_Disease
"forms, it is generally accepted to treat with zinc, which is inexpensive and has few side effects [<xref rid=""REF23"" ref-type=""bibr"">23</xref>]. The difficulty in our country is to obtain D-penicillamine, as this product is not available in Morocco. The deaths recorded in our series could be explained either by a delay in diagnosis of this condition, given the difficulty of biological confirmation of the disease (the high cost of the copper test), or by practitioners' lack of knowledge of the disease, or",19_59,Wilson Disease in Children in the Eastern Region of Morocco: Analysis of 24 Cases,10 5 2024,,Wilson_Disease
"lack of knowledge of the disease, or by a delay in starting treatment or poor compliance. All of this adds up to diagnostic difficulties in our low-income country, especially as the copper test is required to screen all siblings as part of a family survey. These days, two genetic study strategies are used: indirect family diagnosis by haplotype analysis or direct diagnosis by mutation search [<xref rid=""REF17"" ref-type=""bibr"">17</xref>,<xref rid=""REF18"" ref-type=""bibr"">18</xref>]. Our series data align",19_60,Wilson Disease in Children in the Eastern Region of Morocco: Analysis of 24 Cases,10 5 2024,,Wilson_Disease
"ref-type=""bibr"">18</xref>]. Our series data align closely with previous Moroccan studies [<xref rid=""REF24"" ref-type=""bibr"">24</xref>-<xref rid=""REF26"" ref-type=""bibr"">26</xref>], as demonstrated in Table <xref rid=""TAB3"" ref-type=""table"">3</xref>. Interestingly, we observe a notable prevalence of neurological manifestations in series from Western nations [<xref rid=""REF27"" ref-type=""bibr"">27</xref>,<xref rid=""REF28"" ref-type=""bibr"">28</xref>] when compared to their Moroccan counterparts. Limitations of",19_61,Wilson Disease in Children in the Eastern Region of Morocco: Analysis of 24 Cases,10 5 2024,,Wilson_Disease
"to their Moroccan counterparts. Limitations of the study Our study was limited by the fact that we live in a low-income country, which meant that we were unable to carry out a complete copper workup on all patients, in particular the REC ratio. On the other hand, we were unable to follow the progress of all our patients, as four were lost to follow-up. Our study enabled us to identify some specificities in our country, including the underestimated frequency, knowing that our region is very rich in",19_62,Wilson Disease in Children in the Eastern Region of Morocco: Analysis of 24 Cases,10 5 2024,,Wilson_Disease
"knowing that our region is very rich in consanguinity. There is also the diagnostic delay and the marked predominance of hepatic manifestations compared to neurological manifestations, which are much less pronounced. This observation corroborates other Moroccan series and contradicts series from other countries where a significant percentage of neurological involvement is found. Following our results, which identified a 12-year-old girl with a purely neuropsychiatric presentation, raising awareness about",19_63,Wilson Disease in Children in the Eastern Region of Morocco: Analysis of 24 Cases,10 5 2024,,Wilson_Disease
"presentation, raising awareness about the neurological symptoms of Wilson's disease is crucial, as neurological disorders can present with silent or even absent hepatic involvement.",19_64,Wilson Disease in Children in the Eastern Region of Morocco: Analysis of 24 Cases,10 5 2024,,Wilson_Disease
"Non-ceruloplasmin copper and urinary copper in clinically stable Wilson disease: Alignment with recommended targets  <fig id=""undfig1"" position=""anchor""><alt-text id=""alttext0010"">Image 1</alt-text><graphic http://www.w3.org/1999/xlink href=""ga1""></graphic></fig> <list list-type=""simple"" id=""ulist0010""><list-item id=""u0010""><label>•</label><p id=""p0010"">NCC assessed by two novel methods (NCC-Sp and NCC-Ex) and UCE were examined in 76 patients with stable WD on D-PEN.</p></list-item><list-item",20_0,Non-ceruloplasmin copper and urinary copper in clinically stable Wilson disease: Alignment with recommended targets,06 5 2024,,Wilson_Disease
"stable WD on D-PEN.</p></list-item><list-item id=""u0015""><label>•</label><p id=""p0015"">In WD, NCC-Sp using protein speciation and ICP-MS or NCC-Ex (exchangeable Cu) correlated but with systematic deviation.</p></list-item><list-item id=""u0020""><label>•</label><p id=""p0020"">Normal ranges for NCC-Sp (46-213 μg/L) and NCC-Ex (41-71 μg/L) differed from older methods (50-150 μg/L).</p></list-item><list-item id=""u0025""><label>•</label><p id=""p0025"">In WD, NCC-Sp or NCC-Ex were often below and UCE often outside",20_1,Non-ceruloplasmin copper and urinary copper in clinically stable Wilson disease: Alignment with recommended targets,06 5 2024,,Wilson_Disease
"or NCC-Ex were often below and UCE often outside the target ranges recommended in guidelines.</p></list-item><list-item id=""u0030""><label>•</label><p id=""p0030"">NCC-Sp or NCC-Ex below 50 μg/L was associated with tighter control of liver biochemistry but not copper deficiency.</p></list-item></list> Wilson disease (WD) is a rare autosomal recessively inherited disease affecting copper metabolism. Mutations in the <italic toggle=""yes"">ATB7B</italic> gene lead to dysfunction of the ATP7B protein (OMIM:",20_2,Non-ceruloplasmin copper and urinary copper in clinically stable Wilson disease: Alignment with recommended targets,06 5 2024,,Wilson_Disease
"lead to dysfunction of the ATP7B protein (OMIM: 606882; Cu (2+)-transporting, beta polypeptide) that regulates the homeostasis of copper via hepatic excretion of excess copper into bile, and is responsible for the biosynthetic incorporation of copper into ceruloplasmin (Cp). Accumulated copper causes organ damage primarily in the liver and brain. WD is fatal if left untreated. Globally, the most commonly used drug is D-penicillamine (PEN) that was introduced in the 1960s.<xref rid=""bib1""",20_3,Non-ceruloplasmin copper and urinary copper in clinically stable Wilson disease: Alignment with recommended targets,06 5 2024,,Wilson_Disease
"that was introduced in the 1960s.<xref rid=""bib1"" ref-type=""bibr""><sup>1</sup></xref> At that time the focus of medical treatment was on whole body copper balance.<xref rid=""bib2"" ref-type=""bibr""><sup>2</sup></xref> The initial treatment goal was to create a negative copper balance, and the goal of long-term maintenance therapy to secure a level of excretion that balanced with dietary intake, preventing further accumulation of copper. The treatment effect was evaluated by clinical assessment and monitoring",20_4,Non-ceruloplasmin copper and urinary copper in clinically stable Wilson disease: Alignment with recommended targets,06 5 2024,,Wilson_Disease
"evaluated by clinical assessment and monitoring of the 24-hour urinary excretion of copper (UCE). After the very high values of UCE typically observed during the initial (de-coppering) phase of treatment, a target UCE of 200-500 μg/24 h was expected in the maintenance phase of chelation therapy<xref rid=""bib2"" ref-type=""bibr""><sup>2</sup></xref><sup>,</sup><xref rid=""bib3"" ref-type=""bibr""><sup>3</sup></xref> and continues to be recommended by consensus expert opinion.<xref rid=""bib4""",20_5,Non-ceruloplasmin copper and urinary copper in clinically stable Wilson disease: Alignment with recommended targets,06 5 2024,,Wilson_Disease
"by consensus expert opinion.<xref rid=""bib4"" ref-type=""bibr""><sup>4</sup></xref><sup>,</sup><xref rid=""bib5"" ref-type=""bibr""><sup>5</sup></xref> Under physiologic conditions, most of the circulating copper is irreversibly bound to Cp. A minor fraction of plasma copper loosely bound to albumin, amino acids, and peptides<xref rid=""bib6"" ref-type=""bibr""><sup>6</sup></xref> is bioavailable for use in physiological processes. This bioavailable fraction was named the non-ceruloplasmin-bound copper (NCC), and the",20_6,Non-ceruloplasmin copper and urinary copper in clinically stable Wilson disease: Alignment with recommended targets,06 5 2024,,Wilson_Disease
"the non-ceruloplasmin-bound copper (NCC), and the elevated levels found in untreated or ineffectively treated patients is assumed to be responsible for pathologic organ copper loading. Thus, “normalization” of NCC was proposed as an additional aim of treatment.<xref rid=""bib3"" ref-type=""bibr""><sup>3</sup></xref> At that time, NCC was assessed by measurement of serum copper and Cp. Based on the assumption of 6 copper atoms per Cp molecule, NCC-Cal (μg/L) was assumed to equal total serum copper (μg/L) minus",20_7,Non-ceruloplasmin copper and urinary copper in clinically stable Wilson disease: Alignment with recommended targets,06 5 2024,,Wilson_Disease
"assumed to equal total serum copper (μg/L) minus 3.14 times Cp (mg/L).<xref rid=""bib7"" ref-type=""bibr""><sup>7</sup></xref> The normal range in healthy persons of 50-150 μg/L (0.8-2.4 μmol/L) became the treatment target in WD<xref rid=""bib3"" ref-type=""bibr""><sup>3</sup></xref> and is still used in guidelines.<xref rid=""bib4"" ref-type=""bibr""><sup>4</sup></xref><sup>,</sup><xref rid=""bib5"" ref-type=""bibr""><sup>5</sup></xref><sup>,</sup><xref rid=""bib8"" ref-type=""bibr""><sup>8</sup></xref><sup>,</sup><xref",20_8,Non-ceruloplasmin copper and urinary copper in clinically stable Wilson disease: Alignment with recommended targets,06 5 2024,,Wilson_Disease
"rid=""bib9"" ref-type=""bibr""><sup>9</sup></xref> As expected, NCC-Cal was reported to be high at the time of diagnosis and decline with treatment.<xref rid=""bib10"" ref-type=""bibr""><sup>10</sup></xref> The NCC-Cal methodology has since been questioned for several reasons. (A) Even though NCC-Cal was probably more accurate when Cp was measured by an enzymatic assay (as Cp dependents on copper for its oxidase activity) than the more commonly utilized immunological method (the latter cannot discriminate",20_9,Non-ceruloplasmin copper and urinary copper in clinically stable Wilson disease: Alignment with recommended targets,06 5 2024,,Wilson_Disease
"method (the latter cannot discriminate copper-containing holoceruloplasmin from its copper-free precursor peptide, apoceruloplasmin<xref rid=""bib7"" ref-type=""bibr""><sup>7</sup></xref>), most centers found the enzymatic method too demanding to be feasible for routine use. A high inter-laboratory variance and up to 20% biologically impossible zero or negative NCC-Cal values were reported.<xref rid=""bib7"" ref-type=""bibr""><sup>7</sup></xref><sup>,</sup><xref rid=""bib11""",20_10,Non-ceruloplasmin copper and urinary copper in clinically stable Wilson disease: Alignment with recommended targets,06 5 2024,,Wilson_Disease
"rid=""bib11"" ref-type=""bibr""><sup>11</sup></xref><sup>,</sup><xref rid=""bib12"" ref-type=""bibr""><sup>12</sup></xref> (B) The assumption of 6 copper atoms per molecule of Cp may be wrong.<xref rid=""bib13"" ref-type=""bibr"">[13]</xref>, <xref rid=""bib14"" ref-type=""bibr"">[14]</xref>, <xref rid=""bib15"" ref-type=""bibr"">[15]</xref> (C) NCC-Cal was unrelated to adherence to treatment.<xref rid=""bib16"" ref-type=""bibr""><sup>16</sup></xref> For these reasons, recent guidelines advise against the use of NCC-Cal.<xref",20_11,Non-ceruloplasmin copper and urinary copper in clinically stable Wilson disease: Alignment with recommended targets,06 5 2024,,Wilson_Disease
"advise against the use of NCC-Cal.<xref rid=""bib5"" ref-type=""bibr""><sup>5</sup></xref> To overcome these challenges, El Balkhi <italic toggle=""yes"">et al.</italic><xref rid=""bib17"" ref-type=""bibr""><sup>17</sup></xref> developed the exchangeable copper assay, NCC-Ex, which does not require measurement of Cp. The chelating agent EDTA is used to chelate copper from the NCC pool and after separation from Cp by ultrafiltration, NCC-Ex is assessed by measurement of copper in the filtrate. The published normal",20_12,Non-ceruloplasmin copper and urinary copper in clinically stable Wilson disease: Alignment with recommended targets,06 5 2024,,Wilson_Disease
"of copper in the filtrate. The published normal range of NCC-Ex is 41-71 μg/L (0.64-1.12 μmol/L) in healthy adults<xref rid=""bib17"" ref-type=""bibr""><sup>17</sup></xref> and slightly lower in children.<xref rid=""bib18"" ref-type=""bibr""><sup>18</sup></xref> There are some data to support the use of NCC-Ex as a biomarker to monitor treatment in WD: NCC-Ex is elevated at time of diagnosis of WD,<xref rid=""bib19"" ref-type=""bibr""><sup>19</sup></xref> more so in those with extrahepatic disease,<xref rid=""bib20""",20_13,Non-ceruloplasmin copper and urinary copper in clinically stable Wilson disease: Alignment with recommended targets,06 5 2024,,Wilson_Disease
"those with extrahepatic disease,<xref rid=""bib20"" ref-type=""bibr""><sup>20</sup></xref> and decreases during treatment.<xref rid=""bib19"" ref-type=""bibr""><sup>19</sup></xref><sup>,</sup><xref rid=""bib21"" ref-type=""bibr""><sup>21</sup></xref> Maintenance of a lower NCC-Ex is associated with treatment adherence.<xref rid=""bib19"" ref-type=""bibr""><sup>19</sup></xref><sup>,</sup><xref rid=""bib22"" ref-type=""bibr""><sup>22</sup></xref> Preliminary data suggest higher NCC-Ex in WD presenting with acute liver",20_14,Non-ceruloplasmin copper and urinary copper in clinically stable Wilson disease: Alignment with recommended targets,06 5 2024,,Wilson_Disease
"higher NCC-Ex in WD presenting with acute liver failure.<xref rid=""bib23"" ref-type=""bibr""><sup>23</sup></xref> Accordingly, in untreated LEC rats, a WD model, NCC-Ex increased in parallel with disease progression.<xref rid=""bib24"" ref-type=""bibr""><sup>24</sup></xref> However, recent reports suggest that NCC-Ex may be subject to both under- and overestimation of NCC by either formation of a high molecular EDTA-copper-protein complex that is trapped in the filter<xref rid=""bib25""",20_15,Non-ceruloplasmin copper and urinary copper in clinically stable Wilson disease: Alignment with recommended targets,06 5 2024,,Wilson_Disease
"that is trapped in the filter<xref rid=""bib25"" ref-type=""bibr""><sup>25</sup></xref> or removal of some Cp-bound copper by EDTA.<xref rid=""bib26"" ref-type=""bibr""><sup>26</sup></xref> When the recent Chelate trial<xref rid=""bib27"" ref-type=""bibr""><sup>27</sup></xref> planned to use NCC as a primary endpoint, regulatory authorities did not accept NCC-Cal or NCC-Ex for the reasons mentioned above. Consequently, a new method was developed and implemented.<xref rid=""bib25""",20_16,Non-ceruloplasmin copper and urinary copper in clinically stable Wilson disease: Alignment with recommended targets,06 5 2024,,Wilson_Disease
"was developed and implemented.<xref rid=""bib25"" ref-type=""bibr""><sup>25</sup></xref><sup>,</sup><xref rid=""bib26"" ref-type=""bibr""><sup>26</sup></xref> With this method, serum proteins are separated by anion exchange high-performance liquid chromatography (protein speciation) and the copper content in each peak is measured by inductively coupled plasma mass spectrometry (ICP-MS). “NCC by protein speciation”, NCC-Sp, is then calculated as total Serum-Cu x (1 – Cp Cu fraction).<xref rid=""bib25""",20_17,Non-ceruloplasmin copper and urinary copper in clinically stable Wilson disease: Alignment with recommended targets,06 5 2024,,Wilson_Disease
"Serum-Cu x (1 – Cp Cu fraction).<xref rid=""bib25"" ref-type=""bibr""><sup>25</sup></xref> In the present study, we wanted to examine the distribution of NCC values measured by modern techniques and UCE in the “real world” clinical situation, where experienced clinicians judged the maintenance treatment dose of PEN optimal without the need for adjustments. With this goal in mind, we performed a secondary analysis of data from the Chelate trial<xref rid=""bib27"" ref-type=""bibr""><sup>27</sup></xref> to examine",20_18,Non-ceruloplasmin copper and urinary copper in clinically stable Wilson disease: Alignment with recommended targets,06 5 2024,,Wilson_Disease
"ref-type=""bibr""><sup>27</sup></xref> to examine levels of NCC and UCE in patients with WD selected by experienced clinicians as clinically stable in their maintenance phase of therapy. On the first visit, while patients were still on their pre-study PEN medication, NCC-Sp, NCC-Ex, and UCE were assessed. These data provided an opportunity to examine levels of NCC-Sp, NCC-Ex, and UCE present in clinically determined stable patients receiving maintenance therapy with PEN and to assess how newer methodologies",20_19,Non-ceruloplasmin copper and urinary copper in clinically stable Wilson disease: Alignment with recommended targets,06 5 2024,,Wilson_Disease
"with PEN and to assess how newer methodologies for NCC measurement may impact recommended therapeutic targets.  In 75 self-reported healthy persons, the median total plasma copper was 1,030 μg/L (IQR 911-1,210 μg/L and 2.5%-97.5% range of 717-1,731 μg/L) (<xref rid=""tbl1"" ref-type=""table"">Table 1</xref>). There was no effect of gender (<italic toggle=""yes"">p =</italic> 0.55 by Mann-Whitney <italic toggle=""yes"">U</italic> test) but slightly lower values in Caucasian patients (<italic",20_20,Non-ceruloplasmin copper and urinary copper in clinically stable Wilson disease: Alignment with recommended targets,06 5 2024,,Wilson_Disease
"lower values in Caucasian patients (<italic toggle=""yes"">p</italic> = 0.002 by Kruskal-Wallis test) (<xref rid=""appsec1"" ref-type=""sec"">Table S1</xref>). NCC-Sp range was 40-310 μg/L with a median of 86 μg/L (IQR 63-171 μg/L) (<xref rid=""tbl1"" ref-type=""table"">Table 1</xref>). The distribution of NCC-Sp in these healthy persons was bimodal (<xref rid=""appsec1"" ref-type=""sec"">Fig. S1</xref>). NCC-Sp was higher in males than females and higher in Caucasian patients than Black and Hispanic patients (<xref",20_21,Non-ceruloplasmin copper and urinary copper in clinically stable Wilson disease: Alignment with recommended targets,06 5 2024,,Wilson_Disease
"patients than Black and Hispanic patients (<xref rid=""appsec1"" ref-type=""sec"">Table S1</xref>). The normal range of NCC-Sp (46-213 μg/L) was taken as the range from the 2.5% to 97.5% percentiles. NCC-Ex was not measured in this population, since a normal range of 41-71 μg/L (5%-95% percentiles) in adults was previously published.<xref rid=""bib17"" ref-type=""bibr""><sup>17</sup></xref> For comparison 5-95% percentiles for NCC-Sp were 50-209 μg/L. The patients with WD had on average been treated for ≈21 years",20_22,Non-ceruloplasmin copper and urinary copper in clinically stable Wilson disease: Alignment with recommended targets,06 5 2024,,Wilson_Disease
"with WD had on average been treated for ≈21 years before entering the study and the majority presented with neurologic disease. Baseline characteristics are provided in <xref rid=""tbl1"" ref-type=""table"">Table 1</xref>. NCC-Sp (mean±SD: 56.6±26.2 μg/L) was available in 69 out of 76 patients and was within the generally recommended target range of 50-150 μg/L in 42 (61%) patients, while 27 (39%) were below, with 19 (28%) even below 40 μg/L, the lowest value measured in healthy controls (<xref rid=""fig1""",20_23,Non-ceruloplasmin copper and urinary copper in clinically stable Wilson disease: Alignment with recommended targets,06 5 2024,,Wilson_Disease
"measured in healthy controls (<xref rid=""fig1"" ref-type=""fig"">Fig. 1</xref>). None were above 150 μg/L. NCC-Sp was below the normal range of 46-213 μg/L in 25 (36%) and within in the remaining 44 (64%). NCC-Ex (mean±SD: 57.9±24.7 μg/L) was available in 71 patients and was within the 50-150 μg/L range in 38 (54%) and below in 33 (46%). Compared to the normal range for NCC-Ex of 41-71 μg/L, 29 (41%) were within that range, while 22 (31%) were below and 20 (28%) above (<xref rid=""fig1"" ref-type=""fig"">Fig.",20_24,Non-ceruloplasmin copper and urinary copper in clinically stable Wilson disease: Alignment with recommended targets,06 5 2024,,Wilson_Disease
"(28%) above (<xref rid=""fig1"" ref-type=""fig"">Fig. 1</xref>). Thus, with both methodologies, a substantial fraction of patients had values below the current target ranges. NCC-Sp and NCC-Ex correlated positively (r<sup>2</sup>=0.66; <italic toggle=""yes"">p</italic> = 0.001) in 65 out of 76 patients where both were measured (<xref rid=""fig1"" ref-type=""fig"">Fig. 1</xref>A). The mean difference between the assays (0.49 μg/L) was close to zero but with a considerable scatter as seen in the Bland-Altman plot",20_25,Non-ceruloplasmin copper and urinary copper in clinically stable Wilson disease: Alignment with recommended targets,06 5 2024,,Wilson_Disease
"scatter as seen in the Bland-Altman plot (<xref rid=""fig1"" ref-type=""fig"">Fig. 1</xref>B). The Bland-Altman regression line with a negative slope illustrated a systematic deviation with the tendency that NCC-Ex was higher than NCC-Sp when values were below 60 μg/L, and lower above this cut-off.<fig id=""fig1""><label>Fig. 1</label><caption><p>NCC-Sp <italic toggle=""yes"">vs.</italic> NCC-Ex in 69 patients with clinically stable WD on PEN.</p><p>(A) The regression line is dotted and the line of identity solid.",20_26,Non-ceruloplasmin copper and urinary copper in clinically stable Wilson disease: Alignment with recommended targets,06 5 2024,,Wilson_Disease
"line is dotted and the line of identity solid. On both axes the normal ranges are depicted and the recommended target range during maintenance treatment with PEN (50-150 μg/L) marked in shaded green. NCC-Sp was below the target range in 39% and below the lowest value in healthy volunteers (40 μg/L) in 28%. NCC-Sp and NCC-Ex correlated positively (r<sup>2</sup> = 0.66, <italic toggle=""yes"">p</italic> <0.001). (B) Bland-Altman plot. The regression line is black dotted. The mean difference (NCC-Ex minus",20_27,Non-ceruloplasmin copper and urinary copper in clinically stable Wilson disease: Alignment with recommended targets,06 5 2024,,Wilson_Disease
"black dotted. The mean difference (NCC-Ex minus NCC-Sp) was 0.49 μmol/L (red broken line) and close to zero. The confidence limits (-30.5 μg/L; +31.5 μg/L) are depicted in red dotted lines. The slope of the line of regression (-0.13) differed from zero (<italic toggle=""yes"">p</italic> = 0.015), indicating a systematic deviation. NCC, non-ceruloplasmin-bound copper; NCC-Ex, exchangeable copper; NCC-Sp, NCC determined from total copper protein speciation assay; PEN, D-penicillamine; WD, Wilson",20_28,Non-ceruloplasmin copper and urinary copper in clinically stable Wilson disease: Alignment with recommended targets,06 5 2024,,Wilson_Disease
"assay; PEN, D-penicillamine; WD, Wilson disease.</p></caption><alt-text id=""alttext0030"">Fig. 1</alt-text><graphic http://www.w3.org/1999/xlink href=""gr1""></graphic></fig> NCC-Cal was not part of the study protocol but could be calculated from total serum copper and ceruloplasmin in 33 patients with measurable ceruloplasmin (above the LLOQ of 52 mg/L). NCC-Cal was (mean±SD) 156±72 mg/L. Values were generally ≈2 times higher than NCC-Sp or NCC-Ex (<xref rid=""appsec1"" ref-type=""sec"">Fig. S3</xref>). NCC-Cal",20_29,Non-ceruloplasmin copper and urinary copper in clinically stable Wilson disease: Alignment with recommended targets,06 5 2024,,Wilson_Disease
"ref-type=""sec"">Fig. S3</xref>). NCC-Cal was within the 50-150 μg/L target in 14 (42.5%), below in 3 (9%) and above in 16 (48.5%) (<xref rid=""appsec1"" ref-type=""sec"">Fig. S3</xref>). NCC-Cal did not correlate with UCE (<xref rid=""appsec1"" ref-type=""sec"">Fig. S3</xref>). UCE was available in 76 patients. Current guidelines recommend a target range of 200-500 μg/24 h during maintenance treatment with PEN.<xref rid=""bib4"" ref-type=""bibr""><sup>4</sup></xref><sup>,</sup><xref rid=""bib5""",20_30,Non-ceruloplasmin copper and urinary copper in clinically stable Wilson disease: Alignment with recommended targets,06 5 2024,,Wilson_Disease
"rid=""bib5"" ref-type=""bibr""><sup>5</sup></xref><sup>,</sup><xref rid=""bib8"" ref-type=""bibr""><sup>8</sup></xref><sup>,</sup><xref rid=""bib9"" ref-type=""bibr""><sup>9</sup></xref> UCE was within that range in 32 (42%), above in 37 (49%), and below in 7 (9%) (<xref rid=""fig2"" ref-type=""fig"">Fig. 2</xref>).<fig id=""fig2""><label>Fig. 2</label><caption><p>NCC-Sp and NCC-Ex <italic toggle=""yes"">vs.</italic> UCE in patients with stable WD on PEN.</p><p>(A) NCC-Sp and <italic toggle=""yes"">vs.</italic> UCE (n = 69) and",20_31,Non-ceruloplasmin copper and urinary copper in clinically stable Wilson disease: Alignment with recommended targets,06 5 2024,,Wilson_Disease
"toggle=""yes"">vs.</italic> UCE (n = 69) and (B) NCC-Ex <italic toggle=""yes"">vs.</italic> UCE (n = 71). All patients were clinically stable on maintenance dose of PEN. The generally recommended target ranges during maintenance treatment for UCE (200-500 μg/24 h) and NCC (50-150 μg/L) are marked as green shaded areas and normal ranges for the assays on top of the graphs. With NCC-Sp and UCE only 14/69 patients (20%) were within both ranges. The same was true for 14/71 (19%) with NCC-Ex and UCE. NCC-Sp",20_32,Non-ceruloplasmin copper and urinary copper in clinically stable Wilson disease: Alignment with recommended targets,06 5 2024,,Wilson_Disease
"true for 14/71 (19%) with NCC-Ex and UCE. NCC-Sp positively correlated with UCE (<italic toggle=""yes"">p =</italic> 0.02) while NCC-Ex tended to do so (<italic toggle=""yes"">p</italic> = 0.054). NCC, non-ceruloplasmin-bound copper; NCC-Ex, exchangeable copper; NCC-Sp, NCC determined from total copper protein speciation assay; PEN, D-penicillamine; UCE, 24-hour urinary copper excretion; WD, Wilson disease.</p></caption><alt-text id=""alttext0035"">Fig. 2</alt-text><graphic http://www.w3.org/1999/xlink",20_33,Non-ceruloplasmin copper and urinary copper in clinically stable Wilson disease: Alignment with recommended targets,06 5 2024,,Wilson_Disease
"http://www.w3.org/1999/xlink href=""gr2""></graphic></fig> UCE weakly but statistically significantly correlated to NCC-Sp (r<sup>2</sup>=0.07, <italic toggle=""yes"">p =</italic> 0.02) and tended towards the same with NCC-Ex (r<sup>2</sup>= 0.053, <italic toggle=""yes"">p =</italic> 0.054) (<xref rid=""fig2"" ref-type=""fig"">Fig. 2</xref>). The distribution of UCE <italic toggle=""yes"">vs.</italic> NCC-Sp or NCC-Ex according to guideline recommendations are provided in <xref rid=""tbl2""",20_34,Non-ceruloplasmin copper and urinary copper in clinically stable Wilson disease: Alignment with recommended targets,06 5 2024,,Wilson_Disease
"recommendations are provided in <xref rid=""tbl2"" ref-type=""table"">Table 2</xref>. Among 69 patients where both NCC-Sp and UCE were available, only 14 (20%) were within recommended ranges for both NCC-Sp and UCE (<xref rid=""fig2"" ref-type=""fig"">Fig. 2</xref>A). The same percent were found within the recommended ranges for NCC-Ex and UCE, 14/71 (19%) (<xref rid=""tbl2"" ref-type=""table"">Table 2</xref>).<table-wrap position=""float"" id=""tbl2""><label>Table 2</label><caption><p>Relation between UCE and NCC-SP or",20_35,Non-ceruloplasmin copper and urinary copper in clinically stable Wilson disease: Alignment with recommended targets,06 5 2024,,Wilson_Disease
"between UCE and NCC-SP or NCC-Ex in 76 patients with stable WD.</p></caption><alt-text id=""alttext0050"">Table 2</alt-text><table frame=""hsides"" rules=""groups""><thead><tr><th></th><th colspan=""3"">NCC-Ex (μg/L)<hr></hr></th><th colspan=""3"">NCC-Sp (μg/L)<hr></hr></th></tr><tr><th></th><th align=""right""><50<hr></hr></th><th align=""right"">≥50<hr></hr></th><th align=""right"">n.a.<hr></hr></th><th align=""right""><50<hr></hr></th><th align=""right"">≥50<hr></hr></th><th",20_36,Non-ceruloplasmin copper and urinary copper in clinically stable Wilson disease: Alignment with recommended targets,06 5 2024,,Wilson_Disease
"align=""right"">≥50<hr></hr></th><th align=""right"">n.a.<hr></hr></th></tr><tr><th>N</th><th>33</th><th>38</th><th>5</th><th>27</th><th>42</th><th>7</th></tr></thead><tbody><tr><td><bold>UCE",20_37,Non-ceruloplasmin copper and urinary copper in clinically stable Wilson disease: Alignment with recommended targets,06 5 2024,,Wilson_Disease
"(μg/24h)</bold></td><td></td><td></td><td></td><td></td><td></td><td></td></tr><tr><td> <200</td><td>3</td><td>3</td><td>1</td><td>2</td><td>4</td><td>1</td></tr><tr><td> 200-500</td><td>17</td><td>14</td><td>1</td><td>14</td><td>14</td><td>4</td></tr><tr><td> >500</td><td>13</td><td>21</td><td>3</td><td>11</td><td>24</td><td>2</td></tr></tbody></table><table-wrap-foot><fn><p>NCC, non-ceruloplasmin-bound copper; NCC-Ex, exchangeable copper; NCC-Sp, NCC determined from total copper protein speciation assay;",20_38,Non-ceruloplasmin copper and urinary copper in clinically stable Wilson disease: Alignment with recommended targets,06 5 2024,,Wilson_Disease
"from total copper protein speciation assay; UCE, 24-hour urinary copper excretion; WD, Wilson disease.</p></fn></table-wrap-foot></table-wrap> We also examined the relationship of the dose of PEN in mg/kg to NCC-Sp, NCC-Ex and UCE, respectively (<xref rid=""fig3"" ref-type=""fig"">Fig. 3</xref>). In these clinically stable patients with an average of ≈21 years of treatment, the doses in mg/kg varied considerably from the recommended 10-15 mg/kg (<xref rid=""tbl3"" ref-type=""table"">Table 3</xref>). Higher doses",20_39,Non-ceruloplasmin copper and urinary copper in clinically stable Wilson disease: Alignment with recommended targets,06 5 2024,,Wilson_Disease
"ref-type=""table"">Table 3</xref>). Higher doses were associated with lower NCC-Sp (r<sup>2</sup> = 0.052, <italic toggle=""yes"">p =</italic> 0.053), and lower NCC-Ex (r<sup>2</sup>=0.114, <italic toggle=""yes"">p =</italic> 0.004), while no association was seen with UCE (r<sup>2</sup> = 0.01, <italic toggle=""yes"">p</italic> = 0.34) (<xref rid=""fig3"" ref-type=""fig"">Fig. 3</xref>).<fig id=""fig3""><label>Fig. 3</label><caption><p>Relation between daily dose of PEN in mg/kg BW and measures of copper metabolism in",20_40,Non-ceruloplasmin copper and urinary copper in clinically stable Wilson disease: Alignment with recommended targets,06 5 2024,,Wilson_Disease
"in mg/kg BW and measures of copper metabolism in patients with WD who were stable on PEN.</p><p>(A) Dose and NCC-SP (n = 69). (B) Dose and NCC-Ex (n = 71). (C) Dose and UCE (n = 76). PEN dose in mg/kg tended to be negatively correlated with NCC-SP (<italic toggle=""yes"">p =</italic> 0.053) and NCC-Ex (<italic toggle=""yes"">p</italic> = 0.004). PEN dose did not correlate with UCE. BW, body weight; NCC, non-ceruloplasmin-bound copper; NCC-Ex, exchangeable copper; NCC-Sp, NCC determined from total copper",20_41,Non-ceruloplasmin copper and urinary copper in clinically stable Wilson disease: Alignment with recommended targets,06 5 2024,,Wilson_Disease
"copper; NCC-Sp, NCC determined from total copper protein speciation assay; PEN, D-penicillamine; UCE, 24-hour urinary copper excretion; WD, Wilson disease.</p></caption><alt-text id=""alttext0040"">Fig. 3</alt-text><graphic http://www.w3.org/1999/xlink href=""gr3""></graphic></fig><table-wrap position=""float"" id=""tbl3""><label>Table 3</label><caption><p>Doses of PEN in mg/kg/day in 76 patients with WD.</p></caption><alt-text id=""alttext0055"">Table 3</alt-text><table frame=""hsides""",20_42,Non-ceruloplasmin copper and urinary copper in clinically stable Wilson disease: Alignment with recommended targets,06 5 2024,,Wilson_Disease
"frame=""hsides"" rules=""groups""><thead><tr><th>Dose (mg/kg)</th><th>n (N = 76)</th></tr></thead><tbody><tr><td>4-7.5</td><td>6</td></tr><tr><td>7.5-10</td><td>8</td></tr><tr><td>10-12.5</td><td>21</td></tr><tr><td>12.5-15</td><td>13</td></tr><tr><td>15-17.5</td><td>14</td></tr><tr><td>17.5-20</td><td>7</td></tr><tr><td>20-22.5</td><td>3</td></tr><tr><td>22.5-25</td><td>3</td></tr><tr><td>25-30</td><td>1</td></tr></tbody></table><table-wrap-foot><fn id=""tspara0035""><p>The mean±SD dose was",20_43,Non-ceruloplasmin copper and urinary copper in clinically stable Wilson disease: Alignment with recommended targets,06 5 2024,,Wilson_Disease
"id=""tspara0035""><p>The mean±SD dose was 983±292 mg/day.</p></fn><fn id=""tspara0040""><p>PEN, D-penicillamine; WD, Wilson disease.</p></fn></table-wrap-foot></table-wrap> To test the hypotheses that NCC-Sp, NCC-Ex and UCE were related to the clinical course of disease, we examined their relation to liver biochemistry (<xref rid=""tbl4"" ref-type=""table"">Table 4</xref>). With both NCC-Sp and NCC-Ex, patients with values below the 50-150 μg target range had significantly lower aspartate aminotransferase (AST),",20_44,Non-ceruloplasmin copper and urinary copper in clinically stable Wilson disease: Alignment with recommended targets,06 5 2024,,Wilson_Disease
"lower aspartate aminotransferase (AST), alanine aminotransferase (ALT) and gamma-glutamyltransferase levels and higher albumin levels than patients with values within the target range. Thus, either NCC-Sp or NCC-Ex below the recommended target range was associated with better control of liver biochemistry. A similar relationship was not observed with UCE (<xref rid=""tbl4"" ref-type=""table"">Table 4</xref>).<table-wrap position=""float"" id=""tbl4""><label>Table 4</label><caption><p>Hepatic and hematological",20_45,Non-ceruloplasmin copper and urinary copper in clinically stable Wilson disease: Alignment with recommended targets,06 5 2024,,Wilson_Disease
"and hematological values related to NCC-Sp, NCC-Ex and UCE within or outside recommended ranges.</p></caption><alt-text id=""alttext0060"">Table 4</alt-text><table frame=""hsides"" rules=""groups""><thead><tr><th rowspan=""3"">Discrimination value</th><th colspan=""3"">NCC-Sp (μg/L)<hr></hr></th><th colspan=""3"">NCC-Ex (μg/L)<hr></hr></th><th colspan=""3"">UCE",20_46,Non-ceruloplasmin copper and urinary copper in clinically stable Wilson disease: Alignment with recommended targets,06 5 2024,,Wilson_Disease
"(μg/L)<hr></hr></th><th colspan=""3"">UCE (μg/24h)<hr></hr></th><th></th></tr><tr><th><50<hr></hr></th><th>≥50<hr></hr></th><th></th><th><50<hr></hr></th><th>≥50<hr></hr></th><th></th><th><200<hr></hr></th><th>200-500<hr></hr></th><th>>500<hr></hr></th><th></th></tr><tr><th align=""right"">Mean±SD</th><th align=""right"">Mean±SD</th><th align=""right""><italic toggle=""yes"">p</italic> value</th><th align=""right"">Mean±SD</th><th align=""right"">Mean±SD</th><th align=""right""><italic toggle=""yes"">p</italic>",20_47,Non-ceruloplasmin copper and urinary copper in clinically stable Wilson disease: Alignment with recommended targets,06 5 2024,,Wilson_Disease
"align=""right""><italic toggle=""yes"">p</italic> value</th><th align=""right"">Mean±SD</th><th align=""right"">Mean±SD</th><th align=""right"">Mean±SD</th><th><italic toggle=""yes"">p</italic> value</th></tr></thead><tbody><tr><td>N</td><td><bold>25</bold></td><td><bold>39</bold></td><td></td><td><bold>33</bold></td><td><bold>32</bold></td><td></td><td><bold>7</bold></td><td><bold>32</bold></td><td><bold>37</bold></td><td></td></tr><tr><td>Albumin",20_48,Non-ceruloplasmin copper and urinary copper in clinically stable Wilson disease: Alignment with recommended targets,06 5 2024,,Wilson_Disease
"(g/L)</td><td>44.8±2.7</td><td>43.1±3.5</td><td>0.028</td><td>44.5±3.0</td><td>42.6±3.5</td><td>0.014</td><td>44.3±2.3</td><td>44.1±3.0</td><td>43.0±3.7</td><td align=""left"">n.s.</td></tr><tr><td>AST (U/L)</td><td>21.3±6.7</td><td>30.0±10.9</td><td>0.0003</td><td>22.0±6.9</td><td>28.8±11.4</td><td>0.003</td><td>24.6±7.0</td><td>26.0±8.9</td><td>26.1±11.6</td><td align=""left"">n.s.</td></tr><tr><td>ALT",20_49,Non-ceruloplasmin copper and urinary copper in clinically stable Wilson disease: Alignment with recommended targets,06 5 2024,,Wilson_Disease
"align=""left"">n.s.</td></tr><tr><td>ALT (U/L)</td><td>26.0±16.3</td><td>41.0±22.5</td><td>0.006</td><td>25.3±15.2</td><td>39.3±23.8</td><td>0.004</td><td>32.1±18.5</td><td>33.3±22.8</td><td>34.9±22.8</td><td align=""left"">n.s.</td></tr><tr><td>GGT (U/L)</td><td>26.3±13.2</td><td>54.5±87.9</td><td>0.037</td><td>25.2±12.2</td><td>63.1±88.9</td><td>0.013</td><td>37.2±38.1</td><td>31.9±22.9</td><td>54.8±87.8</td><td align=""left"">n.s.</td></tr><tr><td>Bilirubin",20_50,Non-ceruloplasmin copper and urinary copper in clinically stable Wilson disease: Alignment with recommended targets,06 5 2024,,Wilson_Disease
"align=""left"">n.s.</td></tr><tr><td>Bilirubin (μmol/L)</td><td>13.3±5.6</td><td>17.1±8.1</td><td>0.031</td><td>16.6±10.2</td><td>15.6±7.9</td><td>n.s.</td><td>13.4±6.6</td><td>15.8±10.4</td><td>16.2±7.8</td><td align=""left"">n.s.</td></tr><tr><td>LDH (U/L)</td><td>159.4±26.6</td><td>172.2±35.4</td><td>n.s.</td><td>164.6±30.1</td><td>168.3±35.0</td><td>n.s.</td><td>159.6±29.8</td><td>174.4±33.9</td><td>164.0±28.1</td><td align=""left"">n.s.</td></tr><tr><td>Protein",20_51,Non-ceruloplasmin copper and urinary copper in clinically stable Wilson disease: Alignment with recommended targets,06 5 2024,,Wilson_Disease
"align=""left"">n.s.</td></tr><tr><td>Protein (g/L)</td><td>72.2±4.1</td><td>71.5±5.0</td><td>n.s.</td><td>72.0±4.2</td><td>70.8±5.4</td><td>n.s.</td><td>72.5±4.1</td><td>72.2±5.5</td><td>70.6±4.5</td><td align=""left"">n.s.</td></tr><tr><td>PT (sec)</td><td>13.7±0.6</td><td>14.3±2.2</td><td>n.s.</td><td>13.8±0.7</td><td>14.3±2.1</td><td>n.s.</td><td>14.2±2.6</td><td>14.1±2.3</td><td>14.1±0.8</td><td align=""left"">n.s.</td></tr><tr><td>Hb",20_52,Non-ceruloplasmin copper and urinary copper in clinically stable Wilson disease: Alignment with recommended targets,06 5 2024,,Wilson_Disease
"align=""left"">n.s.</td></tr><tr><td>Hb (g/dl)</td><td>14.39±1.07</td><td>14.09±1.35</td><td>n.s.</td><td>14.33±1.13</td><td>14.23±1.23</td><td>n.s.</td><td>14.32±1.13</td><td>14.29±1.12</td><td>14.12±1.31</td><td align=""left"">n.s.</td></tr><tr><td>Reticulocytes (%)</td><td>1.38±0.47</td><td>1.44±0.52</td><td>n.s.</td><td>1.39±0.51</td><td>1.42±0.53</td><td>n.s.</td><td>1.48±0.41</td><td>1.37±0.51</td><td>1.39±0.53</td><td align=""left"">n.s.</td></tr><tr><td>Leukocytes",20_53,Non-ceruloplasmin copper and urinary copper in clinically stable Wilson disease: Alignment with recommended targets,06 5 2024,,Wilson_Disease
"align=""left"">n.s.</td></tr><tr><td>Leukocytes (10<sup>9</sup>/L)</td><td>5.60±1.65</td><td>5.27±1.78</td><td>n.s.</td><td>5.45±1.63</td><td>5.31±1.72</td><td>n.s.</td><td>5.49±1.38</td><td>5.21±1.40</td><td>5.41±1.89</td><td align=""left"">n.s.</td></tr><tr><td>Lymphocytes (10<sup>9</sup>/L)</td><td>1.75±0.55</td><td>1.57±0.54</td><td>n.s.</td><td>1.59±0.50</td><td>1.61±0.57</td><td>n.s.</td><td>1.68±0.46</td><td>1.60±0.45</td><td>1.56±0.57</td><td align=""left"">n.s.</td></tr><tr><td>Monocytes",20_54,Non-ceruloplasmin copper and urinary copper in clinically stable Wilson disease: Alignment with recommended targets,06 5 2024,,Wilson_Disease
"align=""left"">n.s.</td></tr><tr><td>Monocytes (10<sup>9</sup>/L)</td><td>0.30±0.11</td><td>0.32±0.16</td><td>n.s.</td><td>0.31±0.10</td><td>0.34±0.16</td><td>n.s.</td><td>0.30±0.10</td><td>0.30±0.09</td><td>0.35±0.17</td><td align=""left"">n.s.</td></tr><tr><td>Neutrophils (10<sup>9</sup>/L)</td><td>3.37±1.32</td><td>3.20±1.35</td><td>n.s.</td><td>3.36±1.27</td><td>3.18±1.31</td><td>n.s.</td><td>3.33±1.02</td><td>3.11±1.03</td><td>3.34±1.48</td><td align=""left"">n.s.</td></tr><tr><td>Basophils",20_55,Non-ceruloplasmin copper and urinary copper in clinically stable Wilson disease: Alignment with recommended targets,06 5 2024,,Wilson_Disease
"align=""left"">n.s.</td></tr><tr><td>Basophils (10<sup>9</sup>/L)</td><td>0.047±0.032</td><td>0.045±0.021</td><td>n.s.</td><td>0.048±0.029</td><td>0.041±0.022</td><td>n.s.</td><td>0.05±0.02</td><td>0.05±0.02</td><td>0.04±0.03</td><td align=""left"">n.s.</td></tr><tr><td>Platelets (10<sup>9</sup>/L)</td><td>214±65</td><td>187±68</td><td>n.s.</td><td>196±66</td><td>192±69</td><td>n.s.</td><td>223±58</td><td>202±58</td><td>183±73</td><td align=""left"">n.s.</td></tr></tbody></table><table-wrap-foot><fn><p>ALT,",20_56,Non-ceruloplasmin copper and urinary copper in clinically stable Wilson disease: Alignment with recommended targets,06 5 2024,,Wilson_Disease
"alanine aminotransferase; AST, aspartate aminotransferase; GGT, gamma-glutamyltransferase; Hb, hemoglobin; LDH, lactate dehydrogenase; NCC, non-ceruloplasmin-bound copper; NCC-Ex, exchangeable copper; NCC-Sp, NCC determined from total copper protein speciation assay; PT, prothrombin time; UCE, 24-hour urinary copper excretion. <italic toggle=""yes"">p</italic>-values were calculated by unpaired t-test.</p></fn></table-wrap-foot></table-wrap> A value of NCC <50 μg/L and UCE >500 μg/24 h has been taken to",20_57,Non-ceruloplasmin copper and urinary copper in clinically stable Wilson disease: Alignment with recommended targets,06 5 2024,,Wilson_Disease
"<50 μg/L and UCE >500 μg/24 h has been taken to indicate possible overtreatment<xref rid=""bib5"" ref-type=""bibr""><sup>5</sup></xref><sup>,</sup><xref rid=""bib8"" ref-type=""bibr""><sup>8</sup></xref> but no patient in this cohort complained of symptoms of copper deficiency, such as progressive gait instability, muscle weakness, or ascending paresthesia, which are neurological symptoms related to spinal cord demyelination (<italic toggle=""yes"">i.e.</italic> progressive posterior cord syndrome) or fatigue.<xref",20_58,Non-ceruloplasmin copper and urinary copper in clinically stable Wilson disease: Alignment with recommended targets,06 5 2024,,Wilson_Disease
"posterior cord syndrome) or fatigue.<xref rid=""bib31"" ref-type=""bibr"">[31]</xref>, <xref rid=""bib32"" ref-type=""bibr"">[32]</xref>, <xref rid=""bib33"" ref-type=""bibr"">[33]</xref> In addition, there were no hematological disturbances (low white blood cell count, sideroblastic anemia or progressing thrombocytopenia) in patients with NCC-Sp or NCC-Ex below 50 μg/L as would be expected with copper deficiency (<xref rid=""tbl4"" ref-type=""table"">Table 4</xref>). In this study, we examined for the first time how",20_59,Non-ceruloplasmin copper and urinary copper in clinically stable Wilson disease: Alignment with recommended targets,06 5 2024,,Wilson_Disease
"In this study, we examined for the first time how novel assays for measuring non-ceruloplasmin bound copper (NCC-Sp and NCC-Ex) and UCE corresponded to recommendations from current international guidelines in patients with WD who were in the maintenance phase of PEN treatment. To do so, we conducted a secondary analysis of data from the Chelate trial.<xref rid=""bib27"" ref-type=""bibr""><sup>27</sup></xref> The patients were judged clinically stable by their treating physician without a foreseeable need for",20_60,Non-ceruloplasmin copper and urinary copper in clinically stable Wilson disease: Alignment with recommended targets,06 5 2024,,Wilson_Disease
"treating physician without a foreseeable need for dose change. We used data collected at the first visit when all the patients were still on their maintenance dose of PEN before the experimental treatment. Their average length of treatment was 21 years. NCC-Sp and NCC-Ex and UCE were evaluated with respect to the target ranges recommended in current guidelines, originally proposed in the 1980s.<xref rid=""bib3"" ref-type=""bibr""><sup>3</sup></xref> The range of 50-150 μg/L for NCC was chosen because that was",20_61,Non-ceruloplasmin copper and urinary copper in clinically stable Wilson disease: Alignment with recommended targets,06 5 2024,,Wilson_Disease
"50-150 μg/L for NCC was chosen because that was the range of NCC-Cal in normal individuals. The clinical validation is sparse.<xref rid=""bib34"" ref-type=""bibr"">[34]</xref>, <xref rid=""bib35"" ref-type=""bibr"">[35]</xref>, <xref rid=""bib36"" ref-type=""bibr"">[36]</xref>, <xref rid=""bib37"" ref-type=""bibr"">[37]</xref> NCC-Cal is now being abandoned as explained in the introduction but the target range of 50-150 μg/L – based on this method – is still used owing to the absence of additional data.<xref rid=""bib5""",20_62,Non-ceruloplasmin copper and urinary copper in clinically stable Wilson disease: Alignment with recommended targets,06 5 2024,,Wilson_Disease
"the absence of additional data.<xref rid=""bib5"" ref-type=""bibr""><sup>5</sup></xref><sup>,</sup><xref rid=""bib8"" ref-type=""bibr""><sup>8</sup></xref><sup>,</sup><xref rid=""bib9"" ref-type=""bibr""><sup>9</sup></xref> NCC-Ex avoided some of the pitfalls of the NCC-Cal method and there is some degree of clinical validation to support its use.<xref rid=""bib19"" ref-type=""bibr"">[19]</xref>, <xref rid=""bib20"" ref-type=""bibr"">[20]</xref>, <xref rid=""bib21"" ref-type=""bibr"">[21]</xref>, <xref rid=""bib22""",20_63,Non-ceruloplasmin copper and urinary copper in clinically stable Wilson disease: Alignment with recommended targets,06 5 2024,,Wilson_Disease
"ref-type=""bibr"">[21]</xref>, <xref rid=""bib22"" ref-type=""bibr"">[22]</xref>, <xref rid=""bib23"" ref-type=""bibr"">[23]</xref>, <xref rid=""bib24"" ref-type=""bibr"">[24]</xref><sup>,</sup><xref rid=""bib38"" ref-type=""bibr""><sup>38</sup></xref> However, detection of possible bias in NCC-Ex led to the development of NCC-Sp.<xref rid=""bib25"" ref-type=""bibr""><sup>25</sup></xref><sup>,</sup><xref rid=""bib26"" ref-type=""bibr""><sup>26</sup></xref> The primary observation in our analysis was that even in our highly selected",20_64,Non-ceruloplasmin copper and urinary copper in clinically stable Wilson disease: Alignment with recommended targets,06 5 2024,,Wilson_Disease
"our analysis was that even in our highly selected group of patients, a large fraction were below the 50-150 μg/L range: 39% for NCC-Sp and 46% for NCC-Ex values, respectively. These “real world” data suggest a recalibration of the range for NCC using novel technologies for treated patients with WD is necessary. NCC-Ex and NCC-Sp varied around the line of identity with considerable scatter and a trend of overestimation by NCC-Ex in the lower range and underestimation by NCC-Ex in the middle range (<xref",20_65,Non-ceruloplasmin copper and urinary copper in clinically stable Wilson disease: Alignment with recommended targets,06 5 2024,,Wilson_Disease
"by NCC-Ex in the middle range (<xref rid=""fig1"" ref-type=""fig"">Fig. 1</xref>). This suggests a systematic difference between these two assays. The published normal range of NCC-Ex is 41-71 μg/L (0.64-1.12 μmol/L) in adults<xref rid=""bib17"" ref-type=""bibr""><sup>17</sup></xref> and slightly lower in children,<xref rid=""bib18"" ref-type=""bibr""><sup>18</sup></xref> which are notably lower than with NCC-Sp (46-213 μg/L) and NCC-Cal (50-150 μg/L). To understand these differences better, it would have been useful",20_66,Non-ceruloplasmin copper and urinary copper in clinically stable Wilson disease: Alignment with recommended targets,06 5 2024,,Wilson_Disease
"differences better, it would have been useful to compare NCC-Sp and NCC-Ex in the same cohort of healthy controls, but that was beyond our capacity. The reported effects of age and sex on NCC-Ex are minimal<xref rid=""bib17"" ref-type=""bibr""><sup>17</sup></xref> and will likely not explain discrepancies between normal ranges for NCC-Sp and NCC-Ex. As further discussed below, the healthy cohort in the our study displayed an ethnic diversity that was not reported in the NCC-Ex healthy cohort.<xref rid=""bib17""",20_67,Non-ceruloplasmin copper and urinary copper in clinically stable Wilson disease: Alignment with recommended targets,06 5 2024,,Wilson_Disease
"in the NCC-Ex healthy cohort.<xref rid=""bib17"" ref-type=""bibr""><sup>17</sup></xref> The NCC-Sp method was developed and validated according to current standards.<xref rid=""bib25"" ref-type=""bibr""><sup>25</sup></xref> In our control population of 75 healthy persons, NCC-Sp had a bimodal distribution (<xref rid=""appsec1"" ref-type=""sec"">Fig. S1</xref>) with a 2.5-97.5 percentile range of 46-213 μg/L, taken as the normal range for the present study. A bimodal distribution was not reported for NCC-Ex<xref",20_68,Non-ceruloplasmin copper and urinary copper in clinically stable Wilson disease: Alignment with recommended targets,06 5 2024,,Wilson_Disease
"distribution was not reported for NCC-Ex<xref rid=""bib17"" ref-type=""bibr""><sup>17</sup></xref> but may have been overlooked with only 44 participants. This should be further explored because both NCC-Sp and NCC-Ex presented with skewed but monomodal distributions in the WD patient population (<xref rid=""appsec1"" ref-type=""sec"">Fig. S2</xref>). In a recent re-examination of a large dataset, total serum copper was higher in females than males, and lower in Caucasian and Hispanic patients than in Black",20_69,Non-ceruloplasmin copper and urinary copper in clinically stable Wilson disease: Alignment with recommended targets,06 5 2024,,Wilson_Disease
"in Caucasian and Hispanic patients than in Black patients.<xref rid=""bib39"" ref-type=""bibr""><sup>39</sup></xref> In our much smaller sample, a gender difference was not detected but a similar effect of ethnicity was observed for total Cu (<xref rid=""appsec1"" ref-type=""sec"">Table S1</xref>). A similar evaluation of any measure of NCC does not exist. In the initial evaluation of NCC-Ex,<xref rid=""bib17"" ref-type=""bibr""><sup>17</sup></xref> with 29 females and 15 males, no gender difference was detected and",20_70,Non-ceruloplasmin copper and urinary copper in clinically stable Wilson disease: Alignment with recommended targets,06 5 2024,,Wilson_Disease
"15 males, no gender difference was detected and ethnicity was not reported. In our sample, NCC-Sp was higher in males than females and we observed a possible effect of ethnicity on NCC-Sp, as values were higher in Caucasian patients than in Black and Hispanic patients (<xref rid=""appsec1"" ref-type=""sec"">Table S1</xref>). However, our sample size is too small to draw firm conclusions, and further studies are warranted. NCC-Sp was lower (56.61±26.2 μg/L) in patients with WD on maintenance treatment with PEN",20_71,Non-ceruloplasmin copper and urinary copper in clinically stable Wilson disease: Alignment with recommended targets,06 5 2024,,Wilson_Disease
"with WD on maintenance treatment with PEN than in healthy persons (116±62 μg/L; <italic toggle=""yes"">p</italic> <0.001 by unpaired t-test). Indeed, 28% of patients were even below 40 μg/L, the lowest value in healthy volunteers, interestingly without evidence for copper deficiency in these study patients. A similar situation was observed with NCC-Ex (<xref rid=""fig1"" ref-type=""fig"">Fig. 1</xref>). Validated target ranges adapted to the phase of the disease for NCC-Ex have not yet been published, but lower",20_72,Non-ceruloplasmin copper and urinary copper in clinically stable Wilson disease: Alignment with recommended targets,06 5 2024,,Wilson_Disease
"for NCC-Ex have not yet been published, but lower than normal values are often seen during maintenance therapy, without established signs of copper deficiency (Aurelia Poujois, Personal communication). Accordingly, in a study of 36 children with WD treated for a median of 6 years with either PEN (83%) or trientine (17%),<xref rid=""bib21"" ref-type=""bibr""><sup>21</sup></xref> the median (IQR) of NCC-Ex was 24 (14-40) μg/L, which is low relative to the normal range for NCC-Ex but was not associated with signs",20_73,Non-ceruloplasmin copper and urinary copper in clinically stable Wilson disease: Alignment with recommended targets,06 5 2024,,Wilson_Disease
"for NCC-Ex but was not associated with signs of copper deficiency. Calculation of NCC-Cal was only possible in 33 patients with Cp above LLOQ. In these patients, NCC-Cal was considerably higher than with newer methods (<xref rid=""appsec1"" ref-type=""sec"">Fig. S3</xref>). Thus, the NCC-Cal/NCC-Sp ratio was 2.9±1.2 and NCC-Cal/NCC-Ex 2.5±0.9. Our findings are in line with a report of NCC-Cal/NCC-Ex ratios of 2.8 in patients with hepatic and 3.4 in those with neurologic WD.<xref rid=""bib40""",20_74,Non-ceruloplasmin copper and urinary copper in clinically stable Wilson disease: Alignment with recommended targets,06 5 2024,,Wilson_Disease
"3.4 in those with neurologic WD.<xref rid=""bib40"" ref-type=""bibr""><sup>40</sup></xref> We are not able to explain this discrepancy but note that the calculation depends heavily on the Cp concentration, molecular weight and Cu/Cp ratio, where small systematic errors will lead to larger relative errors in the NCC-Cal estimate. NCC-Cal did not correlate to 24 h UCE. These observations add to the concerns about using this methodology. Our data enabled comparison of UCE results to NCC-Sp and NCC-Ex (<xref",20_75,Non-ceruloplasmin copper and urinary copper in clinically stable Wilson disease: Alignment with recommended targets,06 5 2024,,Wilson_Disease
"of UCE results to NCC-Sp and NCC-Ex (<xref rid=""fig2"" ref-type=""fig"">Fig. 2</xref>). UCE was outside the 200-500 μg/24 h range in 58%. Indeed, only 20% fulfilled both criteria of the NCC and UCE target ranges (<xref rid=""tbl2"" ref-type=""table"">Table 2</xref>). In the absence of chelator treatment, UCE has been regarded to reflect NCC in the bloodstream<xref rid=""bib4"" ref-type=""bibr""><sup>4</sup></xref><sup>,</sup><xref rid=""bib36"" ref-type=""bibr""><sup>36</sup></xref> and thus the amount of excess copper",20_76,Non-ceruloplasmin copper and urinary copper in clinically stable Wilson disease: Alignment with recommended targets,06 5 2024,,Wilson_Disease
"and thus the amount of excess copper in the body.<xref rid=""bib36"" ref-type=""bibr""><sup>36</sup></xref> During treatment with PEN, the interpretation of UCE is further complicated by the cupriuretic effect of the drug, and that is pragmatically considered in the recommendation of a target range of 200-500 μg/24 h. If patients had been overtreated for extended periods, UCE would be expected to decline over time and reach low values; however, shorter periods of overtreatment may increase UCE above target",20_77,Non-ceruloplasmin copper and urinary copper in clinically stable Wilson disease: Alignment with recommended targets,06 5 2024,,Wilson_Disease
"of overtreatment may increase UCE above target ranges. Elevated UCE may also be seen when non-adherent patients remember to take their medication during UCE collection. In accordance, the visit-to-visit variability of UCE is known to be very large and single values are not easy to use for clinical decisions.<xref rid=""bib41"" ref-type=""bibr""><sup>41</sup></xref> Our findings reflected this complexity. UCE only weakly correlated with NCC-Sp (<xref rid=""fig2"" ref-type=""fig"">Fig. 2</xref>) and not to PEN dose",20_78,Non-ceruloplasmin copper and urinary copper in clinically stable Wilson disease: Alignment with recommended targets,06 5 2024,,Wilson_Disease
"ref-type=""fig"">Fig. 2</xref>) and not to PEN dose in mg/kg (<xref rid=""fig3"" ref-type=""fig"">Fig. 3</xref>). A large fraction of patients (49%) had UCE above the 200-500 μg/24 h target range. Similar findings were reported in 79 patients with WD on PEN for more than 60 months, where 50% had UCE above 600 μg/24 h,<xref rid=""bib41"" ref-type=""bibr""><sup>41</sup></xref> and in 22 compliant patients treated with PEN for a mean of 12 years and UCE (mean±SD) of 653.95±354.19 μg/24 h.<xref rid=""bib16""",20_79,Non-ceruloplasmin copper and urinary copper in clinically stable Wilson disease: Alignment with recommended targets,06 5 2024,,Wilson_Disease
"of 653.95±354.19 μg/24 h.<xref rid=""bib16"" ref-type=""bibr""><sup>16</sup></xref> In the latter study, UCE did not differ between adherent and non-adherent patients. The origin of the 200-500 μg/24 h target range has been difficult to track. It is assumed to neutralize the pathological copper balance in patients with WD, and that may not always be correct if patients do not follow a low copper diet. In our cross-sectional study we only note that there was no correlation between UCE and dose of penicillamine,",20_80,Non-ceruloplasmin copper and urinary copper in clinically stable Wilson disease: Alignment with recommended targets,06 5 2024,,Wilson_Disease
"between UCE and dose of penicillamine, ALT, or AST (<xref rid=""fig3"" ref-type=""fig"">Fig. 3</xref> and <xref rid=""tbl4"" ref-type=""table"">Table 4</xref>). Given these difficulties with interpretation of UCE, our data illustrates why experienced clinicians may not mechanically use these measures to drive dosage decisions in patients with WD, but rather choose to prioritize clinical symptoms over laboratory values. To overcome uncertainty with the use of UCE and simplify interpretation, some centers use",20_81,Non-ceruloplasmin copper and urinary copper in clinically stable Wilson disease: Alignment with recommended targets,06 5 2024,,Wilson_Disease
"UCE and simplify interpretation, some centers use assessment of UCE after 48 h off PEN therapy,<xref rid=""bib16"" ref-type=""bibr""><sup>16</sup></xref><sup>,</sup><xref rid=""bib41"" ref-type=""bibr""><sup>41</sup></xref> however our data do not allow for evaluation of this alternative. Our dataset reflects standard daily (real world) practice, raising a question of why the observed NCC-Sp and NCC-Ex in patients with stable WD on PEN were lower than recommended in guidelines and values observed in healthy",20_82,Non-ceruloplasmin copper and urinary copper in clinically stable Wilson disease: Alignment with recommended targets,06 5 2024,,Wilson_Disease
"in guidelines and values observed in healthy controls? We suggest two possible hypotheses; first, the treatment was actually optimal, and treatment target ranges for NCC-Sp and NCC-Ex may in fact be lower than the normal ranges for healthy individuals. Secondly, a large proportion of patients with WD below-target NCC-Sp values might be overtreated, and their dosage of PEN could have been reduced without losing clinical efficacy. In the present cross-sectional study, we can only note that biochemical or",20_83,Non-ceruloplasmin copper and urinary copper in clinically stable Wilson disease: Alignment with recommended targets,06 5 2024,,Wilson_Disease
"study, we can only note that biochemical or clinical signs of overtreatment were not detected. Given the associations of lower NCC-Sp and NCC-Ex with lower values of ALT and AST and higher albumin there may be a protective value of keeping NCC low. The level of NCC-Sp below which there is a risk of copper deficiency is still unknown. Further clinical validation in longitudinal studies should aim at determining optimal target ranges for NCC in patients with WD in different phases of specific treatments and",20_84,Non-ceruloplasmin copper and urinary copper in clinically stable Wilson disease: Alignment with recommended targets,06 5 2024,,Wilson_Disease
"WD in different phases of specific treatments and taking different methodologies into account. In conclusion, we examined 76 patients with WD who were judged by expert clinicians to be clinically stable on a given dose of PEN after years of treatment. Nevertheless, only 20% had both NCC-Sp and UCE within currently recommended target ranges. The tendency was that UCE was above and NCC-Sp below current recommendations, as would be expected with overtreatment, but no signs of copper deficiency were detected",20_85,Non-ceruloplasmin copper and urinary copper in clinically stable Wilson disease: Alignment with recommended targets,06 5 2024,,Wilson_Disease
"but no signs of copper deficiency were detected in these patients. Our data raise the question of whether the therapeutic target ranges for NCC-Sp and NCC-Ex should be lower than the normal range in healthy persons in order to provide maximal organ protection in treated patients. In addition, as normal ranges differ by assay, the targeted ranges should be assay specific as well as treatment specific. The observed range of UCE values raise questions about interpretation of values during treatment and the",20_86,Non-ceruloplasmin copper and urinary copper in clinically stable Wilson disease: Alignment with recommended targets,06 5 2024,,Wilson_Disease
"interpretation of values during treatment and the potential benefit of assessment off therapy. Thus, our study provides the first data on the ranges of NCC-Sp for healthy individuals and PEN-treated patients with WD and highlights the need for longitudinal studies to develop and validate methodologic-specific targets for NCC in different phases of treatment of the disorder. ALT, alanine aminotransferase; AST, aspartate aminotransferase; Cp, ceruloplasmin; ICP-MS, inductively coupled plasma mass",20_87,Non-ceruloplasmin copper and urinary copper in clinically stable Wilson disease: Alignment with recommended targets,06 5 2024,,Wilson_Disease
"ICP-MS, inductively coupled plasma mass spectroscopy; NCC, non-ceruloplasmin-bound copper; NCC-Cal, NCC calculated from total Cu and ceruloplasmin; NCC-Ex, exchangeable copper; NCC-Sp, NCC determined from total copper protein speciation assay; PEN, D-penicillamine; UCE, 24-hour urinary copper excretion; WD, Wilson disease. The paper is a secondary analysis of data collected during the Chelate trial (NCT03539952) and the sponsor of the trial (Orphalan, ASA France) generously provided these data. Peter Ott",20_88,Non-ceruloplasmin copper and urinary copper in clinically stable Wilson disease: Alignment with recommended targets,06 5 2024,,Wilson_Disease
"France) generously provided these data. Peter Ott and Thomas Sandahl were supported by The Memorial Foundation of Manufacturer Vilhelm Pedersen & Wife. <bold>PO</bold> received consulting fee from Orphalan, institutional research grant from Alexion, consulting fee from Ultragenyx, Vivet, and MEXBRAIN. <bold>TS</bold> received received consulting fee from Orphalan, institutional research grant from Alexion, consulting fee from Ultragenyx, advisory activities for Vivet. The Department of Hepatology and",20_89,Non-ceruloplasmin copper and urinary copper in clinically stable Wilson disease: Alignment with recommended targets,06 5 2024,,Wilson_Disease
"for Vivet. The Department of Hepatology and Gastroenterology has received an unrestricted research grant from Orphalan. <bold>AA</bold> received institutional research grants from Orphalan, Alexion, Univer, and the Wilson Disease Association;consulting fees from Alexion and Orphalan; speaker’s fee from Orphalan; travel assistance to meetings from Orphalan and Univer. Advisory board at Alexion, Univar, and Orphalan. <bold>DC</bold> received consulting fees, travel reimbursements and honoraria for advisory",20_90,Non-ceruloplasmin copper and urinary copper in clinically stable Wilson disease: Alignment with recommended targets,06 5 2024,,Wilson_Disease
"travel reimbursements and honoraria for advisory activities and speaker assignments, from Orphalan. <bold>EC-B</bold> received consulting fees and honoraria for advisory activities from Alexion, Orphalan, Univar, travel assistance to meetings from Orphalan and Univar. <bold>AC</bold> received research (institutional) grants from Orphalan, Alexion, Public Health Research Institute in Canada; consulting fees from Wilson Therapeutics, Alexion, Vivet Therapeutics, and Orphalan; speaker’s fees from Ever Pharma;",20_91,Non-ceruloplasmin copper and urinary copper in clinically stable Wilson disease: Alignment with recommended targets,06 5 2024,,Wilson_Disease
"and Orphalan; speaker’s fees from Ever Pharma; and travel assistance to meetings from Orphalan. <bold>GD</bold> received lecture fees, honoraria for advisory activities and travel support from AbbVie, Advanz, Alexion, Falk Foundation, Gilead, Intercept, Novartis, Orphalan and Univar. <bold>JM</bold> received consultancy fees from Orphalan and Alexion and honorarium from Shionogi. <bold>AP</bold> received institutional grants from Orphalan, Addmedica, Alexion; consulting fees and honoraria for advisory",20_92,Non-ceruloplasmin copper and urinary copper in clinically stable Wilson disease: Alignment with recommended targets,06 5 2024,,Wilson_Disease
"consulting fees and honoraria for advisory activities from Alexion, Orphalan, Vivet therapeutics, Univar. <bold>KHW</bold> received research (institutional) grants from Orphalan; consulting fees from Orphalan, Univar, Pfizer, Alexion, and Vivet Therapeutics, Desitin, Ultragenyx; speaker’s fees from Falk, AbbVie, Alexion, and Orphalan; travel assistance to meetings from Alexion and Univar. <bold>OK</bold> is employed by Orphalan. <bold>MLS</bold> received research grants from Orphalan, Alexion, Vivet",20_93,Non-ceruloplasmin copper and urinary copper in clinically stable Wilson disease: Alignment with recommended targets,06 5 2024,,Wilson_Disease
"research grants from Orphalan, Alexion, Vivet therapeutics and the Wilson Disease Association, and honoraria and advisory activities for Arbomed and DepYmed. Please refer to the accompanying ICMJE disclosure forms for further details. Peter Ott, Michael Schilsky, Thomas Sandahl and Omar Kamlin conceived and planned the study to be accepted by all authors. Peter Ott and Thomas Sandahl provided initial data analysis and draft manuscript in interaction with Michael Schilsky and Omar Kamlin. All authors",20_94,Non-ceruloplasmin copper and urinary copper in clinically stable Wilson disease: Alignment with recommended targets,06 5 2024,,Wilson_Disease
Michael Schilsky and Omar Kamlin. All authors participated in generating the presented data and critically participated in further revisions of the paper. See Chelate study statement (Lancet Gastroenterol Hepatol 2022 Vol. 7 Issue 12 Pages 1092-1102).,20_95,Non-ceruloplasmin copper and urinary copper in clinically stable Wilson disease: Alignment with recommended targets,06 5 2024,,Wilson_Disease
"Wilson Disease: Copper-Mediated Cuproptosis, Iron-Related Ferroptosis, and Clinical Highlights, with Comprehensive and Critical Analysis Update Wilson disease is a genetic disorder of the liver characterized by excess accumulation of copper, which is found ubiquitously on earth and normally enters the human body in small amounts via the food chain. Many interesting disease details were published on the mechanistic steps, such as the generation of reactive oxygen species (ROS) and cuproptosis causing a",21_0,"Wilson Disease: Copper-Mediated Cuproptosis, Iron-Related Ferroptosis, and Clinical Highlights, with Comprehensive and Critical Analysis Update",26 4 2024,,Wilson_Disease
"oxygen species (ROS) and cuproptosis causing a copper dependent cell death. In the liver of patients with Wilson disease, also, increased iron deposits were found that may lead to iron-related ferroptosis responsible for phospholipid peroxidation within membranes of subcellular organelles. All topics are covered in this review article, in addition to the diagnostic and therapeutic issues of Wilson disease. Excess Cu<sup>2+</sup> primarily leads to the generation of reactive oxygen species (ROS), as",21_1,"Wilson Disease: Copper-Mediated Cuproptosis, Iron-Related Ferroptosis, and Clinical Highlights, with Comprehensive and Critical Analysis Update",26 4 2024,,Wilson_Disease
"generation of reactive oxygen species (ROS), as evidenced by early experimental studies exemplified with the detection of hydroxyl radical formation using the electron spin resonance (ESR) spin-trapping method. The generation of ROS products follows the principles of the Haber–Weiss reaction and the subsequent Fenton reaction leading to copper-related cuproptosis, and is thereby closely connected with ROS. Copper accumulation in the liver is due to impaired biliary excretion of copper caused by the",21_2,"Wilson Disease: Copper-Mediated Cuproptosis, Iron-Related Ferroptosis, and Clinical Highlights, with Comprehensive and Critical Analysis Update",26 4 2024,,Wilson_Disease
"biliary excretion of copper caused by the inheritable malfunctioning or missing ATP7B protein. As a result, disturbed cellular homeostasis of copper prevails within the liver. Released from the liver cells due to limited storage capacity, the toxic copper enters the circulation and arrives at other organs, causing local accumulation and cell injury. This explains why copper injures not only the liver, but also the brain, kidneys, eyes, heart, muscles, and bones, explaining the multifaceted clinical",21_3,"Wilson Disease: Copper-Mediated Cuproptosis, Iron-Related Ferroptosis, and Clinical Highlights, with Comprehensive and Critical Analysis Update",26 4 2024,,Wilson_Disease
"and bones, explaining the multifaceted clinical features of Wilson disease. Among these are depression, psychosis, dysarthria, ataxia, writing problems, dysphagia, renal tubular dysfunction, Kayser–Fleischer corneal rings, cardiomyopathy, cardiac arrhythmias, rhabdomyolysis, osteoporosis, osteomalacia, arthritis, and arthralgia. In addition, Coombs-negative hemolytic anemia is a key feature of Wilson disease with undetectable serum haptoglobin. The modified Leipzig Scoring System helps diagnose Wilson",21_4,"Wilson Disease: Copper-Mediated Cuproptosis, Iron-Related Ferroptosis, and Clinical Highlights, with Comprehensive and Critical Analysis Update",26 4 2024,,Wilson_Disease
Leipzig Scoring System helps diagnose Wilson disease. Patients with Wilson disease are well-treated first-line with copper chelators like D-penicillamine that facilitate the removal of circulating copper bound to albumin and increase in urinary copper excretion. Early chelation therapy improves prognosis. Liver transplantation is an option viewed as ultima ratio in end-stage liver disease with untreatable complications or acute liver failure. Liver transplantation finally may thus be a life-saving approach,21_5,"Wilson Disease: Copper-Mediated Cuproptosis, Iron-Related Ferroptosis, and Clinical Highlights, with Comprehensive and Critical Analysis Update",26 4 2024,,Wilson_Disease
"finally may thus be a life-saving approach and curative treatment of the disease by replacing the hepatic gene mutation. In conclusion, Wilson disease is a multifaceted genetic disease representing a molecular and clinical challenge. All heavy metals, from aurum (gold) to zinc including copper (Cu from Latin cuprum), are found on earth with various amounts, but they all were originally formed in the universe from helium and hydrogen via nuclear fusion inside stars during supernova explosions millions of",21_6,"Wilson Disease: Copper-Mediated Cuproptosis, Iron-Related Ferroptosis, and Clinical Highlights, with Comprehensive and Critical Analysis Update",26 4 2024,,Wilson_Disease
"stars during supernova explosions millions of years ago [<xref rid=""B1-ijms-25-04753"" ref-type=""bibr"">1</xref>,<xref rid=""B2-ijms-25-04753"" ref-type=""bibr"">2</xref>,<xref rid=""B3-ijms-25-04753"" ref-type=""bibr"">3</xref>,<xref rid=""B4-ijms-25-04753"" ref-type=""bibr"">4</xref>]. On our globe, copper entered the flora and became an essential micronutrient for plants, animals, and humans, who may be confronted with metabolic disorders that arise from mishandling of copper [<xref rid=""B5-ijms-25-04753""",21_7,"Wilson Disease: Copper-Mediated Cuproptosis, Iron-Related Ferroptosis, and Clinical Highlights, with Comprehensive and Critical Analysis Update",26 4 2024,,Wilson_Disease
"of copper [<xref rid=""B5-ijms-25-04753"" ref-type=""bibr"">5</xref>]. In plants, copper is a cofactor for a variety of enzymes, and it plays an important role in signal transduction, the antioxidant system, respiration, and photosynthesis [<xref rid=""B5-ijms-25-04753"" ref-type=""bibr"">5</xref>,<xref rid=""B6-ijms-25-04753"" ref-type=""bibr"">6</xref>]. Several mechanisms ensure copper homeostasis in plants [<xref rid=""B6-ijms-25-04753"" ref-type=""bibr"">6</xref>], modify the diurnal and circadian clock rhythms",21_8,"Wilson Disease: Copper-Mediated Cuproptosis, Iron-Related Ferroptosis, and Clinical Highlights, with Comprehensive and Critical Analysis Update",26 4 2024,,Wilson_Disease
"modify the diurnal and circadian clock rhythms [<xref rid=""B7-ijms-25-04753"" ref-type=""bibr"">7</xref>], and take care of abiotic plant stress due to copper [<xref rid=""B8-ijms-25-04753"" ref-type=""bibr"">8</xref>]. Copper found in plants [<xref rid=""B5-ijms-25-04753"" ref-type=""bibr"">5</xref>,<xref rid=""B6-ijms-25-04753"" ref-type=""bibr"">6</xref>,<xref rid=""B7-ijms-25-04753"" ref-type=""bibr"">7</xref>] is taken up by the plants from the soil [<xref rid=""B8-ijms-25-04753"" ref-type=""bibr"">8</xref>], and these",21_9,"Wilson Disease: Copper-Mediated Cuproptosis, Iron-Related Ferroptosis, and Clinical Highlights, with Comprehensive and Critical Analysis Update",26 4 2024,,Wilson_Disease
"ref-type=""bibr"">8</xref>], and these copper containing plants are the first in the food chain providing cattle grazing on the fields with plant-derived copper before humans consume the plants and meat. Copper contaminating food and drinking water can easily enter the human body, but generally does not harm healthy individuals as long as they are not compromised by <italic toggle=""yes"">ATP7B</italic> gene mutations that disturb copper homeostasis, like in Wilson disease. This mutation primarily impairs the",21_10,"Wilson Disease: Copper-Mediated Cuproptosis, Iron-Related Ferroptosis, and Clinical Highlights, with Comprehensive and Critical Analysis Update",26 4 2024,,Wilson_Disease
"disease. This mutation primarily impairs the biliary excretion of excess copper that initiates cuproptosis. Due to the concomitant deposition of iron in the liver, ferroptosis may contribute to liver injury. The consensus exists that both cuproptosis and ferroptosis cause special forms of regulated or programmed cell death. Because Wilson disease is a rare hereditary disorder with interesting molecular and mechanistic aspects, further analyses and discussions are warranted. The current article critically",21_11,"Wilson Disease: Copper-Mediated Cuproptosis, Iron-Related Ferroptosis, and Clinical Highlights, with Comprehensive and Critical Analysis Update",26 4 2024,,Wilson_Disease
"are warranted. The current article critically analyses developments of the pathophysiology including cuproptosis, ferroptosis, and ROS in patients with Wilson disease. It also discusses its gene mutations, clinical features, symptoms, diagnostic criteria, drug therapy with copper chelators, prognosis, and possible liver transplantation as ultima ratio.    Liver transplantation is an option as ultima ratio in untreatable fulminant stages of Wilson disease like acute liver failure or hemolytic crisis. This",21_12,"Wilson Disease: Copper-Mediated Cuproptosis, Iron-Related Ferroptosis, and Clinical Highlights, with Comprehensive and Critical Analysis Update",26 4 2024,,Wilson_Disease
"acute liver failure or hemolytic crisis. This provides a life-saving approach, comprehensive curative treatment of the disease, restoration of the liver function, and mitigation of portal hypertension [<xref rid=""B178-ijms-25-04753"" ref-type=""bibr"">178</xref>,<xref rid=""B179-ijms-25-04753"" ref-type=""bibr"">179</xref>]. Excellent survival rates of one and five years without disease recurrence have now been reported, and in case of deceased donor liver shortage, living relative liver transplantation is an",21_13,"Wilson Disease: Copper-Mediated Cuproptosis, Iron-Related Ferroptosis, and Clinical Highlights, with Comprehensive and Critical Analysis Update",26 4 2024,,Wilson_Disease
"living relative liver transplantation is an option [<xref rid=""B178-ijms-25-04753"" ref-type=""bibr"">178</xref>]. Indication for a liver transplantation has to carefully be considered in Wilson disease patients with severe psycho-neurological symptoms [<xref rid=""B178-ijms-25-04753"" ref-type=""bibr"">178</xref>,<xref rid=""B179-ijms-25-04753"" ref-type=""bibr"">179</xref>].  In the past, substantial work has been done on case evaluation standard, clinical diagnosis, and molecular details with focus on the cascade",21_14,"Wilson Disease: Copper-Mediated Cuproptosis, Iron-Related Ferroptosis, and Clinical Highlights, with Comprehensive and Critical Analysis Update",26 4 2024,,Wilson_Disease
"and molecular details with focus on the cascade of events leading to the liver injury of Wilson disease. Therefore, the characterization of Wilson disease features has gained a good basic level with fair, balanced perspectives. A few issues remain which require clarification. Wilson disease is a multifaceted disorder that benefits from the modified Leipzig scoring method. This algorithm was created in line with principles of artificial intelligence (AI) to improve diagnostic consistency among difficult",21_15,"Wilson Disease: Copper-Mediated Cuproptosis, Iron-Related Ferroptosis, and Clinical Highlights, with Comprehensive and Critical Analysis Update",26 4 2024,,Wilson_Disease
to improve diagnostic consistency among difficult processes by selecting the most essential elements that require a sophisticated scoring system. The sum of highly scored key elements provides causality grades of probability. The well-structured diagnostic algorithm of the modified Leipzig scoring system suggests causality gradings from established diagnosis down to possible and very unlikely diagnosis. Its regular use is strongly recommended in future cases of suspected Wilson disease. Combining cases,21_16,"Wilson Disease: Copper-Mediated Cuproptosis, Iron-Related Ferroptosis, and Clinical Highlights, with Comprehensive and Critical Analysis Update",26 4 2024,,Wilson_Disease
of suspected Wilson disease. Combining cases with an established causality grading due to a score of ≥4 helps form homogenous study cohorts available for additional analytical approaches regarding clinical issues and mechanistic challenges. This can expand our views of mechanistic steps leading to the injury as a basis for new therapeutic approaches.,21_17,"Wilson Disease: Copper-Mediated Cuproptosis, Iron-Related Ferroptosis, and Clinical Highlights, with Comprehensive and Critical Analysis Update",26 4 2024,,Wilson_Disease
Exploring the Content Validity of the Unified Wilson Disease Rating Scale: Insights from Qualitative Research,22_0,Exploring the Content Validity of the Unified Wilson Disease Rating Scale: Insights from Qualitative Research,4 4 2024,,Wilson_Disease
"<table-wrap id=""Taba""><table frame=""hsides"" rules=""groups""><tbody><tr><td align=""left"">The findings presented in this study advance our understanding of the breadth of neurological signs/symptoms and the magnitude of the impacts of  Wilson disease (WD), which was not so well understood.</td></tr><tr><td align=""left"">This work provides evidence to support the content validity of Part II of the Unified Wilson Disease Rating Scale (UWDRS).</td></tr><tr><td align=""left"">This work also includes supportive",22_1,Exploring the Content Validity of the Unified Wilson Disease Rating Scale: Insights from Qualitative Research,4 4 2024,,Wilson_Disease
"align=""left"">This work also includes supportive evidence for the content validity of Part III of the UWDRS based on the patient perspective, which was not previously demonstrated.</td></tr><tr><td align=""left"">The findings suggest that the UWDRS should be used in conjunction with other clinical outcome assessments that measure key hepatic and psychiatric signs/symptoms of WD as all three domains of symptoms are important to the patient experience and together provide a comprehensive assessment of the",22_2,Exploring the Content Validity of the Unified Wilson Disease Rating Scale: Insights from Qualitative Research,4 4 2024,,Wilson_Disease
provide a comprehensive assessment of the patient experience in WD.</td></tr></tbody></table></table-wrap>,22_3,Exploring the Content Validity of the Unified Wilson Disease Rating Scale: Insights from Qualitative Research,4 4 2024,,Wilson_Disease
"Wilson disease (WD) is an inherited autosomal recessive metabolic disorder of impaired copper transport. WD causes an accumulation of copper in multiple organs, namely the liver and brain, resulting in a range of neurological, psychiatric, and hepatic manifestations. WD can be managed with life-long treatment that reduces copper burden; however, without treatment the disease can be fatal [<xref ref-type=""bibr"" rid=""CR1"">1</xref>]. The Unified Wilson Disease Rating Scale (UWDRS) was created by the",22_4,Exploring the Content Validity of the Unified Wilson Disease Rating Scale: Insights from Qualitative Research,4 4 2024,,Wilson_Disease
"Disease Rating Scale (UWDRS) was created by the EuroWilson consortium, in collaboration with the German Network of Hereditary Movement Disorders (GeNeMove), to address the lack of a standardized assessment for the neurological manifestations of WD [<xref ref-type=""bibr"" rid=""CR2"">2</xref>]. This instrument was based on previously validated measures for neurological disorders that assess similar symptoms including the Barthel Index, Unified Parkinson’s Disease Rating Scale (UPDRS), Unified Huntington’s",22_5,Exploring the Content Validity of the Unified Wilson Disease Rating Scale: Insights from Qualitative Research,4 4 2024,,Wilson_Disease
"Rating Scale (UPDRS), Unified Huntington’s Disease Rating Scale (UHDRS), International Cooperative Ataxia Rating Scale (ICARS), and Burke-Fahn-Marsden Dystonia Rating Scale (BFM scale) [<xref ref-type=""bibr"" rid=""CR2"">2</xref>–<xref ref-type=""bibr"" rid=""CR4"">4</xref>]. On their own, none of these scales were able to reflect the multiple motor impairments caused by WD [<xref ref-type=""bibr"" rid=""CR3"">3</xref>]. The UWDRS scale is split into three parts, Part I assesses level of consciousness, Part II is the",22_6,Exploring the Content Validity of the Unified Wilson Disease Rating Scale: Insights from Qualitative Research,4 4 2024,,Wilson_Disease
"assesses level of consciousness, Part II is the patient-reported section, and Part III is a detailed neurological examination. Parts I and III are designed to be completed by a neurologist or other clinician, while Part II is to be completed by a patient, family member, or caregiver. The UWDRS overall, including Part II, was, however, created without the direct input from patients, and to date, evidence that confirms the content validity and relevance of the instrument to patients does not exist. Utilizing",22_7,Exploring the Content Validity of the Unified Wilson Disease Rating Scale: Insights from Qualitative Research,4 4 2024,,Wilson_Disease
instrument to patients does not exist. Utilizing patient input to evaluate content validity of an instrument is a crucial step as quantitative analysis of an instrument’s psychometric properties alone cannot confirm the appropriateness of an instrument to measure the patient experience in a clinical trial. The importance of establishing content validity in clinical outcomes assessments (COAs) from the patient perspective is increasingly emphasized by both the United States (US) Food and Drug Administration,22_8,Exploring the Content Validity of the Unified Wilson Disease Rating Scale: Insights from Qualitative Research,4 4 2024,,Wilson_Disease
"United States (US) Food and Drug Administration (FDA) and the European Medicines Agency (EMA). [<xref ref-type=""bibr"" rid=""CR5"">5</xref>] A key first step in assessing content validity is to understand the experiences of a patient population. A manuscript by Karantzoulis et al.[<xref ref-type=""bibr"" rid=""CR6"">6</xref>] describes the development of a conceptual model of WD that includes the signs, symptoms, and impacts experienced by patients with WD. The conceptual model was created with data from a",22_9,Exploring the Content Validity of the Unified Wilson Disease Rating Scale: Insights from Qualitative Research,4 4 2024,,Wilson_Disease
"The conceptual model was created with data from a targeted literature review, clinician interviews, and concept elicitation (CE) interviews with patients with WD. The findings from that work highlighted the heterogenous presentation of WD, with patients experiencing a range of signs and symptoms including hepatic, neurological, and/or psychiatric, as well as many resulting impacts [<xref ref-type=""bibr"" rid=""CR6"">6</xref>]. This published work also suggests that patients with WD fall into one of two groups",22_10,Exploring the Content Validity of the Unified Wilson Disease Rating Scale: Insights from Qualitative Research,4 4 2024,,Wilson_Disease
"that patients with WD fall into one of two groups based on their symptoms experienced: (1) patients who experience neurological, psychiatric, and hepatic symptoms and (2) patients who experience mostly hepatic and some psychiatric symptoms [<xref ref-type=""bibr"" rid=""CR6"">6</xref>]. In the current work, we sought to evaluate the content validity of the UWDRS Part II—specifically regarding its coverage/ability to assess the neurological aspects of WD—using qualitative interviews and mapping of concepts",22_11,Exploring the Content Validity of the Unified Wilson Disease Rating Scale: Insights from Qualitative Research,4 4 2024,,Wilson_Disease
"qualitative interviews and mapping of concepts identified to the items of the UWDRS to further augment the findings from the previously published work. Specifically, one-on-one interviews were conducted with patients who experience neurological signs/symptoms in order to better understand the many neurological manifestations of WD and how those impact how patients feel and function as well as to assess the conceptual coverage of these symptoms by the UWDRS. Concepts were mapped to Parts II and III of the",22_12,Exploring the Content Validity of the Unified Wilson Disease Rating Scale: Insights from Qualitative Research,4 4 2024,,Wilson_Disease
"Concepts were mapped to Parts II and III of the UWDRS to assess conceptual coverage by the instrument. Cognitive debriefing (CD) interviews were conducted with patients to evaluate the patient-reported Part II items and only select Part III items of the UWDRS to confirm their relevance and clarity, to evaluate the content validity of the instrument. Not all Part III items were discussed given that this section is intended to be completed by a clinician. Content validity can be defined as “the extent to",22_13,Exploring the Content Validity of the Unified Wilson Disease Rating Scale: Insights from Qualitative Research,4 4 2024,,Wilson_Disease
"Content validity can be defined as “the extent to which a scale or questionnaire represents the most relevant and important aspects of a concept in the context of a given measurement” [<xref ref-type=""bibr"" rid=""CR7"">7</xref>]. Content validity can be assessed by utilizing two qualitative interview methodologies. CE interviews are conducted to understand the signs, symptoms, and impacts (“concepts”) of disease that patients experience and culminate in the creation of a conceptual model of the disease",22_14,Exploring the Content Validity of the Unified Wilson Disease Rating Scale: Insights from Qualitative Research,4 4 2024,,Wilson_Disease
"the creation of a conceptual model of the disease experience. CD interviews are conducted to determine if items in a selected instrument are relevant to the patient experience with the disease and are clearly and easily understood. This study was conducted in several steps, starting with CE interviews, then mapping concepts from the patient interviews to items in Parts II and III of the UWDRS, followed by CD interviews of Part II and select items of Part III. The methods for the CE interviews are the same",22_15,Exploring the Content Validity of the Unified Wilson Disease Rating Scale: Insights from Qualitative Research,4 4 2024,,Wilson_Disease
"The methods for the CE interviews are the same as those in the previously published manuscript [<xref ref-type=""bibr"" rid=""CR6"">6</xref>] with the addition of one inclusion criterion for targeted recruitment of patients who currently experience one or more neurological signs/symptoms. For full details, see Karantzoulis et al. [<xref ref-type=""bibr"" rid=""CR6"">6</xref>].  This study aimed to evaluate the content validity of the UWDRS from the patient perspective, utilizing qualitative research methods. The",22_16,Exploring the Content Validity of the Unified Wilson Disease Rating Scale: Insights from Qualitative Research,4 4 2024,,Wilson_Disease
"utilizing qualitative research methods. The results from the CE interviews with the “neuro-enriched sample” of patients with WD generally align with the results previously reported in Karantzoulis et al. [<xref ref-type=""bibr"" rid=""CR6"">6</xref>] and other prior published literature on the WD patient experience regarding the signs, symptoms, and impacts [<xref ref-type=""bibr"" rid=""CR1"">1</xref>, <xref ref-type=""bibr"" rid=""CR8"">8</xref>–<xref ref-type=""bibr"" rid=""CR11"">11</xref>]. These findings are also in",22_17,Exploring the Content Validity of the Unified Wilson Disease Rating Scale: Insights from Qualitative Research,4 4 2024,,Wilson_Disease
"rid=""CR11"">11</xref>]. These findings are also in line with prior research supporting the usefulness of the UWDRS in patients with WD. While patients with WD present with multisystem symptoms and impacts, this CE interview study highlighted a broad range of salient neurological signs/symptoms as well as impacts. The salient neurological concepts identified include change in balance, change in walking, change in writing, drooling, other changes in speech, slurred speech, and tremor. Only one other salient",22_18,Exploring the Content Validity of the Unified Wilson Disease Rating Scale: Insights from Qualitative Research,4 4 2024,,Wilson_Disease
"speech, and tremor. Only one other salient concept, dizziness, identified in the previous study [<xref ref-type=""bibr"" rid=""CR6"">6</xref>], was not identified as salient in this study. In addition to the large number of neurological concepts reported, patients described many of the concepts as being highly bothersome. Bothersome ratings provided highlight a high degree of bother associated with the neurological aspects of WD and negative impact on patients’ lives. Karantzoulis et al. [<xref ref-type=""bibr""",22_19,Exploring the Content Validity of the Unified Wilson Disease Rating Scale: Insights from Qualitative Research,4 4 2024,,Wilson_Disease
"lives. Karantzoulis et al. [<xref ref-type=""bibr"" rid=""CR6"">6</xref>] showed that not all patients with WD experience neurological signs/symptoms due to their WD. However, for those who do, this data underscores the importance of understanding how future treatments may affect these bothersome neurological concepts. Mapping neurological concepts identified in the CE interviews with items of the UWDRS Parts II and III demonstrates almost complete coverage of all neurological signs and symptoms, and complete",22_20,Exploring the Content Validity of the Unified Wilson Disease Rating Scale: Insights from Qualitative Research,4 4 2024,,Wilson_Disease
"all neurological signs and symptoms, and complete coverage of salient neurological signs and symptoms by the UWDRS. This data suggests that the UWDRS Parts II and III is comprehensive in its conceptual coverage of the neurological aspects of WD. UWDRS Part II item debriefing with patients demonstrated that the Part II items of the UWDRS were generally clear and easily understood, and most patients considered items personally relevant to their experience with WD. Three patients expressed concerns regarding",22_21,Exploring the Content Validity of the Unified Wilson Disease Rating Scale: Insights from Qualitative Research,4 4 2024,,Wilson_Disease
"WD. Three patients expressed concerns regarding the clarity of the toilet use item, though the majority reported this item to be clear and relevant. These data provide supportive evidence for the content validity of Part II of the UWDRS. This suggests that patients enrolled in a clinical trial would understand and consider these Part II items to be relevant. The main strengths of this study are the multiple streams of research conducted, including the CE interviews, concept/instrument mapping, and CD",22_22,Exploring the Content Validity of the Unified Wilson Disease Rating Scale: Insights from Qualitative Research,4 4 2024,,Wilson_Disease
"CE interviews, concept/instrument mapping, and CD interviews. The CE interviews conducted with the “neuro-enriched sample” further support the results published in Karantzoulis et al. [<xref ref-type=""bibr"" rid=""CR6"">6</xref>]. The number of patients interviewed and the heterogeneous experiences they reported further strengthens the body of evidence gathered to date. This study has a few potential limitations. Patients actively volunteered to participate in this study, creating the possibility of selection",22_23,Exploring the Content Validity of the Unified Wilson Disease Rating Scale: Insights from Qualitative Research,4 4 2024,,Wilson_Disease
"this study, creating the possibility of selection bias in the sample. The cognitive debriefing interviews were conducted in English with patients primarily located in the US. Therefore, the results of the cognitive debriefing interviews may not be generalizable to other regions/languages for which the UWDRS may be deployed. Additionally, while some patients who reviewed the select Part III items found these items to be relevant, conclusions cannot be made regarding content validity of Part III from this",22_24,Exploring the Content Validity of the Unified Wilson Disease Rating Scale: Insights from Qualitative Research,4 4 2024,,Wilson_Disease
"regarding content validity of Part III from this study. In order to do so, the relevance and clarity of these items will need to be explored with individuals who would complete Part III, i.e., study clinicians. Importantly this work, along with Karantzoulis et al. [<xref ref-type=""bibr"" rid=""CR6"">6</xref>], highlights other important aspects of the patient experiences—specifically, psychiatric and hepatic signs/symptoms. The UWDRS does not cover these concepts and therefore does not assess the full patient",22_25,Exploring the Content Validity of the Unified Wilson Disease Rating Scale: Insights from Qualitative Research,4 4 2024,,Wilson_Disease
"and therefore does not assess the full patient experience. To evaluate the full patient experience, a robust COA strategy that includes the UWDRS and other clinical outcome assessments that map onto the hepatic and psychiatric symptoms is needed. Further, as reported in Karantzoulis et al. [<xref ref-type=""bibr"" rid=""CR6"">6</xref>], only a portion of patients with WD experience neurological signs/symptoms. As such, scales and endpoints created from the UWDRS may be limited in a broad WD population, with a",22_26,Exploring the Content Validity of the Unified Wilson Disease Rating Scale: Insights from Qualitative Research,4 4 2024,,Wilson_Disease
"may be limited in a broad WD population, with a proportion of patients appearing “asymptomatic”, as the coverage of UWDRS is limited to neurological symptoms/impacts. Scales and endpoints derived from the UWDRS must take into consideration the heterogeneity of the WD population. Specifically, in some patients, there is a lack of neurological symptoms/impacts and there is variability even among those patients with neurological symptoms/impacts. Meaningfully derived scales/scores for the UWDRS will be",22_27,Exploring the Content Validity of the Unified Wilson Disease Rating Scale: Insights from Qualitative Research,4 4 2024,,Wilson_Disease
"derived scales/scores for the UWDRS will be critical for this population and instrument, given the heterogeneity of the population and the range of neurological symptoms/impacts measured. Overall, the data from this study provides evidence for the content validity of Part II of the UWDRS as well as further evidence supporting the conceptual relevance and comprehensibility of select items of Part III of the UWDRS. Specifically, all salient neurological signs/symptoms identified in patient interviews are",22_28,Exploring the Content Validity of the Unified Wilson Disease Rating Scale: Insights from Qualitative Research,4 4 2024,,Wilson_Disease
"identified in patient interviews are represented by one or more of the items in Part II and/or Part III of the UWDRS, suggesting that the UWDRS is comprehensive in its coverage of the neurological aspects of WD. Further, Part II of the UWDRS includes items that are confirmed to be well understood and relevant to patients with WD who have a history of neurological signs/symptoms. As the neurological concepts reported are noted by patients as very bothersome, having a COA like the UWDRS that has strong",22_29,Exploring the Content Validity of the Unified Wilson Disease Rating Scale: Insights from Qualitative Research,4 4 2024,,Wilson_Disease
"having a COA like the UWDRS that has strong conceptual coverage, including for bothersome neurological symptoms, and has items that are relevant and understood by the patients supports its use in the context of a clinical trial to evaluate treatment effect. Importantly, the UWDRS should be used in conjunction with other COAs to provide a comprehensive assessment of the patient experience and scales and endpoints derived from the UWDRS (and other instruments) should take into consideration the heterogeneity",22_30,Exploring the Content Validity of the Unified Wilson Disease Rating Scale: Insights from Qualitative Research,4 4 2024,,Wilson_Disease
should take into consideration the heterogeneity of the population.,22_31,Exploring the Content Validity of the Unified Wilson Disease Rating Scale: Insights from Qualitative Research,4 4 2024,,Wilson_Disease
"Research progress in stem cell therapy for Wilson disease Wilson disease (WD), also known as hepatolenticular degeneration, is an autosomal recessive disorder characterized by disorganized copper metabolism caused by mutations in the <italic toggle=""yes"">ATP7B</italic> gene. Currently, the main treatment options for WD involve medications such as d-penicillamine, trientine hydrochloride, zinc acetate, and liver transplantation. However, there are challenges that encompass issues of poor compliance, adverse",23_0,Research progress in stem cell therapy for Wilson disease,15 3 2024,,Wilson_Disease
"that encompass issues of poor compliance, adverse effects, and limited availability of liver sources that persist. Stem cell therapy for WD is currently a promising area of research. Due to the advancement in stem cell directed differentiation technology in vitro and the availability of sufficient stem cell donors, it is expected to be a potential treatment option for the permanent correction of abnormal copper metabolism. This article discusses the research progress of stem cell therapy for WD from",23_1,Research progress in stem cell therapy for Wilson disease,15 3 2024,,Wilson_Disease
"progress of stem cell therapy for WD from various sources, as well as the challenges and future prospects of the clinical application of stem cell therapy for WD. Wilson disease, also known as hepatolenticular degeneration, is a rare autosomal recessive inherited disease characterized by a primary dysfunction of copper metabolism [<xref rid=""bib1"" ref-type=""bibr"">1</xref>]. The pathogenic gene <italic toggle=""yes"">ATP7B</italic> in WD encodes transmembrane copper-transporting ATPase 2, which is",23_2,Research progress in stem cell therapy for Wilson disease,15 3 2024,,Wilson_Disease
"copper-transporting ATPase 2, which is predominantly expressed in hepatocytes. Mutations in the <italic toggle=""yes"">ATP7B</italic> gene result in functional defects or loss of the enzyme, leading to obstacles in ceruloplasmin synthesis and copper excretion in bile [<xref rid=""bib2"" ref-type=""bibr"">2</xref>]. Copper metabolism disorders can cause excessive deposition of copper in liver cells, leading to necrosis of the cells. After cell lysis, copper ions loosely bind to serum albumin and are deposited in",23_3,Research progress in stem cell therapy for Wilson disease,15 3 2024,,Wilson_Disease
"bind to serum albumin and are deposited in large quantities in various organs through the bloodstream, causing liver damage, neurological and psychiatric symptoms, kidney damage, bone and joint disease, and the observation of Kayser-Fleischer rings in the cornea [<xref rid=""bib3"" ref-type=""bibr"">[3]</xref>, <xref rid=""bib4"" ref-type=""bibr"">[4]</xref>, <xref rid=""bib5"" ref-type=""bibr"">[5]</xref>, <xref rid=""bib6"" ref-type=""bibr"">[6]</xref>]. The estimated worldwide frequency of carriers of the <italic",23_4,Research progress in stem cell therapy for Wilson disease,15 3 2024,,Wilson_Disease
"worldwide frequency of carriers of the <italic toggle=""yes"">ATP7B</italic> mutation gene is approximately 1 in 90 individuals, considering the prevalence of symptomatic diseases ranging from 1:2600–1:30000 [<xref rid=""bib7"" ref-type=""bibr"">7</xref>]. WD is underestimated, according to a statistical report from the UK, the estimated frequency of individuals carrying two pathogenic <italic toggle=""yes"">ATP7B</italic> mutant alleles is approximately 1:7000, with potentially up to 2.5% of the general",23_5,Research progress in stem cell therapy for Wilson disease,15 3 2024,,Wilson_Disease
"with potentially up to 2.5% of the general population with heterozygous mutations [<xref rid=""bib8"" ref-type=""bibr"">8</xref>]. The incidence of WD might be underestimated as a result of the intricate nature of its clinical symptoms and the challenges involved in diagnosing it solely through clinical manifestations and physiological or biochemical tests. This may cause misdiagnosis or failure to identify cases. With growing physician awareness and decreasing costs of whole-exome sequencing, there appears to",23_6,Research progress in stem cell therapy for Wilson disease,15 3 2024,,Wilson_Disease
"costs of whole-exome sequencing, there appears to be an increasing trend in the number of diagnosed cases of WD. The common clinical symptoms of WD are mainly in the following areas. Firstly, liver disease is the first clinical manifestation in 40%–60% of patients with WD, including cirrhosis, chronic hepatitis and acute liver failure. Secondly, among the most prevalent neurological manifestations of WD, tremor, dystonia and parkinsonism are predominant. Thirdly, Kayser-Fleischer rings in the cornea and",23_7,Research progress in stem cell therapy for Wilson disease,15 3 2024,,Wilson_Disease
"Thirdly, Kayser-Fleischer rings in the cornea and sunflower cataracts in the eye are pathological manifestations of copper deposition in the eyes of WD patients. Fourthly, skeletal involvement is also a common manifestation of WD, including osteoporosis, chondrocalcinosis, osteoarthritis, and joint pain. Copper buildup in the synovium and cartilage is widely recognized as the primary factor contributing to arthritis in patients with WD. Finally, WD-induced acute copper toxicity results in Coombs-negative",23_8,Research progress in stem cell therapy for Wilson disease,15 3 2024,,Wilson_Disease
"acute copper toxicity results in Coombs-negative hemolytic anemia with varying degrees of rhabdomyolysis and renal tubular damage. In addition to typical clinical symptoms, low serum ceruloplasmin levels, increased urinary copper levels, and abnormal serum biochemical markers such as aspartate transaminase, alanine transaminase, gamma-glutamyl transpeptidase, and bilirubin can also be used as auxiliary diagnostic indicators for WD. WD patients can be reported at any age, but they are mostly observed in the",23_9,Research progress in stem cell therapy for Wilson disease,15 3 2024,,Wilson_Disease
"at any age, but they are mostly observed in the 5 to 35-year-old range, primarily in children and adolescents. The prevalence is comparable between males and females, and significant variations in symptoms exist among different patients [<xref rid=""bib9"" ref-type=""bibr"">9</xref>]. Once diagnosed, WD patients should receive prompt treatment, with the principle being early treatment, lifelong treatment, and lifelong monitoring [<xref rid=""bib10"" ref-type=""bibr"">10</xref>]. Because the organs involved and the",23_10,Research progress in stem cell therapy for Wilson disease,15 3 2024,,Wilson_Disease
"Because the organs involved and the degree of damage also vary, the main symptoms manifest as liver and neurological damage. Of these, symptoms of liver disease appear earliest, with some infant WD patients had symptoms at the age of two weeks after the end of breastfeeding, and the neurological disease develops relatively late, usually after the age of 15 [<xref rid=""bib11"" ref-type=""bibr"">11</xref>,<xref rid=""bib12"" ref-type=""bibr"">12</xref>]. During the initial stages of WD treatment, primary",23_11,Research progress in stem cell therapy for Wilson disease,15 3 2024,,Wilson_Disease
"the initial stages of WD treatment, primary therapeutic approaches encompass the administration of copper chelating agents (such as d-penicillamine and trientine hydrochloride) and zinc acetate therapy (<xref rid=""tbl1"" ref-type=""table"">Table 1</xref>). The pharmacological treatment principle outlined above revolves around inducing a negative copper balance within the body through the administration of specific drugs, chelating copper in the blood and tissues, and promoting urinary excretion of copper, and",23_12,Research progress in stem cell therapy for Wilson disease,15 3 2024,,Wilson_Disease
"and promoting urinary excretion of copper, and reducing copper intake in the digestive tract [<xref rid=""bib13"" ref-type=""bibr"">13</xref>,<xref rid=""bib14"" ref-type=""bibr"">14</xref>]. Presymptomatic WD patients who are taking their medications as prescribed have similar mortality rates to the general population [<xref rid=""bib15"" ref-type=""bibr"">15</xref>]. Although drug therapy for WD has been effective in some patients, particularly those with hepatic symptoms, there are limitations to current treatment",23_13,Research progress in stem cell therapy for Wilson disease,15 3 2024,,Wilson_Disease
"there are limitations to current treatment methods. Approximately 50% of WD patients still experience neurological symptoms during treatment [<xref rid=""bib16"" ref-type=""bibr"">16</xref>]. About 1/3 of WD patients experience adverse drug reactions, with d-penicillamine being associated with more adverse reactions such as nausea, vomiting, skin rash, fever, and even systemic lupus erythematosus [<xref rid=""bib17"" ref-type=""bibr"">17</xref>,<xref rid=""bib18"" ref-type=""bibr"">18</xref>]. The treatment regimens",23_14,Research progress in stem cell therapy for Wilson disease,15 3 2024,,Wilson_Disease
"The treatment regimens for WD are often complex and cumbersome (3 times daily, 2 h before meals, etc.) with a high number of adverse effects, resulting in poor medication adherence, ultimately leading to a mortality rate for WD patients that is 5–6.1% higher compared to the general population, mainly due to severe liver disease or severe neurological symptoms, with a few patients committing suicide due to disease burden or depression [<xref rid=""bib1"" ref-type=""bibr"">1</xref>,<xref rid=""bib10""",23_15,Research progress in stem cell therapy for Wilson disease,15 3 2024,,Wilson_Disease
"ref-type=""bibr"">1</xref>,<xref rid=""bib10"" ref-type=""bibr"">10</xref>,<xref rid=""bib19"" ref-type=""bibr"">19</xref>]. Hence, it is imperative to expedite the development of novel therapeutic alternatives that can both relieve neurological symptoms, reduce the number of medications taken, improve patient confidence in adhering to treatment, and also restore ATP7B function.<table-wrap position=""float"" id=""tbl1""><label>Table 1</label><caption><p>Clinical symptoms and current corresponding treatment",23_16,Research progress in stem cell therapy for Wilson disease,15 3 2024,,Wilson_Disease
"symptoms and current corresponding treatment strategies.</p></caption><alt-text id=""alttext0025"">Table 1</alt-text><table frame=""hsides"" rules=""groups""><thead><tr><th>Clinical Diseases</th><th>Specific symptoms</th><th>Current treatment strategies</th><th>References</th></tr></thead><tbody><tr><td rowspan=""2"">Hepatopathy</td><td>Cirrhosis, chronic hepatitis</td><td>D-penicillamine, zinc acetate, DMPS, DMSA</td><td>[<xref rid=""bib26"" ref-type=""bibr"">[26]</xref>, <xref rid=""bib27""",23_17,Research progress in stem cell therapy for Wilson disease,15 3 2024,,Wilson_Disease
"ref-type=""bibr"">[26]</xref>, <xref rid=""bib27"" ref-type=""bibr"">[27]</xref>, <xref rid=""bib28"" ref-type=""bibr"">[28]</xref>]</td></tr><tr><td>acute liver failure</td><td>liver transplantation</td><td></td></tr><tr><td>Neuropsychology</td><td>Mild dystonia, Tremor, muscle rigidity, movement disorders, dysarthria, severe dystonia</td><td>DMPS, DMSA (first choice), zinc acetate, D-penicillamine (use cautiously or not)</td><td>[<xref rid=""bib29"" ref-type=""bibr"">[29]</xref>, <xref rid=""bib30""",23_18,Research progress in stem cell therapy for Wilson disease,15 3 2024,,Wilson_Disease
"ref-type=""bibr"">[29]</xref>, <xref rid=""bib30"" ref-type=""bibr"">[30]</xref>, <xref rid=""bib31"" ref-type=""bibr"">[31]</xref>]</td></tr><tr><td>Ophthalmic diseases</td><td>Kayser-Fleischer ring, sunflower cataract</td><td>D-penicillamine, DMPS, DMSA, zinc acetate</td><td>[<xref rid=""bib1"" ref-type=""bibr"">1</xref>]</td></tr><tr><td>Osteoarticular diseases</td><td>Osteoporosis, chondrocalcinosis, osteoarthritis, joint pain</td><td>D-penicillamine, DMPS, DMSA, zinc acetate</td><td>[<xref rid=""bib32""",23_19,Research progress in stem cell therapy for Wilson disease,15 3 2024,,Wilson_Disease
"DMSA, zinc acetate</td><td>[<xref rid=""bib32"" ref-type=""bibr"">32</xref>]</td></tr><tr><td>Other systemic diseases</td><td>Coombs-negative haemolytic anaemia, rhabdomyolysis</td><td>Hemodialysis, plasmapheresis</td><td>[<xref rid=""bib33"" ref-type=""bibr"">33</xref>,<xref rid=""bib34"" ref-type=""bibr"">34</xref>]</td></tr></tbody></table></table-wrap> When WD patients experience late-stage symptoms, such as, acute liver failure or decompensated cirrhosis, liver transplantation (LT) is the only feasible treatment",23_20,Research progress in stem cell therapy for Wilson disease,15 3 2024,,Wilson_Disease
"(LT) is the only feasible treatment option [<xref rid=""bib20"" ref-type=""bibr"">[20]</xref>, <xref rid=""bib21"" ref-type=""bibr"">[21]</xref>, <xref rid=""bib22"" ref-type=""bibr"">[22]</xref>]. Given that WD primarily affects the liver and is characterized by impaired copper metabolism in hepatocytes, liver transplantation can be viewed as a corrective measure for the gene deficiency, effectively restoring copper homeostasis and addressing the phenotypic manifestations of the disease. After LT, biliary copper",23_21,Research progress in stem cell therapy for Wilson disease,15 3 2024,,Wilson_Disease
"of the disease. After LT, biliary copper excretion is restored, neurologic and mental illness stabilize or improve, and Kayser-Fleischer rings gradually disappear [<xref rid=""bib23"" ref-type=""bibr"">[23]</xref>, <xref rid=""bib24"" ref-type=""bibr"">[24]</xref>, <xref rid=""bib25"" ref-type=""bibr"">[25]</xref>]. Nevertheless, LT is not without its inherent limitations, namely the scarcity of liver donors, the heightened frequency of postoperative complications, and the requirement for prolonged administration of",23_22,Research progress in stem cell therapy for Wilson disease,15 3 2024,,Wilson_Disease
"the requirement for prolonged administration of immunosuppressive agents. Additionally, paradoxical neurological deterioration may be seen in transplant recipients, and there is still ongoing debate about whether uncontrolled neurological symptoms alone should be considered a sufficient indication for liver transplantation [<xref rid=""bib20"" ref-type=""bibr"">20</xref>]. Given the ability of transplanted hepatocytes to integrate into the liver parenchyma and reinstate crucial functions, such as facilitating",23_23,Research progress in stem cell therapy for Wilson disease,15 3 2024,,Wilson_Disease
"reinstate crucial functions, such as facilitating copper transfer into bile, it seems that cell-based therapies hold promise as a feasible approach for treating WD [<xref rid=""bib35"" ref-type=""bibr"">35</xref>]. Park et al. conducted intrasplenic injection of healthy hepatocytes into 8-week-old Long-Evans Cinnamon (LEC) rats exhibiting clinical symptoms of WD due to mutant <italic toggle=""yes"">ATP7B</italic> [<xref rid=""bib36"" ref-type=""bibr"">36</xref>]. After 16 weeks post-transplantation, all transplanted",23_24,Research progress in stem cell therapy for Wilson disease,15 3 2024,,Wilson_Disease
"16 weeks post-transplantation, all transplanted rats exhibited restored biliary copper excretion and reduced hepatic copper concentration, causing improved 6-month survival rates in LEC rats. The results were further confirmed by Sauer et al. through repeated transplantation, they found that multiple hepatocyte transplantations led to better outcomes without requiring preconditioning [<xref rid=""bib37"" ref-type=""bibr"">37</xref>]. Based on current data, it is estimated that restoring normal copper",23_25,Research progress in stem cell therapy for Wilson disease,15 3 2024,,Wilson_Disease
"it is estimated that restoring normal copper metabolism requires the transplantation of approximately 40% of healthy hepatocytes. However, the limited supply of primary human hepatocytes (PHHs) poses a barrier, thereby limiting the feasibility of PHHs therapy as a potential treatment option for WD [<xref rid=""bib38"" ref-type=""bibr"">38</xref>]. Stem cells have the advantages of self-renewal and differentiation into various cell types, including hepatocytes. With the ongoing advancement of in vitro-directed",23_26,Research progress in stem cell therapy for Wilson disease,15 3 2024,,Wilson_Disease
"With the ongoing advancement of in vitro-directed induced differentiation techniques, stem cell-derived hepatocytes have the potential to serve as a stable source of cells. Recent scientific research has showcased the immense potential of various types of stem cells in the field of regenerative medicine, such as mesenchymal stem cells (MSCs), induced pluripotent stem cells (iPSCs), embryonic stem cells (ESCs) and other stem cells. Through in vitro induction technology, stem cells can be programmed to",23_27,Research progress in stem cell therapy for Wilson disease,15 3 2024,,Wilson_Disease
"technology, stem cells can be programmed to differentiate into hepatocytes [<xref rid=""bib39"" ref-type=""bibr"">[39]</xref>, <xref rid=""bib40"" ref-type=""bibr"">[40]</xref>, <xref rid=""bib41"" ref-type=""bibr"">[41]</xref>], providing a continuous source of cells for WD patients or obtaining “customized” cells through gene modification technology. Moreover, the use of patient-derived MSCs or iPSCs to circumvent immune rejection reactions [<xref rid=""bib42"" ref-type=""bibr"">42</xref>]. Establishing a large-scale",23_28,Research progress in stem cell therapy for Wilson disease,15 3 2024,,Wilson_Disease
"Establishing a large-scale bank of adult stem cells to screen for high-matching cell lines or using CRISPR-Cas9 technology to artificially construct low-immunogenic pluripotent stem cell lines are also a feasible approach for reducing alloimmune antigenicity [<xref rid=""bib43"" ref-type=""bibr"">43</xref>]. These approaches have brought stem cell therapy a step closer to clinical practice, and numerous research has demonstrated that hepatocytes derived from multiple sources of stem cells can effectively",23_29,Research progress in stem cell therapy for Wilson disease,15 3 2024,,Wilson_Disease
"multiple sources of stem cells can effectively replace damaged hepatocytes and function effectively [<xref rid=""bib44"" ref-type=""bibr"">44</xref>]. Additionally, these treatments utilizing them for WD have been put into practice in both clinical and preclinical settings (<xref rid=""fig1"" ref-type=""fig"">Fig. 1</xref>).<fig id=""fig1""><label>Fig. 1</label><caption><p>Schematic representation of different sources of stem cells for the treatment of WD.</p></caption><alt-text",23_30,Research progress in stem cell therapy for Wilson disease,15 3 2024,,Wilson_Disease
"for the treatment of WD.</p></caption><alt-text id=""alttext0010"">Fig. 1</alt-text><graphic http://www.w3.org/1999/xlink href=""gr1""></graphic></fig> Currently, numerous studies have demonstrated that BMSCs infusion for WD is safe, the low immunogenicity of BMSCs has been fully confirmed, and the therapeutic efficacy of BMSCs or their derivatives has been demonstrated in animal experiments in WD models. However, several obstacles persist, hindering the broad application of BMSCs in clinical therapy for WD.",23_31,Research progress in stem cell therapy for Wilson disease,15 3 2024,,Wilson_Disease
"application of BMSCs in clinical therapy for WD. Firstly, in clinical situations, the symptoms in patients with WD often present initially as liver cirrhosis, at which time structurally compromised MSCs may become trapped in the pulmonary capillary bed or fail to properly home in the cirrhotic liver. Therefore, MSCs transplantation for these patients may be suboptimal. Secondly, infusing cells via the portal vein can potentially cause sinusoidal occlusion and portal hypertension, and many of the cells are",23_32,Research progress in stem cell therapy for Wilson disease,15 3 2024,,Wilson_Disease
"portal hypertension, and many of the cells are deposited in the hepatic sinusoids and only some of the cells enter the liver to function. Thirdly, although MSCs possess the capability to migrate towards the liver and differentiate into hepatocytes, either naturally or through in vitro induction, but the efficiency of generating fully functional hepatocytes from MSCs remains relatively low [<xref rid=""bib88"" ref-type=""bibr"">88</xref>]. Fourthly, although BMSC<sup>ATP7B</sup> increased the expression of",23_33,Research progress in stem cell therapy for Wilson disease,15 3 2024,,Wilson_Disease
"BMSC<sup>ATP7B</sup> increased the expression of <italic toggle=""yes"">ATP7B</italic>, but the safety profile of the lentiviral vector in human subjects remains uncertain. However, the therapeutic effect of MSCs in treating WD may be primarily attributed to their immunomodulatory and paracrine effects rather than the restoration of the hepatic copper metabolism. While validating the potential of iPSCs as a stem cell therapy in animal models of WD, the application of iPSCs in the treatment of WD needs",23_34,Research progress in stem cell therapy for Wilson disease,15 3 2024,,Wilson_Disease
"application of iPSCs in the treatment of WD needs further investigation. One concern is the potential risk of malignant transformation due to the unlimited proliferative capacity and tumorigenicity of iPSCs. Additionally, one of the major drawbacks of iPSCs is their genomic instability, which may confer completely different phenotypes to the cells [<xref rid=""bib89"" ref-type=""bibr"">89</xref>]. In comparison, ESCs represent a naturally occurring and pluripotent stem cell population obtained from embryos,",23_35,Research progress in stem cell therapy for Wilson disease,15 3 2024,,Wilson_Disease
"stem cell population obtained from embryos, thereby avoiding the issue of genomic instability. However, concerns also exist regarding the tumorigenic risk associated with hESCs and the safety of cell products derived from them. Additionally, hESCs are obtained from aborted embryos, which carries ethical considerations, as well as the risk of immunological rejection in allogeneic transplantation. Therefore, further exploration is needed for the clinical application of ESCs in treating WD. In vitro expansion",23_36,Research progress in stem cell therapy for Wilson disease,15 3 2024,,Wilson_Disease
"of ESCs in treating WD. In vitro expansion or genetic correction of patient-derived LPCs into hepatocytes for transfusion back into WD is the preferred option, as there is no immune rejection of autologous LPCs and the efficiency of LPCs induced differentiation into hepatocytes is the highest. However, the acquisition of LPCs increases patient distress and the safety of lentiviral vectors needs to be strictly monitored (<xref rid=""tbl2"" ref-type=""table"">Table 2</xref>).<table-wrap position=""float""",23_37,Research progress in stem cell therapy for Wilson disease,15 3 2024,,Wilson_Disease
"position=""float"" id=""tbl2""><label>Table 2</label><caption><p>Advantages and disadvantages of stem cell therapies for WD from different sources.</p></caption><alt-text id=""alttext0030"">Table 2</alt-text><table frame=""hsides"" rules=""groups""><thead><tr><th>Cell types</th><th>Sources</th><th>Advantages</th><th>Disadvantages</th></tr></thead><tbody><tr><td>MSCs</td><td>Diverse tissue sources</td><td>Widely sourced and easily accessible, Low immunogenicity, Reducing inflammation, promoting the regeneration of",23_38,Research progress in stem cell therapy for Wilson disease,15 3 2024,,Wilson_Disease
"inflammation, promoting the regeneration of impaired liver tissues by secreting trophic factors</td><td>Lower differentiation efficiency, Unclear mechanism of copper excretion</td></tr><tr><td>iPSCs</td><td>Reprogramming human epithelial cells</td><td>Autologous source without immune rejection, No ethical risks, Individualized treatment</td><td>Risk of tumorigenicity, Genome instability, Safety of iPSCs after gene correction is unknown</td></tr><tr><td>ESCs</td><td>Donated blastocysts</td><td>Genome",23_39,Research progress in stem cell therapy for Wilson disease,15 3 2024,,Wilson_Disease
"blastocysts</td><td>Genome stability, Easy establishment of cell lines</td><td>Ethical risks, risk of tumorigenicity, Immunogenicity concerns</td></tr><tr><td>LPCs</td><td>Adult liver</td><td>Low cost, High differentiation efficiency, No immune rejection</td><td>Not easily accessible, Safety of HLCs after gene correction is unknown</td></tr></tbody></table></table-wrap> Takebe et al. demonstrated that when MSCs were co-cultured with hepatocytes and endothelial cells, the three cell types aggregated and",23_40,Research progress in stem cell therapy for Wilson disease,15 3 2024,,Wilson_Disease
"cells, the three cell types aggregated and formed liver organoids. These liver organoids were transplanted into mice through mesenteric transplantation. Within 48 h after transplantation, the organoids established vascular connections with the host and successfully rescued a murine model of drug-induced acute liver failure [<xref rid=""bib90"" ref-type=""bibr"">90</xref>]. Nantasanti et al. extracted autologous LPCs from Commd1-deficient dogs, corrected the genetic defect using lentiviral vectors in vitro, and",23_41,Research progress in stem cell therapy for Wilson disease,15 3 2024,,Wilson_Disease
"defect using lentiviral vectors in vitro, and expanded the cells using organoid culture medium. Subsequently, the organoids were reintroduced into the affected dogs through intrahepatic injection, leading to the long-term engraftment and survival of organoid-derived hepatocytes in the liver for a duration of two years [<xref rid=""bib91"" ref-type=""bibr"">91</xref>]. Organoids have the potential to integrate with the host and replace damaged liver tissue, making them a promising new therapy for treating WD.",23_42,Research progress in stem cell therapy for Wilson disease,15 3 2024,,Wilson_Disease
"them a promising new therapy for treating WD. In conclusion, further investigations are warranted to determine the ideal timing and optimal delivery method for stem cell transplantation in WD patients. Additionally, efforts should be made to enhance the efficiency, maturity, and, most importantly, safety of hepatocyte differentiation. There are currently various induction protocols reported for hepatocytes, the majority of approaches employ recombinant growth factors, including activin A, Wnt3a, hepatocyte",23_43,Research progress in stem cell therapy for Wilson disease,15 3 2024,,Wilson_Disease
"factors, including activin A, Wnt3a, hepatocyte growth factor (HGF), Oncostatin M (OSM), and dexamethasone (DEX). However, the high cost, long culture time of cytokines, and sustained consumption pose the biggest challenges for clinical applications. White et al. achieved the reprogramming of mouse fibroblasts into functional HLCs by employing chemical induction of phenotypic plasticity. To induce the cells to differentiate into hepatic lineage, they employed a continuous stimulation approach within the",23_44,Research progress in stem cell therapy for Wilson disease,15 3 2024,,Wilson_Disease
"a continuous stimulation approach within the culture medium, utilizing small molecule cocktails to enhance the endogenous expression of key transcription factors (<italic toggle=""yes"">Hnf4a, Nr1i2, and Nr1h4</italic>) [<xref rid=""bib92"" ref-type=""bibr"">92</xref>]. Chemically induced hepatocytes (CiHeps) demonstrate comparable activity and functionality to primary hepatocytes, particularly in terms of liver regeneration potential, which has been proven to be beneficial for rescuing liver failure in FRG",23_45,Research progress in stem cell therapy for Wilson disease,15 3 2024,,Wilson_Disease
"be beneficial for rescuing liver failure in FRG mice. The differentiation of human iPSCs into HLCs using small molecules is a more cost-effective strategy, chemical small molecule induction techniques will be a hot topic in the future. In addition, the treatment of WD requires not only the maturation of hepatic cells derived from stem cells but also need the hepatocytes expressed higher levels of <italic toggle=""yes"">ATP7B</italic> to rapidly restore the hepatic copper excretion capability. The optimal",23_46,Research progress in stem cell therapy for Wilson disease,15 3 2024,,Wilson_Disease
"hepatic copper excretion capability. The optimal treatment strategy involves the gene correction of autologous-sourced iPSCs or LPCs, followed by in vitro induction of differentiation into hepatocytes and transplantation back into the patient. Alternatively, a relatively cost-effective treatment approach involves the genetic modification of BMSCs through overexpression of the <italic toggle=""yes"">ATP7B</italic> gene to compensate for the patient's deficiencies. Despite studies demonstrating the effective",23_47,Research progress in stem cell therapy for Wilson disease,15 3 2024,,Wilson_Disease
"Despite studies demonstrating the effective amelioration of liver disease induced by WD in animal models through stem cell-derived hepatocytes, further exploration is needed to determine if other symptoms of WD can be relieved and improved. Although extensive research has showcased the promising potential of stem cell therapy in liver disease treatment, the clinical implementation of this treatment for WD still encounters substantial obstacles. Firstly, the effectiveness of stem cell-derived hepatocytes in",23_48,Research progress in stem cell therapy for Wilson disease,15 3 2024,,Wilson_Disease
"effectiveness of stem cell-derived hepatocytes in replacing damaged liver tissue and restoring hepatic copper excretion in WD remains elusive. Secondly, obtaining highly differentiated and <italic toggle=""yes"">ATP7B</italic>-expressing hepatocytes without additional genetic modifications remains a challenging task, indicating the immediate necessity to develop an integrated strategy combining stem cell therapy and gene therapy. Lastly, before stem cell therapy can be applied in clinical trials, it must",23_49,Research progress in stem cell therapy for Wilson disease,15 3 2024,,Wilson_Disease
"can be applied in clinical trials, it must meet stringent requirements for clinical treatment. These requirements include minimizing allograft rejection, exploring the optimal route, timing, and dosage of cell transplantation, as well as rigorous validation of safety and efficacy. In summary, stem cell therapy shows promise in the treatment of WD and holds the potential to permanently correct copper metabolism abnormalities in affected patients. All authors contributed to the conception and the main idea",23_50,Research progress in stem cell therapy for Wilson disease,15 3 2024,,Wilson_Disease
"contributed to the conception and the main idea of the work. YS supervised the work and provided comments and additional scientific information. All authors read and approved the final manuscript. XX: writing-original draft preparation. CG, XM, AL and XG: writing-review and editing. XX, CG: visualization. All authors have reviewed and consented to the published version of the manuscript. This research work was supported by <funding-source id=""gs1""><institution-wrap><institution-id",23_51,Research progress in stem cell therapy for Wilson disease,15 3 2024,,Wilson_Disease
"id=""gs1""><institution-wrap><institution-id institution-id-type=""doi"">10.13039/501100019091</institution-id><institution>Key Research and Development Program of Hunan Province</institution></institution-wrap></funding-source> (2023SK2069), <funding-source id=""gs2"">Hunan Xiangjiang New District (Changsha High-tech Zone) key core technology research project in 2023</funding-source>, the <funding-source id=""gs3"">Natural Science Foundation of Changsha</funding-source> (kq2208260), <funding-source",23_52,Research progress in stem cell therapy for Wilson disease,15 3 2024,,Wilson_Disease
"(kq2208260), <funding-source id=""gs4""><institution-wrap><institution-id institution-id-type=""doi"">10.13039/501100004735</institution-id><institution>Natural Science Foundation of Hunan Province</institution></institution-wrap></funding-source> (2019JJ40353), and the <funding-source id=""gs5""><institution-wrap><institution-id institution-id-type=""doi"">10.13039/100014717</institution-id><institution>National Natural Science Foundation of China</institution></institution-wrap></funding-source> (81101510). This",23_53,Research progress in stem cell therapy for Wilson disease,15 3 2024,,Wilson_Disease
"(81101510). This is a review article, and no new data were generated or analyzed in this study. Therefore, data sharing does not apply in this article. The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.",23_54,Research progress in stem cell therapy for Wilson disease,15 3 2024,,Wilson_Disease
"Atypical Presentation of Wilson Disease: Unravelling a Clinical and Radiological Complexity in a Rare Case Wilson disease (WD) is an autosomal recessive disorder marked by aberrations in copper metabolism, leading to its accumulation in vital organs such as the liver, brain, cornea, kidneys, and heart. While WD typically presents with hepatic symptoms in early childhood, neuropsychiatric manifestations are more prevalent during adolescence. This case report highlights an extraordinary instance of WD in an",24_0,Atypical Presentation of Wilson Disease: Unravelling a Clinical and Radiological Complexity in a Rare Case,25 2 2024,,Wilson_Disease
"highlights an extraordinary instance of WD in an eight-year-old girl, characterized by intricate clinical and radiological features. The patient exhibited atypical symptoms, emphasizing the importance of recognizing diverse presentations of WD. Delayed diagnosis and treatment initiation can prove fatal in WD cases, underscoring the significance of awareness regarding these unusual clinical and radiological features to facilitate prompt intervention and prevent adverse outcomes. Wilson disease (WD) is a",24_1,Atypical Presentation of Wilson Disease: Unravelling a Clinical and Radiological Complexity in a Rare Case,25 2 2024,,Wilson_Disease
"adverse outcomes. Wilson disease (WD) is a hereditary condition that impacts the body's metabolism of copper. A mutation that causes hepatolenticular degeneration occurs in the ATP7B gene, which facilitates the excretion of copper into bile and supplies copper for the proper synthesis of ceruloplasmin. This blood protein transports copper [<xref rid=""REF1"" ref-type=""bibr"">1</xref>]. The liver is impacted by WD since it is where dietary copper is metabolized. Additionally, excessive amounts of",24_2,Atypical Presentation of Wilson Disease: Unravelling a Clinical and Radiological Complexity in a Rare Case,25 2 2024,,Wilson_Disease
"metabolized. Additionally, excessive amounts of non-ceruloplasmin-bound copper build up in the brain, causing neuropsychiatric symptoms, and in red blood cells, causing hemolytic anaemia to appear, or in the cornea, causing the formation of Kayser-Fleischer (KF) rings. Still, it may also affect organs like kidneys, heart, and bones [<xref rid=""REF2"" ref-type=""bibr"">2</xref>]. Hepatic symptoms typically manifest in early childhood, while neurological problems usually appear in adolescence [<xref rid=""REF3""",24_3,Atypical Presentation of Wilson Disease: Unravelling a Clinical and Radiological Complexity in a Rare Case,25 2 2024,,Wilson_Disease
"usually appear in adolescence [<xref rid=""REF3"" ref-type=""bibr"">3</xref>]. Unrecognized impulsivity, behavioural problems, and subpar scholastic achievement are common neuropsychiatric signs; in children, neurological symptoms such as involuntary movements, speech disturbances, and autonomic dysfunction are seen [<xref rid=""REF4"" ref-type=""bibr"">4</xref>]. Magnetic resonance imaging (MRI) is the most effective method for evaluating neuro-WD, which shows brain stem and basal ganglia grey matter typically",24_4,Atypical Presentation of Wilson Disease: Unravelling a Clinical and Radiological Complexity in a Rare Case,25 2 2024,,Wilson_Disease
"stem and basal ganglia grey matter typically involved due to copper build-up [<xref rid=""REF5"" ref-type=""bibr"">5</xref>]. Here, we report a case of atypical Wilson disease in an eight-year-old girl who showed complexities in clinical presentation and radiological features exhibiting cortical involvement. An eight-year-old girl was brought to our tertiary care hospital in central India, presenting with a one-year history of difficulty in walking, tremors while grasping objects, a slow-paced gait, and",24_5,Atypical Presentation of Wilson Disease: Unravelling a Clinical and Radiological Complexity in a Rare Case,25 2 2024,,Wilson_Disease
"while grasping objects, a slow-paced gait, and frequent episodes of imbalance. A systemic examination revealed a wide-based, high-stepping gait, and swaying towards the left on Romberg's test. Normal tone and deep tendon reflexes were noted during the examination. Baseline blood investigations, including haemoglobin (12.1 gm%), total leucocyte count (7900/cumm), platelets (1.50 lacs/cumm), alanine transaminase (35 mg/dl), and aspartate transaminase (65 mg/dl) levels, were within normal limits. In light of",24_6,Atypical Presentation of Wilson Disease: Unravelling a Clinical and Radiological Complexity in a Rare Case,25 2 2024,,Wilson_Disease
"levels, were within normal limits. In light of the suspected Wilson disease, an ophthalmic assessment was conducted to identify KF rings, although their absence did not preclude the pursuit of further diagnostic measures. Given the heightened clinical suspicion, serum ceruloplasmin levels and 24-hour urinary copper excretion tests were subsequently ordered. MRI of the brain revealed non-enhancing altered signal intensity areas in bilateral cortical and subcortical regions, predominantly in bilateral",24_7,Atypical Presentation of Wilson Disease: Unravelling a Clinical and Radiological Complexity in a Rare Case,25 2 2024,,Wilson_Disease
"subcortical regions, predominantly in bilateral fronto-parietal and temporal lobes, and symmetrical hyperintensities in bilateral basal ganglia, including corpus striatum, putamen, and thalamus (Figures <xref rid=""FIG1"" ref-type=""fig"">1A</xref>, <xref rid=""FIG1"" ref-type=""fig"">1B</xref>). These neuroimaging findings indicated atypical Wilson disease, as it affected the subcortical region and involved the cortical region's grey matter. The patient was initiated on oral zinc supplements (75 mg/day), with",24_8,Atypical Presentation of Wilson Disease: Unravelling a Clinical and Radiological Complexity in a Rare Case,25 2 2024,,Wilson_Disease
"on oral zinc supplements (75 mg/day), with plans to start D-penicillamine pending confirmation of elevated 24-hour urinary copper excretion and lower serum ceruloplasmin levels. After discharge, she returned a week later with complaints of vomiting, severe diffuse headache, persistent tremors, and difficulty in walking. An examination revealed slightly increased tone with exaggerated deep tendon reflexes. Serum ceruloplasmin levels were 8.5 mg/dl, falling below the typical 20-60 mg/dl range. This finding",24_9,Atypical Presentation of Wilson Disease: Unravelling a Clinical and Radiological Complexity in a Rare Case,25 2 2024,,Wilson_Disease
"below the typical 20-60 mg/dl range. This finding aligns with our clinical diagnosis of Wilson's disease. However, the 24-hour urinary copper excretion was measured at 24.3 mcg/24 hours, remaining within the normal range of 3-35 mcg/24 hours. This result deviated from the anticipated pattern, giving an atypical aspect to our diagnostic considerations. The patient was started on a tablet of D-penicillamine (20 mg/kg/day) as Trientine was unavailable. Genome sequencing to detect ATP7B gene mutation was also",24_10,Atypical Presentation of Wilson Disease: Unravelling a Clinical and Radiological Complexity in a Rare Case,25 2 2024,,Wilson_Disease
"sequencing to detect ATP7B gene mutation was also sent because of the inconsistencies of other WD markers. Two weeks later, she presented with worsened headache, vomiting, severe neck pain, irritability, and echolalia. A lumbar puncture was performed to eliminate the possibility of meningitis, revealing normal levels of glucose, protein, and cellularity. Subsequent revaluation of markers for WD demonstrated an average serum ceruloplasmin level of 14.6 mg/dl while the 24-hour urinary copper excretion was",24_11,Atypical Presentation of Wilson Disease: Unravelling a Clinical and Radiological Complexity in a Rare Case,25 2 2024,,Wilson_Disease
"while the 24-hour urinary copper excretion was at 6.90 mcg/24 hours, which persisted remarkably within the normal range for the second consecutive time, even following the administration of the D-penicillamine challenge test. Cervical spine MRI was insignificant, and tab amitriptyline was started for the headache, showing gradual improvement. The patient was then shifted to tab Trientine (20 mg/kg/day), and D-penicillamine was stopped. Genome sequencing conclusively verified a heterozygous compound",24_12,Atypical Presentation of Wilson Disease: Unravelling a Clinical and Radiological Complexity in a Rare Case,25 2 2024,,Wilson_Disease
"conclusively verified a heterozygous compound autosomal recessive inheritance pattern, confirming the diagnosis of atypical Wilson disease. The sequencing identified a variant in Intron 11, specifically c.2730+1G>A, affecting the 5' splice site. Additionally, within Exon 2, a variation denoted as c.728_732inv (p.Phe243_Asn244 delinsTyrTer) was observed. These genetic findings align with the established association of the presented case with Wilson's disease (OMIM#277900). As symptoms improved,",24_13,Atypical Presentation of Wilson Disease: Unravelling a Clinical and Radiological Complexity in a Rare Case,25 2 2024,,Wilson_Disease
"disease (OMIM#277900). As symptoms improved, amitriptyline was stopped, zinc was reduced to 50 mg/day, and the patient was discharged on tab Trientine. Regular follow-ups revealed gradual improvement in neurological symptoms and tone. During one follow-up, the patient's elder brother, asymptomatic for hepatic or neurological issues, was screened. KF rings were absent, but the serum ceruloplasmin level was 10 mg/dl. He was started on D-penicillamine at 20 mg/kg/day and has shown no deterioration while on",24_14,Atypical Presentation of Wilson Disease: Unravelling a Clinical and Radiological Complexity in a Rare Case,25 2 2024,,Wilson_Disease
"mg/kg/day and has shown no deterioration while on treatment. The patient remains compliant with regular follow-ups. The presented case underscores the intricate nature of diagnosing and managing WD, mainly when it manifests with atypical neurological features in pediatric patients. Atypical Wilson disease poses a diagnostic challenge due to its rarity and the variability of clinical presentations. Our patient exhibited a unique combination of symptoms, including difficulty in walking, tremors, imbalance,",24_15,Atypical Presentation of Wilson Disease: Unravelling a Clinical and Radiological Complexity in a Rare Case,25 2 2024,,Wilson_Disease
"difficulty in walking, tremors, imbalance, severe headache and neck pain, and neurological deterioration, which prompted a comprehensive investigation and an interdisciplinary approach to treatment. Neuroimaging played a pivotal role in elucidating the complexities of the case. MRI results unveiled the involvement of not only the subcortical region, as typically observed in WD, but also the cortical region, thus signifying an atypical manifestation. The participation of both the subcortical and cortical",24_16,Atypical Presentation of Wilson Disease: Unravelling a Clinical and Radiological Complexity in a Rare Case,25 2 2024,,Wilson_Disease
"of both the subcortical and cortical areas, as observed in our patient, has been reported in a limited number of cases, highlighting the need for vigilance in recognizing such atypical presentations [<xref rid=""REF6"" ref-type=""bibr"">6</xref>]. In our case, the absence of KF rings during the ophthalmic evaluation was initially perplexing. KF rings, though a hallmark of Wilson disease, may not be present in all cases, particularly in the early stages [<xref rid=""REF7"" ref-type=""bibr"">7</xref>]. A similar",24_17,Atypical Presentation of Wilson Disease: Unravelling a Clinical and Radiological Complexity in a Rare Case,25 2 2024,,Wilson_Disease
"rid=""REF7"" ref-type=""bibr"">7</xref>]. A similar absence of KF rings has been documented in pediatric cases with neurological presentations, reinforcing that their absence should not preclude the consideration of Wilson's disease [<xref rid=""REF8"" ref-type=""bibr"">8</xref>]. Genetic confirmation through genome sequencing played a pivotal role in establishing the diagnosis. Heterozygous compound autosomal recessive inheritance was identified, consolidating the atypical nature of the case. A similar",24_18,Atypical Presentation of Wilson Disease: Unravelling a Clinical and Radiological Complexity in a Rare Case,25 2 2024,,Wilson_Disease
"the atypical nature of the case. A similar confirmation of atypical WD through genetic testing has been reported in the literature, highlighting the significance of molecular diagnostics in refining diagnostic accuracy [<xref rid=""REF9"" ref-type=""bibr"">9</xref>]. Treatment strategies for WD primarily involve copper chelation and dietary modifications. Our patient initially responded positively to oral zinc supplementation, a standard therapeutic approach for the disease. However, the subsequent need for",24_19,Atypical Presentation of Wilson Disease: Unravelling a Clinical and Radiological Complexity in a Rare Case,25 2 2024,,Wilson_Disease
"for the disease. However, the subsequent need for Trientine underscores the importance of individualized treatment regimens and ongoing monitoring [<xref rid=""REF10"" ref-type=""bibr"">10</xref>]. Trientine, a copper-chelating agent, has demonstrated efficacy in neurological presentations of Wilson disease, aligning with its successful use in patients [<xref rid=""REF11"" ref-type=""bibr"">11</xref>]. Our case report contributes to the growing body of evidence on the diversity of clinical and radiological",24_20,Atypical Presentation of Wilson Disease: Unravelling a Clinical and Radiological Complexity in a Rare Case,25 2 2024,,Wilson_Disease
"on the diversity of clinical and radiological presentations in Wilson disease, emphasizing the need for a nuanced approach to diagnosis and management. This case represents the sole documented instance of WD characterized by consistently average values in 24-hour urinary copper excretion, an occurrence observed on two separate occasions. This distinctive presentation renders the case atypical. While the neurological variant of Wilson disease is rare in childhood, its recognition is vital for timely",24_21,Atypical Presentation of Wilson Disease: Unravelling a Clinical and Radiological Complexity in a Rare Case,25 2 2024,,Wilson_Disease
"in childhood, its recognition is vital for timely intervention and improved patient outcomes. Further research and the accumulation of similar case reports will enhance our understanding of the spectrum of WD presentations, guiding clinicians in providing optimal care for affected individuals. In conclusion, this case highlights the significance of identifying atypical neurological presentations of Wilson's disease in pediatric patients. Timely diagnosis, proper treatment, and continuous follow-up are",24_22,Atypical Presentation of Wilson Disease: Unravelling a Clinical and Radiological Complexity in a Rare Case,25 2 2024,,Wilson_Disease
"proper treatment, and continuous follow-up are imperative for effectively addressing the intricacies associated with atypical WD, thereby securing a favourable clinical outcome. The consideration of genetic mutations is warranted, particularly given the emphasized importance; however, the absence of Kayser-Fleischer rings suggests that the type of mutation may alter the presentation, necessitating further detailed examination.",24_23,Atypical Presentation of Wilson Disease: Unravelling a Clinical and Radiological Complexity in a Rare Case,25 2 2024,,Wilson_Disease
"Wilson disease and pregnancy 
<fig position=""float"" id=""GA1""><graphic http://www.w3.org/1999/xlink href=""xcl-23-e0110-g001"" position=""float""></graphic></fig>
 
<fig id=""videoga1"" position=""anchor""><media http://www.w3.org/1999/xlink href=""xcl-23-e0110-s001.mp4"" mimetype=""video"" mime-subtype=""mp4""><object-id pub-id-type=""other"" content-type=""media-stream-id"">1_kq968puk</object-id><object-id pub-id-type=""other"" content-type=""media-source"">Kaltura</object-id></media></fig>
 Full text not available in PMC",25_0,Wilson disease and pregnancy,Jan-Jun 2024,,Wilson_Disease
"Myocardial involvement characteristics by cardiac MR imaging in neurological and non-neurological Wilson disease patients Wilson disease (WD) is a genetic disorder of copper metabolism caused by variants in the ATP7B gene [<xref ref-type=""bibr"" rid=""CR1"">1</xref>, <xref ref-type=""bibr"" rid=""CR2"">2</xref>]. Globally, the prevalence of the disease gene is 1 in every 90 individuals, and the occurrence of the disease ranges from approximately 0.25/10,000 to 4/10,000 [<xref ref-type=""bibr"" rid=""CR3"">3</xref>,",26_0,Myocardial involvement characteristics by cardiac MR imaging in neurological and non-neurological Wilson disease patients,25 1 2024,,Wilson_Disease
"[<xref ref-type=""bibr"" rid=""CR3"">3</xref>, <xref ref-type=""bibr"" rid=""CR4"">4</xref>]. Copper overload mainly occurs in the liver and brain and causes a variety of liver damage and neurological symptoms. Patients can be divided into WD-neuro + (patients with at least one neurological symptom) and WD-neuro − (patients with a primarily hepatic involvement) patients [<xref ref-type=""bibr"" rid=""CR5"">5</xref>, <xref ref-type=""bibr"" rid=""CR6"">6</xref>]. However, several studies have shown that copper deposition",26_1,Myocardial involvement characteristics by cardiac MR imaging in neurological and non-neurological Wilson disease patients,25 1 2024,,Wilson_Disease
"several studies have shown that copper deposition can also occur in the heart and lead to clinical symptoms of related cardiovascular disease (e.g. arrhythmias, atrial fibrillation, heart failure, etc.) [<xref ref-type=""bibr"" rid=""CR6"">6</xref>–<xref ref-type=""bibr"" rid=""CR13"">13</xref>]. Therefore, early detection of myocardial involvement is important even in asymptomatic WD patients. Electrocardiogram and echocardiography are the most commonly used cardiac examination to evaluate WD [<xref",26_2,Myocardial involvement characteristics by cardiac MR imaging in neurological and non-neurological Wilson disease patients,25 1 2024,,Wilson_Disease
"used cardiac examination to evaluate WD [<xref ref-type=""bibr"" rid=""CR14"">14</xref>–<xref ref-type=""bibr"" rid=""CR17"">17</xref>]. However, their ability to detect alteration in myocardial microstructure and function is limited, and the absence of distinctive characteristics poses a challenge in recognizing myocardial damage caused by WD. [<xref ref-type=""bibr"" rid=""CR13"">13</xref>, <xref ref-type=""bibr"" rid=""CR18"">18</xref>]. Endomyocardial biopsy is the gold standard for the diagnosis of many primary and",26_3,Myocardial involvement characteristics by cardiac MR imaging in neurological and non-neurological Wilson disease patients,25 1 2024,,Wilson_Disease
"standard for the diagnosis of many primary and secondary cardiac conditions [<xref ref-type=""bibr"" rid=""CR19"">19</xref>]. Unfortunately, it is difficult to be widely carried out in clinical work because it is an invasive method and has the risk of complications. Cardiac magnetic resonance (CMR) imaging has become a non-invasive and reliable tool for detecting and diagnosing myocardial involvement in a variety of diseases [<xref ref-type=""bibr"" rid=""CR20"">20</xref>, <xref ref-type=""bibr""",26_4,Myocardial involvement characteristics by cardiac MR imaging in neurological and non-neurological Wilson disease patients,25 1 2024,,Wilson_Disease
"rid=""CR20"">20</xref>, <xref ref-type=""bibr"" rid=""CR21"">21</xref>]. CMR provides comprehensive evaluation of cardiac morphology, function, and myocardial fibrosis by CMR-T1 mapping, T2 mapping, and late gadolinium enhancement (LGE) [<xref ref-type=""bibr"" rid=""CR7"">7</xref>, <xref ref-type=""bibr"" rid=""CR22"">22</xref>, <xref ref-type=""bibr"" rid=""CR23"">23</xref>]. Previous study [<xref ref-type=""bibr"" rid=""CR6"">6</xref>] had shown that in German cohorts, WD-neuro + patients exhibit more adverse cardiac",26_5,Myocardial involvement characteristics by cardiac MR imaging in neurological and non-neurological Wilson disease patients,25 1 2024,,Wilson_Disease
"WD-neuro + patients exhibit more adverse cardiac remodeling and dysfunction compared to WD-neuro − patients. However, the characteristics of myocardial involvement in WD patients among Asian populations remain unclear. We aimed (1) to evaluate the segmental involvement characteristics of myocardium in WD patients using CMR and (2) to compare the differences between WD-neuro + and WD-neuro − patients.   To date, this study is the largest Asian population prospective clinical and imaging study evaluating a",26_6,Myocardial involvement characteristics by cardiac MR imaging in neurological and non-neurological Wilson disease patients,25 1 2024,,Wilson_Disease
"clinical and imaging study evaluating a cardiac manifestation of patients suffering from WD. This study suggested the clinical application value of CMR imaging by detecting the characteristics of myocardial involvement in WD patients. The key findings of this study included: (1) native T1 and T2 and ECV values increased in WD patients without significant left ventricular dysfunction; (2) WD-neuro + patients presented with more severe myocardial damage compared to WD-neuro − patients. In our study, most of",26_7,Myocardial involvement characteristics by cardiac MR imaging in neurological and non-neurological Wilson disease patients,25 1 2024,,Wilson_Disease
"to WD-neuro − patients. In our study, most of the WD patients had no obvious clinical symptoms, and the ventricular ejection fractions were preserved. Nevertheless, in clinical context, myocardial injury in patients with WD was suspected based on electrocardiogram findings or self-reported symptoms like chest tightness, chest pain, and palpitations. Hence, the significance in utilizing CMR tissue characterization imaging to accurately detect myocardial involvement and understand its specific",26_8,Myocardial involvement characteristics by cardiac MR imaging in neurological and non-neurological Wilson disease patients,25 1 2024,,Wilson_Disease
"involvement and understand its specific characteristics. Previous studies have demonstrated that native T1 can reflect myocardial edema, necrosis, and fibrosis [<xref ref-type=""bibr"" rid=""CR29"">29</xref>, <xref ref-type=""bibr"" rid=""CR30"">30</xref>]. ECV can further detect the degree of myocardial interstitial fibrosis [<xref ref-type=""bibr"" rid=""CR22"">22</xref>, <xref ref-type=""bibr"" rid=""CR31"">31</xref>, <xref ref-type=""bibr"" rid=""CR32"">32</xref>]. Both can be used to quantitatively evaluate diffuse",26_9,Myocardial involvement characteristics by cardiac MR imaging in neurological and non-neurological Wilson disease patients,25 1 2024,,Wilson_Disease
"can be used to quantitatively evaluate diffuse fibrosis [<xref ref-type=""bibr"" rid=""CR29"">29</xref>]. In our study, compared with the controls, the values of native T1 and ECV in WD patients were significantly increased, which was consistent with the studies of Salatzki et al. [<xref ref-type=""bibr"" rid=""CR6"">6</xref>] and Deng et al. [<xref ref-type=""bibr"" rid=""CR7"">7</xref>] In myocardial segmental analysis, 42.1% of native T1 values and 66.5% of ECV values were prolonged. Therefore, we believe that",26_10,Myocardial involvement characteristics by cardiac MR imaging in neurological and non-neurological Wilson disease patients,25 1 2024,,Wilson_Disease
"values were prolonged. Therefore, we believe that myocardial diffuse fibrosis is one of the characteristics of myocardial damage in WD patients. Moreover, Factor et al. [<xref ref-type=""bibr"" rid=""CR12"">12</xref>] found myocardial fibrosis in autopsies of young WD patients, which further verified the rationality of our conclusion. In addition, we also observed that the T2 value of WD patients was significantly increased compared with the controls, and 59.5% of T2 values were prolonged in myocardial",26_11,Myocardial involvement characteristics by cardiac MR imaging in neurological and non-neurological Wilson disease patients,25 1 2024,,Wilson_Disease
"59.5% of T2 values were prolonged in myocardial segmental analysis. Elevated transverse relaxation time (T2) is specific for increased myocardial water content, increased free water, and is used as an index of myocardial edema [<xref ref-type=""bibr"" rid=""CR33"">33</xref>]. Therefore, we infer that potential myocardial edema may also be one of the characteristics of myocardial damage in patients with WD. However, Salatzki et al. [<xref ref-type=""bibr"" rid=""CR6"">6</xref>] did not reveal a noteworthy",26_12,Myocardial involvement characteristics by cardiac MR imaging in neurological and non-neurological Wilson disease patients,25 1 2024,,Wilson_Disease
"rid=""CR6"">6</xref>] did not reveal a noteworthy distinction in T2 values between the WD group and control group. This finding could potentially be attributed to variations in factors such as a smaller number of short-axis slices or differences in ethnicity and sample size. In our study, there was a significant difference in ECV between the WD-neuro + group and WD-neuro − group, and the same results also were found in myocardial segmental analysis (Figs. <xref rid=""Fig4"" ref-type=""fig"">4</xref> and <xref",26_13,Myocardial involvement characteristics by cardiac MR imaging in neurological and non-neurological Wilson disease patients,25 1 2024,,Wilson_Disease
"rid=""Fig4"" ref-type=""fig"">4</xref> and <xref rid=""Fig5"" ref-type=""fig"">5</xref>). To our knowledge, this is the first report delineating variations in myocardial involvement between WD-neuro + and WD-neuro − patients in Asia. These findings align with prior work by Salatzki et al. [<xref ref-type=""bibr"" rid=""CR6"">6</xref>]. The more severe myocardial damage observed in WD-neuro + patients compared to WD-neuro − patients can be attributed to the longer duration of copper overload in those with neurological",26_14,Myocardial involvement characteristics by cardiac MR imaging in neurological and non-neurological Wilson disease patients,25 1 2024,,Wilson_Disease
"of copper overload in those with neurological manifestations. WD-neuro + patients are considered to be at a more advanced disease stage, as the emergence of neurological symptoms typically occurs later in the disease course [<xref ref-type=""bibr"" rid=""CR34"">34</xref>, <xref ref-type=""bibr"" rid=""CR35"">35</xref>]. The subtle initial signs of WD often delay clinical diagnosis and treatment. Consequently, by the time neurological symptoms appear, WD-neuro + patients have likely been exposed to elevated copper",26_15,Myocardial involvement characteristics by cardiac MR imaging in neurological and non-neurological Wilson disease patients,25 1 2024,,Wilson_Disease
"have likely been exposed to elevated copper levels for an extended period compared to WD-neuro − patients. The prolonged copper overload supports the direct cardiotoxic effects of copper on myocardial tissues in WD, though the specific mechanisms require further investigation.<fig id=""Fig4""><label>Fig. 4</label><caption><p>Bull’s eye plots comparing the global native T1 and the ECV values of WD-neuro + and WD-neuro − group. Segmentation was performed according to the AHA 16-segment model in three",26_16,Myocardial involvement characteristics by cardiac MR imaging in neurological and non-neurological Wilson disease patients,25 1 2024,,Wilson_Disease
"according to the AHA 16-segment model in three short-axis slices. The native T1 and ECV values of more than the cut-off 1090 ms and 29% are shown with red color. AHA American Heart Association, ECV extracellular volume</p></caption><graphic http://www.w3.org/1999/xlink href=""13244_2023_1583_Fig4_HTML"" id=""MO5""></graphic></fig><fig id=""Fig5""><label>Fig. 5</label><caption><p>A 31-year-old male neurological WD patient showed late gadolinium enhancement in the septal and RVIP regions indicated by the white",26_17,Myocardial involvement characteristics by cardiac MR imaging in neurological and non-neurological Wilson disease patients,25 1 2024,,Wilson_Disease
"septal and RVIP regions indicated by the white arrow (<bold>a</bold>), increased T1 value (1100.2 ms) (<bold>b</bold>), and elevated ECV value (31.8%) (<bold>c</bold>). A 25-year-old female non-neurological WD patient showed late gadolinium enhancement in the RVIP indicated by the white arrow (<bold>d</bold>), increased T1 value (1082.7 ms) (<bold>e</bold>), and elevated ECV value (30.3%) (<bold>f</bold>)</p></caption><graphic http://www.w3.org/1999/xlink href=""13244_2023_1583_Fig5_HTML""",26_18,Myocardial involvement characteristics by cardiac MR imaging in neurological and non-neurological Wilson disease patients,25 1 2024,,Wilson_Disease
"href=""13244_2023_1583_Fig5_HTML"" id=""MO6""></graphic></fig> LGE-MRI is the reference standard for the detection of myocardial fibrosis and has been shown to have excellent sensitivity and specificity in the detection of myocardial scar tissue [<xref ref-type=""bibr"" rid=""CR36"">36</xref>, <xref ref-type=""bibr"" rid=""CR37"">37</xref>]. Previous studies have shown that myocardial LGE is associated with prognosis and the incidence of adverse events [<xref ref-type=""bibr"" rid=""CR38"">38</xref>, <xref ref-type=""bibr""",26_19,Myocardial involvement characteristics by cardiac MR imaging in neurological and non-neurological Wilson disease patients,25 1 2024,,Wilson_Disease
"rid=""CR38"">38</xref>, <xref ref-type=""bibr"" rid=""CR39"">39</xref>]. In our study, 78% (32/41) of the patients showed positive LGE. The location of LGE mainly appeared in RVIP (15/41) and interventricular septum (9/41) and a few appeared in the inferior wall (3/41) and inferolateral wall (5/41). The LGE pattern and incidence of WD patients found in our study were similar to the study of Salatzki et al. [<xref ref-type=""bibr"" rid=""CR6"">6</xref>], but the presence of LGE in RVIP was much lower than that in the",26_20,Myocardial involvement characteristics by cardiac MR imaging in neurological and non-neurological Wilson disease patients,25 1 2024,,Wilson_Disease
"of LGE in RVIP was much lower than that in the study by Quick et al. [<xref ref-type=""bibr"" rid=""CR13"">13</xref>] (15/41 vs. 58/61). This difference could be clarified by noting that, in contrast to Quick’s study, the participants in our study were younger (28 years vs. 44 years) and experienced a shorter duration of copper exposure, potentially resulting in mild cardiac damage. In addition, a recent case report illustrating sudden cardiac death associated with LGE in a patients with Wilson disease",26_21,Myocardial involvement characteristics by cardiac MR imaging in neurological and non-neurological Wilson disease patients,25 1 2024,,Wilson_Disease
"with LGE in a patients with Wilson disease underscores the significance of fibrosis as a potential significant indicator of WD [<xref ref-type=""bibr"" rid=""CR40"">40</xref>]. Interestingly, there was no significant difference between LGE negative group and LGE positive group in native T1 and ECV values. This lack of discrepancy can be attributed to fundamental disparities between LGE and quantitative mapping techniques. LGE accentuates focal myocardial fibrosis based on regional differences in gadolinium",26_22,Myocardial involvement characteristics by cardiac MR imaging in neurological and non-neurological Wilson disease patients,25 1 2024,,Wilson_Disease
"based on regional differences in gadolinium uptake, yet its utility in detecting diffuse interstitial expansion is restricted. Conversely, native T1 and ECV relaxation times and ECV delineate global myocardial fibrosis burden irrespective of regional involvement [<xref ref-type=""bibr"" rid=""CR29"">29</xref>, <xref ref-type=""bibr"" rid=""CR41"">41</xref>]. Consequently, diffuse extracellular matrix expansion in LGE-negative segments may yield native T1 and ECV measures comparable to those obtained in",26_23,Myocardial involvement characteristics by cardiac MR imaging in neurological and non-neurological Wilson disease patients,25 1 2024,,Wilson_Disease
"and ECV measures comparable to those obtained in LGE-positive regions exhibiting concomitant focal scarring. In our study, no significant difference was observed in 2D LV-Strain (GRS, GCS, GLS) between the WD and control groups, which was inconsistent with previous studies [<xref ref-type=""bibr"" rid=""CR6"">6</xref>, <xref ref-type=""bibr"" rid=""CR8"">8</xref>]. In the studies of Salatzki et al. [<xref ref-type=""bibr"" rid=""CR6"">6</xref>] and Zhang et al. [<xref ref-type=""bibr"" rid=""CR8"">8</xref>], LV-GRS and",26_24,Myocardial involvement characteristics by cardiac MR imaging in neurological and non-neurological Wilson disease patients,25 1 2024,,Wilson_Disease
"ref-type=""bibr"" rid=""CR8"">8</xref>], LV-GRS and LV-GCS in WD patients were significantly lower than those in controls. This difference may be due to the younger patients in our study and the shorter duration of copper exposure. The UWDRS score was positively correlated with ECV values in this study. The same findings were found in the study of Salatzki et al. [<xref ref-type=""bibr"" rid=""CR6"">6</xref>]. It showed that the severity of neurological symptoms is related to the degree of myocardial fibrosis. But",26_25,Myocardial involvement characteristics by cardiac MR imaging in neurological and non-neurological Wilson disease patients,25 1 2024,,Wilson_Disease
"related to the degree of myocardial fibrosis. But we did not find a correlation between the UWDRS score and cardiac function or other CMR tissue characteristic parameters. Therefore, whether the UWDRS score is related to the degree of cardiac involvement needs to be verified in a larger cohort and pathological examination. The findings of this study have significant clinical implications for the management of WD. CMR enabled early detection of myocardial involvement in WD patients, even in those with",26_26,Myocardial involvement characteristics by cardiac MR imaging in neurological and non-neurological Wilson disease patients,25 1 2024,,Wilson_Disease
"involvement in WD patients, even in those with normal cardiac function and subtle or absent clinical symptoms. This early identification is profoundly clinically relevant as it permits risk stratification and identification of patients at higher risk of cardiac complications. Moreover, the differences in myocardial involvement between WD patients with and without neurological symptoms highlights the heterogeneity of the disease. CMR could facilitate personalized treatment by revealing the extent of",26_27,Myocardial involvement characteristics by cardiac MR imaging in neurological and non-neurological Wilson disease patients,25 1 2024,,Wilson_Disease
"personalized treatment by revealing the extent of myocardial damage in individual patients. Additionally, longitudinal CMR follow-up allows dynamic monitoring of cardiovascular disease progression, informing treatment adjustments and evaluating therapeutic efficacy. While providing valuable insights, this study underscores the need for further research on cardiac involvement in WD. Future investigations should aim to validate these findings in larger cohorts, explore the potential of CMR-guided",26_28,Myocardial involvement characteristics by cardiac MR imaging in neurological and non-neurological Wilson disease patients,25 1 2024,,Wilson_Disease
"cohorts, explore the potential of CMR-guided interventions, and elucidate the mechanisms underlying copper-induced myocardial damage. In conclusion, CMR can detect myocardial injury in WD patients prior to the onset of cardiac functional impairments. Additionally, the nature of myocardial involvement exhibited distinction between WD-neuro + patients and WD-neuro − patients. Myocardial engagement is more pronounced in WD-neuro + patients.",26_29,Myocardial involvement characteristics by cardiac MR imaging in neurological and non-neurological Wilson disease patients,25 1 2024,,Wilson_Disease
"Could Urinary Copper/Zinc Ratio Be a Newer Tool to Replace 24-Hour Urinary Copper Excretion for Diagnosing Wilson Disease in Children? Wilson disease (WD) is a rare autosomal recessive disease that affects approximately one in every 30,000 live births, with a higher prevalence in countries where consanguineous marriages are common [<xref rid=""B1"" ref-type=""bibr"">1</xref>]. In WD, a mutation in the <italic toggle=""yes"">ATP7B</italic> gene leads to reduced ceruloplasmin formation and the excessive",27_0,Could Urinary Copper/Zinc Ratio Be a Newer Tool to Replace 24-Hour Urinary Copper Excretion for Diagnosing Wilson Disease in Children?,1 2024,,Wilson_Disease
"reduced ceruloplasmin formation and the excessive accumulation of copper in various organs, primarily affecting the liver, followed by the brain, cornea, and other organs. Copper accumulation typically occurs over an extended period after birth, with symptoms manifesting subsequently [<xref rid=""B2"" ref-type=""bibr"">2</xref><xref rid=""B3"" ref-type=""bibr"">3</xref>]. The prognosis for WD depends on early diagnosis and the prompt initiation of treatment. Remarkable hepatic damage occurs after the first decade,",27_1,Could Urinary Copper/Zinc Ratio Be a Newer Tool to Replace 24-Hour Urinary Copper Excretion for Diagnosing Wilson Disease in Children?,1 2024,,Wilson_Disease
"hepatic damage occurs after the first decade, and neurological symptoms typically emerge after adolescence. Timely diagnosis, especially before the age of 10, can prevent significant organ damage through appropriate therapy [<xref rid=""B4"" ref-type=""bibr"">4</xref><xref rid=""B5"" ref-type=""bibr"">5</xref><xref rid=""B6"" ref-type=""bibr"">6</xref>]. Early intervention allows patients to enjoy an uneventful life like a healthy individual. The diagnosis of WD in children poses a challenge due to the absence of a",27_2,Could Urinary Copper/Zinc Ratio Be a Newer Tool to Replace 24-Hour Urinary Copper Excretion for Diagnosing Wilson Disease in Children?,1 2024,,Wilson_Disease
"poses a challenge due to the absence of a singular diagnostic test, aside from molecular genetic testing, which can definitively confirm or exclude WD. The advancement of molecular diagnostic techniques has significantly changed the natural course of WD, enabling precise diagnoses for both affected individuals and those with heterozygous genes through mutation analysis. However, molecular genetic testing is an expensive and time-consuming procedure that has limited accessibility, particularly in",27_3,Could Urinary Copper/Zinc Ratio Be a Newer Tool to Replace 24-Hour Urinary Copper Excretion for Diagnosing Wilson Disease in Children?,1 2024,,Wilson_Disease
"that has limited accessibility, particularly in resource-constrained countries. Additionally, there are over 600 mutations and polymorphisms associated with the <italic toggle=""yes"">ATP7B</italic> gene in WD, adding to the difficulty of the analysis. Alternatively, hepatic copper evaluation holds significant value as a diagnostic method for WD. Nonetheless, its invasive nature of sampling, potential for false-negative results, and inhomogeneous liver copper distribution preclude its effectiveness [<xref",27_4,Could Urinary Copper/Zinc Ratio Be a Newer Tool to Replace 24-Hour Urinary Copper Excretion for Diagnosing Wilson Disease in Children?,1 2024,,Wilson_Disease
"distribution preclude its effectiveness [<xref rid=""B7"" ref-type=""bibr"">7</xref>]. Although a combination of clinical features and laboratory parameters, such as Kayser-Fleischer (KF) rings, low serum ceruloplasmin concentrations, and increased urinary copper excretion, is commonly used to establish a diagnosis, none of these are pathognomonic for WD. KF rings, for instance, may not always be present in WD and can also occur in other chronic liver diseases (CLDs) [<xref rid=""B7""",27_5,Could Urinary Copper/Zinc Ratio Be a Newer Tool to Replace 24-Hour Urinary Copper Excretion for Diagnosing Wilson Disease in Children?,1 2024,,Wilson_Disease
"chronic liver diseases (CLDs) [<xref rid=""B7"" ref-type=""bibr"">7</xref><xref rid=""B8"" ref-type=""bibr"">8</xref>]. Similarly, serum ceruloplasmin concentrations may appear normal in WD, while low concentrations can be observed in conditions such as protein-energy malnutrition, protein-losing enteropathy, or severely impaired hepatic function [<xref rid=""B4"" ref-type=""bibr"">4</xref><xref rid=""B9"" ref-type=""bibr"">9</xref>]. Among the diagnostic tests available, the 24-hour urinary copper (Cu) level is the",27_6,Could Urinary Copper/Zinc Ratio Be a Newer Tool to Replace 24-Hour Urinary Copper Excretion for Diagnosing Wilson Disease in Children?,1 2024,,Wilson_Disease
"the 24-hour urinary copper (Cu) level is the simplest and most sensitive. This test reflects the amount of non-ceruloplasmin-bound Cu in circulation [<xref rid=""B10"" ref-type=""bibr"">10</xref><xref rid=""B11"" ref-type=""bibr"">11</xref>]. However, it requires precisely timed urinary sample collection, posing a practical challenge, especially in young children who may experience difficulties in providing complete and accurately timed urine samples. This may result in an inaccurate estimation of 24-hours urinary",27_7,Could Urinary Copper/Zinc Ratio Be a Newer Tool to Replace 24-Hour Urinary Copper Excretion for Diagnosing Wilson Disease in Children?,1 2024,,Wilson_Disease
"in an inaccurate estimation of 24-hours urinary Cu excretion. Furthermore, the extended collection process introduces the risk of unexpected contaminations, and preserving a 24-hours urine sample can be challenging, particularly in hot weather. Early diagnosis and treatment are the key determinants of prognosis; thus, it is important to develop a rapid, reliable, noninvasive, and discriminative diagnostic tool for WD. Herein, we investigated the copper/zinc (Cu/Zn) ratio as a potential alternative to the",27_8,Could Urinary Copper/Zinc Ratio Be a Newer Tool to Replace 24-Hour Urinary Copper Excretion for Diagnosing Wilson Disease in Children?,1 2024,,Wilson_Disease
"(Cu/Zn) ratio as a potential alternative to the 24-hours urinary Cu excretion tool. Zinc was selected for this study because, like copper, zinc is a trace element, and both can be simultaneously detected using the same instrument [<xref rid=""B12"" ref-type=""bibr"">12</xref><xref rid=""B13"" ref-type=""bibr"">13</xref>]. In WD, there is an increase in copper accumulation in the liver, and urinary zinc excretion is highly correlated with hepatic copper concentration. Notably, we did not include iron despite being",27_9,Could Urinary Copper/Zinc Ratio Be a Newer Tool to Replace 24-Hour Urinary Copper Excretion for Diagnosing Wilson Disease in Children?,1 2024,,Wilson_Disease
"Notably, we did not include iron despite being a trace element, as its urinary excretion does not correlate with hepatic copper concentration [<xref rid=""B14"" ref-type=""bibr"">14</xref>]. Moreover, the Cu/Zn ratio has a positive association with hepatic copper concentration [<xref rid=""B14"" ref-type=""bibr"">14</xref>]. A previous study identified the urinary Cu/Zn ratio as a viable alternative to 24-hours urinary Cu excretion after penicillamine challenge in diagnosing WD [<xref rid=""B15""",27_10,Could Urinary Copper/Zinc Ratio Be a Newer Tool to Replace 24-Hour Urinary Copper Excretion for Diagnosing Wilson Disease in Children?,1 2024,,Wilson_Disease
"challenge in diagnosing WD [<xref rid=""B15"" ref-type=""bibr"">15</xref>]. Give the challenges associated with 24-hours urine collection in the pediatric population, our research used spot samples for both copper and zinc. The rationale for selecting copper and zinc is due to their properties of low diurnal variation for copper and intermediate variation for zinc [<xref rid=""B16"" ref-type=""bibr"">16</xref>]. Moreover, this approach is rapid, cost-effective, noninvasive, and straightforward, making it",27_11,Could Urinary Copper/Zinc Ratio Be a Newer Tool to Replace 24-Hour Urinary Copper Excretion for Diagnosing Wilson Disease in Children?,1 2024,,Wilson_Disease
"noninvasive, and straightforward, making it particularly suitable for countries with limited research resources. This cross-sectional study was conducted between June 2019 and May 2021 at the Paediatric Gastroenterology and Nutrition Department of Bangabandhu Sheikh Mujib Medical University (BSMMU), Dhaka, Bangladesh, a tertiary-care hospital. The study protocol received approval from the local Ethics Committee at BSMMU (approval no. 12235). Informed written consent was obtained from each patient or their",27_12,Could Urinary Copper/Zinc Ratio Be a Newer Tool to Replace 24-Hour Urinary Copper Excretion for Diagnosing Wilson Disease in Children?,1 2024,,Wilson_Disease
"consent was obtained from each patient or their parents prior to participating in this study, and a guarantee of data privacy was provided. Additionally, parents and, where appropriate, the participants, were pre-trained for the accurate collection of urinary samples. Exclusion criteria encompassed individuals with abnormal renal functions, those who had undergone zinc therapy for any reason within 1 month of hospitalization, and those who did not adhere to the 24-hours urine collection instructions. No",27_13,Could Urinary Copper/Zinc Ratio Be a Newer Tool to Replace 24-Hour Urinary Copper Excretion for Diagnosing Wilson Disease in Children?,1 2024,,Wilson_Disease
"to the 24-hours urine collection instructions. No special dietary requirements were needed for the study purposes. None of the participants were using copper containers in their daily lives. A total of 67 patients (ages 3–18 years) were enrolled in the study. Among them, 27 were diagnosed with WD and 40 with non-Wilsonian liver disease (non-WD), all of whom were hospitalized for liver-related conditions between June 2019 and May 2021. The diagnosis of WD was established with a score ≥4 according to the",27_14,Could Urinary Copper/Zinc Ratio Be a Newer Tool to Replace 24-Hour Urinary Copper Excretion for Diagnosing Wilson Disease in Children?,1 2024,,Wilson_Disease
"was established with a score ≥4 according to the modified Leipzig score in children above 3 years of age [<xref rid=""B17"" ref-type=""bibr"">17</xref>]. The scoring system considered the following criteria: In addition to CLD, acute viral hepatitis was included as a control. Studies have indicated that both acute and chronic viral hepatitis can lead to an increase in urine copper excretion [<xref rid=""B18"" ref-type=""bibr"">18</xref><xref rid=""B19"" ref-type=""bibr"">19</xref>]. The justification for using acute",27_15,Could Urinary Copper/Zinc Ratio Be a Newer Tool to Replace 24-Hour Urinary Copper Excretion for Diagnosing Wilson Disease in Children?,1 2024,,Wilson_Disease
"The justification for using acute viral hepatitis as a control lies in the observed rise in urine copper excretion associated with this condition. The study encompassed 67 children, aged 3–18 years, of whom 27 were confirmed to have WD (score ≥4 according to modified Leipzig criteria) and 40 were classified as non-WD. The non-WD group comprised of 21 cases of acute hepatitis and 19 cases of CLDs. In the acute hepatitis subgroup, 16 patients tested positive for the hepatitis A virus, three were positive for",27_16,Could Urinary Copper/Zinc Ratio Be a Newer Tool to Replace 24-Hour Urinary Copper Excretion for Diagnosing Wilson Disease in Children?,1 2024,,Wilson_Disease
"the hepatitis A virus, three were positive for both the hepatitis A and E viruses, and the remaining two cases had non-A, non-B hepatitis. CLDs within the non-WD group encompassed various conditions, including cryptogenic CLD (n=13), autoimmune hepatitis (n=2), chronic hepatitis B virus (HBV) infection (n=1), caroli disease (n=1), and glycogen storage disease (n=2). The demographic features, laboratory findings, including serum ceruloplasmin levels, and ophthalmological features are presented in <xref",27_17,Could Urinary Copper/Zinc Ratio Be a Newer Tool to Replace 24-Hour Urinary Copper Excretion for Diagnosing Wilson Disease in Children?,1 2024,,Wilson_Disease
"ophthalmological features are presented in <xref rid=""T1"" ref-type=""table"">Table 1</xref>. Of the 67 patients, 27 were diagnosed with WD with a mean age of 9.24±3.19 years, while 40 were identified as non-WD patients with a mean age of 9.2±3.12 years. There was no significant differences in demographic characteristics between WD patients and those without WD, except for a more common occurrence of positive family history in WD patients (<italic toggle=""yes"">p</italic>=0.007). Alanine aminotransferase (ALT)",27_18,Could Urinary Copper/Zinc Ratio Be a Newer Tool to Replace 24-Hour Urinary Copper Excretion for Diagnosing Wilson Disease in Children?,1 2024,,Wilson_Disease
"Alanine aminotransferase (ALT) was observed to be higher in non-WD patients compared to WD patients (<italic toggle=""yes"">p</italic>=0.046). This difference could be attributed to the higher incidence of acute hepatitis cases in the control group (non-WD group). In this study, ALT levels exceeding ten times the normal value (>400 U/L) were considered high ALT. Serum ceruloplasmin levels were significantly lower in the WD group compared to the non-WD group (<italic toggle=""yes"">p</italic><0.001), and",27_19,Could Urinary Copper/Zinc Ratio Be a Newer Tool to Replace 24-Hour Urinary Copper Excretion for Diagnosing Wilson Disease in Children?,1 2024,,Wilson_Disease
"(<italic toggle=""yes"">p</italic><0.001), and Coombs’ negative hemolytic anemia was significantly more prevalent in the WD group (<italic toggle=""yes"">p</italic><0.001). There were also significant differences in the positivity of KF rings and in the presence of coagulopathy (<italic toggle=""yes"">p</italic><0.001). A prothrombin time of INR 2.2 was chosen as a significant indicator of severe coagulopathy [<xref rid=""B23"" ref-type=""bibr"">23</xref>]. The WD group exhibited a significantly higher baseline",27_20,Could Urinary Copper/Zinc Ratio Be a Newer Tool to Replace 24-Hour Urinary Copper Excretion for Diagnosing Wilson Disease in Children?,1 2024,,Wilson_Disease
"group exhibited a significantly higher baseline 24-hours urinary Cu excretion, and this difference was statistically significant <italic toggle=""yes"">p</italic><0.001. In the sub-analysis, comparing WD, acute viral hepatitis, and CLD, a significant difference in urinary copper levels between the groups was observed (<italic toggle=""yes"">p</italic>=0.009). The post-hoc analysis revealed a significant difference between the WD groups with acute hepatitis and those with CLD, but no significant difference was",27_21,Could Urinary Copper/Zinc Ratio Be a Newer Tool to Replace 24-Hour Urinary Copper Excretion for Diagnosing Wilson Disease in Children?,1 2024,,Wilson_Disease
"those with CLD, but no significant difference was found between acute hepatitis and CLD. In contrast, urinary zinc levels did not show any significant difference between the groups. The spot urinary Cu/Zn ratio demonstrated a significant difference between the WD group and the non-WD group. The mean urinary zinc level for WD was 1.33 µg/mL, while the mean urinary zinc level for non-WD was 0.72 µg/mL. The mean Cu/Zn ratio for WD was 9.14±24.62 for the 27 cases, and 0.27±0.44 for the control group (<xref",27_22,Could Urinary Copper/Zinc Ratio Be a Newer Tool to Replace 24-Hour Urinary Copper Excretion for Diagnosing Wilson Disease in Children?,1 2024,,Wilson_Disease
"cases, and 0.27±0.44 for the control group (<xref rid=""T2"" ref-type=""table"">Table 2</xref>). The Cu/Zn ratio, coupled with baseline 24-hours urine Cu in the 27 WD patients, showed a moderate but significant correlation (r=0.60, <italic toggle=""yes"">p</italic><0.001) (<xref rid=""F1"" ref-type=""fig"">Fig. 1</xref>). The area under the ROC, with 95% CI, for the morning urinary Cu/Zn ratio measured using a 24-hours urine sample was 0.843 (95% CI: 0.743-0.940) (standard error, 0.05; <italic",27_23,Could Urinary Copper/Zinc Ratio Be a Newer Tool to Replace 24-Hour Urinary Copper Excretion for Diagnosing Wilson Disease in Children?,1 2024,,Wilson_Disease
"CI: 0.743-0.940) (standard error, 0.05; <italic toggle=""yes"">p</italic><0.001) (<xref rid=""F2"" ref-type=""fig"">Fig. 2</xref>). WD is one of the most common pediatric inborn metabolic disorders. Early diagnosis and treatment is crucial in possibly altering the natural course of the disease, leading to a more benign prognosis when identified at an early stage [<xref rid=""B24"" ref-type=""bibr"">24</xref>]. Typically, WD manifests in childhood with hepatic involvement. The presence of low ceruloplasmin levels and",27_24,Could Urinary Copper/Zinc Ratio Be a Newer Tool to Replace 24-Hour Urinary Copper Excretion for Diagnosing Wilson Disease in Children?,1 2024,,Wilson_Disease
"The presence of low ceruloplasmin levels and the KF ring can significantly facilitate the diagnosis of WD. However, diagnosing WD in children might be challenging, primarily due to the absence of the KF ring and the ambiguity surrounding serum ceruloplasmin levels. In certain WD patients, serum ceruloplasmin levels may be normal, while in some carriers, it may be low [<xref rid=""B24"" ref-type=""bibr"">24</xref>]. Therefore, numerous studies have emphasized the 24-hours urine Cu excretion as one of the most",27_25,Could Urinary Copper/Zinc Ratio Be a Newer Tool to Replace 24-Hour Urinary Copper Excretion for Diagnosing Wilson Disease in Children?,1 2024,,Wilson_Disease
"24-hours urine Cu excretion as one of the most sensitive tests for diagnosing WD, and a test that can differentiate WD from other liver diseases in the pediatric population [<xref rid=""B25"" ref-type=""bibr"">25</xref><xref rid=""B26"" ref-type=""bibr"">26</xref>]. Despite the diagnostic value, the 24-hours urine collection method is time-consuming and challenging, particularly with the potential for incomplete collections that may yield unreliable results [<xref rid=""B27"" ref-type=""bibr"">27</xref>]. This",27_26,Could Urinary Copper/Zinc Ratio Be a Newer Tool to Replace 24-Hour Urinary Copper Excretion for Diagnosing Wilson Disease in Children?,1 2024,,Wilson_Disease
"[<xref rid=""B27"" ref-type=""bibr"">27</xref>]. This prompted us to explore the feasibility of adopting a morning spot urine Cu/Zn ratio as an alternative to the 24-hours urinary Cu excretion. Copper and zinc are both trace elements that can be concurrently measured using the same equipment and may interact negatively with one another [<xref rid=""B12"" ref-type=""bibr"">12</xref><xref rid=""B13"" ref-type=""bibr"">13</xref>]. WD is characterized by increased hepatic copper accumulation, and urinary zinc excretion is",27_27,Could Urinary Copper/Zinc Ratio Be a Newer Tool to Replace 24-Hour Urinary Copper Excretion for Diagnosing Wilson Disease in Children?,1 2024,,Wilson_Disease
"accumulation, and urinary zinc excretion is highly correlated with hepatic copper concentration [<xref rid=""B14"" ref-type=""bibr"">14</xref>]. Due to significant hepatobiliary excretory impairment of copper, patients with WD may display a slightly elevated hepatic zinc concentration [<xref rid=""B28"" ref-type=""bibr"">28</xref>]. A positive association was observed between the morning urine Cu/Zn ratio and the estimated 24-hours urinary Cu excretion in patients with WD. This finding aligns with a similar",27_28,Could Urinary Copper/Zinc Ratio Be a Newer Tool to Replace 24-Hour Urinary Copper Excretion for Diagnosing Wilson Disease in Children?,1 2024,,Wilson_Disease
"with WD. This finding aligns with a similar positive correlation reported by Wang et al. [<xref rid=""B15"" ref-type=""bibr"">15</xref>]. Similar to the study, both the urine Cu/Zn ratios and baseline 24-hours urine Cu excretion demonstrated similar areas under the ROC curve. Notably, all participants with WD in this study were newly diagnosed and treatment-inexperienced. This study excluded individuals with a history of zinc and copper-containing multivitamin tablet use within a month of hospitalization. To",27_29,Could Urinary Copper/Zinc Ratio Be a Newer Tool to Replace 24-Hour Urinary Copper Excretion for Diagnosing Wilson Disease in Children?,1 2024,,Wilson_Disease
"tablet use within a month of hospitalization. To achieve accurate results, creatinine excretion measurement was performed simultaneously with the 24-hours urinary Cu excretion as it may be challenging to correctly collect urine from the younger patients. Furthermore, the presence of renal tubular acidosis in patients with WD could contribute to increased urine copper excretion. Unfortunately, a limitation of this study is the lack of concurrent creatinine excretion measurement and screening for renal",27_30,Could Urinary Copper/Zinc Ratio Be a Newer Tool to Replace 24-Hour Urinary Copper Excretion for Diagnosing Wilson Disease in Children?,1 2024,,Wilson_Disease
"excretion measurement and screening for renal tubular acidosis. Another limitation was the inability to store urine in an acid-washed container, necessitating the estimation of 24-hours urine Cu by multiplying the copper of the spot morning urine with the total 24-hours urinary volume. A firm conclusion could not be formed from this study because of the relatively small sample size. However, the findings regarding the morning urine Cu/Zn ratio as a potentially promising alternative to the assessment of",27_31,Could Urinary Copper/Zinc Ratio Be a Newer Tool to Replace 24-Hour Urinary Copper Excretion for Diagnosing Wilson Disease in Children?,1 2024,,Wilson_Disease
"promising alternative to the assessment of estimated 24-hours urinary Cu excretion for the diagnosis of WD are noteworthy. The simplicity and rapid collection of morning urine samples, on top of encouraging results, suggest the potential utility of this approach; however, a prospective trial involving a larger sample size is necessary.",27_32,Could Urinary Copper/Zinc Ratio Be a Newer Tool to Replace 24-Hour Urinary Copper Excretion for Diagnosing Wilson Disease in Children?,1 2024,,Wilson_Disease
"Hepatic oxylipin profiles in mouse models of Wilson disease: New insights into early hepatic manifestations Hepatic inflammation is commonly identified in Wilson disease (WD), a genetic disease of hepatic and brain copper accumulation. Copper accumulation is associated with increased oxidative stress and reactive oxygen species generation which may result in non-enzymatic oxidation of membrane-bound polyunsaturated fatty acids (PUFA). PUFA can be oxidized enzymatically via lipoxygenases (LOX),",28_0,Hepatic oxylipin profiles in mouse models of Wilson disease: New insights into early hepatic manifestations,29 6 2024,,Wilson_Disease
"oxidized enzymatically via lipoxygenases (LOX), cyclooxygenases (COX), and cytochrome P450 monooxygenases (CYP). Products of PUFA oxidation are collectively known as oxylipins (OXL) and are bioactive lipids that modulate hepatic inflammation. We examined hepatic OXL profiles at early stages of WD in two mouse models, the toxic milk mouse from The Jackson Laboratory (tx-j) and the <italic toggle=""yes"">Atp7b</italic> knockout on a C57Bl/6 background (<italic toggle=""yes"">Atp7b</italic><sup>−/−</sup> B6).",28_1,Hepatic oxylipin profiles in mouse models of Wilson disease: New insights into early hepatic manifestations,29 6 2024,,Wilson_Disease
"toggle=""yes"">Atp7b</italic><sup>−/−</sup> B6). Targeted lipidomic analysis performed by ultra-high-performance liquid chromatography-electrospray ionization-tandem mass spectrometry showed that in both tx-j and <italic toggle=""yes"">Atp7b</italic><sup>−/−</sup> B6 mice, hepatic OXL profiles were altered with higher thromboxane and prostaglandins levels. The levels of oxidative stress marker, 9-HETE were increased more markedly in tx-j mice. However, both genotypes showed upregulated transcript levels of",28_2,Hepatic oxylipin profiles in mouse models of Wilson disease: New insights into early hepatic manifestations,29 6 2024,,Wilson_Disease
"genotypes showed upregulated transcript levels of many genes related to oxidative stress and inflammation. Both genotypes showed higher prostaglandins, thromboxin along with higher PUFA-derived alcohols, diols, and ketones with altered epoxides; the expression of <italic toggle=""yes"">Alox5</italic> was upregulated and many CYP-related genes were dysregulated. Pathway analyses show dysregulation in arachidonic acid and linoleic acid metabolism characterizes mice with WD. Our findings indicate alterations in",28_3,Hepatic oxylipin profiles in mouse models of Wilson disease: New insights into early hepatic manifestations,29 6 2024,,Wilson_Disease
"with WD. Our findings indicate alterations in hepatic PUFA metabolism in early-stage WD and suggest the upregulation of both, non-enzymatic ROS-dependent and enzymatic PUFA oxidation, which could have implications for hepatic manifestations in WD and represent potential targets for future therapies. Wilson disease (WD) is an autosomal recessive disorder caused by a loss of function mutations in the <italic toggle=""yes"">ATP7B</italic> gene, which encodes for the transmembrane copper-transporter, P-type",28_4,Hepatic oxylipin profiles in mouse models of Wilson disease: New insights into early hepatic manifestations,29 6 2024,,Wilson_Disease
"for the transmembrane copper-transporter, P-type ATPase beta [<xref rid=""R1"" ref-type=""bibr"">1</xref>]. These mutations impair biliary copper excretion and result in excessive copper accumulation in the liver and other tissues [<xref rid=""R2"" ref-type=""bibr"">2</xref>]. WD age of onset is broad and clinical presentations are variable, including hepatic and neurologic/psychiatric signs and symptoms with abnormalities shown also in kidneys and heart [<xref rid=""R2"" ref-type=""bibr"">2</xref>]. The hepatic",28_5,Hepatic oxylipin profiles in mouse models of Wilson disease: New insights into early hepatic manifestations,29 6 2024,,Wilson_Disease
"rid=""R2"" ref-type=""bibr"">2</xref>]. The hepatic manifestations of WD include hepatocellular steatosis with various degrees of necro-inflammation, cirrhosis, and fibrosis that may progress to liver dysfunction and failure [<xref rid=""R3"" ref-type=""bibr"">3</xref>]. WD is also characterized by dysregulation in lipid metabolism, with impaired cholesterol synthesis, altered lipogenesis and plasma lipidomic profile [<xref rid=""R4"" ref-type=""bibr"">4</xref>–<xref rid=""R6"" ref-type=""bibr"">6</xref>]. If left",28_6,Hepatic oxylipin profiles in mouse models of Wilson disease: New insights into early hepatic manifestations,29 6 2024,,Wilson_Disease
"rid=""R6"" ref-type=""bibr"">6</xref>]. If left untreated, WD can be disabling and fatal due to its multi-organ manifestations. The toxic milk mice from The Jackson Laboratory (tx-j) and the <italic toggle=""yes"">Atp7b</italic> global knockout on a C57Bl/6 background (<italic toggle=""yes"">Atp7b</italic><sup>−/−</sup> B6) are two rodent models of WD. The tx-j mouse is characterized by a spontaneous missense mutation of the <italic toggle=""yes"">Atp7b</italic> gene, while the <italic",28_7,Hepatic oxylipin profiles in mouse models of Wilson disease: New insights into early hepatic manifestations,29 6 2024,,Wilson_Disease
"gene, while the <italic toggle=""yes"">Atp7b</italic><sup>−/−</sup> B6 mouse is genetically engineered with global inactivation of the same gene and was originally generated to define the role of the genetic background in comparison with the <italic toggle=""yes"">Atp7b</italic><sup>−/−</sup> hybrid mouse model [<xref rid=""R7"" ref-type=""bibr"">7</xref>,<xref rid=""R8"" ref-type=""bibr"">8</xref>]. Similar to human WD phenotype, both mouse models show features of copper accumulation and hepatic manifestation and are",28_8,Hepatic oxylipin profiles in mouse models of Wilson disease: New insights into early hepatic manifestations,29 6 2024,,Wilson_Disease
"accumulation and hepatic manifestation and are considered valid models to investigate the pathological mechanisms of liver injury in WD. The natural history of liver pathology in tx-j mice is characterized by early fibrosis by 24–28 weeks of age, preceded by inflammatory infiltrate starting at 20 weeks with hepatocyte irregular and enlarged nuclei. The <italic toggle=""yes"">Atp7b</italic><sup>−/−</sup> B6 mouse model is particularly well characterized and it shows remarkable liver regeneration features with",28_9,Hepatic oxylipin profiles in mouse models of Wilson disease: New insights into early hepatic manifestations,29 6 2024,,Wilson_Disease
"shows remarkable liver regeneration features with hyperplastic nodules as observed in the <italic toggle=""yes"">Atp7b</italic><sup>−/−</sup> model with hybrid phenotype [<xref rid=""R9"" ref-type=""bibr"">9</xref>] as well as marked inflammation with mononuclear hepatitis. Therefore, the <italic toggle=""yes"">Atp7b</italic><sup>−/−</sup> B6 model can be used to study compensatory regulatory mechanisms and metabolic changes in the state of liver disease related to copper toxicity [<xref rid=""R7""",28_10,Hepatic oxylipin profiles in mouse models of Wilson disease: New insights into early hepatic manifestations,29 6 2024,,Wilson_Disease
"related to copper toxicity [<xref rid=""R7"" ref-type=""bibr"">7</xref>,<xref rid=""R8"" ref-type=""bibr"">8</xref>,<xref rid=""R10"" ref-type=""bibr"">10</xref>]. At 16 weeks of age, we have also demonstrated extensive metabolic derangements associated with gut microbiome differences in both mouse strains. Therefore, both mouse models are very predictable in terms of copper accumulation and chronic liver damage with fibrosis development and presence of regenerative features. The mechanisms by which copper induces",28_11,Hepatic oxylipin profiles in mouse models of Wilson disease: New insights into early hepatic manifestations,29 6 2024,,Wilson_Disease
"features. The mechanisms by which copper induces tissue toxicity are not well understood. In WD, oxidative stress is a hallmark feature that intensifies with disease progression, and is thought to play a role in its pathogenesis [<xref rid=""R11"" ref-type=""bibr"">11</xref>]. When free/aqueous copper ions are present, these are thought to induce the formation of reactive oxygen species (ROS), as hydroperoxyl and hydroxyl radicals, via Fenton- and Haber-Weiss reactions [<xref rid=""R12""",28_12,Hepatic oxylipin profiles in mouse models of Wilson disease: New insights into early hepatic manifestations,29 6 2024,,Wilson_Disease
"and Haber-Weiss reactions [<xref rid=""R12"" ref-type=""bibr"">12</xref>], which may form adducts with proteins and DNA bases and impair cellular structures and machineries [<xref rid=""R13"" ref-type=""bibr"">13</xref>,<xref rid=""R14"" ref-type=""bibr"">14</xref>]. However, in WD, these irreversible changes are associated with substantially augmented hepatocellular oxidative stress and are features of advanced stages of liver disease, rather than early stages [<xref rid=""R11"" ref-type=""bibr"">11</xref>,<xref",28_13,Hepatic oxylipin profiles in mouse models of Wilson disease: New insights into early hepatic manifestations,29 6 2024,,Wilson_Disease
"[<xref rid=""R11"" ref-type=""bibr"">11</xref>,<xref rid=""R15"" ref-type=""bibr"">15</xref>]. To date, the early drivers of hepatocellular damage in WD are not clear. Most of the available studies investigated liver samples with advanced liver damage, and the limited work available examining stages associated with minimal liver changes indicate that oxidative stress and lipid peroxidation markers are unaffected, however increasing with the progression of liver damage [<xref rid=""R16""",28_14,Hepatic oxylipin profiles in mouse models of Wilson disease: New insights into early hepatic manifestations,29 6 2024,,Wilson_Disease
"the progression of liver damage [<xref rid=""R16"" ref-type=""bibr"">16</xref>–<xref rid=""R18"" ref-type=""bibr"">18</xref>]. Also, ROS may react with membrane-bound unsaturated fatty acids and result in lipid peroxidation. Polyunsaturated fatty acids (PUFAs) may undergo ROS-dependent non-enzymatic auto-oxidation at a rate that is inversely correlated with oxidative stress to generate lipid mediators including 9-hydroxyeicosatetraenoic acid (9-HETE) which is derived from arachidonic acid (C20:4n6, AA) and",28_15,Hepatic oxylipin profiles in mouse models of Wilson disease: New insights into early hepatic manifestations,29 6 2024,,Wilson_Disease
"derived from arachidonic acid (C20:4n6, AA) and considered an in vivo marker of oxidative stress, and 9-hydroxyeicosapentaenoic acid (9-HEPE) which is derived from eicosapentaenoic acid (C20:5n3) [<xref rid=""R19"" ref-type=""bibr"">19</xref>,<xref rid=""R20"" ref-type=""bibr"">20</xref>]. Alternatively, PUFAs may undergo enzymatic oxygenation in reactions catalyzed by cyclooxygenases (i.e. COX-1 and −2) to produce lipid mediators including prostaglandins (PGs) and thromboxane B<sub>2</sub> (TXB<sub>2</sub>);",28_16,Hepatic oxylipin profiles in mouse models of Wilson disease: New insights into early hepatic manifestations,29 6 2024,,Wilson_Disease
"and thromboxane B<sub>2</sub> (TXB<sub>2</sub>); lipoxygenases (e.g. 5-, 12-, and 15-LOXs) to produce fatty acid alcohols, ketones, hydroperoxides, lipoxins, and resolvins; and members of the cytochrome P450 monooxygenases (CYPs) to produce fatty acid alcohols and epoxides, and the latter are further hydrolyzed by the action of soluble epoxide hydrolases (sEH) to vicinal diols [<xref rid=""R21"" ref-type=""bibr"">21</xref>,<xref rid=""R22"" ref-type=""bibr"">22</xref>]. Products of PUFA oxidation are bioactive",28_17,Hepatic oxylipin profiles in mouse models of Wilson disease: New insights into early hepatic manifestations,29 6 2024,,Wilson_Disease
"Products of PUFA oxidation are bioactive signaling lipids, collectively known as oxylipins (OXL). This diverse class acts in an autocrine, paracrine, or endocrine fashion via receptors to mediate processes, including lipid metabolism and inflammation, and are recognized components of the hepatic inflammatory milieu in multiple liver diseases [<xref rid=""R21"" ref-type=""bibr"">21</xref>–<xref rid=""R27"" ref-type=""bibr"">27</xref>]. For example, lipidomic analyses showed that dysregulated PUFAs metabolism and",28_18,Hepatic oxylipin profiles in mouse models of Wilson disease: New insights into early hepatic manifestations,29 6 2024,,Wilson_Disease
"showed that dysregulated PUFAs metabolism and altered OXLs profile is associated with metabolic dysfunction-associated steatotic liver disease (MAFLD) and can predict its severity [<xref rid=""R28"" ref-type=""bibr"">28</xref>–<xref rid=""R31"" ref-type=""bibr"">31</xref>]. However, lipidomic profiling studies are limited in WD and the hepatic tissue lipidome is uncharacterized [<xref rid=""R5"" ref-type=""bibr"">5</xref>,<xref rid=""R32"" ref-type=""bibr"">32</xref>]. It is not clear if early stages of liver disease in",28_19,Hepatic oxylipin profiles in mouse models of Wilson disease: New insights into early hepatic manifestations,29 6 2024,,Wilson_Disease
"is not clear if early stages of liver disease in WD are associated with alterations in the hepatic OXL profile that is relevant to inflammation and oxidative stress. This knowledge is important as it will shed light on pathways implicated in the onset and progression of liver disease in WD and highlight potential early therapeutic targets aimed at its delay, amelioration, or prevention. To fill in current knowledge gaps, the objective of this study is to examine hepatic OXL profiles in two mouse models of",28_20,Hepatic oxylipin profiles in mouse models of Wilson disease: New insights into early hepatic manifestations,29 6 2024,,Wilson_Disease
"hepatic OXL profiles in two mouse models of WD, tx-j and <italic toggle=""yes"">Atp7b</italic><sup>−/−</sup> B6 mice, compared with corresponding controls at an early stage of hepatic disease. To accomplish this, we conducted quantitative lipidomic profiling of OXLs in liver tissue performed by ultra-high-performance liquid chromatography-electrospray ionization-tandem mass spectrometry (UPLC-ESI-MS/MS).   The current work explored hepatic lipidomic profiling in two animal models of WD, tx-j and <italic",28_21,Hepatic oxylipin profiles in mouse models of Wilson disease: New insights into early hepatic manifestations,29 6 2024,,Wilson_Disease
"in two animal models of WD, tx-j and <italic toggle=""yes"">Atp7b</italic><sup>−/−</sup> B6 mice. Our findings highlight strain-related predisposition to hepatic inflammation, and indicate that, at 16 weeks of age, mice with early stage WD but with evident hepatic inflammation are characterized by altered PUFA metabolism. The main results include 1) elevated levels of 9-HETE, the ROS-dependent non-enzymatic marker of oxidative stress, that is more marked in tx-j mice, with an upregulation of genes related to",28_22,Hepatic oxylipin profiles in mouse models of Wilson disease: New insights into early hepatic manifestations,29 6 2024,,Wilson_Disease
"mice, with an upregulation of genes related to oxidative stress and inflammation in both genotypes; 2) higher PGs and TXB, indicating upregulated COX pathways; 3) higher PUFA ketones, diols, and alcohols along with higher transcript levels of <italic toggle=""yes"">Alox5</italic> indicating upregulated LOX (s) pathways; and 4) altered PUFA epoxides and vicinal diols with altered expression of CYP- and sEH-related genes, indicating dysregulated CYP(s) and sEH(s) pathways. The genetic loss of function in ATP7B",28_23,Hepatic oxylipin profiles in mouse models of Wilson disease: New insights into early hepatic manifestations,29 6 2024,,Wilson_Disease
"pathways. The genetic loss of function in ATP7B results in copper accumulation, primarily affecting the liver and manifesting with hepatocellular steatosis, necro inflammation, and fibrosis [<xref rid=""R3"" ref-type=""bibr"">3</xref>]. At 16 weeks of age, both animal models show marked hepatic copper accumulation, with ~60-fold increase in tx-j compared to C3H control mice and ~30-fold in <italic toggle=""yes"">Atp7b</italic><sup>−/−</sup> B6 compared to WT [<xref rid=""R8"" ref-type=""bibr"">8</xref>,<xref",28_24,Hepatic oxylipin profiles in mouse models of Wilson disease: New insights into early hepatic manifestations,29 6 2024,,Wilson_Disease
"WT [<xref rid=""R8"" ref-type=""bibr"">8</xref>,<xref rid=""R42"" ref-type=""bibr"">42</xref>]. At this time point, liver pathology is still in the early development phases, with evidence of hepatocellular portal and lobular inflammation, however, no steatosis or fibrosis. Our findings are in line with previous observations and are indicative of hepatocellular inflammation that is more evident in <italic toggle=""yes"">Atp7b</italic><sup>−/−</sup> B6 mice [<xref rid=""R8"" ref-type=""bibr"">8</xref>]. Interestingly,",28_25,Hepatic oxylipin profiles in mouse models of Wilson disease: New insights into early hepatic manifestations,29 6 2024,,Wilson_Disease
"ref-type=""bibr"">8</xref>]. Interestingly, control mice with normal copper metabolism of both strains presented mild inflammatory infiltrates which could indicate a background predisposition to inflammation that is accentuated by copper accumulation. These results are in agreement with previously described strain differences [<xref rid=""R7"" ref-type=""bibr"">7</xref>,<xref rid=""R43"" ref-type=""bibr"">43</xref>], and with the strain-related differences in responses to excessive dietary copper reported in other",28_26,Hepatic oxylipin profiles in mouse models of Wilson disease: New insights into early hepatic manifestations,29 6 2024,,Wilson_Disease
"to excessive dietary copper reported in other animals [<xref rid=""R44"" ref-type=""bibr"">44</xref>]. At early stages of liver disease that are associated with hepatocellular inflammation, both tx-j and <italic toggle=""yes"">Atp7b</italic><sup>−/−</sup> B6 mice were characterized by changes in hepatic lipidomic profile and signs of altered PUFA metabolism. The arachidonic acid alcohol 9-HETE is derived from free-radical mediated non-enzymatic oxidation and is a marker of oxidative stress [<xref rid=""R20""",28_27,Hepatic oxylipin profiles in mouse models of Wilson disease: New insights into early hepatic manifestations,29 6 2024,,Wilson_Disease
"is a marker of oxidative stress [<xref rid=""R20"" ref-type=""bibr"">20</xref>]. In tx-j mice, the higher levels of 9-HETE, and the strong positive correlation found between 9-HETE and several PUFA alcohols is consistent with auto-oxidative processes induced by oxidative stress. Changes in 9-HETE were less marked in <italic toggle=""yes"">Atp7b</italic><sup>−/−</sup> B6 compared with WT, however, the moderately positive association between 9-HETE and many PUFA alcohols may suggests auto-oxidation. Findings from",28_28,Hepatic oxylipin profiles in mouse models of Wilson disease: New insights into early hepatic manifestations,29 6 2024,,Wilson_Disease
"may suggests auto-oxidation. Findings from gene expression analysis support lipidomic findings with an upregulation in the transcript levels of many genes related to oxidative stress and inflammation. Together, our data indicate lipid auto-oxidation and signs of oxidative stress are evident at early stages (16 weeks of age) in WD mouse models, with possible genotype-related variations. Oxidative stress plays a critical role in the development of many liver diseases as ROS interact with cellular components",28_29,Hepatic oxylipin profiles in mouse models of Wilson disease: New insights into early hepatic manifestations,29 6 2024,,Wilson_Disease
"diseases as ROS interact with cellular components to perpetuate oxidative damage, inflammation, apoptosis, and necrosis [<xref rid=""R45"" ref-type=""bibr"">45</xref>]. The role of oxidative stress in the early development of hepatic inflammation in WD is unclear. However, studies from animal models of copper-hepatotoxicity demonstrated that the chronic exposure to sublethal doses of copper induced hepatic oxidative stress via the overproduction of ROS and diminished antioxidants enzymatic activities;",28_30,Hepatic oxylipin profiles in mouse models of Wilson disease: New insights into early hepatic manifestations,29 6 2024,,Wilson_Disease
"and diminished antioxidants enzymatic activities; increased lipid peroxidation; induced hepatic apoptosis via mitochondrial apoptotic pathway with the activation of the tumor necrosis factor receptor-1 signaling pathway; and provoked liver inflammation by stimulating the mitogen-activated protein kinases and nuclear factor kappa B signaling pathways [<xref rid=""R44"" ref-type=""bibr"">44</xref>,<xref rid=""R46"" ref-type=""bibr"">46</xref>–<xref rid=""R48"" ref-type=""bibr"">48</xref>]. In vitro studies also show",28_31,Hepatic oxylipin profiles in mouse models of Wilson disease: New insights into early hepatic manifestations,29 6 2024,,Wilson_Disease
"In vitro studies also show that hepatocytes exposure to copper (100 or 200 μM) increased ROS, lipid peroxidation, and resulted in mitochondrial dysfunction and apoptosis via mitochondrial pathway [<xref rid=""R44"" ref-type=""bibr"">44</xref>,<xref rid=""R49"" ref-type=""bibr"">49</xref>,<xref rid=""R50"" ref-type=""bibr"">50</xref>]. In the current study, hepatic liver content was significantly higher in both mouse models, although we did not assess free hepatic copper levels. We also cannot conclude on the source of",28_32,Hepatic oxylipin profiles in mouse models of Wilson disease: New insights into early hepatic manifestations,29 6 2024,,Wilson_Disease
"levels. We also cannot conclude on the source of oxidative stress at early-stage liver inflammation in WD. While current data indicate that unbound copper-generated free radicals at early stages of WD are unlikely, as excess copper is buffered via protective mechanisms, including mitochondria copper sequestering [<xref rid=""R11"" ref-type=""bibr"">11</xref>,<xref rid=""R15"" ref-type=""bibr"">15</xref>], structural and functional mitochondrial dysfunction are reported at early stages of WD [<xref rid=""R51""",28_33,Hepatic oxylipin profiles in mouse models of Wilson disease: New insights into early hepatic manifestations,29 6 2024,,Wilson_Disease
"reported at early stages of WD [<xref rid=""R51"" ref-type=""bibr"">51</xref>–<xref rid=""R54"" ref-type=""bibr"">54</xref>], and are suggested to be the first responder to hepatic copper load [<xref rid=""R54"" ref-type=""bibr"">54</xref>]. Therefore, mitochondrial dysfunction may be a potential sources of ROS at early stages of WD [<xref rid=""R55"" ref-type=""bibr"">55</xref>]. Our results show both mice models of WD were characterized by higher hepatic levels of the arachidonic acid derived TXB<sub>2</sub> and several",28_34,Hepatic oxylipin profiles in mouse models of Wilson disease: New insights into early hepatic manifestations,29 6 2024,,Wilson_Disease
"acid derived TXB<sub>2</sub> and several PGs. TXB<sub>2</sub> and several PGs are produced exclusively via COX pathways (COX-1 and COX-2) and mediate inflammation and necrosis [<xref rid=""R21"" ref-type=""bibr"">21</xref>,<xref rid=""R56"" ref-type=""bibr"">56</xref>]. Our findings from gene expression analysis indicate an upregulation of COX pathways with the higher transcript levels of <italic toggle=""yes"">Ptgs1</italic> and <italic toggle=""yes"">Ptgs2</italic> detected in tx-j mice, with a trend observed in",28_35,Hepatic oxylipin profiles in mouse models of Wilson disease: New insights into early hepatic manifestations,29 6 2024,,Wilson_Disease
"detected in tx-j mice, with a trend observed in <italic toggle=""yes"">Atp7b</italic><sup>−/−</sup> B6 mice. An increase in COX expression was reported in Long-Evans Cinnamon rats, an animal model of WD [<xref rid=""R57"" ref-type=""bibr"">57</xref>]. COX-1 is expressed ubiquitously in most cell types, while COX-2 plays a role in inflammation, angiogenesis, and cell proliferation in a variety of tissues [<xref rid=""R23"" ref-type=""bibr"">23</xref>,<xref rid=""R24"" ref-type=""bibr"">24</xref>]. COX-2 is upregulated",28_36,Hepatic oxylipin profiles in mouse models of Wilson disease: New insights into early hepatic manifestations,29 6 2024,,Wilson_Disease
"ref-type=""bibr"">24</xref>]. COX-2 is upregulated with inflammation and liver injury and plays an important role in the activation of hepatic stellate cells and fibrogenesis [<xref rid=""R58"" ref-type=""bibr"">58</xref>]. ROS and COX-2 are shown to be reciprocally linked, with ROS inducing the expression of COX-2 by multiple mechanisms, including the induction by nuclear factor kappa B and COX contributing to inflammation, ROS production, and lipid oxygenation [<xref rid=""R59"" ref-type=""bibr"">59</xref>–<xref",28_37,Hepatic oxylipin profiles in mouse models of Wilson disease: New insights into early hepatic manifestations,29 6 2024,,Wilson_Disease
"[<xref rid=""R59"" ref-type=""bibr"">59</xref>–<xref rid=""R61"" ref-type=""bibr"">61</xref>]. This could explain the moderately positive correlation between both TXB<sub>2</sub> and prostaglandins with the oxidative stress marker 9-HETE in both mice models of WD. Although sex differences in PG production during inflammation were reported as higher in males [<xref rid=""R62"" ref-type=""bibr"">62</xref>], we did not observe sex interaction in the current study (data not shown). In general, both mouse models of WD",28_38,Hepatic oxylipin profiles in mouse models of Wilson disease: New insights into early hepatic manifestations,29 6 2024,,Wilson_Disease
"not shown). In general, both mouse models of WD showed higher PUFA alcohols, ketones, and diols, which suggest an upregulation of LOX pathway(s). Gene expression analysis results are in agreement, as there was upregulation in the transcript levels of LOX-related genes in both mouse models. However, the positive correlation observed between 9-HETE and some PUFA alcohols in both models also suggests a contribution of non-enzymatic pathways in the origin of these OXLs. Animal studies show LOX pathways play a",28_39,Hepatic oxylipin profiles in mouse models of Wilson disease: New insights into early hepatic manifestations,29 6 2024,,Wilson_Disease
"OXLs. Animal studies show LOX pathways play a key role in the pathogenesis of liver disease [<xref rid=""R63"" ref-type=""bibr"">63</xref>]. In general, n-6 PUFA-derived alcohols are pro-inflammatory [<xref rid=""R21"" ref-type=""bibr"">21</xref>]. Therefore, the alterations observed in PUFA alcohols may be relevant to early stages of hepatocellular inflammation in WD. Together, our findings indicate upregulation of LOX pathways with contribution of non-enzymatic ROS-dependent oxidation pathway in both WD mouse",28_40,Hepatic oxylipin profiles in mouse models of Wilson disease: New insights into early hepatic manifestations,29 6 2024,,Wilson_Disease
"ROS-dependent oxidation pathway in both WD mouse models. The CYP450-generated PUFA epoxides were altered in both mice models of WD along with dysregulation in the transcript levels of many CYP genes. We also observed altered PUFA vicinal diols profile with dysregulation in the transcript levels of sEH genes. These findings indicate dysregulated CYP and sEH pathways in both mouse models of WD. In general, PUFA epoxides have anti-inflammatory pro-resolving properties, though with a relatively short half-life",28_41,Hepatic oxylipin profiles in mouse models of Wilson disease: New insights into early hepatic manifestations,29 6 2024,,Wilson_Disease
"though with a relatively short half-life as they are radially hydrolyzed to vicinal diols that are inactive or less potent [<xref rid=""R22"" ref-type=""bibr"">22</xref>]. The implication of these alteration on hepatic inflammation and the observed genotype-related differences awaits further examination. In agreement with our lipidomic and gene expression findings that indicate altered PUFA metabolism in animal models of WD, results from pathway analysis show that the hepatic metabolism of arachidonic acid and",28_42,Hepatic oxylipin profiles in mouse models of Wilson disease: New insights into early hepatic manifestations,29 6 2024,,Wilson_Disease
"the hepatic metabolism of arachidonic acid and linoleic acid are significantly altered in both tx-j and <italic toggle=""yes"">Atp7b</italic><sup>−/−</sup> B6 mice, compared to controls. In conclusion, we present data indicating that early stages of liver pathology in WD animals is associated with altered PUFA metabolism. In specific, our findings highlight signs of oxidative stress and non-enzymatic PUFA oxidation that are more evident in tx-j mice. They also indicate enzymatic PUFA oxidation via COX and",28_43,Hepatic oxylipin profiles in mouse models of Wilson disease: New insights into early hepatic manifestations,29 6 2024,,Wilson_Disease
"indicate enzymatic PUFA oxidation via COX and LOX pathways, with alterations in hepatic arachidonic acid and linoleic acid metabolism in both tx-j and <italic toggle=""yes"">Atp7b</italic><sup>−/−</sup> B6 mice. We postulate a role of these pathways in early stages of WD that needs to be further examined and confirmed in humans. Our findings support antioxidant therapy to alleviate oxidative stress and suggest COX and LOX inhibitors as potential therapeutic targets. Our results also imply the utility of high",28_44,Hepatic oxylipin profiles in mouse models of Wilson disease: New insights into early hepatic manifestations,29 6 2024,,Wilson_Disease
"Our results also imply the utility of high n-3 PUFA supplementation, which can modulate inflammation by conversion to anti-inflammatory lipid mediators [<xref rid=""R64"" ref-type=""bibr"">64</xref>,<xref rid=""R65"" ref-type=""bibr"">65</xref>]. Of note, in the Long-Evans Cinnamon rat, a mixture of docosahexaenoic acid and soy supplementation resulted in improved liver histological outcomes and downregulation in the expression of COX-2 [<xref rid=""R57"" ref-type=""bibr"">57</xref>]. Our findings further highlight",28_45,Hepatic oxylipin profiles in mouse models of Wilson disease: New insights into early hepatic manifestations,29 6 2024,,Wilson_Disease
"Our findings further highlight genotype-related variations. The underlying cause of this variability has yet to be elucidated, but it is reflective of the varied human WD phenotypes and it is well described in different mouse strains [<xref rid=""R66"" ref-type=""bibr"">66</xref>]. Our data show that at 16 weeks of age, compared to correspondent controls, both mouse models showed increased oxidative stress that was more marked in tx-j mice, upregulated COX and LOX, with altered CYP and sEH(s) levels. However,",28_46,Hepatic oxylipin profiles in mouse models of Wilson disease: New insights into early hepatic manifestations,29 6 2024,,Wilson_Disease
"LOX, with altered CYP and sEH(s) levels. However, <italic toggle=""yes"">Atp7b</italic><sup>−/−</sup> B6 mice were characterized by more advanced inflammatory infiltrate (>4 foci). Interestingly, despite the advanced liver pathology, this model demonstrates remarkable hepatic regeneration [<xref rid=""R7"" ref-type=""bibr"">7</xref>], which is indicated by the observed higher liver weight as compared to body weight. These findings imply the existence of protective mechanisms against copper overload and suggest",28_47,Hepatic oxylipin profiles in mouse models of Wilson disease: New insights into early hepatic manifestations,29 6 2024,,Wilson_Disease
"mechanisms against copper overload and suggest the <italic toggle=""yes"">Atp7b</italic><sup>−/−</sup> mouse model as a candidate for studying compensatory mechanisms in liver disease related to copper toxicity [<xref rid=""R7"" ref-type=""bibr"">7</xref>].",28_48,Hepatic oxylipin profiles in mouse models of Wilson disease: New insights into early hepatic manifestations,29 6 2024,,Wilson_Disease
"The mutation spectrum and ethnic distribution of Wilson disease, a review Wilson's disease is a complicated medical condition caused by the accumulation of copper, mostly in the liver and brain. The genetic basis of Wilson's disease is attributed to the presence of pathogenic variants in the <italic toggle=""yes"">ATP7B</italic> copper-transporting gene, which prevents the excretion of copper through the biliary tract. To date, <italic toggle=""yes"">ATP7B</italic> remains the only identified gene that has been",29_0,"The mutation spectrum and ethnic distribution of Wilson disease, a review",06 12 2023,,Wilson_Disease
"remains the only identified gene that has been linked to the development of this disease. Our understanding of the disease has been associated with the identification of particular disease-causing variants that present specific impairments in copper transporters. It is crucial to identify the most frequent variant in terms of ethnicity to facilitate testing of its functionality. This study represents the initial comprehensive analysis of <italic toggle=""yes"">ATP7B</italic> variants, providing insights into",29_1,"The mutation spectrum and ethnic distribution of Wilson disease, a review",06 12 2023,,Wilson_Disease
"variants, providing insights into the extensive range of disease-causing mutations. Here, we describe the 1275 distinct <italic toggle=""yes"">ATP7B</italic> variants documented so far, with particular emphasis on their regional and ethnic prevalence. The H1069Q missense variant is the most frequently reported in Europe, Northern America, and North Africa, whereas the R778L, C271*, and M645R variants are the most prevalent in the East Asian, Middle Eastern-South Asian, and South American populations,",29_2,"The mutation spectrum and ethnic distribution of Wilson disease, a review",06 12 2023,,Wilson_Disease
"Asian, and South American populations, respectively. Acquiring such knowledge would facilitate the implementation of a selective mutation screening approach<underline>,</underline> targeting the most predominant variant identified within a specific ethnic group or geographic region for better diagnosis of the disease. Wilson disease, also known as hepatolenticular degeneration (HLD), is an autosomal recessive inherited disorder of copper metabolism [<xref rid=""bb0005"" ref-type=""bibr"">1</xref>]. It is",29_3,"The mutation spectrum and ethnic distribution of Wilson disease, a review",06 12 2023,,Wilson_Disease
"rid=""bb0005"" ref-type=""bibr"">1</xref>]. It is caused by pathogenic variants in the <italic toggle=""yes"">ATP7B</italic> gene, which is located on chromosome 13q14.3 and consists of 21 exons and 20 introns, with a total genomic length of 80 kb. It encodes a copper-transporting ATPase type P, containing 1465 amino acids. The protein is synthesized in the endoplasmic reticulum (ER) and then relocated to the Golgi apparatus in hepatocytes [<xref rid=""bb0010"" ref-type=""bibr"">2</xref>]. ATP7B gene is mostly",29_4,"The mutation spectrum and ethnic distribution of Wilson disease, a review",06 12 2023,,Wilson_Disease
"ref-type=""bibr"">2</xref>]. ATP7B gene is mostly expressed in the liver but is also found in the kidney, mammary glands, placenta, lung, and brain. Mutations in the <italic toggle=""yes"">ATP7B</italic> gene disrupt the synthesis and function of the ATP7B protein, leading to further impairment of the copper excretion pathway. The deficient incorporation of copper into ceruloplasmin results in a decrease in biliary copper excretion and an increase in copper accumulation, mainly in the liver, brain, and eyes.",29_5,"The mutation spectrum and ethnic distribution of Wilson disease, a review",06 12 2023,,Wilson_Disease
"mainly in the liver, brain, and eyes. The deposition of copper in the body is toxic and results in clinically heterogeneous manifestations, including liver function impairment, neurological disturbance, and developmental delay [<xref rid=""bb0015"" ref-type=""bibr"">3</xref>]. Regarding the management of Wilson patients and the detection of disease-causing variants, it would be beneficial to report all variants for diagnosis and future mutation-targeted therapeutic options [<xref rid=""bb0020""",29_6,"The mutation spectrum and ethnic distribution of Wilson disease, a review",06 12 2023,,Wilson_Disease
"therapeutic options [<xref rid=""bb0020"" ref-type=""bibr"">4</xref>]. Despite numerous papers on the subject, no clear analysis of the relationship between genotype, phenotype, and mutation distribution has been reported. Therefore, the review was focused on identifying and summarizing the reported variants in the <italic toggle=""yes"">ATP7B</italic> gene and their corresponding manifestations in related patients to date. To prepare this manuscript, a literature search was conducted by the authors using the",29_7,"The mutation spectrum and ethnic distribution of Wilson disease, a review",06 12 2023,,Wilson_Disease
"search was conducted by the authors using the electronic PubMed (Medline) database and the following search terms: “Wilson disease”, “Hepatolenticular Degeneration”, “mutation,” and “genetic variation.” The authors selected the most relevant English language articles. After cross-checking the literature and genetic databases on <italic toggle=""yes"">ATP7B</italic> from the oldest to the present day (from 1995 to 2022), we updated the number of variants with the recently reported articles. To date, 1275",29_8,"The mutation spectrum and ethnic distribution of Wilson disease, a review",06 12 2023,,Wilson_Disease
"the recently reported articles. To date, 1275 unique variants in the <italic toggle=""yes"">ATP7B</italic> gene from 260 articles (16,183 patients) have been identified. Of 1275 unique variants, 618 missense-reported variants illustrate the predominant type (48%) in the <italic toggle=""yes"">ATP7B</italic> gene of Wilson disease. Furthermore, 304 frameshift variants (24%), 111 nonsense variants (9%), 17 promoter variants (1%), 86 deletions (7%), and 15 large deletions (1%) are reported (<xref rid=""f0005""",29_9,"The mutation spectrum and ethnic distribution of Wilson disease, a review",06 12 2023,,Wilson_Disease
"deletions (1%) are reported (<xref rid=""f0005"" ref-type=""fig"">Fig. 1</xref>). 124 intronic variants (10%) have been reported. These results suggest that intronic variants of <italic toggle=""yes"">ATP7B</italic> could potentially be an overlooked contributing factor in the development of Wilson's disease. However, it is worth noting that promoter mutations and large whole exon deletions/duplications of the ATP7B gene are rare occurrences. Thus, it appears that utilizing multiplex ligation-dependent probe",29_10,"The mutation spectrum and ethnic distribution of Wilson disease, a review",06 12 2023,,Wilson_Disease
"that utilizing multiplex ligation-dependent probe amplification (MLPA) or other methods for <italic toggle=""yes"">ATP7B</italic> analysis may be time-consuming, costly, and of limited value in the molecular diagnosis of Wilson's disease.<fig id=""f0005""><label>Fig. 1</label><caption><p>Pie chart representing the distribution of different types of identified variants in Wilson patients.</p></caption><alt-text id=""al0005"">Fig. 1</alt-text><graphic http://www.w3.org/1999/xlink href=""gr1""",29_11,"The mutation spectrum and ethnic distribution of Wilson disease, a review",06 12 2023,,Wilson_Disease
"http://www.w3.org/1999/xlink href=""gr1"" id=""lk0005""></graphic></fig> The clustering of variants in specific subregions of the <italic toggle=""yes"">ATP7B</italic> gene across diverse populations has been well recognized [<xref rid=""bb0025"" ref-type=""bibr"">5</xref>]. In our study, in all exonic and intronic regions of the ATP7B gene, the variants are reported (<xref rid=""f0010"" ref-type=""fig"">Fig. 2</xref>). However, the frequency of regional clustering of variants was considerably higher in eight exons",29_12,"The mutation spectrum and ethnic distribution of Wilson disease, a review",06 12 2023,,Wilson_Disease
"variants was considerably higher in eight exons consisting of 2, 8, 11, 13, 14, 16, 18, and 20. It has been demonstrated that a restricted screen of eight exons can detect 56.3% (717/1275) of all variants, which offers a more convenient option for patients with distinct presentations of Wilson's disease. Additionally, identifying the causative region of the gene enables molecular genetic testing to be conducted without the need for a time-consuming and costly process. It helps clinicians decide on the",29_13,"The mutation spectrum and ethnic distribution of Wilson disease, a review",06 12 2023,,Wilson_Disease
"costly process. It helps clinicians decide on the appropriate time to begin proper treatment. Nevertheless, it should be noted that 43.7% (558/1275) of all variants were outside of the hotspot clustering regions, and due to the nature of Wilson's disease, compound heterozygote variants occur. Therefore, the decision on whether to sequence the entire or partial <italic toggle=""yes"">ATP7B</italic> coding region depends on the clinical and biochemical data of the patients and the population under study.<fig",29_14,"The mutation spectrum and ethnic distribution of Wilson disease, a review",06 12 2023,,Wilson_Disease
"the patients and the population under study.<fig id=""f0010""><label>Fig. 2</label><caption><p>The number and location of the 1275 unique variants, identified on the ATP7B gene.</p></caption><alt-text id=""al0010"">Fig. 2</alt-text><graphic http://www.w3.org/1999/xlink href=""gr2"" id=""lk0010""></graphic></fig> The frequency of reported alleles based on the origin of patients can be found in assisting clinicians in focusing on specific variants in certain regions, which facilitates the targeted detection of",29_15,"The mutation spectrum and ethnic distribution of Wilson disease, a review",06 12 2023,,Wilson_Disease
"which facilitates the targeted detection of diseased alleles. Therefore, we decided to reclassify them into a unique list including the count of known alleles from patients and the predominant geographical distribution specific to each ethnic group (<xref rid=""f0015"" ref-type=""fig"">Fig. 3</xref>). More than 80% of the described variants are reported from East Asia and Europe, whereas the remaining (less than 20%) are from North/South- America, North Africa, and Middle East-South Asia.<fig",29_16,"The mutation spectrum and ethnic distribution of Wilson disease, a review",06 12 2023,,Wilson_Disease
"North Africa, and Middle East-South Asia.<fig id=""f0015""><label>Fig. 3</label><caption><p><bold>Geographical distribution of the most common ATP7B alleles causing variants worldwide.</bold> It represents the distribution of ATP7B alleles in different continents. Where the paper's provenance was not clear or had different ethnic patients, the mutation is included in the mix on the graphic.</p></caption><alt-text id=""al0015"">Fig. 3</alt-text><graphic http://www.w3.org/1999/xlink href=""gr3""",29_17,"The mutation spectrum and ethnic distribution of Wilson disease, a review",06 12 2023,,Wilson_Disease
"http://www.w3.org/1999/xlink href=""gr3"" id=""lk0015""></graphic></fig> In East Asia, the most prevalent variant was the missense R778L variant, which is represented in only 4% of the reported population i.e., China, South Korea, Taiwan, Vietnam, and Hong Kong. It is demonstrated that the R778L variant is located in exon 8 and the transmembrane domain 4 (TM4) region of the protein, which affects both its localization and trafficking of ATP7B [<xref rid=""bb0030"" ref-type=""bibr"">6</xref>]. Other common variants",29_18,"The mutation spectrum and ethnic distribution of Wilson disease, a review",06 12 2023,,Wilson_Disease
"ref-type=""bibr"">6</xref>]. Other common variants are P992L, A874V, I1148T, N1270S, and R919G, while each one is only 2% of reported variants. In Europe, the H1069Q missense variant is the most common variant with a frequency of 6.9% among all reported variants. The observed variant induced a histidine to glutamic acid substitution within the SEHPL motif located in the N-domain of the ATP7B gene. This leads to protein misfolding, abnormal phosphorylation in the P-domain, diminished ATP binding affinity,",29_19,"The mutation spectrum and ethnic distribution of Wilson disease, a review",06 12 2023,,Wilson_Disease
"in the P-domain, diminished ATP binding affinity, compromised heat stability, and aberrant protein localization to the Trans-Golgi network (TGN) [<xref rid=""bb0035"" ref-type=""bibr"">7</xref>]. The H1069Q variant is found frequently in patients from a wide range of ethnic groups i.e., Middle East-Asia (Iran), North Africa (Egypt), North and South America (USA, Brazil, El Salvador, Cuba) over a large geographical distribution. Considering the notable prevalence and extensive distribution of this variant, it",29_20,"The mutation spectrum and ethnic distribution of Wilson disease, a review",06 12 2023,,Wilson_Disease
"and extensive distribution of this variant, it represents a highly ancient genetic variant, the origins of which remain unidentified so far, which needs further investigation. The other common variants were R969Q, A1135Qfs*, W779*, T977M, and R778G which occur in less than 2% of the population. Our findings have demonstrated that several disease-causing variants exhibit relatively low frequencies within specific populations, while the prevalence of these variants exhibits significant geographical variation",29_21,"The mutation spectrum and ethnic distribution of Wilson disease, a review",06 12 2023,,Wilson_Disease
"exhibits significant geographical variation across different regions [<xref rid=""bb0040"" ref-type=""bibr"">8</xref>]. In the Middle East-South Asia, many of the reported variants are typical to a specific region. The most common is a nonsense variant C271* (4.4%), which is reported in Indian and Pakistani patients. Other variants that are often detected in patients from the Middle East are N1270S, G1061E, A1003V, I1102T, and G1341S. In Iran, the H1069Q variant, which has not been reported from elsewhere in",29_22,"The mutation spectrum and ethnic distribution of Wilson disease, a review",06 12 2023,,Wilson_Disease
"which has not been reported from elsewhere in Middle Eastern Asia, accounts for 50% of the reported alleles. However, further studies are needed in this region to identify the most prevalent variants. Given the extremely limited number of reported variants in North America, South America, and North Africa, the conclusion regarding prevalence should be considered with caution (<xref rid=""t0005"" ref-type=""table"">Table 1</xref>).<table-wrap position=""float"" id=""t0005""><label>Table 1</label><caption><p>The",29_23,"The mutation spectrum and ethnic distribution of Wilson disease, a review",06 12 2023,,Wilson_Disease
"id=""t0005""><label>Table 1</label><caption><p>The predominant geographical distribution of variants specific to each ethnic group and country.</p></caption><alt-text id=""al0020"">Table 1</alt-text><table frame=""hsides"" rules=""groups""><thead><tr><th></th><th><bold>East Asia</bold></th><th></th><th><bold>Europe</bold></th><th></th><th><bold>Middle East-South Asia</bold></th><th></th><th><bold>South America</bold></th><th></th><th><bold>North America</bold><xref rid=""tf0005""",29_24,"The mutation spectrum and ethnic distribution of Wilson disease, a review",06 12 2023,,Wilson_Disease
"America</bold><xref rid=""tf0005"" ref-type=""table-fn"">⁎</xref></th><th><bold>North Africa</bold><xref rid=""tf0010"" ref-type=""table-fn"">⁎⁎</xref></th></tr></thead><tbody><tr><td colspan=""11""><bold>Total number of Reported variants</bold></td></tr><tr><td></td><td>1808</td><td></td><td>1258</td><td></td><td>320</td><td></td><td>57</td><td></td><td>8</td><td>68</td></tr><tr><td colspan=""11"">  </td></tr><tr><td colspan=""11""><bold>Most prevalent variant in the continent (%)</bold></td></tr><tr><td></td><td>R778L",29_25,"The mutation spectrum and ethnic distribution of Wilson disease, a review",06 12 2023,,Wilson_Disease
"(%)</bold></td></tr><tr><td></td><td>R778L (4%)<break></break>P992L (2%)<break></break>A874V (2%)<break></break>I1148T (2%)<break></break>N1270S (2%)<break></break><bold>Others (89%)</bold></td><td></td><td>H1069Q (6.9%)<break></break>R969Q (1.8%)<break></break>A1135Qfs<xref rid=""tf0005"" ref-type=""table-fn"">⁎</xref>13 (1.8%)<break></break>W779<xref rid=""tf0005"" ref-type=""table-fn"">⁎</xref> (1.7%)<break></break>T977M (1.5%)<break></break><bold>Others (88.4%)</bold></td><td></td><td>C271<xref rid=""tf0005""",29_26,"The mutation spectrum and ethnic distribution of Wilson disease, a review",06 12 2023,,Wilson_Disease
"rid=""tf0005"" ref-type=""table-fn"">⁎</xref>(4.4%)<break></break>N1270S (3.8%)<break></break>G1061E (2.8%)<break></break>A1003V (2.2%)<break></break>I1102T (2.1%)<break></break><bold>Others (85%)</bold></td><td></td><td>M645R (7.1%)<break></break>A1135Qfs<xref rid=""tf0005"" ref-type=""table-fn"">⁎</xref>13(5.3%)<break></break>H1069Q (5.3%)<break></break>IVS1 + 4 A > T (5.3%)<break></break>L1088<xref rid=""tf0005"" ref-type=""table-fn"">⁎</xref>(5.3%)<break></break><bold>Others (72%)</bold></td><td></td><td>H1069Q",29_27,"The mutation spectrum and ethnic distribution of Wilson disease, a review",06 12 2023,,Wilson_Disease
"(72%)</bold></td><td></td><td>H1069Q (50%)<break></break>K1248Tfs<xref rid=""tf0005"" ref-type=""table-fn"">⁎</xref>83 (12.5%)<break></break>M645R (12.5%)<break></break><bold>Others (25%)</bold></td><td>H1069Q (4.4%)<break></break>C703Y (2.9%)<break></break><bold>Others (93%)</bold></td></tr><tr><td colspan=""11"">  </td></tr><tr><td colspan=""11""><bold>Most prevalent variant in the country (%)</bold></td></tr><tr><td></td><td>China</td><td>R778L (2.8%) P992L (2.1%) A874V (1.9%)</td><td>France</td><td>H1069Q",29_28,"The mutation spectrum and ethnic distribution of Wilson disease, a review",06 12 2023,,Wilson_Disease
"(2.1%) A874V (1.9%)</td><td>France</td><td>H1069Q (2.8%) G1099S (1.4%)<break></break>I1148T (1.4%)</td><td>India</td><td>C271<xref rid=""tf0005"" ref-type=""table-fn"">⁎</xref> (4.9%) G1061E (3.4%) N1270S (3.1%)</td><td>Brazil</td><td>M645R (7.3%)<break></break>S921N (4.8%)<break></break>IVS1 + 4 A > T (4.8%)</td><td></td><td></td></tr><tr><td></td><td>Japan</td><td>R778L (8.1%) N958Tfs<xref rid=""tf0005"" ref-type=""table-fn"">⁎</xref>(7.2%) A874V (4.1%)</td><td>Italy</td><td>H1069Q (6%)<break></break>M645R",29_29,"The mutation spectrum and ethnic distribution of Wilson disease, a review",06 12 2023,,Wilson_Disease
"(6%)<break></break>M645R (3%)<break></break>R919W (3%)</td><td>Iran</td><td>H1069Q (50%) N1270S (12%) A874V (8%)</td><td>Venezuela</td><td>M645R (12.3%) A1135Qfs<xref rid=""tf0005"" ref-type=""table-fn"">⁎</xref>13(1.3%)</td><td></td><td></td></tr><tr><td></td><td>South Korea</td><td>R778L (7%) A874V (3%)<break></break>N1270S (3%)</td><td>Germany</td><td>H1069Q (5.4%), R969Q (4.3%)</td><td>Saudi Arabia</td><td>G1341S (33%)</td><td></td><td></td><td></td><td></td></tr><tr><td></td><td>Taiwan</td><td>R778L",29_30,"The mutation spectrum and ethnic distribution of Wilson disease, a review",06 12 2023,,Wilson_Disease
"(5.8%) P992L (5.8%) G943D (4.8%)</td><td>Czech</td><td>H1069Q (6.3%) A1135Qfs<xref rid=""tf0005"" ref-type=""table-fn"">⁎</xref>(3.2%) D1047fs (3.2%)</td><td></td><td></td><td></td><td></td><td></td><td></td></tr><tr><td></td><td>Vietnam</td><td>S105<xref rid=""tf0005"" ref-type=""table-fn"">⁎</xref> (4.8%) R778L (3%)<break></break>P992L (3%)</td><td>Spain</td><td>L708P (3.7%)<break></break>M645R (7.5%) A1135Qfs<xref rid=""tf0005"" ref-type=""table-fn"">⁎</xref>13",29_31,"The mutation spectrum and ethnic distribution of Wilson disease, a review",06 12 2023,,Wilson_Disease
"rid=""tf0005"" ref-type=""table-fn"">⁎</xref>13 (3.8%)</td><td></td><td></td><td></td><td></td><td></td><td></td></tr><tr><td></td><td></td><td></td><td>Poland</td><td>H1069Q (8.7%)<break></break>S653Y (3.3%)</td><td></td><td></td><td></td><td></td><td></td><td></td></tr><tr><td></td><td></td><td></td><td>Greece</td><td>H1069Q (5.8%) I1148T (5.8%)<break></break>IVS18-2 A > G (5.8%)</td><td></td><td></td><td></td><td></td><td></td><td></td></tr></tbody></table><table-wrap-foot><fn id=""tf0005""><label>⁎</label><p",29_32,"The mutation spectrum and ethnic distribution of Wilson disease, a review",06 12 2023,,Wilson_Disease
"id=""tf0005""><label>⁎</label><p id=""np0005"">All study in North America was reported from the USA.</p></fn></table-wrap-foot><table-wrap-foot><fn id=""tf0010""><label>⁎⁎</label><p id=""np0010"">All study in North Africa was reported from Egypt</p></fn></table-wrap-foot></table-wrap> To the best of our knowledge, no mutations in Wilson patients have been reported in Central America, South Africa, or the continent of Oceania. The correlation between genotype and phenotype is described as the association between a",29_33,"The mutation spectrum and ethnic distribution of Wilson disease, a review",06 12 2023,,Wilson_Disease
"is described as the association between a specific variant and/or class of variants with a particular clinical abnormality. Therefore, finding genotype-phenotype correlations in rare inherited metabolic disorders can be complicated due to a variety of factors. In Wilson disease, these factors include the large phenotypic heterogeneity associated with the same variant and a high proportion of subclinical variants. The majority of variants in the <italic toggle=""yes"">ATP7B</italic> gene are subclinical",29_34,"The mutation spectrum and ethnic distribution of Wilson disease, a review",06 12 2023,,Wilson_Disease
"toggle=""yes"">ATP7B</italic> gene are subclinical variants, so, genotype-phenotype correlations or correlations between type and location of the variant and clinical manifestation have not been established so far. To achieve this goal, we have compiled a comprehensive list of patients identified from the literature, along with their clinical and biochemical data. This has enabled us not only to precisely estimate the number of published patients with Wilson disease but also to stratify patients for",29_35,"The mutation spectrum and ethnic distribution of Wilson disease, a review",06 12 2023,,Wilson_Disease
"Wilson disease but also to stratify patients for genotype-phenotype correlations. Data on clinical, biochemical, and pathological results of Wilson's disease were available for some of the patients (<xref rid=""t0010"" ref-type=""table"">Table 2</xref>). Overall, of 16,183 patients, 5589 male, 4455 female, and 6139 unspecified genders were reported. The mean age of patients at the time of presentation was 15.7 years old. Out of the 9473 patients, the disease presentation was comprised of 45.6% hepatic, 38.3%",29_36,"The mutation spectrum and ethnic distribution of Wilson disease, a review",06 12 2023,,Wilson_Disease
"was comprised of 45.6% hepatic, 38.3% neurologic, 10.7% mixed presentation, and 5.6% asymptomatic. Out of the 260 studies, 61 included a liver biopsy to measure hepatic copper content and/or pathological results. Among the patients who received a biopsy, 74 (9.7%) had fibrosis, 178 (23.4%) had steatosis, and 509 (66.9%) had cirrhosis. The mean Copper level in the liver was 424.8 (μg/g dry) among the 2319 patients. Additionally, the mean 24-h urine copper level was 435 (μg) and the mean serum ceruloplasmin",29_37,"The mutation spectrum and ethnic distribution of Wilson disease, a review",06 12 2023,,Wilson_Disease
"was 435 (μg) and the mean serum ceruloplasmin level was 11.47 (mg/dL) among the 14,240 patients.<table-wrap position=""float"" id=""t0010""><label>Table 2</label><caption><p>Participant characteristics included Wilson patients.</p></caption><alt-text id=""al0025"">Table 2</alt-text><table frame=""hsides"" rules=""groups""><thead><tr><th>Variable</th><th>Data</th></tr></thead><tbody><tr><td>Presentation</td><td></td></tr><tr><td>Hepatic</td><td>4302 (45.4%)</td></tr><tr><td>Neurologic</td><td>3631",29_38,"The mutation spectrum and ethnic distribution of Wilson disease, a review",06 12 2023,,Wilson_Disease
(45.4%)</td></tr><tr><td>Neurologic</td><td>3631 (38.3%)</td></tr><tr><td>Mix (hepatic and neurologic)</td><td>1002 (10.7%)</td></tr><tr><td>Asymptomatic</td><td>538 (5.6%)</td></tr><tr><td>Liver biopsy</td><td></td></tr><tr><td>Fibrosis</td><td>74 (9.7%)</td></tr><tr><td>Steatosis</td><td>178 (23.4%)</td></tr><tr><td>Cirrhosis</td><td>509 (66.9%)</td></tr><tr><td>Hepatic Cu (μg/g dry)</td><td>424.8 (113–1128)</td></tr><tr><td>Urine Cu 24 h (μg per 24 h)</td><td>435 (109–3084)</td></tr><tr><td>Serum,29_39,"The mutation spectrum and ethnic distribution of Wilson disease, a review",06 12 2023,,Wilson_Disease
"(109–3084)</td></tr><tr><td>Serum Ceruloplasmin (mg/dL)</td><td>11.47 (1.34–19)</td></tr></tbody></table><table-wrap-foot><fn id=""sp0030""><p>Data are given as n (%) or mean (range).</p></fn><fn id=""sp0035""><p>The mean age at presentation was 15.7 years (range, 0.8–40 years).</p></fn><fn id=""sp0040""><p>Normal ceruloplasmin serum: 20–35 (mg/dL); Normal urine cu 24 h: 10–30 μg per 24 h; Normal hepatic copper concentration: 10–35 μg/g dry weight.</p></fn></table-wrap-foot></table-wrap> Regarding genetic",29_40,"The mutation spectrum and ethnic distribution of Wilson disease, a review",06 12 2023,,Wilson_Disease
"Regarding genetic variation, affected patients carrying an identical genotype in different families or even within the same family present extensive variation in hepatic and neurological manifestations [<xref rid=""bb0020"" ref-type=""bibr"">4</xref>,<xref rid=""bb0040"" ref-type=""bibr"">[8]</xref>, <xref rid=""bb0045"" ref-type=""bibr"">[9]</xref>, <xref rid=""bb0050"" ref-type=""bibr"">[10]</xref>, <xref rid=""bb0055"" ref-type=""bibr"">[11]</xref>, <xref rid=""bb0060"" ref-type=""bibr"">[12]</xref>, <xref rid=""bb0065""",29_41,"The mutation spectrum and ethnic distribution of Wilson disease, a review",06 12 2023,,Wilson_Disease
"ref-type=""bibr"">[12]</xref>, <xref rid=""bb0065"" ref-type=""bibr"">[13]</xref>, <xref rid=""bb0070"" ref-type=""bibr"">[14]</xref>]. It is unknown why a particular genotype is not associated with a specific behavior of the disease. In the most prevalent variant of East Asia, some articles report that Wilson's patients with the R778L variant present with an earlier onset of disease and predominantly hepatic symptoms [<xref rid=""bb0065"" ref-type=""bibr"">13</xref>,<xref rid=""bb0075"" ref-type=""bibr"">[15]</xref>, <xref",29_42,"The mutation spectrum and ethnic distribution of Wilson disease, a review",06 12 2023,,Wilson_Disease
"rid=""bb0075"" ref-type=""bibr"">[15]</xref>, <xref rid=""bb0080"" ref-type=""bibr"">[16]</xref>, <xref rid=""bb0085"" ref-type=""bibr"">[17]</xref>, <xref rid=""bb0090"" ref-type=""bibr"">[18]</xref>, <xref rid=""bb0095"" ref-type=""bibr"">[19]</xref>]. Patients with the H1069Q variant, which is the most prevalent variant in Europe, North America, and North Africa, show a complete range of clinical manifestations; this mutation is not predominantly associated with a late or neurologic presentation [<xref rid=""bb0100""",29_43,"The mutation spectrum and ethnic distribution of Wilson disease, a review",06 12 2023,,Wilson_Disease
"or neurologic presentation [<xref rid=""bb0100"" ref-type=""bibr"">[20]</xref>, <xref rid=""bb0105"" ref-type=""bibr"">[21]</xref>, <xref rid=""bb0110"" ref-type=""bibr"">[22]</xref>, <xref rid=""bb0115"" ref-type=""bibr"">[23]</xref>]. The variants, C271*, and N1270S are the most common in Middle East-South Asia especially the Indian and Pakistani populations with allelic frequencies of 4.4% and 3.8%, respectively. The correlation between genotype and phenotype for these variants is controversial. While some papers",29_44,"The mutation spectrum and ethnic distribution of Wilson disease, a review",06 12 2023,,Wilson_Disease
"variants is controversial. While some papers document severe neurological impairment and K–F rings in patients during the first or early second decade of life, others report hepatic presentations [<xref rid=""bb0120"" ref-type=""bibr"">[24]</xref>, <xref rid=""bb0125"" ref-type=""bibr"">[25]</xref>, <xref rid=""bb0130"" ref-type=""bibr"">[26]</xref>, <xref rid=""bb0135"" ref-type=""bibr"">[27]</xref>, <xref rid=""bb0140"" ref-type=""bibr"">[28]</xref>]. It is worth mentioning that most studies have reported a lack of",29_45,"The mutation spectrum and ethnic distribution of Wilson disease, a review",06 12 2023,,Wilson_Disease
"that most studies have reported a lack of correlation between ATP7B gene variants and the phenotype. Currently, available data illustrate that a single gene causes Wilson's disease. Many patients may not possess the characteristic findings and may present when their clinical disease is relatively mild. ATP7B molecular analysis can be particularly useful in patients with an atypical presentation and in identifying affected siblings including those without definitive symptoms. The most common variant in",29_46,"The mutation spectrum and ethnic distribution of Wilson disease, a review",06 12 2023,,Wilson_Disease
"definitive symptoms. The most common variant in Europe, Northern America, and North Africa is the missense variant H1069Q, and the most prevalent ones in East Asian, Middle East-South Asian, and South American populations are the R778L, C271*, and M645R, respectively. Detecting a wide range of variants, noting the variability in disease manifestation despite carrying the same variants, and the predominance of compound heterozygosity are some of the difficulties encountered in establishing a",29_47,"The mutation spectrum and ethnic distribution of Wilson disease, a review",06 12 2023,,Wilson_Disease
"of the difficulties encountered in establishing a genotype-phenotype correlation, premarital screening, prenatal testing, and pre-implantation genetic diagnosis of Wilson's disease in different population. Not applicable. Not required. This research did not receive any specific grant from funding agencies in the public, commercial, or not-for-profit sectors. <bold>Zahra Beyzaei:</bold> Conceptualization, Data curation, Formal analysis, Writing – original draft. <bold>Arman Mehrzadeh:</bold> Data curation,",29_48,"The mutation spectrum and ethnic distribution of Wilson disease, a review",06 12 2023,,Wilson_Disease
"<bold>Arman Mehrzadeh:</bold> Data curation, Methodology, Writing – review & editing. <bold>Niko Hashemi:</bold> Data curation, Methodology, Writing – review & editing. <bold>Bita Geramizadeh:</bold> Conceptualization, Supervision, Validation, Writing – review & editing. All authors declare no competing interests.",29_49,"The mutation spectrum and ethnic distribution of Wilson disease, a review",06 12 2023,,Wilson_Disease
